Page last updated: 2024-08-17

levodopa and Dyskinesia, Drug-Induced

levodopa has been researched along with Dyskinesia, Drug-Induced in 1837 studies

Research

Studies (1,837)

TimeframeStudies, this research(%)All Research%
pre-1990171 (9.31)18.7374
1990's226 (12.30)18.2507
2000's538 (29.29)29.6817
2010's730 (39.74)24.3611
2020's172 (9.36)2.80

Authors

AuthorsStudies
Gilmour, TP; Handly, E; Iyer, V; Kunselman, AR; Lieu, CA; Savaliya, S; Subramanian, T; Venkiteswaran, K1
Kaneko, S; Kusaka, H; Morise, S; Murakami, A; Nakamura, M; Oki, M; Takenouchi, N; Tohge, R; Yakushiji, Y1
Bartlett, MJ; Falk, T; Morrison, HW; Pottenger, AE; Sherman, SJ1
Gourdon, JC; Huot, P; Maddaford, S; Nuara, SG1
Annesi, G; Blankenburg, H; Ciullo, M; Domingues, FS; Esposito, T; Gialluisi, A; Hicks, AA; König, E; Melotti, R; Modugno, N; Nicoletti, A; Pattaro, C; Picard, A; Pichler, I; Pramstaller, PP; Schwienbacher, C; Zappia, M1
Feldman, M; Margolesky, J; Marmol, S; Singer, C1
Liu, L; Xie, ZY; Zhao, Y; Zhao, YT1
Bariotto-Dos-Santos, K; Guimarães, RP; Padovan-Neto, FE; Ribeiro, DL1
Fabbri, M; Poewe, W; Rascol, O1
Caulfield, ME; Stancati, JA; Steece-Collier, K1
Baik, K; Chung, SJ; Jeong, SH; Jeong, Y; Jung, JH; Kim, YJ; Lee, HS; Lee, PH; Lee, YG; Lee, YH; Sohn, YH; Ye, BS; Yoo, HS1
Blass, BE; Bohmann, J; Chen, PJ; Daadi, ES; Daadi, EW; Daadi, MM; Kim, J; Oh, T; Roy-Choudhury, G1
Harrison, DJ; Hills, R; Lane, EL; Lelos, MJ; Ramos-Varas, E; Turner, S1
Brambilla, R; Brugnoli, A; Fasano, S; Mazzocchi, M; Mercatelli, D; Morari, M; Morella, I; Neubig, RR; O'Keeffe, GW; Pisanò, CA; Zaveri, NT1
Armstrong, MJ; Billinghurst, L; Cothros, N; Day, GS; de Bie, RMA; Espay, AJ; Fitts, MS; Gronseth, G; Gurwell, JA; Hagerbrant, L; Hall, DA; Hastings, T; Hauser, RA; Lang, AE; Licking, N; Martello, JP; Miyasaki, JM; O'Brien, MD; Pringsheim, T; Rae-Grant, A; Rafferty, M; Roze, E; Silsbee, H; Smith, DB; Sullivan, K1
Bortolanza, M; Del-Bel, EA; Faccioli, LH; Gardinassi, LG; Peti, APF; Pimentel, ÂV; Santos-Lobato, BL; Tumas, V1
Müller, T2
Bédard, D; Belliveau, S; Frouni, I; Huot, P; Kang, W; Kim, E; Kwan, C1
Bédard, D; Clarke, PB; Frouni, I; Hamadjida, A; Huot, P; Kwan, C; Lévesque, C; Lévesque, D; Yesuf, JM1
Lin, CH; Lin, FJ; Tai, CH; Wang, CC; Wu, RM; Wu, TL1
Annarumma, S; Hansen, CA; Khoshbouei, H; Miller, DR; Ramirez-Zamora, A; Rusch, CT1
Kimura, T; Kinoshita, I; Kon, T; Miki, Y; Mori, F; Nakamura, T; Nishijima, H; Suzuki, C; Tomiyama, M; Wakabayashi, K1
Bourque, M; Di Paolo, T; Morissette, M; Tremblay, MÈ1
Chagraoui, A; De Deurwaerdère, P; Di Giovanni, G1
deVries, T; Jacobs, D; Jaros, M; Quartel, A; Rascol, O; Tönges, L1
Cenci, MA; Odin, P; Skovgård, K1
Arias-García, M; Bargas, J; Calderón, VM; Galarraga, E; Gómez-Paz, A; Lara-González, E; Luna-Leal, A; Ramírez-López, F1
Kochoian, BA; Leventhal, L; Masilamoni, GJ; McRiner, AJ; Papa, SM; Singh, A; Sinon, CG1
Drummond, N; Elabi, OF; Kirkeby, A; Kunath, T; Lane, EL; Nolbrant, S; Parmar, M; Pass, R; Sormonta, I1
Bishop, C; Budrow, C; Centner, A; Cohen, SR; Coyle, M; Glinski, J; Lipari, N; Manfredsson, FP; Smith, S; Terry, ML; Wheelis, E1
Murer, MG; Paz, RM; Rela, L; Stahl, AM; Tubert, C1
Frouni, I; Huot, P1
Takeda, A1
Chen, YH; Hoffer, BJ; Huang, EY; Kuo, TT; Ma, KH; Olson, L; Tseng, KY; Wang, V1
Brys, I; Dias, CMV; Leal, DAB1
Combes, A; Coutant, B; Degos, B; Frontera, JL; Léna, C; Mailhes-Hamon, C; Menardy, F; Perez, S; Perrin, E; Popa, D; Tarpin, T; Venance, L1
Cerquera-Cleves, C; Dulski, J; Koziorowski, D; Kwiatek-Majkusiak, J; Milanowski, L; Pentela-Nowicka, J; Ross, OA; Sławek, J; Wszolek, ZK1
Bédard, D; Belliveau, S; Bourgeois-Cayer, É; Frouni, I; Hadj-Youssef, S; Hamadjida, A; Huot, P; Kang, W; Kwan, C; Ohlund, L; Sleno, L1
Chung, SJ; Lee, EC; Lee, PH; Seong, JK; Sohn, YH; Ye, BS; Yoo, HS1
Anceaume, E; Caboche, J; Calabrese, V; Calabresi, P; Campanelli, F; Charvin, D; Conquet, F; Cuoc, E; Ghiglieri, V; Heck, N; Marino, G; Natale, G; Picconi, B; Sciaccaluga, M; Tozzi, A1
Christensen, KV; Fryland, T; Hansen, JB; Mikkelsen, JD; Stoica, A; Thomsen, M1
Chung, J; Chung, SJ; Min, S; Ryu, HS; Yoon, W1
Cao, X; Gan, C; Si, Q; Sun, H; Wang, L; Wang, M; Yuan, Y; Zhang, H; Zhang, K1
Barrientos, SA; Cenci, MA; Halje, P; Petersson, P; Skovgård, K1
Bourque, M; Di Paolo, T; Dickens, D; Grégoire, L; Patel, W; Snodgrass, R1
Blandini, F; Cerri, S; Cesaroni, V1
Ko, HS; Kwatra, M; Kwon, DK; Wang, J1
Bishop, C; Centner, A; Cohen, S; Glinski, J; Lipari, N; Manfredsson, FP1
Morelli, M; Parekh, P; Pinna, A1
Cenci, MA; Espa, E; Fanni, S; Skovgård, K; Song, L1
Goetz, CG; Kaasinen, V; Luo, S; Martinez-Martin, P; Stebbins, GT1
Cao, X; Lian, P; Wu, Y; Xu, Y; Yuan, Y; Zhang, X1
Chen, J; Ge, YL; Jin, H; Li, D; Li, K; Li, W; Liu, CF; Mao, CJ; Wang, F; Wang, PZ; Yan, JH; Zhang, JR1
Farhadi, K; Hosseini, N; Mehrabi, S; Mohtasham Kia, Y; Noori, A1
Braccagni, G; Carta, M; Caruso, D; Cioffi, L; Corsi, S; Diviccaro, S; Fanni, S; Frau, R; Gambarana, C; Gentile, M; Melcangi, RC; Pardu, A; Scheggi, S; Stancampiano, R1
Chen, YH; Choi, HI; Greig, NH; Hoffer, BJ; Huang, EY; Jung, J; Kuo, TT; Ma, KH; Olson, L; Tseng, KY; Wang, V1
Feng, J; Gao, R; Gao, S; Liu, K; Song, M; Wang, L; Wang, Y; Yao, L; Zhang, L1
Furukawa, T; Kinoshita, I; Kon, T; Murakami, Y; Nakamura, T; Nishijima, H; Suzuki, C; Tomiyama, M1
Xiao, Q; Yang, X1
Kuhn, W; Müller, T1
Aguirre-Pérez, A; Alfaro-Rodriguez, A; Arias-Montaño, JA; Avila-Luna, A; Bueno-Nava, A; Gálvez-Rosas, A; Hidalgo-Bravo, A; Ríos, C1
Buberwa, W; Gao, D; Kambey, PA; Liu, WY; Nyalali, AMK; Saro, A; Tang, C; Wu, J1
Bi, Y; Deng, Y; Guan, J; Wang, P; Wang, Z; Yang, H; Yu, J; Zhang, W1
Al-Kassmy, J; Huot, P; Sun, C1
Almela, P; Arenas-Betancur, L; Cuenca-Bermejo, L; De Pablos, V; Del Bel, E; Fernández-Villalba, E; Gonzalez-Cuello, A; Herrero, MT; Navarro-Zaragoza, J; Yuste, JE1
Brito, MMCM; Cavalcanti, RTO; Del-Bel, E; Pimentel, ÂV; Santos-Lobato, BL; Tumas, V1
Huot, P2
Cenci, MA; Espa, E; Grigoriou, S; Jakobsson, A; Odin, P; Timpka, J; von Grothusen, G1
Alberico, SL; Ding, Y; Hu, Y; Jin, L; Kang, UJ; Ma, TC1
Girault, JA; Hervé, D; Nakamura, Y; Pelosi, A1
Cenci, MA; Elabi, OF; Espa, E; Fanni, S; Skovgård, K1
Bédard, D; Frouni, I; Gourdon, JC; Hamadjida, A; Huot, P; Kang, W; Kwan, C; Nuara, SG1
Del-Bel, E; Dias, FJ; Escobar-Espinal, D; Jacob, G; Leal-Luiz, G; Malzone, BL; Milan, BA; Nascimento, GC; Vivanco-Estela, AN1
Abe, Y; Dantsuji, M; Hata, J; Inoue, T; Matsumoto, M; Mochizuki, A; Nambu, A; Ohno, N; Okano, H; Sano, H; Suematsu, M; Sugiura, Y; Suzuki, T; Taira, S; Takeuchi, H; Tanaka, KF; Watanabe, M; Yagishita, S; Yoshimaru, D1
Bartlett, MJ; Falk, T; Flores, AJ; Heien, ML; Lu, D; Porreca, F; Samtani, G; Seaton, BT; Sexauer, MR; Sherman, SJ; Siegenthaler, JR; Weintraub, NC1
Dunnett, SB; Lane, EL; Lelos, MJ; Lindgren, HS; Murphy, EM1
Liu, M; Tuo, J; Xu, Z; Yu, C; Zhang, F; Zhang, J; Zhang, L1
Caron, MG; Jin, J; Martini, ML; Pogorelov, VM; Wetsel, WC1
Goehring, CM; Herfert, K; Kuebler, L; Pichler, BJ; Walker, M1
Espiritu, AI; Jamora, RDG; Pajo, AT1
Aristieta, A; Miguelez, C; Morera-Herreras, T; Ruiz-Ortega, JA; Ugedo, L2
Calabresi, P; Standaert, DG1
Chen, H; Feng, T; Jiang, Y; Liu, G; Ma, H; Su, D; Wang, D; Wang, X; Wang, Z; Yang, Y; Zhang, M1
Beck, G; Mochizuki, H; Mouradian, MM; Papa, SM; Park, ES; Potts, LF; Singh, A; Woo, JM; Zhang, J1
Altwal, F; Beverley, JA; F Voelkner, NM; Padovan-Neto, FE; Patterson, S; Steiner, H; West, AR1
Luan, XQ; Shao, B; Wang, WW; Wang, XS; Wang, XY; Xie, CL; Zhang, XR; Zhang, ZR1
Chou, KL; Mossner, JM; Patil, PG1
Antonini, A; Chaudhuri, KR; Jenner, P; Leta, V1
Gan, C; Ma, K; Si, Q; Wang, L; Wang, M; Yuan, Y; Zhang, K1
Del Bel, E; Dos-Santos-Pereira, M; Guimarães, FS; Junior, NCF1
Choi, YH; Chung, SJ; Lee, JM; Lee, PH; Lee, YH; Sohn, YH; Ye, BS; Yoo, HS1
Mannoury-la-Cour, C; Mantas, I; Millan, MJ; Svenningsson, P; Yang, Y; Zhang, X1
Clark, I; Egan, T; Rentsch, P; Stayte, S; Vissel, B1
Klivényi, P; Salamon, A; Szpisjak, L; Vécsei, L; Zádori, D1
Afonso, ND; Chapela, D; Coelho, JE; Ferreira, JJ; Lopes, LV; Outeiro, TF; Sousa, S; Vaz, RL1
Barroso, SDS; Gomes, MZ; Lopes, LES; Santos, KS1
Cao, SW; Gan, CT; Ma, KW; Shen, YT; Si, QQ; Wang, LN; Wang, M; Yuan, YS; Zhang, KZ; Zhi, Y1
Arca, R; Cossu, G; di Biase, L; Di Lazzaro, V; Di Santo, A; Fasano, A; Marano, M; Marano, P; Naranian, T; Poon, YY1
Cannas, A; Dagostino, S; Follesa, P; Marrosu, F; Pisu, MG; Puligheddu, M; Sanna, A; Serra, M; Solla, P; Tacconi, P1
Eisinger, RS; Fan, SY; Han, A; Han, CL; Hu, W; Meng, FG; Michitomo, S; Ramirez-Zamora, A; Wang, F; Wang, KL; Wang, Q; Zhang, JG1
Antonini, A; Chaudhuri, KR; Jenner, P3
Bishop, C1
Cenci, MA; Eidelberg, D; Hauser, RA; Pahwa, R; Riggare, S1
Andrén, PE; Bezard, E; Fridjonsdottir, E; Gunnarsdottir, H; Hulme, H; Nilsson, A; Shariatgorji, R; Svenningsson, P; Vallianatou, T; Wadensten, H; Zhang, X1
Chernick, D; Hauser, RA; Hubble, J; Isaacson, SH; Jankovic, J; Johnson, R; Oertel, WH; Pahwa, R; Tanner, CM1
Beaudry, F; Bédard, D; Gaudette, F; Gourdon, JC; Hamadjida, A; Huot, P; Michaud, V; Nuara, SG; Panisset, M; Sid-Otmane, L1
Chalimoniuk, M; Fiszer, U; Jówko, E; Krygowska-Wajs, A; Langfort, J; Michałowska, M; Przybylska, I; Toczylowska, B1
Baik, K; Chung, SJ; Jung, JH; Lee, PH; Lee, YH; Sohn, YH; Ye, BS; Yoo, HS2
Castello, J; Cortés, M; Friedman, E; Kottmann, A; Malave, L; Rebholz, H; Sibley, DR1
Cao, X; Chen, G; Cheng, C; Nie, S; Tan, Y; Wang, J; Xu, Y; Yang, X; Zeng, W; Zhang, Z; Zheng, C1
Arakawa, K; Maehara, S; Yuge, N1
Bartlett, MJ; Falk, T; Heien, ML; Parent, KL; Polt, R; Sherman, SJ; Skinner, DP; So, LY; Szabò, L; Vanderah, TW1
Agosta, F; Canu, E; Donzuso, G; Filippi, M1
Chen, X; Cheng, C; Le, W; Wang, Y; Wu, H1
Auger, F; Barthelemy, C; Bezard, E; Bordet, R; Carta, N; Defebvre, L; Demailly, A; Deramecourt, V; Devedjian, JC; Devos, D; Duce, J; Fisichella, M; Kuchcinski, G; Laloux, C; Lannoy, D; Li, Q; Moreau, C; Odou, P; Pioli, E; Rolland, AS1
Koski, SK; Leino, S; Panula, P; Rannanpää, S; Salminen, O1
Altwal, F; Collier, TJ; Kordower, JH; Manfredsson, FP; Sandoval, IM; Sellnow, RC; Sortwell, CE; Steece-Collier, K; West, AR1
Duty, S; Fisher, R; Jackson, M; Lincoln, L; Mann, E; Rose, S1
Shao, M; Wang, R1
Borges, V; Ferraz, HB; Hutz, MH; Mata, IF; Rieder, CRM; Santos-Lobato, BL; Schumacher-Schuh, AF; Tumas, V; Zabetian, CP1
George, AL; Mitra, A; Ren, W; Shen, W; Surmeier, DJ; Vanoye, CG; Yang, B; Zhai, S1
Kempster, P1
Chang, Y; Li, Y; Liu, X; Wang, L; Yan, Y; Zhang, L1
AlShimemeri, S; Fox, SH; Visanji, NP1
Bishop, C; Cole-Strauss, A; Collier, TJ; Conti, MM; Lipton, JW; Manfredsson, FP; Mercado, NM; Nillni, EA; Sellnow, R; Sortwell, CE; Stancati, JA; Steece-Collier, K; Winn, ME1
Bermúdez de León, M; González-Hernández, B; González-Horta, A; Leija-Salazar, M1
Bezard, E; Crynen, G; De Rosa, A; Eshraghi, M; Galli, N; Li, Q; Nuzzo, T; Ramírez-Jarquín, UN; Rivera, O; Scharager-Tapia, C; Shahani, N; Subramaniam, S; Swarnkar, S; Thiolat, ML; Tsaprailis, G; Usiello, A1
Cannas, A; Carta, M; Defazio, G; Farris, R; Figorilli, M; Meloni, M; Puligheddu, M; Sanna, F; Tronci, E1
Mukai, Y; Nishikawa, N; Shiraishi, T; Takahashi, Y1
Evans, AH; Farrell, M; Sung, S; Vijiaratnam, N1
Arai, A; Ichinohe, N; Kon, T; Mori, F; Nishijima, H; Okada, M; Suzuki, C; Tomiyama, M; Ueno, S; Wakabayashi, K; Zhu, G1
Bédard, D; Frouni, I; Gourdon, JC; Hamadjida, A; Huot, P; Kwan, C; Nuara, SG2
Bartlett, MJ; Besselsen, DG; Cowen, SL; Dollish, HK; Doyle, KP; Falk, T; Farrell, DC; Flores, AJ; Heien, ML; Parent, KL; Sherman, SJ; Smidt, SI; Stancati, JA; Steece-Collier, K; Ye, T1
Amara, RR; Beck, G; Dyavar Shetty, BL; Dyavar, SR; Fletcher, CV; Lawson, B; Papa, SM; Podany, AT; Potts, LF1
Bonastre, M; Fuentes, M; Marin, C; Mullol, J2
Awogbindin, IO; Benadjal, A; Bordeleau, M; Bourque, M; Cantin, L; Di Paolo, T; Gagnon, D; Ibanez, FG; Lecours, C; Parent, M; Picard, K; St-Pierre, MK; Tremblay, ME1
Hatano, T; Hattori, N; Kanai, K; Oyama, G; Shimo, Y; Ueno, SI1
Bézard, E; Blanchet, PJ; Bogard, S; Duval, C; Goubault, E; Martino, D; Monchi, O; Sarna, J; Vincent, C1
Crippa, JAS; Marchioni, C; Queiroz, MEC; Santos-Lobato, BL; Tumas, V1
Brugnoli, A; Morari, M; Pisanò, CA1
Franco, R; Labandeira-García, JL; Muñoz, A; Navarro, G; Reyes-Resina, I; Rivas-Santisteban, R; Rodriguez-Perez, AI1
Hong, JY; Kang, SY; Kim, SH; Lee, PH; Sohn, YH; Sunwoo, MK; Yoon, JH1
Cho, JW; Kim, JS; Kim, M; Park, H; Youn, J1
Brotchie, JM; Depoortere, R; Fox, SH; Johnston, TH; Newman-Tancredi, A1
Beaudry, F; Huot, P1
Labandeira, CM; Labandeira-Garcia, JL; Lopez-Lopez, A; Muñoz, A1
Anderson, C; Booth, S; Jackson, MF; Kirouac, G; Ko, JH; Lu, L; Ramadan, A; Zhang, D1
Lang, AE; Saranza, G1
Adar, L; Case, RJ; Ellenbogen, AL; Espay, AJ; Leinonen, M; Olanow, CW; Oren, S; Orenbach, SF; Poewe, W; Stocchi, F; Yardeni, T1
Angelopoulou, E; Julian, T; Paudel, YN; Piperi, C; Shaikh, MF1
Boezwinkle, SA; Collier, TJ; Duffy, MF; Fischer, DL; Manfredsson, FP; Mercado, NM; Mueller, RL; Sandoval, IM; Sortwell, CE; Stancati, JA; Steece-Collier, K1
Altschüler, J; Böckmann, S; Güttler, C; Haumesser, JK; Kühn, AA; Nikulin, VV; Tanev, K; van Riesen, C1
Bishop, C; Centner, A; Coyle, M; Del Priore, I; Lanza, K; Manfredsson, FP1
Bédard, D; Frouni, I; Hamadjida, A; Huot, P; Kwan, C1
Baschi, R; Cicero, CE; Davì, M; Luca, A; Monastero, R; Mostile, G; Nicoletti, A; Restivo, V; Zappia, M1
Altun, M; Bezard, E; Borgkvist, A; Dehay, B; Feyder, M; Fisone, G; Li, Q; Lieberman, OJ; Nilsson, P; Piccin, A; Plewnia, C; Santini, E; Spigolon, G; Sulzer, D; Urbina, L1
Jang, M; Jeon, B; Kim, A; Kim, HJ; Kim, Y; Paek, SH1
Andrén, PE; Bezard, E; Crossman, AR; Fernagut, PO; Fridjonsdottir, E; Nilsson, A; Odell, LR; Schembri, LS; Shariatgorji, R; Svenningsson, P; Vallianatou, T1
Betrouni, N; Carrière, N; Chupin, M; Defebvre, L; Devos, D; Kuchcinski, G; Lopes, R; Moreau, C; Rolland, AS; Viard, R1
Agostinho, P; Aguiar, AS; Cunha, RA; Ferreira, SG; Prediger, RD; Silva, HB; Speck, AE; Tomé, ÂR1
Di Fonzo, A; Fabbrini, G; Falla, M; Hicks, AA; Pramstaller, PP1
Chiken, S; Dwi Wahyu, I; Hasegawa, T; Nambu, A; Sano, H1
Bartlett, MJ; Cowen, SL; Falk, T; Sherman, SJ; Ye, T1
Bortolanza, M; Del Bel, EA; Ferrari, DP1
Beck, G; Fong, K; Mochizuki, H; Mouradian, MM; Papa, SM; Zhang, J1
Bortolanza, M; Del-Bel, E; do Nascimento, GC; Raisman-Vozari, R1
Enomoto, T; Fujii, Y; Goda, M; Ikeda, K; Kitamura, A; Nakako, T; Wada, E1
Carta, M; Corsi, S; Stancampiano, R1
Burack, MA; Ghoraani, B; Hssayeni, MD; Jimenez-Shahed, J1
Cheng, L; Li, L; Wang, Y1
Grill, WM; Schmidt, SL1
Güttler, C; Nikulin, VV; van Riesen, C1
Baik, K; Chung, SJ; Hong, N; Jeong, SH; Jung, JH; Lee, PH; Lee, YH; Sohn, YH; Yoo, HS1
Liu, Z; Song, L; Yan, A; Yang, S; Zhao, J1
Murer, MG; Paz, RM1
Fukuda, T; Kawahara, Y; Kuroiwa, M; Miyamoto, Y; Nishi, A; Ohnishi, YN; Shuto, T; Sugiyama, K1
Baik, K; Chung, SJ; Jeong, SH; Jung, JH; Lee, PH; Lee, YH; Sohn, YH; Yoo, HS1
Aranyi, T; Barta, C; Devay, P; Fothi, A; Hengerer, B; Liko, I; Nespoli, E; Pagliaroli, L; Szeri, F; Veto, B1
Contu, L; Costa, G; Morelli, M; Pinna, A; Serra, M1
Andica, C; Aoki, S; Hatano, T; Hattori, N; Hori, M; Ito, M; Iwamuro, H; Kamagata, K; Ogawa, T; Oyama, G; Saito, Y; Shimo, Y; Takeshige-Amano, H; Uchida, W; Umemura, A1
Cao, B; Chen, YP; Gu, XJ; Hou, YB; Lin, JY; Liu, KC; Ou, RW; Shang, HF; Wei, QQ; Wu, Y; Zhang, LY; Zhao, B1
Zhang, F; Zheng, C1
Barone, P; Buonomo, AR; Erro, R; Pellecchia, MT1
Asensio, MJ; García-Montes, JR; Garcia-Sanz, P; Herranz, AS; Hiroi, N; Kang, G; Moratalla, R; Solís, O1
Arai, A; Baba, M; Funamizu, Y; Haga, R; Kon, T; Nishijima, H; Nunomura, JI; Suzuki, C; Tomiyama, M; Ueno, T1
Amanzio, M; Leotta, D; Lopiano, L; Palermo, S; Rosato, R; Zibetti, M1
Brodsky, M; Factor, SA; Fox, SH; Knowles, N; Lang, AE; Metman, LV; Nutt, JG; Pope, LE; Siffert, J1
Berardelli, A; Blankenburg, H; Domingues, FS; Fabbrini, G; Falla, M; Pramstaller, PP; Schwienbacher, C1
Ahn, S; Hong, S; Jang, J; Jeon, S; Jung, YR; Kim, J; Oh, JY; Park, HJ; Park, SU; Shin, HS; Song, MA; Song, TJ1
Kordower, JH1
Alam, M; Grothe, C; Jin, X; Krauss, JK; Ratzka, A; Rumpel, R; Schwabe, K; Tschirner, SK; von Wrangel, C1
Ghilardi, MF; Kishore, A; Popa, T; Quartarone, A; Rajan, R1
Espay, AJ; Lang, AE1
Ehm, G; Jeon, B; Kim, A; Kim, HJ; Kim, YE; Lee, WW; Yang, HJ; Yun, JY1
Blandini, F; Cerri, S; Siani, F1
Bastide, MF; Bézard, E; Bourdenx, M; Doudnikoff, E; Dumont, ÉC; Fernagut, PO; Georges, F; Glangetas, C; Li, Q1
Hashizume, T; Kaneko, S; Kusaka, H; Morise, S; Nakamura, M; Oki, M; Takenouchi, N; Tsuge, A; Wate, R1
Casteels, C; de Vries, EFJ; Dierckx, RAJO; Doorduin, J; Elsinga, PH; Zhou, X1
Agarwal, P; Hauser, RA; Hull, KL; Isaacson, SH; Johnson, R; Lyons, KE; Nausieda, PA; Pahwa, R; Stempien, MJ; Tanner, CM; Truong, DD1
Andersen, AD; Binzer, M; Blaabjerg, M; Faergeman, NJ; Gramsbergen, JB; Havelund, JF; Heegaard, NHH; Stenager, E1
Bishop, C; Cantu, MA; Chotibut, T; Kasanga, EA; McInnis, T; Meadows, S; Salvatore, MF1
Barichella, M; Cassani, E; Cereda, E; Cilia, R; Contin, M; Isaias, IU; Laguna, J; Pezzoli, G; Pozzi, NG1
Asselta, R; Barbella, G; Benfante, R; Cereda, E; Cilia, R; Fornasari, D; Goldwurm, S; Marabini, L; Pezzoli, G; Vallauri, D1
de Souza, A; de Souza, RJ1
Bichon, A; Broussolle, E; Carnicella, S; Castrioto, A; Delpont, B; Fraix, V; Kistner, A; Klinger, H; Krack, P; Lhommée, E; Lüscher, C; Pélissier, P; Pollak, P; Quesada, JL; Schmitt, E; Thobois, S1
Bezard, E; Carta, M; Cheng, LY; Ko, WKD; Li, Q; Morelli, M1
Björklund, A; Carta, M; Fidalgo, C; Muñoz, A; Napolitano, F; Rossi, F; Tronci, E; Usiello, A1
Felt, L; Hauser, RA; Isaacson, SH; Johnson, R; Oertel, W; Pahwa, R; Stempien, MJ; Tanner, CM1
Espay, AJ; Verhagen Metman, L1
Bezard, E; Calabresi, P; De Rosa, A; Di Luca, M; Gardoni, F; Ghiglieri, V; Li, Q; Longhi, A; Mellone, M; Minocci, D; Napolitano, F; Picconi, B; Racca, C; Stanic, J; Thiolat, ML; Usiello, A; Zianni, E1
Azulay, JP; Eggert, K; Ehret, R; Felt, L; Hauser, RA; Isaacson, S; Oertel, W; Pahwa, R; Stempien, MJ; Tanner, CM; Trenkwalder, C1
Avale, ME; Bernardi, MA; Bordone, MP; Damianich, A; Ferrario, JE; Gershanik, OS; Gomez, G; Hanger, DP; Isaja, L; Sanz-Blasco, S; Taravini, IR1
Funamizu, Y; Nishijima, H; Tomiyama, M; Ueno, S; Ueno, T1
Gourdon, JC; Hamadjida, A; Huot, P; Nuara, SG2
Bourque, M; Di Paolo, T; Grégoire, L1
Damier, P; Delval, A; Derkinderen, P; Destée, A; Meissner, WG; Negre-Pages, L; Perez-Lloret, S; Rascol, O; Tison, F1
Abbruzzese, G; Antonini, A; Biundo, R; Calandra-Buonaura, G; Cortelli, P; Jori, MC; Lopiano, L; Marconi, R; Matinella, A; Morgante, F; Nicoletti, A; Tamburini, T; Tinazzi, M; Vorovenci, RJ; Weis, L; Zappia, M1
Pagano, G; Politis, M; Yousaf, T1
Aldrin-Kirk, P; Björklund, T; Davidsson, M; Heuer, A; Mattsson, B; Rylander Ottosson, D1
Choi, DH; Go, J; Hwang, JH; Kim, KS; Kim, YH; Lee, CH; Lee, TG; Noh, JR; Park, HY; Ryu, YK1
Carras, N; Choi, YY; Dhawan, V; Eidelberg, D; Feigin, A; Jourdain, VA; Ma, Y; Markowitz, D; Nardi, D; Nazem, A; Niethammer, M; Peng, S; Schindlbeck, KA; Tang, CC1
Fox, SH; Li, MH; Mestre, TA; Taati, B3
Asser, T; Kadastik-Eerme, L; Taba, N; Taba, P1
Castello, J; Cenci, MA; Cortés, M; Flajolet, M; Friedman, E; Malave, L; Rebholz, H1
Cicchetti, F; David, LS; Lamontagne-Proulx, J; Saint-Pierre, M1
Lin, JY; Liu, ZG; Wang, MH; Wang, XJ; Xie, CL; Zhang, SF1
Borgkvist, A; Lieberman, OJ; Sulzer, D1
Olanow, CW; Stocchi, F4
Bronstein, JM; Farrer, MJ; Guella, I; Kusters, CDJ; Paul, KC; Ritz, BR; Sinsheimer, JS1
Brotchie, JM; Corey, R; Fox, SH; Hill, MP; Howson, PA; Johnston, TH; Ravenscroft, P; Reidenberg, BE; Versi, E1
Calabresi, P; Hernández, LF; Obeso, JA; Picconi, B1
Arcuri, L; Brambilla, R; Fasano, S; Frassineti, M; Journigan, BV; Mercatelli, D; Meyer, ME; Morari, M; Morella, I; Novello, S; Pisanò, CA; Polgar, WE; Zaveri, NT1
Choi, H; Koh, SH1
Bernardi, MA; Ferrario, JE; Gershanik, OS; Gomez, G; Saborido, MD; Taravini, IR1
Francardo, V; Tronci, E1
Bishop, C; Lanza, K1
Chondrogiorgi, M; Giannakis, A; Konitsiotis, S; Tatsioni, A; Tsironis, C1
Bhide, N; Bishop, C; George, JA; Goldenberg, AA; Ostock, CY1
Gardoni, F; Mellone, M1
Fisone, G; Spigolon, G1
Morelli, M; Pinna, A; Serra, M; Simola, N1
Bair-Marshall, CJ; Girasole, AE; Guenthner, CJ; Kreitzer, AC; Lum, MY; Luo, L; Nathaniel, D; Nelson, AB1
Matarazzo, M; Perez-Soriano, A; Stoessl, AJ1
Cui, G; Ding, X; Hua, F; Wang, X; Xiang, J; Yang, X; Zhu, Z1
Bendi, VS; Joy, S; Shou, J; Torres-Russotto, D1
Koski, SK; Leino, S; Rannanpää, S; Salminen, O1
Björklund, A; Carta, M1
Cenci, MA; Crossman, AR1
Calabresi, P; De Leonibus, E; Picconi, B1
Bordia, T; Perez, XA; Quik, M1
Beck, G; Chang, PL; Maehara, S; Papa, SM1
Perez-Lloret, S; Rascol, O1
Alcázar, JP; Caro Aponte, PA; Guzmán, JC; Mayorga, EL; Otálora, CA; Turner, LF1
Hoshino, N; Ishikawa, T; Muraoka, S; Nishimura, T; Okano, M; Satoyoshi, H; Takahata, K; Tsunekawa, H1
Baillargeon, J; Darlix, N; Lévesque, C; Lévesque, D; Maheux, J; Majeur, S; Paquet, B; Rouillard, C; St-Hilaire, M1
Boi, L; Carta, AR; Fenu, S; Mulas, G; Pisanu, A; Spiga, S1
Du, CX; Liu, J; Sun, YN; Wang, HS; Wang, Y; Yao, L; Zhang, GJ; Zhang, L1
Bahroo, LB; Elkurd, MT; Pahwa, R1
Bariotto-Dos-Santos, K; Bortolanza, M; Del-Bel, EA; Leite-Panissi, CRA; Nascimento, GC1
Cenci, MA; Sebastianutto, I1
Cenci, MA; Jörntell, H; Petersson, P1
Pal, PK; Prasad, S1
Baufreton, J; Bessière, B; Bezard, E; Chazalon, M; Courtine, G; Farjot, G; Ko, WKD; Li, Q; McGuire, S; Milekovic, T; Milet, A; Moraud, EM; Morin, S; Normand, E; Pioli, E; Porras, G; Pype, J; Sun, S1
Bishop, C; Chambers, N; Conti, MM1
Ayton, S; Bush, AI; Chung, SJ; Kim, J; Kim, K; Kim, MJ; Kim, MS; Lee, JY; Oh, SB; Ryu, HS1
Brotchie, JM; Fox, SH; Johnston, TH; Lacoste, AMB; Lang, AE; Visanji, NP1
Bair-Marshall, C; Nelson, AB; Ryan, MB1
Hänninen, R; Koski, SK; Leino, S; Rannanpää, S; Salminen, O; Tapanainen, T1
Breger, LS; Cenci, MA; Fieblinger, T; Lockowandt, M; Lundberg, C; Quintino, L; Sebastianutto, I; Zanetti, L1
Frei, K; Tran, TN; Truong, DD; Vo, TNN1
Brusa, L; Caltagirone, C; Koch, G; Picazio, S; Ponzo, V1
Antonelli, F; Cerquera, C; Ezquerra, M; Fernández-Santiago, R; Malagelada, C; Martí, MJ; Martín-Flores, N; Moreno, V1
Choi, DH; Go, J; Han, PL; Hwang, JH; Kim, KS; Kim, YH; Lee, CH; Noh, JR; Park, HY; Rhee, M; Ryu, YK1
Carta, M; Hirsch, E1
Bariotto-Dos-Santos, K; Bortolanza, M; Del Bel, E; Dos-Santos-Pereira, M; Padovan-Neto, FE; Raisman-Vozari, R; Tumas, V1
Chung, SJ; Jeong, HE; Kim, JS; Kim, SJ; Lee, HS; Lee, PH; Oh, JS; Sohn, YH; Yoo, HS1
Ahn, S; Jeon, SH; Kim, J; Kim, YK; Lee, AR; Park, H; Park, HJ; Yoo, J1
Cunha, RA; Prediger, RD; S Aguiar, A; Schamne, MG; Speck, AE1
Alifirova, VM; Bokhan, NA; Fedorenko, OY; Freidin, MB; Ivanova, SA; Loonen, AJM; Mironova, YA; Osmanova, DZ; Pozhidaev, IV; Tiguntsev, VV; Wilffert, B; Zhukova, IA; Zhukova, NG1
Keam, SJ; Paik, J1
Beaudoin-Gobert, M; Duperrier, S; Météreau, E; Sgambato, V; Thobois, S; Tremblay, L1
Arnulfo, G; Canessa, A; Isaias, IU; Marotta, G; Olivieri, C; Palmisano, C; Pezzoli, G; Pozzi, NG; Turco, F; Volkmann, J1
Lane, EL1
Ba, M; Kong, M; Wang, Y; Yang, H; Yu, G; Yu, L1
Chen, SY; Shao, B; Wang, XS; Xie, CL; Zhang, XR; Zhang, ZR1
Bartlett, MJ; Falk, T; Flores, AJ; Heien, ML; Parent, KL; Polt, R; Porreca, F; Root, BK; Sherman, SJ1
Bezard, E; Charvin, D; Conquet, F; Di Paolo, T; Duvey, G; Gregoire, L; Halldin, C; Medori, R; Pioli, E; Takano, A1
Drucker-Colín, R; Enríquez-Traba, J; García-Montes, JR; Moratalla, R; Ruiz-DeDiego, I; Solís, O1
Bezard, E; Calabresi, P; Campanelli, F; Di Luca, M; Gardoni, F; Ghiglieri, V; Li, Q; Longhi, A; Marino, G; Mellone, M; Picconi, B; Stanic, J; Thiolat, ML; Zianni, E1
Brotchie, JM; Fox, SH2
Brugnoli, A; Caccia, C; Gardoni, F; Keywood, C; Kulisevsky, J; Mellone, M; Melloni, E; Morari, M; Novello, S; Padoani, G; Pisanò, CA; Sosti, V; Vailati, S1
Azulay, JP; Benel, L; Boraud, T; Chaigneau, V; Cormier-Dequaire, F; Corvol, JC; Debilly, B; Dellapina, E; Durif, F; Eusebio, A; Galitzky, M; Guimarães-Costa, R; Haddad, R; Houot, M; Lacomblez, L; Mariani, LL; Meissner, WG; Rascol, O; Salis, A; Thalamas, C1
Di Battista, ME; Fattapposta, F; Lucarelli, M; Meco, G; Moret, F; Pascale, E; Pierandrei, S; Purcaro, C; Rubino, A; Vanacore, N1
Amato, N; Galati, S; Kaelin-Lang, A; Manconi, M; Möller, JC; Sarasso, S; Staedler, C; Stanzione, P1
Bezard, E; Calabresi, P; Espay, AJ; Fasano, A; Fox, SH; Lang, AE; Marsili, L; Merola, A; Morgante, F; Picconi, B1
Fidani, L; Kalinderi, K; Papaliagkas, V1
Ahlskog, JE; Bower, JH; Cutsforth-Gregory, JK; Mielke, MM; Parisi, JE; Savica, R; Turcano, P1
Dragašević-Mišković, N; Kostić, VS; Petrović, I; Stanković, I1
Duvvuri, S; Gray, DL; Liu, W; Papapetropoulos, S; Thayer, K1
Barta, C; Glennon, J; Hengerer, B; Hildebrandt, T; Nespoli, E; Pagliaroli, L; Poelmans, G; Widomska, J1
Jenner, P7
Avnor, Y; Bishop, C; Chambers, NE; Conti, MM; Gross, L; Lanza, K; Meadows, SM; Ostock, CY1
Kohtala, S; Koski, SK; Leino, S; Rannanpää, S; Rantamäki, T; Salminen, O1
Chen, J; Li, M; Li, N; Luo, F; Lv, S; Wang, J; Wang, N; Wang, Q; Xie, Z; Zhang, W1
Nambu, A; Sano, H1
Benskey, MJ; Bishop, C; Chambers, N; Manfredsson, FP; Newman, JH; Sandoval, IM; Sellnow, RC; Steece-Collier, K; West, AR1
Abd El Fattah, MA; Badawi, GA; El Sayed, MI; Zaki, HF1
Ba, F; Nathoo, N; Sankar, T; Suchowersky, O1
Chung, SJ; Lee, HS; Lee, PH; Sohn, YH; Yoo, HS1
Beck, G; Calabresi, P; Cardinale, A; Costa, C; de Iure, A; Durante, V; Ghiglieri, V; Mancini, A; Mazzocchetti, P; Megaro, A; Napolitano, F; Papa, SM; Picconi, B; Punzo, D; Quiroga Varela, A; Sciaccaluga, M; Tantucci, M; Tozzi, A; Usiello, A1
Morris, GP; Rentsch, P; Stayte, S; Vissel, B1
Arias-Montaño, JA; Avila-Luna, A; Bueno-Nava, A; Gálvez-Rosas, A; Montes, S; Ríos, C1
Chung, SJ; Lee, HS; Lee, PH; Lee, YH; Sohn, YH; Ye, BS; Yoo, HS1
Abdelkarim, AH; Alkanj, S; Aziz, MAE; Bahbah, EI; Diab, A; Ebada, M; Ebada, MA; Fayed, N; Negida, A; Soliman, AM1
Martini, ML; Mocco, J; Panov, F1
Dashtipour, K; Lyons, KE; Pahwa, R; Tafreshi, AR1
Keifman, E; Moratalla, R; Murer, MG; Pafundo, DE; Paz, RM; Ruiz-DeDiego, I; Solís, O1
Graves, SM; Shen, W; Surmeier, DJ; Zhai, S1
Del Bello, F; Giannella, M; Giorgioni, G; Piergentili, A; Quaglia, W1
Collier, NJ; Collier, TJ; Manfredsson, FP; Mercado, NM; Sandoval, IM; Sortwell, CE; Stancati, JA; Steece-Collier, K1
Kuhn, W; Möhr, JD; Müller, T1
Elmer, LW; Hauser, RA; Howard, R; Johnson, R; Kreitzman, DL; Kremens, DE; Nguyen, JT; Patni, R; Walsh, RR1
Bezard, E; Fernagut, PO; Li, Q1
Buhmann, C; Jost, WH; Kassubek, J; Lingor, P; Schrag, A; Schwarz, J; Tönges, L1
Bezard, E; Delamarre, A; Galitzky, M; Li, Q; Meissner, WG; Rascol, O; Tison, F1
Kumar, PM; Lim, EC; Nadkarni, NV; Tan, EK; Wu, J1
Baig, F; Barber, TR; Ben-Shlomo, Y; Hu, MT; Kelly, MJ; Klein, JC; Lawton, MA; Lo, C; Ruffmann, C1
Bishop, C; Deak, T; Lanza, K; Perkins, AE1
Ahmed, MR; Ahmed, MS; Jayakumar, M; Job, JK; Li, EH; Ohtsu, H; Pittenger, C; Rajadas, J; Tao, J; Zamaleeva, AI1
Möhr, JD; Müller, T1
Boi, L; Carboni, E; Carta, AR; Fenu, S; Greig, NH; Mulas, G; Pisanu, A; Scerba, MT; Spiga, S; Tweedie, D1
Aristieta, A; Lafuente, JV; Miguelez, C; Paredes-Rodriguez, E; Ugedo, L; Vegas-Suarez, S1
McFarthing, K; Prakash, N; Simuni, T1
Di Paolo, T; Grégoire, L; Jourdain, VA; Roach, A; Townsend, M1
Gago, B; Marin, C; Obeso, JA; Rodríguez-Oroz, MC1
da Silva, CA; de Aguiar, D; de Oliveira-Tavares, D; Del Bel, E; Ferreira, NR; Padovan-Neto, FE; Raisman-Vozari, R1
Bastide, M; Bézard, E1
Boroojerdi, B; Giladi, N; Surmann, E1
Carignan, B; Daneault, JF; Duval, C; Panisset, M; Sadikot, AF1
Backer, F; Balachandran, A; Chandran, S; Kishore, A; Krishnan, S; Meunier, S; Popa, T; Pradeep, S1
Contini, A; De Deurwaerdère, P; Lagière, M; Navailles, S1
Aguiar, AS; Córdova, FM; Cunha, RA; Glaser, V; Hoeller, AA; Latini, A; Leal, RB; Moreira, EL; Oliveira, PA; Prediger, RD; Walz, R1
Liu, Z; Song, L; Wu, N; Yang, X; Yuan, W1
Bordia, T; Campos, C; Jordan, K; Letchworth, S; McIntosh, JM; Quik, M; Strachan, JP; Zhang, J1
Ivanova, SA; Loonen, AJ1
Auberson, YP; Budri, M; Calcagno, M; Dekundy, A; Mabrouk, OS; Mela, F; Morari, M; Parsons, CG; Viaro, R1
Lambrecht, C; Richter, A; Sander, SE1
Emre, M; Kieburtz, K; Leinonen, M; Nissinen, H; Poewe, W; Rascol, O; Schapira, AH; Stocchi, F; Warren Olanow, C1
Damier, P; Derkinderen, P1
Factor, SA; Silver, M1
Asselta, R; Cilia, R; Cohen, OS; Goldwurm, S; Greenbaum, L; Hassin-Baer, S; Inzelberg, R; Kohn, Y; Lerer, B; Lifschytz, T; Tesei, S; Yahalom, G; Zozulinsky, P1
Di Paolo, T; Gasparini, F; Gomez-Mancilla, B; Grégoire, L; Morin, N; Morissette, M1
Caramés, JM; Moratalla, R; Murer, MG; Solís, JM; Solís, O; Suárez, LM; Taravini, IR1
Arabia, G; Cerasa, A; Gioia, CM; Morelli, M; Novellino, F; Pugliese, P; Quattrone, A; Salsone, M1
Brotchie, JM; Fox, SH; Graef, JD; Hill, MP; Huot, P; James, JW; Johnston, TH; Jordan, KG; Koprich, JB; Letchworth, SR; Szeliga, KT1
Bézard, E; Obeso, JA; Olanow, CW1
Anselmo-Franci, J; da-Silva, CA; Del-Bel, E; Guimaraes, FS; Padovan-Neto, FE; Raisman-Vozari, R; Romano-Dutra, AC; Szawka, RE1
Ly, J; Mallela, A; Quik, M; Zhang, D1
Bleickardt, C; Hodgson, R; Jones, N; Mullins, D; Parker, E1
Mendoza-Elias, N; Meredith, GE; Rademacher, DJ; Steece-Collier, K; Tseng, KY; Zhang, Y1
Destee, A; Gao, H; Graf, A; Hattori, N; Hauser, RA; Kenney, C; Lang, AE; Merschhemke, M; Nagel, J; Poewe, W; Rascol, O; Stacy, M; Stocchi, F; Tolosa, E; Trenkwalder, C1
Fox, S1
Coelho, M; Ferreira, JJ; Mestre, TA; Pita Lobo, P; Rosa, MM1
Altieri, M; Berardelli, A; Bloise, M; Bologna, M; Fabbrini, G; Fasano, A; Latorre, A; Pietracupa, S; Sarchioto, M1
Bencherif, M; Carroll, FI; Letchworth, S; Mallela, A; Quik, M; Sohn, D; Zhang, D1
Halje, P; Petersson, P; Richter, U1
Fox, SH1
Andersson, M; Cenci, MA; Iderberg, H; Lees, AJ; Lindgren, HS; O'Sullivan, SS; Rylander, D; Williams, DR1
Dunnett, SB; Heuer, A; Klein, A; Lane, EL; Smith, GA; Vinh, NN1
Manson, A; Schrag, A; Stirpe, P1
Björklund, A; Decressac, M1
Acher, F; Bonito-Oliva, A; Fisone, G; Lopez, S; Pallottino, S1
Salat, D; Tolosa, E1
Burack, MA; Giuffrida, JP; Mera, TO2
Hashim, HZ; Nafisah, WY; Norlinah, MI; Raymond, AA; Tamil, AM; Tan, HJ1
Di Paolo, T; Morissette, M; Parent, M; Riahi, G; Samadi, P1
Jackson, MJ; Jenner, P; Pearce, RK; Swart, T1
Carta, M; Collu, M; Devoto, P; Fidalgo, C; Lisci, C; Stancampiano, R; Tronci, E1
Bertram, K; Bras, J; Cheshire, P; Foltynie, T; Halliday, G; Ling, H; McLean, C; O'Sullivan, SS; Storey, E; Williams, DR1
Bimpisidis, Z; Cenci, MA; Iderberg, H; Rylander, D1
Fiorentini, C; Missale, C; Savoia, P; Savoldi, D1
Bishop, C; Conti, MM; Dell'isola, R; Goldenberg, AA; Kampton, E; Katzman, AC; Lindenbach, D; Ostock, CY1
Bastide, MF; Bézard, E; Charron, G; Dovero, S; Fernagut, PO; Gross, CE; Porras, G1
Edwards, MJ; Rothwell, JC1
Björklund, A; Carta, M; Fidalgo, C; Lisci, C; Shin, E; Stancampiano, R; Tronci, E1
Bézard, E; Björklund, A; Carta, M; Li, Q; Muñoz, A; Pioli, EY; Porras, G; Tronci, E1
Guo, JF; Liu, ZH; Lou, MX; Song, CY; Tang, BS; Xu, Q; Yan, XX; Yu, RH; Zhang, YH1
Bonastre, M; Cortés, R; Marin, C; Mengod, G; Obeso, JA; Rodríguez-Oroz, MC1
González-Aparicio, R; Moratalla, R1
Andrén, PE; Bezard, E; Bourdenx, M; Crossman, AR; Fälth, M; Li, Q; Nilsson, A; Wadensten, H1
Cenci, MA; Francardo, V1
Chondrogiorgi, M; Konitsiotis, S; Reichmann, H; Tatsioni, A1
Aristieta, A; Azkona, G; Pérez-Navarro, E; Ruíz-Ortega, JA; Sagarduy, A; Sánchez-Pernaute, R; Ugedo, L; Vazquez, N; Zubillaga, V1
Af Bjerkén, S; Gerhardt, GA; Nevalainen, N; Strömberg, I1
Azulay, JP; Bonnet, AM; Brefel-Courbon, C; Corvol, JC; Damier, P; Dellapina, E; Destée, A; Durif, F; Galitzky, M; Lebouvier, T; Meissner, W; Ory-Magne, F; Rascol, O; Salis, A; Sommet, A; Thalamas, C; Tison, F; Viallet, F; Vidailhet, M1
Narayanan, NS; Rodnitzky, RL1
Rajput, AH1
Liu, Z; Song, L; Wei, J; Wu, N; Yang, X1
Balan, G; Barreiro, G; Boscoe, BP; Chen, L; Chenard, LK; Cianfrogna, J; Claffey, MM; Coffman, KJ; Drozda, SE; Dunetz, JR; Fonseca, KR; Galatsis, P; Grimwood, S; Lazzaro, JT; Mancuso, JY; Miller, EL; Reese, MR; Rogers, BN; Sakurada, I; Shaffer, CL; Skaddan, M; Smith, DL; Stepan, AF; Trapa, P; Tuttle, JB; Verhoest, PR; Walker, DP; Wright, AS; Zaleska, MM; Zasadny, K; Zhang, L1
Arai, A; Baba, M; Migita, K; Nishijima, H; Tomiyama, M; Ueno, S; Ueno, T; Yamada, J1
Kelsey, JE; Neville, C1
Kieburtz, K; Olanow, CW; Stocchi, F1
Brotchie, JM; Fox, SH; Huot, P; Johnston, TH; Koprich, JB; Lewis, KD; Piggott, MJ; Reyes, MG2
Di Paolo, T; Grégoire, L; Jourdain, VA; Morin, N; Morissette, M2
Bleickardt, C; Chitravanshi, VC; Cote, SR; Kuzhikandathil, EV; Sapru, HN1
Loane, C; Niccolini, F; Politis, M1
Chen, H; Chen, HB; Chen, SD; Chen, X; Li, L; Liu, YM; Liu, ZG; Qu, QM; Shao, M; Sun, SG; Wan, X; Wang, G; Wang, J; Wen, HB; Xu, Q; Zhang, BR; Zhang, ZX1
Gan, J; Liu, ZG; Pan, JL; Xie, CL; Zhang, SF1
Bordia, T; Decker, MW; McGregor, M; McIntosh, JM; Quik, M; Zhang, D1
Burn, DJ; Crossman, AR; Kass-Iliyya, L; Kellett, MW; Kobylecki, C; Silverdale, MA1
Bain, P; Brooks, DJ; Kiferle, L; Loane, C; Molloy, S; Piccini, P; Politis, M; Turkheimer, FE; Wu, K1
Ding, Y; Kang, UJ; Singh, P; Won, L1
Nagy, H; Radics, P; Takáts, A; Tamás, G; Tóth, A1
Bezard, E; Ko, WK; Li, Q1
Arai, A; Baba, M; Funamizu, Y; Haga, R; Ichinohe, N; Kimura, T; Kon, T; Meguro, R; Migita, K; Miki, Y; Nishijima, H; Suzuki, C; Suzuki, S; Tomiyama, M; Ueno, S; Ueno, T; Yamada, J1
Calabresi, P; Picconi, B1
Cenci, MA; Fenster, RJ; Francardo, V; Greengard, P; Heilbut, A; Heiman, M; Kolaczyk, ED; Kulicke, R; Mesirov, JP; Surmeier, DJ1
Liu, J; Wang, HS; Wang, T; Wang, Y; Zhang, QJ1
Chatterjee, S; Choudhury, S; Das, M; Ghosh, P; Gupta, A; Paul, P; Pradhan, R1
Bezard, E; Dufour, A; Facheris, MF; Ko, WK; Li, Q; McGuire, S; Pioli, E; Sherer, TB1
Dollé, F; Hantraye, P; Kirik, D; Lavisse, S; Ozgur, M; Rbah-Vidal, L; Sahin, G; Thompson, LH1
Cakmur, R; Sayın, S; Uğurel, B; Uzunel, F; Yaka, E; Yener, GG1
Cohen, OS; Friedman, E; Hassin-Baer, S; Inzelberg, R; Kaplan, N; Korczyn, AD; Kozlova, E; Laitman, Y; Milgrom, R; Rosset, S; Vituri, A; Yahalom, G1
Corrigan, F; Hassall, MM; Thornton, E; Vink, R1
Chase, A1
Doo, AR; Hahm, DH; Jeon, S; Kim, J; Kim, SN; Lee, H; Park, HJ; Park, JY; Park, SU; Yoo, HH1
Ham, JH; Hong, JY; Kim, JS; Lee, I; Lee, JE; Lee, PH; Oh, JS; Sohn, YH; Sunwoo, MK1
Lewitt, PA; Mouradian, MM1
Deutch, AY1
Björklund, A; Carta, M; Devoto, P; Rogers, JT; Shin, E1
Bezard, E; De Deurwaerdère, P; Engeln, M; Fernagut, PO; Li, Q1
Visanji, NP1
Bishop, C; Goldenberg, AA; Kampton, E; Lindenbach, D; Ostock, CY1
Bagetta, V; Brambilla, R; Calabresi, P; Cerovic, M; Fasano, S; Ghiglieri, V; Giampà, C; Hardingham, N; Heuer, A; Marchisella, F; Morella, I; Papale, A; Pendolino, V; Picconi, B1
Mellstrom, B; Moratalla, R; Naranjo, JR; Ruiz-DeDiego, I; Vallejo, M1
Bezard, E; Girard, F; Keywood, C; Li, Q; Mutel, V; Pioli, EY; Poli, SM; Rascol, O; Tison, F1
Christensen, MS; Haagensen, BN; Herz, DM; Løkkegaard, A; Madsen, KH; Rowe, JB; Siebner, HR2
Amalric, M; Beurrier, C; Chabbert, D; Concetta, L; Jaouen, F; Kerkerian-Le Goff, L; Langa, F; Marie, H; Melon, C; Révy, D; Salin, P; Tafi, E1
Fang, X; Guo, L; Jia, J; Liu, Z; Lu, W; Yang, Z; Ye, N; Zhang, A; Zhao, B; Zhao, J; Zhao, R; Zhen, X; Zheng, L1
Auladell, C; Beas-Zarate, C; Camins, A; Canudas, AM; de Lemos, ML; Folch, J; Lazarowski, A; Pallàs, M; Pedros, I; Petrov, D1
Bezard, E; Crossman, AR; Ko, WK; Martin-Negrier, ML; Ravenscroft, P1
Huang, C; Liu, J; Wang, HS; Wang, T; Wang, Y1
Bandak, S; Docu-Axelerad, A; Hauser, RA; Kenney, C; Kieburtz, KD; Kozyolkin, O; Lew, M; Meya, U; Neale, A; Olanow, CW; Pourcher, E; Resburg, C1
Antonini, A; Poewe, W1
Ivanova, EA; Kapitsa, IG; Kokshenev, II; Nepoklonov, AV; Val'dman, EA; Voronina, TA2
Decker, MW; McGregor, M; Quik, M; Zhang, D1
Adjei, P; Akassi, J; Akpalu, A; Amboni, M; Bonetti, A; Cereda, E; Cham, M; Cilia, R; Fabbri, M; Pezzoli, G; Sarfo, FS1
Anand, R; Bhatt, MH; Borgohain, R; Chirilineau, D; Forrest, E; Giuliani, R; Lucini, V; Meshram, C; Rice, P; Stanzione, P; Stocchi, F; Szasz, J1
Di Paolo, T; Grégoire, L; Morin, N; Morissette, M2
Amanzio, M; Geminiani, G; Leotta, D; Lopiano, L; Palermo, S; Rosato, R; Zibetti, M1
Dostrovsky, JO; Hodaie, M; Hutchison, WD; Liu, LD; Lozano, AM; Prescott, IA1
Bastide, MF; Bezard, E; Boué-Grabot, E; Bourdenx, M; Dehay, B; Doudnikoff, E; Engeln, M; Fernagut, PO; Gross, CE; Li, Q; Pisani, A; Toulmé, E1
Al Dakheel, A; Beaulieu-Boire, I; Fox, SH1
Fox, SH; Johnston, TM1
Iravani, M; Jackson, M; Jenner, P; McCreary, AC; Papathanou, M; Rose, S; Stockwell, K; Strang, I; Zeng, BY1
Dominguez-Meijide, A; Garrido-Gil, P; Labandeira-Garcia, JL; Muñoz, A1
Chung, BH; Han, PL; Hwang, JH; Kang, Y; Kang, YM; Kim, KS; Kim, MR; Kim, YH; Lee, CH; Nam, KH; Park, HY; Park, TS; Ryu, YK1
Dyavarshetty, B; Greven, AC; Mouradian, MM; Papa, SM; Potts, LF; Uthayathas, S1
Brotchie, JM; Chen, B; Gertler, TS; Lo, C; Nash, JE; Surmeier, JD; Thiele, SL; Warre, R1
Di Paolo, T; Elbast, W; Feuerbach, D; Gomez-Mancilla, B; Grégoire, L; Weiss, M1
Berretta, N; Bonito-Oliva, A; Cappellacci, L; Fisone, G; Ledonne, A; Mango, D; Mercuri, NB; Nisticò, R; Petrelli, R1
Bishop, C; Conti, MM; Lindenbach, D; Ostock, CY; Palumbo, N; Vilceus, N1
Tomiyama, M1
Di Paolo, T; Morin, N1
Caboche, J; Feyder, M; Fisone, G; Hansen, K; LaPlant, Q; Nestler, EJ; Santini, E; Södersten, E; Spigolon, G; Vialou, V; Watts, EL1
Anselmo-Franci, J; Carolino, RO; Cavalcanti-Kiwiatkoviski, R; Del Bel, E; Padovan-Neto, FE1
Chotibut, T; Fields, V; Salvatore, MF1
Bonuccelli, U; Ceravolo, R; Frosini, D; Linsalata, G; Mazzucchi, S; Nicoletti, V; Ripoli, A1
Del-Bel, EA; Espadas, I; Moratalla, R; Solís, O1
Brotchie, JM; Espinosa, MC; Fox, SH; Huot, P; Johnston, TH; Koprich, JB; Reyes, MG1
Sharma, JC; Vassallo, M1
Bilbe, G; Bouhelal, R; Desrayaud, S; Enz, A; Flor, PJ; Gasparini, F; Kuhn, R; McAllister, K; Ofner, S; Vranesic, I1
Danysz, W; Dekundy, A; Hofmann, M; Mela, F1
Berg, D; Pilotto, A; Schaeffer, E1
Canela, EI; Canet-Pons, J; Casadó, V; Cortés, A; Dopeso-Reyes, IG; Farré, D; Franco, R; Labandeira-García, JL; Lanciego, JL; Lluís, C; Mallol, J; Moreno, E; Muñoz, A; Navarro, G; Reyes-Resina, I; Rico, AJ1
Augimeri, A; Brusa, L; Caltagirone, C; Cerasa, A; Donzuso, G; Koch, G; Mangone, G; Morelli, M; Passamonti, L; Picazio, S; Ponzo, V; Quattrone, A; Salsone, M; Stampanoni Bassi, M1
Bastide, MF; Bézard, E; Boraud, T; de la Crompe, B; Doudnikoff, E; Fernagut, PO; Gross, CE; Mallet, N1
Bortolanza, M; Cavalcanti-Kiwiatkoski, R; da-Silva, CA; Del-Bel, E; Mitkovski, M; Padovan-Neto, FE; Raisman-Vozari, R1
Ando, K; Inoue, T; Itoh, T1
Borgkvist, A; Mosharov, EV; Sulzer, D1
Bernardi, G; Castelli, V; Cavaliere, F; D'Angelo, V; Ferrazzoli, D; Giorgi, M; Martorana, A; Morrone, LA; Sancesario, G; Sica, F; Sorge, R1
Berardelli, A; Bloise, MC; Colosimo, C; Defazio, G; Di Biasio, F; Fabbrini, G; Latorre, A1
Di Luca, M; Gardoni, F1
Amalric, M1
Antonini, A; Pilleri, M1
Carta, AR; Cassano, T; Giuffrida, A; Macheda, T; Martinez, AA; Morgese, MG; Paquette, MA; Pisanu, A; Seillier, A1
Aquino, CC; Fox, SH1
Aguiar, AS; Bortolanza, M; Del-Bel, E; Padovan-Neto, FE; Prediger, RD; Raisman-Vozari, R; Tumas, V1
Brotchie, JM; Fox, SH; Huot, P; Johnston, TH1
Ba, M; Kong, M; Ma, G1
Alcacer, C; Carpentier, W; Charbonnier-Beaupel, F; Corvol, JC; During, M; Girault, JA; Hervé, D; Malerbi, M; Tahiri, K; Wang, C; Worley, PF; Xu, D1
Ba, M; Kong, M; Liu, C; Qiu, H; Zhang, H; Zhang, Y1
Antonini, A; Konitsiotis, S; Stathis, P1
di Biase, L; Di Lazzaro, V; Marano, M; Melgari, JM; Salomone, G; Scrascia, F1
Baracchi, F; Bassetti, CL; Galati, S; Kaelin-Lang, A; Möller, JC; Pace, M; Salvadè, A; Sarasso, S; Städler, C; Stanzione, P1
Obeso, JA; Rothwell, JC1
Cenci, MA; Iderberg, H; McCreary, AC; Newman-Tancredi, A; Varney, MA1
Ayton, S; Bertram, KL; Cheshire, P; Finkelstein, DI; Halliday, GM; Li, A; Ling, H; McLean, C; O'Sullivan, SS; Revesz, T; Storey, E; Williams, DR1
Hauser, RA; Isaacson, S; McClure, NL; Pahwa, R; Ruby, AE; Sethi, K; Stempien, MJ; Struck, L; Tanner, CM; Truong, D; Went, GT1
Kenney, C; Landrian, A; Lenderking, WR; Mannix, S; Petrillo, J; Schrag, AE1
Ding, Y; Hitchcock, SA; Kang, UJ; Lim, SAO; McGehee, DS; Ray, WJ; Won, L; Xia, R1
Bezard, E; Carta, M2
Af Edholm Arvidsson, K; Björklund, A; Keywood, C; Lowe, DA; Rosenblad, C; Shankar, B; Svenningsson, P; Wictorin, K; Widner, H1
Niccolini, F; Politis, M; Rocchi, L1
Ahmed, MR; Bychkov, E; Dalby, KN; Gurevich, EV; Kook, S; Zurkovsky, L1
Fahn, S; Kestenbaum, M1
Berg, D; Liepelt-Scarfone, I; Maetzler, W; Reilmann, R; Sass, C; Schaeffer, E1
Aschermann, Z; Bereczki, D; Dézsi, L; Dibó, G; Klivényi, P; Komoly, S; Kovács, N; Nagy, H; Takáts, A; Tóth, A; Valikovics, A; Varannai, L; Vécsei, L; Zemlényi, G1
Bubser, M; Cenci, MA; Conn, PJ; Hopkins, CR; Iderberg, H; Jones, CK; Lindsley, CW; Maslava, N; Niswender, CM; Thompson, AD1
Abrams, MB; Galter, D; Gellhaar, S; Marcellino, D1
Cenci, MA; Fieblinger, T1
Collier, TJ; Gebremedhin, KG; O'Malley, J; Paumier, KL; Rademacher, DJ; Sisson, KA; Sortwell, CE; Stancati, JA; Steece-Collier, K1
Di Paolo, T; Goodenowe, D; Grégoire, L; Miville-Godbout, E; Mochizuki, A; Senanayake, V; Smith, T1
Deshmukh, R; Sharma, S; Sharma, V; Singh, S; Singh, VP1
Cao, X; Chen, Z; Shi, Q; Tang, B; Wang, T; Zhang, T1
Bordia, T; Drenan, RM; McGregor, M; McIntosh, JM; Quik, M1
Bhide, N; Bishop, C; Conti, M; George, JA; Hallmark, J; Ostock, CY; Palumbo, N1
Braithwaite, SP; Dyavar Shetty, BL; Mouradian, MM; Papa, SM; Park, ES; Potts, LF; Singh, A; Voronkov, M; Woo, JM1
Barnum, CJ; Bhide, N; Bishop, C; George, JA; Lindenbach, D; Surrena, MA1
Altmann, V; Callegari-Jacques, SM; Hutz, MH; Rieck, M; Rieder, CR; Schneider Medeiros, M; Schumacher-Schuh, AF1
Carlsson, T; Depboylu, C; Höglinger, GU; Keber, U; Klietz, M; Oertel, WH; Schäfer, MK; Weihe, E1
Hwang, BY; Lee, CK; Lee, MK; Park, HJ; Park, KH; Shin, KS; Zhao, TT1
Bezard, E; Carta, M; Chuan, Q; Fidalgo, C; Ko, WK; Li, Q; Stancampiano, R; Tronci, E1
Bass, CE; Bezard, E; Bido, S; Caron, MG; Daigle, TL; Gainetdinov, RR; Peterson, SM; Urs, NM1
Gan, J; Liu, Z; Qi, C1
Cui, G; Hua, F; Shen, X; Shi, H; Wang, X; Yang, X; Zhang, S; Zhang, W; Zhang, Z; Zhao, H; Zu, J1
Antonelli, F; Buongiorno, M; Calopa, M; Cámara, A; Campolongo, A; de Fabregues-Nebot, O; Hernandez-Vara, J; Kulisevsky, J; Martí, MJ; Pascual-Sedano, B; Puente, V; Tolosa, E; Valldeoriola, F1
Bortolanza, M; Cavalcanti-Kiwiatkoski, R; Del-Bel, E; Dos Santos-Pereira, M; Mitkovski, M; Padovan-Neto, FE; Raisman-Vozari, R1
Bardin, L; Cenci, MA; Depoortère, R; Iderberg, H; Kleven, MS; Koek, W; McCreary, AC; Newman-Tancredi, A; Varney, MA1
Brotchie, JM; Fox, SH; Huot, P; Johnston, TH; Newman-Tancredi, A1
Counsell, CE; Macleod, AD; Scott, NW1
Bäckman, CM; Cadet, JL; Chiang, YH; Diaz, O; Hoffer, BJ; Ladenheim, B; Olson, L; Shan, L; Zhang, Y1
Bonuccelli, U; Ceravolo, R; Frosini, D; Mazzucchi, S1
Bonastre, M; Cortés, R; Marin, C; Mengod, G; Rodríguez-Oroz, MC1
Guan, R; Staisch, J; Towle, VL; Warnke, P; Xie, T1
Chaote, P; Dewhurst, F; Dotchin, CL; Gray, WK; Massawe, J; Walker, RW1
Calandra-Buonaura, G; Chiari, L; Contin, M; Cortelli, P; Lopane, G; Mellone, S1
Chammas, C; Soghomonian, JJ; Zhang, K1
Arcuri, L; Brugnoli, A; Mercatelli, D; Morari, M; Paolone, G1
Alcacer, C; Angela Cenci, M; Bastide, MF; Bézard, E; Bourdenx, M; Brambilla, R; Carta, M; Crossman, AR; De Deurwaerdère, P; Ding, Y; Engeln, M; Fasano, S; Fernagut, PO; Feyder, M; Fisone, G; Fox, S; Francardo, V; Gardoni, F; Groc, L; Guehl, D; Gurevich, EV; Jon Stoessl, A; Kang, UJ; Ko, WK; Meissner, WG; Mellone, M; Morari, M; Morelli, M; Navailles, S; Picconi, B; Quik, M; Rodriguez, MC; Simola, N; Steece-Collier, K; Tison, F; Tronci, E1
Wictorin, K; Widner, H1
Di Paolo, T; Grégoire, L; Morin, N; Morissette, M; Rajput, A; Rajput, AH2
Chang, JW; Chang, WS; Jung, HH; Kim, JH1
Arabia, G; Augimeri, A; Cerasa, A; Donzuso, G; Mangone, G; Morelli, M; Passamonti, L; Quattrone, A; Salsone, M1
Ferreira, JJ; Perez-Lloret, S; Rascol, O1
Bishop, C; Conti, MM; Dupre, KB; Lindenbach, D; Ostock, CY1
Feld, Y; Finberg, JP; Gross, RE; Gutekunst, CA; Mewes, K; Papa, SM; Singh, A; Uthayathas, S1
Bloem, BR; Borm, GF; Haaxma, CA; Horstink, MW; Lemmens, WA; Zijlmans, JC1
Daniels, WM; Mabandla, MV; Ndlovu, BC1
Bastide, MF; Bézard, E; Bido, S; Duteil, N1
Garcia-Montes, JR; González-Granillo, A; Moratalla, R; Solís, O; Xu, M1
Brugnoli, A; Morari, M; Napolitano, F; Usiello, A1
Fedorova, NV; Gubanova, ЕN; Kulua, TK1
Altunbaev, RA; Yakovleva, LA; Zalyalova, ZA1
Ardolino, G; Bianchi, M; Bocci, T; Borroni, B; Cogiamanian, F; Cortese, F; Di Fonzo, A; Ferrucci, R; Padovani, A; Pittera, D; Priori, A; Turrone, R; Vergari, M1
Case, DT; Collier, TJ; Divito, CB; Edwards, RH; Rubio, ME; Seal, RP; Sortwell, CE; Stancati, JA; Steece-Collier, K; Sulzer, D; Williams, SP; Zhang, H; Zhi, L1
Bordia, T; Decker, MW; McGregor, M; McIntosh, JM; Perez, XA; Quik, M; Zhang, D1
Beaudoin-Gobert, M; Sgambato-Faure, V; Tremblay, L1
Alves, G; Bjornestad, A; Forsaa, EB; Larsen, JP; Pedersen, KF; Tysnes, OB1
Cruz, AV; Delaville, C; Dupre, KB; Eyring, KW; Gerber, CM; McCoy, AJ; Walters, JR1
Girasole, AE; Nelson, AB1
Bezard, E; Cenci, MA; Conn, PJ; Fieblinger, T; Francardo, V; Greengard, P; Ko, WK; Li, Q; Lindsley, CW; Neubig, RR; Plotkin, JL; Shen, W; Surmeier, DJ; Wess, J; Xie, Z1
Feng, Z; Gupta, DK; Hang, X; Hasan, A; Liu, R1
Cacace, F; Calabresi, P; Carta, M; di Maio, A; Fidalgo, C; Gardoni, F; Ghiglieri, V; Mancini, M; Mellone, M; Mineo, D; Napolitano, F; Pendolino, V; Picconi, B; Stancampiano, R; Stanic, J; Tronci, E; Usiello, A; Vannelli, A1
Tan, LC; Zhang, J1
Bartlett, MJ; Estevez, M; Falk, T; Heien, ML; Joseph, RM; Laude, ND; Lazarus, LB; LePoidevin, LM; Parent, KL; Sherman, SJ1
Llorente, J; Miguelez, C; Morera-Herreras, T; Ruiz-Ortega, JA; Sagarduy, A; Ugedo, L1
Daumas, S; El Mestikawy, S; Gangarossa, G; Guzman, M; Prado, MA; Prado, VF; Valjent, E1
Stoessl, AJ1
Adams, JR; Boileau, I; Furukawa, Y; Guttman, M; Houle, S; Kish, SJ; Payer, DE; Rusjan, P; Tong, J; Wilson, AA1
Alam, M; Jin, X; Krauss, JK; Schwabe, K1
Ferreira, JJ; Lees, A; Poewe, W; Rascol, O; Rocha, JF; Soares-da-Silva, P1
Carrault, G; Jalloul, N; L'Hostis, P; Porée, F; Viardot, G1
Bonato, P; Daneault, JF; Golabchi, FN; Lee, SI; Paganoni, S; Patel, S; Shih, L1
Brys, I; Halje, P; Ivica, N; Petersson, P; Richter, U; Tamtè, M1
Carta, M; Cenci, MA1
Nicoletti, A; Zappia, M1
McCreary, AC; Newman-Tancredi, A; Varney, MA1
Baeken, C; Cordenier, A; De Keyser, J; De Raedt, S; Flamez, A; Michiels, V; Parys, E; Smetcoren, S; Van Merhaegen-Wieleman, A1
De Deurwaerdère, P; Miguelez, C; Navailles, S; Ugedo, L1
Antonini, A; Benesh, JA; Boyd, JT; Chatamra, K; Eaton, S; Fung, VS; Hall, C; Slevin, JT1
Gurevich, EV1
Benussi, A; Brusa, L; Caltagirone, C; Di Lorenzo, F; Koch, G; Picazio, S; Ponzo, V1
Bezard, E; Carta, M; Costa, G; Fidalgo, C; Ko, WK; Li, Q; Morelli, M; Pinna, A; Simola, N; Tabrizi, MA; Tronci, E1
Fülöp, F; Majláth, Z; Toldi, J; Vécsei, L1
Choi, DH; Go, J; Hwang, JH; Kim, KS; Kim, YH; Lee, CH; Park, HY; Park, TS; Rhee, M; Ryu, YK1
Cheng, J; Fan, Q; Gan, J; Hu, R; Li, L; Liu, Z; Song, L; Wu, N; Zhang, Z; Zhou, M1
Barbon, A; Bono, F; Busi, C; Fiorentini, C; Missale, C; Savoia, P; Savoldi, D1
Piccini, P; Politis, M; Roussakis, AA; Towey, D1
Bordia, T; Heiss, J; Perez, XA; Quik, M; Zhang, D1
Cerasa, A; Dileone, M; Obeso, I; Quattrone, A1
Azulay, JP; Boulamery, A; Eusebio, A; Gayraud, D; Simon, N; Viallet, F1
Berg, D; Braatz, U; Ferreira, JJ; Graessner, H; Heger, T; Hobert, MA; Hucker, S; Maetzler, W; Manoli, Y; Meckler, S; Ramsperger, R; Serrano, JA; van Uem, J1
Haagensen, BN; Herz, DM; Løkkegaard, A; Madsen, KH; Nielsen, SH; Siebner, HR1
Hwang, E; Hwang, O; Jeon, SR; Lee, CJ; Min, J; Suh, JK; Yoon, HH1
Arabia, G; Barone, P; Iliceto, G; Lamberti, P; Marconi, R; Morgante, L; Mostile, G; Nicoletti, A; Nicoletti, G; Quattrone, A; Zappia, M1
Asensio, MJ; García-Sanz, P; Herranz, AS; Moratalla, R; Solís, O1
Black, MA; Dearden, PK; Duncan, EJ; Gemmell, NJ; Parr-Brownlie, LC; Reynolds, JN; Smith, LM1
Azulay, JP; Berg, D; Broussolle, E; Ceballos-Baumann, A; Corvol, JC; Defebvre, L; Derkinderen, P; Di Paolo, T; Durif, F; Eggert, K; Espay, AJ; Feigin, A; Feuerbach, D; Geny, C; Gomez-Mancilla, B; Gostkowski, M; Hockey, HU; Houeto, JL; Jaeger, J; Jakab, A; Johns, D; Linazasoro, G; Maruff, P; Rascol, O; Rozenberg, I; Schwarz, J; Sovago, J; Stocchi, F; Storch, A; Tranchant, C; Trenkwalder, C; Weiss, M; Zhang, L1
Lin, JY; Liu, ZG; Wang, MH; Wang, XJ; Xie, CL; Zhang, SF; Zhang, Y1
Moustafa, YM; Teema, AM; Zaitone, SA1
Dhall, R; Kreitzman, DL1
Bariotto-Dos-Santos, KD; Bortolanza, M; da-Silva, CA; Del-Bel, E; Dos-Santos-Pereira, M1
Capper-Loup, C; Kaelin-Lang, A; Paganetti, P; Sgroi, S1
Boon, WC; Chua, HK; Horne, M; Stanic, D; Tomas, D; White, K1
Aguilera, J; Candalija, A; Limón, ID; Mendieta, L; Palafox-Sánchez, V; Ramírez-García, G1
Jankovic, J; Vijayakumar, D1
Kanaya, Y; Kono, R; Kuriyama, M; Shiga, Y; Shimoe, Y; Takeshima, S1
Dronamraju, N; Graf, A; Kenney, C; Poewe, W; Shah, A; Stocchi, F; Trenkwalder, C; von Raison, F1
Bezard, E; Corvol, JC; Durif, F; Eggert, K; Goetz, CG; Isaacson, S; Keywood, C; Lew, M; Poli, SM; Rascol, O; Tison, F; Trenkwalder, C; Wakefield, M1
Eskow Jaunarajs, KL; Figge, DA; Standaert, DG1
Bez, F; Cenci, MA; Francardo, V1
Carlsson, T; Chiu, WH; Depboylu, C; Höglinger, GU; Keber, U; Klietz, M; Schäfer, MK; Weihe, E1
Alty, JE; Cosgrove, J; Jamieson, S; Lones, MA; Smith, SL; Trefzer, MA; Turner, AP; Tyrrell, AM1
da-Silva, CA; Del-Bel, E; Dos-Santos-Pereira, M; Guimarães, FS1
Cao, X; Hou, D; Li, S; Ping, Q; Sun, S; Wang, L; Xu, Y1
Fiszer, U; Michałowska, M; Szatanowski, T1
Chu, Y; Isacson, O; Kordower, JH; Redmond, DE; Vinuela, A1
Bezard, E; Camus, SM; Ko, WKD; Li, Q; McGuire, S; Pioli, EY; Yang, J1
Chiou, SM1
Benitez-Rivero, S; Cheeran, B; Del-Olmo, MF; Hu, M; Jenkinson, N; Koch, G; Lago-Rodriguez, A; Ponzo, V1
Brzuszkiewicz-Kuzmicka, G; Gorecki, W; Mossakowski, Z; Sobstyl, M; Zabek, M; Zaczynski, A1
Cenci, MA; Hopkins, CR; Maslava, N; Sebastianutto, I1
Aguado, C; Lujan, R; Moratalla, R; Solis, O; Suarez, LM1
Ba, M; Guan, L; Kong, M; Yi, M; Zhang, H1
Bariotto, K; Bortolanza, M; Del-Bel, E; Dos-Santos-Pereira, M; Raisman-Vozari, R1
Hardy, GA; Lee, HJ; Schallert, T; Smith, ES1
Hallett, M; Li, J; Li, X; Li, Y; Zhang, Y; Zhuang, P1
Angius, F; Batetta, B; Carboni, E; Carta, AR; Cossu, G; Espa, E; Fenu, S; Giuffrida, A; Jadžić, D; Lecca, D; Mulas, G; Pillai, E; Simbula, G; Spiga, S; Spolitu, S1
Choi, YY; Dhawan, V; Dresel, C; Eidelberg, D; Holtbernd, F; Jourdain, VA; Ma, Y; Tang, CC1
Bonenfant, J; Drapier, S; Haegelen, C; Houvenaghel, JF; Naudet, F; Sauleau, P; Vérin, M1
Cao, X; Chen, G; Han, C; Ma, K; Nie, S; Papa, SM; Wang, T; Xiong, N; Xu, Y; Zhang, Z1
Alberico, SL; Kim, YC; Lence, T; Narayanan, NS1
James, P; Kishore, A; Krishnan, S; Meunier, S; Popa, T; Yahia-Cherif, L1
Cohen, OS; Elincx-Benizri, S; Greenbaum, L; Hassin-Baer, S; Israeli-Korn, S; Shabat, C; Stein, E; Strauss, H; Warmann-Alaluf, N; Yahalom, G1
Cannas, A; Marrosu, F; Mascia, MM; Meloni, M; Solla, P1
Wang, Q; Zhang, W1
Mizuno, Y; Origasa, H; Shimoda, S1
Alonso-Frech, F; Catalán, MJ; Escribano, PM1
Frouni, I; Gourdon, JC; Hamadjida, A; Harraka, MJ; Huot, P; Kwan, C; Nuara, SG; Sid-Otmane, L; Veyres, N1
Abreu, D; Albuquerque, L; Carvalho, H; Cattoni, B; Coelho, M; Correia-Guedes, L; Domingos, J; Fabbri, M; Ferreira, AG; Ferreira, JJ; Freitas, V; Godinho, C; Lobo, PP; Pereira, JM; Reimão, S; Rosa, MM1
Cicero, CE; Contrafatto, D; Dibilio, V; Luca, A; Mostile, G; Nicoletti, A; Raciti, L; Sciacca, G; Vasta, R; Zappia, M1
Bezard, E; Fernagut, PO; Frank, MJ; Grace, AA; Napier, TC; Obeso, J; Rodriguez-Oroz, M; Sgambato-Faure, V; Voon, V1
Andersen, AD; Binzer, M; Blaabjerg, M; Gramsbergen, JBP; Kamal, A; Kjaer, TW; Stenager, E; Thagesen, H1
Herz, DM; Løkkegaard, A; Siebner, HR; Thomsen, BL1
Bimpisidis, Z; Cenci, MA; Lundblad, C; Maslava, N; Öberg, CM1
A Figge, D; Standaert, DG1
Betz, AJ; Bibbiani, F; Chase, TN; Davis, RE; Kielaite, A; Salamone, JD; Vanover, KE; Weber, SM; Weiner, DM1
Bishop, C; Dupre, KB; Eskow, KL; Klioueva, A; Lormand, L; Negron, GE; Park, JY; Steiniger, A1
Björklund, A; Carlsson, T; Carta, M; Kirik, D; Muñoz, A2
Bourdeix, I; Damier, P; Rerat, K; Viallet, F; Ziegler, M1
Bagetta, V; Barone, I; Calabresi, P; Ghiglieri, V; Picconi, B; Sgobio, C1
Carta, AR; Frau, L; Morelli, M; Pinna, A; Pontis, S1
Ferrario, JE; Gershanik, OS; Larramendy, C; Murer, MG; Saborido, MD; Taravini, IR1
Busi, C; Fiorentini, C; Missale, C; Spano, P1
Bordia, T; Campos, C; Huang, L; Quik, M1
Barnum, CJ; Bishop, C; Blandino, P; Deak, T; Dupre, K; Eskow, KL1
Danysz, W; Dekundy, A; Gravius, A; Morè, L; Nagel, J; Pietraszek, M1
Bernardi, G; D'Angelo, V; Esposito, Z; Giorgi, M; Martorana, A; Nuccetelli, V; Sancesario, G; Sorge, R; Stefani, A1
Danysz, W; Dekundy, A; Quack, G; Valastro, B1
Brotchie, JM; Chuang, R; Fox, SH1
Sethi, K1
Kieburtz, K1
Albanese, A; Del Sorbo, F1
Ballerini, R; Hauser, RA; Mori, A; Roberts, JW; Shulman, LM; Sussman, NM; Trugman, JM1
Fung, VS; Herawati, L; Wan, Y1
Bezard, E; Gerfen, CR; Nadjar, A1
Aubert, I; Berthet, A; Bezard, E; Bloch, B; Cenci, MA; Doudnikoff, E; Hengerer, B; Ittrich, C; Rylander, D; Schuster, S; Surmeier, DJ1
Cardoso, F; Gomide, L; Kummer, A; Teixeira, AL1
Bhatia, K; Filipović, SR; Rothwell, JC; van de Warrenburg, BP1
Bezard, E; Björklund, A; Carlsson, T; Carta, M; Di Luca, M; Gardoni, F; Kirik, D; Li, Q; Marcello, E; Muñoz, A; Qin, C1
Barker, RA; Bhatia, KP; Cheeran, B; Edwards, MJ; Foltynie, T; Rothwell, JC; Schneider, SA; Weinberger, D; Williams-Gray, CH1
Caron, MG; Gainetdinov, RR; Hallett, PJ; Isacson, O; Patterson, M; Reske-Nielsen, C; Sotnikova, TD; Vinuela, A1
Freeman, T; Godbold, J; Goetz, CG; Gracies, JM; Kordower, JH; Obeso, JA; Olanow, CW; Stoessl, AJ1
Marti, M; Morari, M; Trapella, C1
Björklund, A; Carlsson, T; Carta, M; Kirik, D; Mattsson, B; Muñoz, A; Winkler, C1
Dunnett, SB; Lane, EL; Monville, C; Pekarik, V; Torres, EM1
Barnum, CJ; Bishop, C; Deak, T; Dupre, KB; Eskow, KL; Krolewski, DM; Walker, PD1
Brotchie, JM; Fox, SH; Johnston, T; Millan, MJ; Reyes, G; Visanji, NP1
Fahn, S5
Hattori, N; Ohizumi, H; Tanaka, S; Yoritaka, A1
Murata, M2
Buck, K; Ferger, B4
Destée, A; Moreau, C1
Pal, PK; Prashantha, DK1
Aguilar, E; Bartoszyk, GD; Marin, C; Obeso, JA; Rodríguez-Oroz, MC1
Bodenheimer, RE; Davis, TL; Dawant, BM; Li, R; Rao, AS; Voight, C1
Bono, G; Garavaglia, P; Guidotti, M; Leva, S; Pianezzola, C; Raudino, F; Riboldazzi, G1
Ben-Shlomo, Y; Morris, HR; Wickremaratchi, MM1
García-Horsman, JA; Kääriäinen, TM; Männistö, PT; Piltonen, M1
af Bjerkén, S; Cenci, MA; Gerhardt, GA; Lundblad, M; Pomerleau, F; Strömberg, I1
Bartoszyk, GD; Bédard, PJ; Di Paolo, T; Graham, J; Grégoire, L; Samadi, P1
Baker, WL; Coleman, CI; Patel, AA; Reinhart, K; Talati, R1
Lyons, KE; Pahwa, R2
Pisani, A; Shen, J1
Bhidayasiri, R; Ling, H1
Berger, SP; Brudney, EG; Foley, K; Johnson, SW; Meshul, CK; Paquette, MA1
Calon, F; Di Paolo, T; Grégoire, L; Hornykiewicz, O; Rajput, A; Rajput, AH; Samadi, P1
Del-Bel, EA; Echeverry, MB; Padovan-Neto, FE; Tumas, V1
Barnum, CJ; Bishop, C; Dickinson, SO; Dupre, KB; Eskow, KL; Park, JY1
Cenci, MA; Danysz, W; Dekundy, A; Mela, F; Recchia, A; Rylander, D1
Berthet, A; Bezard, E; Bloch, B; Cador, M; Doudnikoff, E; Porras, G; Stark, H1
Abbruzzese, G1
Antonini, A; Odin, P; Wolters, E1
Brundin, P; Cenci, MA; Lane, EL; Vercammen, L1
Collier, TJ; Maries-Lad, E; Soderstrom, KE; Sortwell, CE; Steece-Collier, K1
García-Gutiérrez, MS; Ledent, C; Leiva, C; Leza, JC; Manzanares, J; Molina, JA; Pérez-Nievas, BG; Pérez-Rial, S1
Durairajan, SS; Fong, WL; Gao, J; Kum, WF; Li, M; Lu, JH; Man, SC; Xie, LX1
Aubert, I; Berton, O; Bezard, E; Bioulac, BH; Dileone, RJ; Gross, CE; Guigoni, C; Li, Q; Nestler, EJ1
Björklund, A; Carlsson, T; Carta, M; Kirik, D; Muñoz, A; Tronci, E1
Astradsson, A; Brownell, AL; Choi, JK; Hallett, PJ; Isacson, O; Jenkins, BG; Levesque, MA; McDowell, JS; Spealman, RD1
Edelstyn, NM; Ellis, SJ; Jenkinson, PM; Stephens, R1
Ares, S; Darmopil, S; De Diego, IR; Martín, AB; Moratalla, R1
Montgomery, EB3
Bernardi, S; Edito, F; Meco, G; Purcaro, C; Stirpe, P; Valente, M; Vanacore, N1
Blond, S; Defebvre, L; Delval, A; Destée, A; Devos, D; Dujardin, K; Kreisler, A; Krystkowiak, P; Salleron, J; Simonin, C; Tir, M1
Emre, M; Jenner, P; Poewe, W; Schapira, AH1
Di Paolo, T; Grégoire, L; Lévesque, D; Morissette, M; Ouattara, B; Rouillard, C; Samadi, P; Tamim, MK1
Klivényi, P; Vécsei, L1
Brusa, L; Caltagirone, C; Carrillo, F; Koch, G; Lo Gerfo, E; Mir, P; Oliveri, M; Stanzione, P; Torriero, S1
Kerkerian-Le Goff, L; Khaindrava, V; Lacombe, E; Melon, C; Oueslati, A; Salin, P1
Iravani, MM; Jackson, MJ; Jenner, P; Olanow, CW; Rose, S; Scheller, D; Smith, LA; Stockwell, KA; Tayarani-Binazir, K1
Fisone, G; Greengard, P; Heiman, M; Santini, E; Valjent, E1
Bishop, C; Dupre, KB; Jaunarajs, KL; Kelly, C; Klioueva, A; Moore, A; Steiniger, A1
Di Paolo, T; Gilbert, F; Grégoire, L; Lévesque, D; Mahmoudi, S; Morissette, M; Ouattara, B; Rouillard, C; Samadi, P1
Aguilar, E; Bonastre, M; Jiménez, A; Marin, C2
Soghomonian, JJ; Yamamoto, N1
Berardelli, A; Bloise, M; Colosimo, C; Defazio, G; Fabbrini, G; Suppa, A1
Aguilar, E; Barbanoj, M; Kulisevsky, J; Marin, C; Pérez, V; Rubio, A1
Brocco, M; Mela, F; Millan, MJ; Morari, M1
Balfour, RH; Jackson, MJ; Jenner, P; Rose, S; Zeng, BY1
Maertens de Noordhout, A1
Barichella, M; Cereda, E; Pezzoli, G1
Andree, TH; Hansard, M; Hoffman, DC; Hurtt, MR; Jackson, MJ; Jenner, P; Kehne, JH; Pitler, TA; Smith, LA; Stack, G1
Bode, M1
Iravani, MM; Jackson, MJ; Jenner, P; Rose, S; Scheller, DK; Smith, LA; Stockwell, KA1
Bezard, E; Brotchie, JM; Dunah, AW; Hallett, PJ; Kobylecki, C; Li, Q; Ravenscroft, P; Silverdale, MA1
Chelaru, MI; Duval, C; Jog, M1
Buck, K; Ferger, B; Voehringer, P2
Baunez, C; Bezard, E; Fernagut, PO; Juncos, JL; Obeso, JA; Pavon, N; Rodriguez, M; Voon, V; Wickens, J1
Di Rocco, A; Howard, J; Varanese, S1
Di Paolo, T; Lévesque, D; Morissette, M; Samadi, P1
Bélanger, N; Di Paolo, T; Hadj Tahar, A; Morissette, M; Samadi, P1
Bilbe, G; Di Paolo, T; Gasparini, F; Gomez-Mancilla, B; Grégoire, L; Hornykiewicz, O; Johns, DR; Morissette, M; Ouattara, B; Rajput, A; Rajput, AH; Vranesic, I1
Andersson, DR; Cenci, MA; Lagerkvist, S; Lindgren, HS; Nissbrandt, H1
Bureau, G; Chagniel, L; Cyr, M; Lebel, M1
Brodsky, MA; Nutt, JG; Park, BS1
Adam, OR; Ferrara, JM; Ondo, WG1
Di Paolo, T; Gasparini, F; Gomez-Mancilla, B; Grégoire, L; Morin, N1
Anderson, AM; Johnson, SW; Lewis, JR; Meshul, CK; Paquette, MA; Paul Berger, S1
Bonanni, L; Cossu, G; Manca, D; Onofrj, M; Stocchi, F; Thomas, A1
Cenci, MA; Ohlin, KE; Rylander, D1
Bezard, E; Guigoni, C1
Stocchi, F3
Antonini, A; Chaudhuri, KR; Martinez-Martin, P; Odin, P1
Cenci, MA; Ohlin, KE1
Berthet, A; Bezard, E1
Brotchie, JM; Fox, SH; Gomez-Ramirez, J; Huot, P; Johnston, T; Reyes, G; Visanji, N1
Auff, E; Haubenberger, D; Hochschorner, G; Katzenschlager, R; Kloiber, I; Ott, E; Poewe, W; Ransmayr, G; Schwingenschuh, P; Seppi, K; Wolf, E1
Bordia, T; Campos, C; McIntosh, JM; Quik, M1
Duval, C; Edwards, R; Jog, M; Mann, RK; Zhou, J1
Chung, KA; Horak, F; Lobb, BM; McNames, J; Nutt, JG1
Chung, KA; Holford, NH; Nutt, JG1
Brotchie, JM; Fox, SH; Johnston, TH; McIldowie, MJ; Piggott, MJ1
Gil, S; Koh, H; Lee, J; Park, C1
Lewitt, PA2
Di Paolo, T; Gasparini, F; Gomez-Mancilla, B; Grégoire, L; Hoyer, D; Morissette, M; Ouattara, B1
Glass, GA; Ku, S1
Fukaya, C; Katayama, Y; Kobayashi, K; Nishikawa, Y; Ogasawara, K; Ogawa, A; Oshima, H; Yamamoto, T1
Marconi, S; Stocchi, F1
Dunnett, SB; Lane, EL1
Baishen, R; Bezard, E; Cenci, MA; Danysz, W; Dekundy, A; Iderberg, H; Li, H; Li, Q; Rylander, D; Zhang, J1
Cenci, MA; Crossman, AR; Kobylecki, C; Ravenscroft, P1
Adams, B; Earl, NL; Gray, AM; Hauser, RA; Lyons, KE; Olanow, W; Pahwa, R; Sethi, K; Stern, M; Watts, RL1
Guan, Q; He, Y; Jin, L; Liu, X; Zhao, L1
Nodel', MR1
Alachkar, A; Brotchie, JM; Jones, OT2
Brotchie, JM; Fox, SH; Huot, P; Johnston, TH; Winkelmolen, L1
Kleiner-Fisman, G; Lang, AE; Lozano, A; Moro, E; Poon, YY1
Fisone, G; Santini, E; Valjent, E2
Barone, P; Jankovic, J; Kieburtz, K; Lang, AE; Olanow, CW; Poewe, W; Rascol, O; Stocchi, F; Tolosa, E1
Mink, JW; Zinner, SH1
Kirik, D; Sahin, G; Ulusoy, A1
Calabresi, P; Ghiglieri, V; Picconi, B2
Belujon, P; Grace, AA; Lodge, DJ1
Chen, CC; Chen, RS; Grattan-Smith, P; Jung, SM; Lai, SC; Lang, AE; Lin, YW; Lu, CS; Sugo, E; Wu-Chou, YH1
Liu, Z; Ren, T; Song, L; Wu, N; Yang, X; Yuan, W1
Alken, RG; Cenci, MA; Malmlöf, T; Rylander, D; Schilström, B; Schneider, F; Svensson, TH1
Adeli, GM; Arenovich, T; Fox, SH; Hung, SW; Lang, AE1
Espay, AJ; Metman, LV; O'Sullivan, JD; Paviour, DC; Revilla, FJ; Schmidt, RE1
Bateup, HS; Birnbaum, S; Fisone, G; Greengard, P; Nestler, EJ; Santini, E; Shen, W; Surmeier, DJ; Valjent, E1
Cenci, MA; Konradi, C1
Iravani, MM; Jackson, MJ; Jenner, P; Parent, A; Rose, S; Zeng, BY1
Koch, G1
Fang, C; Gao, C; Wang, Y; Xu, H; Xu, Z; Yin, J; Zhou, H1
Aceves, J; Erlij, D; Florán, B; Lopéz-Santiago, LM; Rangel-Barajas, C; Silva, I1
Kaczmarska, J; Konradi, C; Luksik, AS; Naydenov, AV; Vassoler, F1
Grählert, X; Löhle, M; Reichmann, H; Schneider, C; Schwanebeck, U; Schwarz, J; Storch, A; Strecker, K; Wolz, M1
Brotchie, JM; Fox, SH; Johnston, TH; Piggott, MJ; Savola, JM1
Burdett, TC; Cassin, JJ; Chen, JF; Fredholm, BB; Healy, B; Schwarzschild, MA; Xiao, D1
Antonini, A; Burkhard, PR; Poewe, W; Vingerhoets, F; Zijlmans, JC1
Inoue, T; Koyama, M; Ogata, A; Tani, Y1
Calabresi, P; Di Filippo, M; Ghiglieri, V; Picconi, B; Tambasco, N1
Bezard, E; Cenci, MA; Descarries, L; Dovero, S; Lees, AJ; O'Sullivan, SS; Parent, M; Rylander, D1
Dowd, E; Finn, DP; Gorman, AM; Walsh, S1
Cho, J; Jeon, BS; Lee, EK; Lee, JY; Park, SS1
Bartolini, WP; Brotchie, JM; Fox, SH; Huot, P; Johnston, TH; Milne, GT; Pearson, JP; Sykes, KA; Wakefield, JD1
Brotchie, JM; Fox, SH; Huot, P; Johnston, TH; Koprich, JB; Winkelmolen, L1
Alegre, M; Artieda, J; Garcia-Garcia, D; Guridi, J; López-Azcárate, J; Obeso, JA; Rodriguez-Oroz, MC; Toledo, J; Valencia, M1
Bakay, RA; Deogaonkar, M; Lieu, CA; Subramanian, T1
Auguet, M; Chabrier, PE; Charnet, C; Cornet, S; Roubert, V; Spinnewyn, B1
Hametner, E; Poewe, W; Seppi, K1
Cantuti-Castelvetri, I; Crittenden, JR; Graybiel, AM; Hernandez, LF; Hollingsworth, ZR; Keller-McGandy, CE; Kett, LR; Landy, A; Nillni, EA; Saka, E; Standaert, DG; Young, AB1
da-Silva, CA; Del Bel, EA; Novaretti, N; Padovan-Neto, FE; Tumas, V1
Bougia, P; Fotiadis, DI; Konitsiotis, S; Rigas, G; Tsipouras, MG; Tzallas, AT1
Chapman, J; Cohen, OS; Hassin-Baer, S; Katzav, A; Korczyn, AD; Molchadski, I; Nitzan, Z1
Bezard, E; Brambilla, R; Cenci, MA; Cerovic, M; D'Antoni, A; Doveró, S; Fasano, S; Francardo, V; Indrigo, M; Qin, L1
Auguet, M; Chabrier, PE; Ferrandis, E; Grandoulier, AS; Marin, JG; Mautino, G; Rocher, MN; Spinnewyn, B1
Danysz, W; Dekundy, A; Gravius, A; Hechenberger, M; Mela, F; Nagel, J; Parsons, CG; Pietraszek, M; Tober, C; van der Elst, M1
Gil, SJ; Koh, HC; Lee, JE; Minn, YK; Park, CH1
Bagetta, V; Calabresi, P; Di Filippo, M; Fusco, FR; Ghiglieri, V; Giampà, C; Paillè, V; Pendolino, V; Picconi, B; Sgobio, C; Tozzi, A1
Bogdanov, RR; Kotov, SV; Kunitsyna, AN; Turbina, LG1
Gerlach, M; Grünblatt, E; Riederer, P; Scheller, DK; Schmidt, WJ1
Hu, WD; Huang, YX; Li, D; Liu, CF; Luo, WF1
Daly, CS; Dunnett, SB; Lane, EL; Smith, GA1
Campos, C; Huang, LZ; Ivy Carroll, F; Ly, J; Quik, M1
Bartoszyk, GD; Dean, O; Gerlach, M; Riederer, P; van den Buuse, M1
Rascol, O4
Andersson, D; Cenci, MA; Francardo, V; Nissbrandt, H; Popovic, N; Recchia, A1
Bilbe, G; Di Paolo, T; Gasparini, F; Gomez-Mancilla, B; Grégoire, L; Johns, D; Morin, N; Ouattara, B; Sahasranaman, S; Vranesic, I1
Bishop, C; Button, T; Dupre, KB; Eskow Jaunarajs, KL; Ostock, CY; Savage, LM; Wolf, W1
Brotchie, JM; Fahana, N; Johnston, TH; Khademullah, CS; Lam, D; Lo, C; Nash, JE; Talwar, S; Thiele, SL; Warre, R1
Ahmed, I; Bose, SK; Brooks, DJ; Hammers, A; Hotton, G; Pavese, N; Ramlackhansingh, A; Turkheimer, F1
Del-Bel, E; Lazzarini, M; Padovan-Neto, FE; Raisman-Vozari, R1
Arabia, G; Cerasa, A; Lanza, P; Messina, D; Morelli, M; Nicoletti, G; Novellino, F; Pugliese, P; Quattrone, A; Salsone, M1
Aquilonius, SM; Askmark, H; Nyholm, D1
Barnum, CJ; Bhide, N; Bishop, C; Dupre, KB; Eskow Jaunarajs, KL; Lindenbach, D; Ostock, CY1
Konitsiotis, S; Peterson, D; Stathis, P; Tagaris, G1
Duker, AP; Espay, AJ; Gartner, M; Revilla, FJ; Sahay, A; Shukla, R; Vaughan, JE1
Dotchin, C; Jusabani, A; Walker, R1
Brotchie, JM; DeHaven, RN; DeHaven-Hudkins, DL; Dolle, RE; Fox, SH; Goodman, A; Johnston, TH; Koprich, JB; Le Bourdonnec, B; Little, PJ1
Abi-Saab, W; Berg, D; Cooke, K; Csoti, I; Di Paolo, T; Eggert, K; Gasparini, F; Godau, J; Gomez-Mancilla, B; Hariry, S; Huber, H; Johns, D; Morelli-Canelo, M; Ries, V; Schneider, C; Stamelou, M; Storch, A; Trenkwalder, C; Vandemeulebroecke, M; Wolz, M1
Lee, MS; Lyoo, CH1
Di Paolo, T; Morissette, M; Parent, M; Riahi, G1
Barroso-Chinea, P; Conte-Perales, L; Gómez-Bautista, V; Lanciego, JL; Luquin, N; Rico, AJ; Roda, E; Sierra, S1
Cohen, OS; Efrati, L; Hassin-Baer, S; Korczyn, AD; Kozlova, E; Molchadski, I; Nitzan, Z; Tunkel, O1
Af Bjerkén, S; Gerhardt, GA; Lundblad, M; Nevalainen, N; Strömberg, I1
Alty, JE; Goy, AG; Kempster, PA; Raghav, S; Reutens, DC; Wong, KK1
Bloem, BR; Hovestadt, A; van Laar, T; Vlaar, A1
Gao, B; Guo, L; Liu, Z; Ye, N; Zhang, A; Zhang, H; Zhen, X; Zheng, L; Zhou, S1
Carlsson, T; Döbrössy, M; García, J; Nikkhah, G; Winkler, C2
Ahmed, I; Bose, SK; Brooks, DJ; Pavese, N; Ramlackhansingh, AF; Turkheimer, FE1
Bishop, C; Dupre, KB; George, J; Jaunarajs, KL; Krolewski, D; Ostock, CY; Walker, PD; Walters, H1
Grady, SR; Huang, LZ; Quik, M1
Irie, S; Kanazawa, N; Mochizuki, H; Nomura, Y; Ryoh, M; Segawa, M1
Andersson, M; Bergquist, J; Fälth, M; Hanrieder, J; Ljungdahl, A; Mammo, SE1
Bido, S; Marti, M; Morari, M1
Chen, RS; Chuang, WL; Huang, YZ; Lu, CS; Rothwell, JC1
Cenci, MA; Francardo, V; Konradi, C; Lees, AJ; Lindgren, HS; Luksik, AS; O'Sullivan, SS; Ohlin, KE; Sillivan, SE; Vassoler, FM1
Calabresi, P; Di Luca, M; Gardoni, F; Pendolino, V; Picconi, B; Sgobio, C1
Ballinari, P; Kaelin-Lang, A; Kipfer, S; Schüpbach, WM; Stephan, MA1
Cai, XY; Fang, Q; Kong, XM; Ning, P; Xu, YJ; Xue, SR; Zhang, B1
McKeown, MJ; Oishi, MM; Stevenson, JK; Talebifard, P; Ty, E1
Fernandez, HH; Foote, KD; Hwynn, N; Iyer, SS; Jacobson, CE; Malaty, IA; Okun, MS; Oyama, G; Rodriguez, RL; Zeilman, P1
Iravani, MM; Jenner, P1
Johnston, TH; Lane, EL1
Bezard, E; Fisone, G1
Brotchie, J; Jenner, P1
Lozano, AM; Sankar, T1
Brusa, L; Ceravolo, R; Iani, C; Kiferle, L; Koch, G; Monteleone, F; Schillaci, O; Stanzione, P1
Bagetta, V; Bonito-Oliva, A; Calabresi, P; Carta, M; Di Luca, M; Errico, F; Fisone, G; Gardoni, F; Marinucci, S; Napolitano, F; Picconi, B; Romano, R; Usiello, A; Vitucci, D; Zianni, E1
Dunnett, SB; Heuer, A; Lane, EL; Smith, GA1
Brotchie, JM; Visanji, NP1
Crossman, AR; Hill, MP; Kobylecki, C; Ravenscroft, P1
Geng, XC; Yin, LL; Zhu, XZ1
Espay, AJ; Giuffrida, JP; Heldman, DA; Mera, TO; Payne, M1
Barnum, CJ; Bhide, N; Bishop, C; Goldenberg, AA; Klioueva, A; Lindenbach, D; Surrena, MA; Tignor, S; Walters, H1
Bido, S; Cenci, MA; Marti, M; Mela, F; Morari, M1
Ondo, WG1
Chagniel, L; Cyr, M; Lebel, M; Robitaille, C1
Becker, N; Munhoz, RP; Teive, HA1
Arbelo, JM; del Val, JL; Sesar, A1
Gerlach, M; Riederer, P; Scheller, D1
Arabia, G; Cerasa, A; Gioia, MC; Messina, D; Morelli, M; Nicoletti, G; Novellino, F; Pugliese, P; Quattrone, A; Salsone, M1
Jann, MW1
Alstrup, AK; Doudet, DJ; Gjedde, A; Høltzermann, M; Jakobsen, S; Landau, AM; Møller, A; Nahimi, A; Simonsen, M; Vang, K; Wegener, G1
Iravani, MM; Jenner, P; McCreary, AC1
Barrow, R; Errico, F; Kim, S; Mealer, RG; Napolitano, F; Shahani, N; Snyder, SH; Subramaniam, S; Tyagi, R; Usiello, A1
Giuffrida, A; Macheda, T; Martinez, A; Morgese, MG; Trabace, L1
Barroso-Chinea, P; Baufreton, J; Berthet, A; Bezard, E; Bloch, B; Dehay, B; Fasano, S; Giros, B; Li, Q; Martin-Negrier, ML; Martinez, A; Nosten-Bertrand, M; Porras, G; Thiolat, ML1
Cheshire, PA; Williams, DR1
Bronzova, J; Hauser, RA; Lang, AE; Rascol, O; Sampaio, C; Theeuwes, A; van de Witte, SV1
Evans, AH; Farrell, MJ; Gibson, SJ; Helme, RD; Lim, SY1
Konitsiotis, S; Maranis, S; Stamatis, D; Tsironis, C1
Aron, AR; Obeso, J1
Duval, C; Edwards, R; Fenney, A; Jog, M; Mann, RK; Zhou, J1
Djaldetti, R; Gad, A; Khlebtovsky, A; Melamed, E; Rigbi, A; Steiner, I; Ziv, I1
Ago, Y; Hiramatsu, N; Matsuda, T; Ota, Y; Takahashi, T; Takuma, K; Tanaka, T1
Björklund, A; Carta, M; Shin, E; Tronci, E1
Francardo, V; Iderberg, H; Pioli, EY1
Fotiadis, DI; Konitsiotis, S; Rigas, G; Tsipouras, MG; Tsouli, S; Tzallas, AT1
Bacolod, MD; Bennouar, KE; Cajina, M; Doller, D; Gubellini, P; Jimenez, HN; Kerkerian-Le Goff, L; Melon, C; Uberti, MA1
Ardouin, C; Aya Kombo, M; Benabid, AL; Bichon, A; Bosson, JL; Broussolle, E; Carnicella, S; Chabardès, S; Fraix, V; Kistner, A; Klinger, H; Krack, P; Lhommée, E; Mertens, P; Pollak, P; Polo, G; Quesada, JL; Schmitt, E; Seigneuret, E; Thobois, S; Xie, J1
Alcacer, C; Gaven, F; Girault, JA; Hervé, D; Santini, E; Valjent, E1
Eidelberg, D; Feigin, A; Niethammer, M1
De Deurwaerdère, P; Navailles, S1
Adamaszek, M; Beck, J; Ohm, S; Schwarz, J; Strecker, K; Wegner, F1
Billet, F; Costentin, J; Dourmap, N1
Grady, SR; Hrachova, M; Huang, LZ; Mallela, A; McIntosh, JM; Park, KM; Quik, M1
Björklund, A; Carta, M; Garcia, J; Shin, E; Winkler, C1
Gerlach, M; Halley, P; Riederer, P; van den Buuse, M1
Balachandran, A; Joseph, T; Kishore, A; Meunier, S; Popa, T; Velayudhan, B1
Cai, Y; Liao, M; Liu, Z; Yang, X; Yuan, W; Zheng, R1
Mallya, U; Pahwa, R; Suh, DC1
Balbi, P; Bertotti, G; Boveri, N; Comi, C; Felicetti, G; Frazzitta, G; Leva, S; Maestri, R; Morelli, M; Pelosin, E; Riboldazzi, G; Turla, M1
Sabetay, S; Schwartz, M1
Cohen, OS; Friedman, E; Hassin-Baer, S; Inzelberg, R; Kaplan, N; Korczyn, AD; Kozlova, E; Rosset, S; Vituri, A; Yahalom, G1
Tarsy, D2
Brotchie, JM; Fox, SH; Huot, P; Johnston, TH; Koprich, JB2
Debicki, D; Jog, M1
Chen, R; Elahi, B; Phielipp, N1
Arabia, G; Augimeri, A; Cerasa, A; Gioia, MC; Morelli, M; Novellino, F; Quattrone, A; Salsone, M1
Derkinderen, P; Lebouvier, T; Pouclet, H1
Coppard, N; Hauser, RA; Leinonen, M; Lewitt, PA; Lu, M; Nicholas, AP; Savola, JM; Weiner, W1
Bishop, C; Buchta, W; Dickinson, SO; Eissa, S; Eskow Jaunarajs, KL; George, JA; Goldenberg, AA; Mohamed, M1
Fischer, K; Lettfuss, NY; Pichler, BJ; Sossi, V; von Ameln-Mayerhofer, A1
Al Hadithy, AF; Alifirova, VM; Brouwers, JR; Fedorenko, OY; Freidin, MB; Govorin, NV; Ivanova, SA; Loonen, AJ; Pechlivanoglou, P; Rudikov, EV; Semke, AV; Sorokina, VA; Wilffert, B; Zhukova, IA1
Daragon, A; Derrey, S; Lefaucheur, R; Maltête, D; Nicolau, J; Verdet, M1
Aristieta, A; Azkona, G; Miguelez, C; Ruiz-Ortega, JÁ; Sagarduy, A; Sanchez-Pernaute, R; Ugedo, L1
Desrayaud, S; Di Paolo, T; Gasparini, F; Gomez-Mancilla, B; Grégoire, L; Morin, N; Morissette, M1
Brotchie, JM; Damude, S; Fox, SH; Huot, P; Johnston, TH; Jones, SW; Rusche, JR1
Broussolle, E; Castrioto, A; Chabardès, S; Fraix, V; Kistner, A; Klinger, H; Krack, P; Lhommée, E; Mertens, P; Pollak, P; Quesada, JL; Schmitt, E; Thobois, SC1
Barbin, L; Damier, P; Leux, C; Meyniel, C; Nguyen, JM; Pereon, Y; Sauleau, P1
Bordia, T; Chin, M; Mallela, A; McIntosh, JM; Perez, XA; Quik, M1
Berthet, A; Bezard, E; Bloch, B; Boué-Grabot, E; Choquet, D; Chuan, Q; Dehay, B; Doudnikoff, E; Dovero, S; Groc, L; Ladepeche, L; Li, Q; Martin-Négrier, ML; Martinez, A; Normand, E; Porras, G1
Breger, LS; Dunnett, SB; Lane, EL1
Allorge, D; Blum, D; Bordet, R; Defebvre, L; Delval, A; Destée, A; Devos, D; Duhamel, A; Dujardin, K; Hossein-Foucher, C; Moreau, C; Petyt, G; Sablonnière, B; Schraen, S; Tiffreau, V1
Di Paolo, T; Grégoire, L; Jourdain, VA; Morin, N; Morissette, M; Parent, M1
Duty, S1
Bhatia, KP; Filipović, SR; Rothwell, JC1
Bezard, E; Brambilla, R; Calabresi, P; Fasano, S; Guerrini, R; Li, Q; Marti, M; Morari, M; Morella, I; Rodi, D; Simonato, M; Tozzi, A1
Altmann, V; Callegari-Jacques, SM; Fagundes, PT; Francisconi, CL; Hutz, MH; Monte, TL; Rieck, M; Rieder, CR; Schumacher-Schuh, AF1
Calleja-Castillo, J; Cervantes-Arriaga, A; Corona, T; Morales-Briceño, H; Rodríguez-Violante, M1
Cenci, MA; Halje, P; Mohammed, M; Petersson, P; Richter, U; Tamtè, M1
Bodenheimer, RE; Davis, T; Dawant, BM; Fang, J; Hedera, P; Li, R; Phibbs, F; Rao, AS1
Chen, Y; Hong, X; Liu, Z; Song, L; Wu, N; Yang, X; Yuan, W1
Bagetta, V; Calabresi, P; Del Papa, G; Gardoni, F; Ghiglieri, V; Giampà, C; Pendolino, V; Picconi, B; Sgobio, C; Tozzi, A; Zianni, E1
Arai, A; Baba, M; Kimura, T; Migita, K; Mori, F; Nishijima, H; Tomiyama, M; Ueno, S; Wakabayashi, K; Yamada, J1
Brotchie, JM; Fox, SH; Hill, MP; Huot, P; Johnston, TH; Koprich, JB; Snoeren, T1
Bezard, E; Dupouy, S; Galitzky, M; Li, Q; Marquine, L; Meissner, WG; Milhet, A; Nègre-Pagès, L; Ory-Magne, F; Rascol, O; Spampinato, U; Thiolat, ML; Thiollier, T; Tison, F1
Brotchie, JM; Fox, SH; Huot, P; Jarvie, K; Koprich, JB; Lang, AE; Seeman, P1
Fukushima, FB; Valle, AP; Vidal, EI; Villas Boas, PJ1
Barbon, A; Fiorentini, C; Missale, C; Savoia, P; Savoldi, D1
Chen, JF; Eberly, S; Kamp, C; Lang, AE; McDermott, MP; Messing, S; Oakes, D; Schwarzschild, MA; Tanner, CM; Tennis, M; Togasaki, D; Wills, AM1
Li, L; Zhou, FM1
Crossman, AR; Kobylecki, C; Ravenscroft, P1
Hashida, H; Hattori, N; Iijima, M; Kano, O; Kubo, S; Matsumura, M; Murakami, H; Nanri, K; Okuma, Y; Suzuki, M; Suzuki, Y; Tomimitsu, H; Utsumi, H1
Bordia, T; McIntosh, JM; Quik, M1
Hong, JY; Kim, KM; Lee, PH; Sohn, YH; Sunwoo, MK1
Berger, SP; Bhide, N; Bishop, C; Goldenberg, AA; Lindenbach, D; Paquette, MA; Surrena, MA1
Bezard, E; Björklund, A; Carta, M; Li, Q; Pioli, EY; Porras, G; Tronci, E1
Artuch, R; Cormand, B; Dinopoulos, A; Garzía-Cazorla, A; Orfanou, I; Ormazabal, A; Pons, R; Serrano, M; Syrengelas, D; Youroukos, S1
Gerhardt, GA; Lundblad, M; Nevalainen, N; Strömberg, I1
Antic, R; Rice, JE; Thompson, PD1
Björklund, A; Cenci, MA; Kirik, D; Winkler, C1
Calon, F; Di Paolo, T1
Cheetham, SC; Hansard, MJ; Jackson, MJ; Jenner, P; Smith, LA2
Coelho, C; Goberman, AM2
Collins, DR; Wanklyn, P1
Bonhomme, C; Braceras, R; Chezaubernard, C; Del Signore, S; Hansard, MJ; Jackson, MJ; Jenner, P; Rose, S; Smith, LA; Tel, BC1
Choe, GY; Choi, YL; Jeon, BS; Kim, JM; Lee, KH1
Cenci, MA3
Chase, TN; Oh, JD1
Verhagen Metman, L1
Andrén, PE; Gunne, L; Klintenberg, R; Svenningsson, P1
Katzenschlager, R; Lees, AJ1
Kondo, T1
Djaldetti, R; Melamed, E1
Ohye, C; Shibazaki, T1
Benabid, AL; Esselink, RJ; Moro, E; Pollak, P1
Bibbiani, F; Chase, TN; Oh, JD1
Bédard, PJ; Calon, F; Di Paolo, T; Grégoire, L; Grondin, R; Hadj Tahar, A1
Widner, H1
Blanchet, PJ; Chase, TN; Metman, LV1
Onofrj, M; Stocchi, F; Vacca, L1
Cannizzaro, C; Jenner, P; Pearce, RK; Rose, S; Tel, BC; Zeng, BY1
Brotchie, JM; Nicholson, SL1
Brotchie, J; Crossman, A; Fox, SH; Henry, B; Hill, M1
Kempster, PA; McColl, CD; Reardon, KA; Shiff, M1
Lees, AJ; Manson, AJ; Turner, K1
Al-Barghouthy, G; Jackson, M; Jenner, P; Kuoppamäki, M; Quinn, N; Smith, L; Zeng, BY1
Bonastre, M; Hirsch, EC; Marin, C; Périer, C; Tolosa, E1
Bonnet, AM; Houeto, JL1
Cannizzaro, C; Jackson, MJ; Jenner, P; Maratos, EC; Pearce, RK1
Gielen, SC; Horstink, MW; Keijsers, NL2
Cho, IS; Ha, JH; Im, JH; Lee, MC1
Lang, AE; Marras, C1
Zegers de Beyl, D1
Bernardini, S; Bonuccelli, U; Dell'Agnello, G; Gambaccini, G; Lucetti, C; Petrozzi, L; Rossi, G1
Bergamasco, B; Bosticco, E; Lanotte, M; Lopiano, L; Perozzo, P; Rizzone, M; Tavella, A; Torre, E1
Albin, RL; Frey, KA1
Gordin, A; Larsen, JP; Leinonen, M; Reinikainen, K; Sidén, A; Worm-Petersen, J1
Cenci, MA; Lundblad, M; Vaudano, E1
Bédard, PJ; Calon, F; Di Paolo, T; Hornykiewicz, O; Morissette, M; Rajput, AH1
Gerlach, M; Riederer, P1
Bernardi, G; Calabresi, P; Cenci, MA; Centonze, D; Fisone, G; Greengard, P; Håkansson, K; Picconi, B1
Gudín, M; Hernández, A; Ibáñez, R; Vaamonde, J1
Bordet, R; Destée, A1
Derkinderen, P; Vidailhet, M1
Brefel-Courbon, Ch; Ferreira, JJ; Montastruc, JL; Payoux, P; Rascol, O1
Dunnett, S1
Hansard, MJ; Jackson, MJ; Jenner, P; Maratos, E; Smith, LA1
Burke, MA; Fernandez, HH; Friedman, JH; Jacques, C; Trieschmann, ME1
Bakay, RA; Barnhart, H; Chockkan, V; DeLong, MR; Evatt, M; Freeman, A; Green, J; Haber, M; McDonald, W; Mewes, K; Triche, S; Vitek, JL; Wahlay, N; Zhang, JY1
Bézard, E; Boraud, T; Ferry, S; Gross, C; Leriche, L; Mach, U; Sokoloff, P; Stark, H1
Calandrella, D; Martignoni, E; Riboldazzi, G; Riva, N1
Brockmöller, J; Gasser, T; Grapengiesser, A; Hofer, A; Kaiser, R; Kupsch, A; Roots, I1
Love, R1
Brotchie, JM; Crossman, AR; Engstrom, M; Fox, SH; Hill, M; McGuire, SG; Merivuori, H; Savola, JM; Wurster, S1
Chassain, C; Durif, F; Eschalier, A1
Hauser, RA; Hubble, JP; Truong, DD1
Nakatsuka, A; Nomoto, M1
Barone, P1
Olanow, CW1
Asbrock, N; Ferrer, B; Giuffrida, A; Kathuria, S; Piomelli, D1
Cao, X; Sun, S; Xu, Y1
Iravani, MM; Jackson, MJ; Jenner, P; Kuoppamäki, M; Smith, LA1
Baron, MS; Dalton, WB1
Decamp, E; Gonczi, H; Schneider, JS1
Bédard, PJ; Grégoire, L; Samadi, P1
Ardouin, C; Batir, A; Benabid, AL; Benazzouz, A; Chabardes, S; Fraix, V; Koudsie, A; Krack, P; LeBas, JF; Limousin, PD; Pollak, P; Van Blercom, N1
Bibbiani, F; Castagnoli, N; Chase, TN; Chen, JF; Oh, JD; Petzer, JP; Schwarzschild, MA1
Chan, DK1
Standaert, DG1
Ongini, E1
Bastia, E; Chen, JF; Fredduzzi, S; Moratalla, R; Ongini, E; Schwarzschild, MA; Yu, L1
Aoyama, S; Bedard, P; Borrelli, E; Chase, TN; Hauser, RA; Ichimura, M; Ikeda, K; Ishii, A; Jenner, P; Kanda, T; Kase, H; Koga, K; Koike, N; Kurokawa, M; Kuwana, Y; Mori, A; Nakamura, J; Nonaka, H; Ochi, M; Richardson, PJ; Saki, M; Shimada, J; Shindou, T; Shiozaki, S; Suzuki, F; Takeda, M; Yanagawa, K1
Agid, Y; Bonnet, AM; Cornu, P; Duyckaerts, C; Hauw, JJ; Houeto, JL; Jarraya, B1
Bédard, PJ; Calon, F; Di Paolo, T; Hornykiewicz, O; Rajput, AH1
Brotchie, JM; Chalon, S; Crossman, AR; Ravenscroft, P1
Koller, WC; Tse, W1
LeWitt, PA; Nyholm, D1
Evans, A; Katzenschlager, R; Lees, AJ; Manson, AJ; Watt, H1
Krahn, M; Lang, A; Marras, C; Naglie, G; Tomlinson, G1
Argyriou, AA; Chroni, E; Ellul, J; Papapetropoulos, S1
Bezard, E; Brotchie, JM; Crossman, AR; Grimée, R; Hill, MP; Klitgaard, H; Michel, A1
Borg, M; Broussolle, E; Debilly, B; Durif, F; Galitzky, M; Morand, D; Rascol, O; Thobois, S; Viallet, F1
Calne, DB; de la Fuente-Fernández, R; Mak, E; Schulzer, M; Stoessl, AJ1
Foster, HD; Hoffer, A1
Kostić, VS1
Bédard, PJ; Bézard, E; Grondin, R; Gross, CE; Hadj Tahar, A1
Pagni, CA; Zeme, S; Zenga, F1
Burbaud, P; Coman, I; Cuny, E; Gin, H; Guehl, D; Macia, F; Perlemoine, C; Rigalleau, V; Tison, F1
Bédard, PJ; Bélanger, N; Darré, A; Grégoire, L; Hadj Tahar, A; Meltzer, L1
Swope, DM1
Ando, T; Itoh, M; Nakajima, T; Nimura, T; Shirane, R; Tominaga, T; Yamaguchi, K1
Lasa, A; Linazaroso, G; van Blercom, N1
Bonuccelli, U; Del Dotto, P1
Marciani, MG; Placidi, F; Romigi, A1
Di Paolo, T; Fenton, ME; Hornykiewicz, O; Pifl, C; Rajput, AH; Sitte, H1
Brotchie, J; Crossman, A; Davies, R; Fletcher, N; Fox, S; Kellett, M; Silverdale, M; Steiger, M1
Fellows, SJ; Noth, J1
Bain, PG; Carroll, CB1
Fisone, G; Håkansson, K; Lindskog, M; Pozzi, L; Usiello, A1
Cenci, MA; Lindgren, H; Lundblad, M; Picconi, B1
Brotchie, JM; Crossman, AR; McGuire, S; Menniti, FS; Nash, JE; Ravenscroft, P1
Bogousslavsky, J; Burkhard, PR; Combrement, P; Ghika, J; Russmann, H; Villemure, JG; Vingerhoets, FJ1
Linazasoro, G5
Hamani, C; Lozano, A; Toda, H1
Follett, KA1
Alterman, RL; Gudesblatt, M; Shils, JL; Tagliati, M1
Lo, TC; Thanvi, BR1
Calne, DB; de la Fuente-Fernández, R; Furtado, S; Huang, Z; Lu, JQ; Ruth, TJ; Sossi, V; Stoessl, AJ1
Battaglia, A; Bracco, F; Chouza, C; Dupont, E; Gershanik, O; Marti Masso, JF; Montastruc, JL1
Agid, Y; Albanese, A; Bonuccelli, U; Bonucelli, U; Damier, P; De Yebenes, J; Gershanik, O; Grandas, F; Guttman, M; Hallett, M; Hornykiewicz, O; Jenner, P; Katzenschlager, R; Langston, WJ; LeWitt, P; Melamed, E; Mena, MA; Michel, PP; Mizuno, Y; Mytilineou, C; Obeso, JA; Olanow, CW; Poewe, W; Quinn, N; Raisman-Vozari, R; Rajput, AH; Rascol, O; Sampaio, C; Stocchi, F1
Chapuis, S; Durif, F; Gerbaud, L; Metz, O; Ouchchane, L1
Filiano, JJ; Furukawa, Y; Kish, SJ1
Annesi, F; Annesi, G; Bellesi, M; Candiano, IC; Capecci, M; Carrideo, S; Ceravolo, MG; Civitelli, D; De Marco, EV; Iacoangeli, M; Passamonti, L; Provinciali, L; Quattrone, A; Ricciuti, R; Scerrati, M; Tarantino, P; Zappia, M1
Mizusawa, H; Nishina, K1
Carta, M; Cenci, MA; Dekundy, A; Eaton, ME; Konradi, C; Kuter, K; Lundblad, M; Westin, JE1
Al-Barghouthy, G; Jackson, MJ; Jenner, P; Kuoppamaki, M; Olanow, W; Rose, S; Smith, LA1
Aubert, I; Barthe, N; Bezard, E; Bioulac, BH; Bloch, B; Dovero, S; Fisone, G; Gross, CE; Guigoni, C; Håkansson, K; Li, Q1
Fukaya, C; Hashimoto, T; Itakura, T; Katayama, Y; Kobayashi, K; Tanaka, K; Yamamoto, T; Yokoyama, T1
Ahlskog, JE; Bower, JH; Kumar, N; Van Gerpen, JA1
Brotchie, JM; Crossman, AR; Nicholson, SL; Silverdale, MA1
Brotchie, JM; Lee, J; Venderova, K1
Braga-Neto, P; da Silva-Júnior, FP; Monte, FS; Nobre E Souza, MÂ; Sales de Bruin, VM1
Chang, S; Davis, M; Eunson, L; Graham, E; Horta, W; Johnson, JO; Khan, NL; Lees, AJ; Singleton, A; Wood, NW1
Brotchie, JM; Fox, SH; Gomez-Ramirez, J; Johnston, TH; Lee, J1
Björklund, A; Burger, C; Carlsson, T; Cenci, A; Kirik, D; Mandel, RJ; Muzyczka, N; Winkler, C1
Aquilonius, SM; Askmark, H; Constantinescu, R; Dizdar, N; Holmberg, B; Jansson, R; Nilsson Remahl, AI; Nyholm, D1
Alvarez, E; Alvarez, L; DeLong, MR; Guridi, J; Juncos, JL; Koller, W; Litvan, I; Lopez, G; Macias, R; Maragoto, C; Obeso, JA; Pavon, N; Rodriguez-Oroz, MC; Tolosa, ES; Vitek, J1
Aguilar, E; Bonastre, M; Marin, C; Obeso, JA; Tolosa, E1
Bernardi, G; Calabresi, P; Centonze, D; Pisani, A1
Di Monte, DA; Langston, JW; Protell, P; Quik, M; Tan, LC; Togasaki, DM1
Aubert, I; Bezard, E; Bioulac, BH; Bloch, B; Crossman, AR; Dovero, S; Gross, CE; Guigoni, C; Li, Q2
Ross, IN; Sharma, JC; Vassallo, M1
Gerlach, M; Reichmann, H; Riederer, P1
Kurlan, R1
Jech, R; Mecír, P; Roth, J; Růzicka, E; Urgosík, D; Vladyka, V; Vymazal, J1
De Reuck, J; De Weweire, M; Santens, P; Van Maele, G1
Metman, LV; O'Leary, ST1
Waters, C1
Widnell, K1
Jankovic, J2
Jankovic, J; Olanow, CW1
Di Rocco, A; Huang, N; Marinelli, L; Mazzella, L; Moshier, E; Yahr, MD1
Annesi, F; Annesi, G; Arabia, G; Carrideo, S; Cirò-Candiano, IC; Civitelli, D; De Marco, EV; Gambardella, A; Messina, D; Nicoletti, G; Pugliese, P; Quattrone, A; Spadafora, P; Tarantino, P; Zappia, M1
Bain, PG; Carroll, CB; Liu, X; Wang, SY; Zajicek, J1
Cook, R; Garrick, R; Halliday, GM; Huang, Y; Morris, J; O'Sullivan, D1
Aubert, I; Benovic, JL; Bezard, E; Bioulac, BH; Bloch, B; Ferry, S; Fisone, G; Gross, CE; Guigoni, C; Gurevich, EV; Gurevich, VV; Håkansson, K; Leriche, L; Li, Q; Mach, U; Sokoloff, P; Stark, H1
Baba, M; Kannari, K; Kimura, T; Maeda, T; Matsunaga, M; Tomiyama, M1
Brotchie, JM; Crossman, AR; Di Marzo, V; Fox, SH; Hill, M; Petrosino, S; van der Stelt, M1
Carta, M; Cenci, MA; Fisone, G; Håkansson, K; Lundblad, M; Usiello, A1
Barone, I; Bernardi, G; Bonsi, P; Calabresi, P; Centonze, D; Picconi, B; Pisani, A1
Subramanian, T; Tousi, B1
Bédard, PJ; Grégoire, L; Guidetti, P; Izzo, E; Rassoulpour, A; Samadi, P; Schwarcz, R1
Hauser, RA; Maldonado, JL; Sullivan, KL; Tatum, WO; Zesiewicz, TA1
Agid, Y; Albanese, A; Benabid, AL; Bonnet, AM; Contarino, MF; Fraix, V; Gironell, A; Guridi, J; Hariz, MI; Houeto, JL; Kulisevsky, J; Lang, AE; Lozano, AM; Molet, J; Obeso, JA; Pascual-Sedano, B; Pidoux, B; Pollak, P; Quinn, NP; Rehncrona, S; Rodriguez-Oroz, MC; Romito, L; Saint-Cyr, J; Scerrati, M; Speelman, JD; Van Blercom, N; Volkmann, J; Xie, J; Zamarbide, I1
Wedekind, S1
Brotchie, JM4
Brown, P; Di Lazzaro, V; Insola, A; Mazzone, P; Oliviero, A; Silberstein, P1
Bishop, C; Taylor, JL; Walker, PD1
Hurley, MJ; Jackson, MJ; Jenner, P; Rose, S; Smith, LA1
Brown, P; Di Lazzaro, V; Fogelson, N; Insola, A; Kühn, AA; Kupsch, A; Limousin, P; Mazzone, P; Pogosyan, A; Quartarone, A; Speelman, H; Tijssen, M; van Bruggen, G1
Aubert, I; Bezard, E; Bioulac, BH; Bloch, B; Dovero, S; Gross, CE; Guigoni, C; Gurevich, EV; Li, Q1
Agostino, R; Bagnato, S; Berardelli, A; Dinapoli, L; Modugno, N1
Bédard, PJ; Calon, F; Di Paolo, T; Dridi, M; Hadj Tahar, A; Meltzer, LT; Morissette, M2
Martín, AB; Mendialdua, A; Moratalla, R; Pavón, N1
Braga-Neto, P; da Silva-Júnior, FP; de Bruin, VM; Sueli Monte, F1
Hedrich, K; Kann, M; Kis, B; Klein, C; Kömpf, D; Pramstaller, PP; Schwinger, E1
Al-Bargouthy, G; Costa, S; Iravani, MM; Jackson, MJ; Jenner, P; Kuoppamäki, M; Obeso, JA; Zeng, BY1
Bédard, PJ; Bélanger, N; Di Paolo, T; Grégoire, L1
Benabid, AL; Berger, F; Buggia, V; Gilbert, F; Lévesque, D; Sgambato-Faure, V1
Kitagawa, M; Tashiro, K1
Borek, LL; Friedman, JH1
Ransmayr, G1
Brotchie, JM; Fox, SH; Johnston, TH1
Dunnett, SB; Monville, C; Torres, EM1
Goto, S; Kaji, R; Kuratsu, J; Yamada, K1
Caroff, SN; Duda, JE; Eisa, M; Gallop, R; Kleiner-Fisman, G; Lorry, A; Martine, R; Stern, MB1
Bontempi, S; Busi, C; Collo, G; Fiorentini, C; Missale, C; Rizzetti, MC; Spano, P1
Ludolph, A; Odin, P; Oehlwein, C; Polzer, U; Renner, R; Schüler, P; Shing, M; Storch, A; Werner, G1
Brundin, P; Cenci, MA; Lane, EL; Winkler, C1
Dalvi, A; Gartner, M; Gong, J; Revilla, FJ; Sahay, A; Samaha, FJ; Strong, JA; Welge, JA; Yu, L; Yue, X1
Bédard, PJ; Berthiaume, L; Calon, F; Di Paolo, T; Hadj-Tahar, A; Julien, C; Julien, P; Rajput, AH1
Cannas, A; Floris, G; Solla, P; Tacconi, P1
Chen, R; Espay, AJ; Gunraj, C; Lang, AE; Morgante, F1
Adams, J; de la Fuente-Fernández, R; Schulzer, M; Sossi, V; Stoessl, J1
Ahlskog, JE; Bower, JH; Kumar, N; Van Gerpen, JA; Weigand, S1
Carta, M; Cenci, MA; Fadda, F; Lindgren, HS; Lundblad, M; Stancampiano, R1
Apaydin, H; Benbir, G; Delil, S; Erginöz, E; Ozekmekçi, S1
Morelli, M; Pinna, A; Pontis, S1
Konitsiotis, S; Tsironis, C1
Duval, C; Edwards, R; Ghassemi, M; Jog, M; Lemieux, S2
Alegre, M; Alonso-Frech, F; Artieda, J; Guridi, J; Manrique, M; Obeso, JA; Rodríguez-Oroz, MC; Valencia, M; Zamarbide, I1
Kulkantrakorn, K; Pongchaiyakul, C; Pulkes, T; Tiamkao, S1
Aksu, M; Bara-Jimenez, W; Chase, TN; Dimitrova, TD; Sherzai, A1
Hatano, T; Hattori, N; Izawa, N; Kagohashi, M; Mizuno, Y; Mochizuki, H; Mori, H; Nishioka, K; Sato, K; Yamashiro, K1
Bishop, C; Eskow, KL; Kuhn, DM; Park, JY; Taylor, JL; Walker, PD1
Corvol, JC; Girault, JA; Hervé, D1
Obeso, JA; Olanow, CW; Stocchi, F2
Bernardi, G; Brusa, L; Centonze, D; Iani, C; Koch, G; Stanzione, P; Versace, V1
Fukaya, C; Kano, T; Katayama, Y; Kobayashi, K; Oshima, H; Yamamoto, T1
Bédard, PJ; Rouillard, C; Samadi, P1
Chung, EJ; Ki, CS; Kim, IS; Kim, JY; Lee, WY1
Carminati, P; Jackson, MJ; Jenner, P; Johnson, L; Rose, S; Smith, LA; Stockwell, K1
Hasoon, M; Macnamara, L; Ross, I; Sharma, JC; Vassallo, M1
Carta, AR; Morelli, M; Pinna, A1
Cenci, MA; Lundblad, M2
Abdalla, M; Brooks, DJ; Clarke, CE; De Deyn, PP; Korczyn, AD; Lang, AE; Rascol, O1
Chu, WB; Iravani, MM; Jackson, MJ; Jenner, P; Tayarani-Binazir, K1
Brotchie, JM; Fox, SH; Gomez-Ramirez, J; Johnston, TH; Pires, D; Visanji, NP; Voon, V1
Brundin, P; Cenci, MA; Gardi, J; Lindgren, HS; Mohapel, P; Nyengaard, JR; Westin, JE1
Hauser, RA1
Evans, AH; Katzenschlager, R; Lees, AJ; Silveira-Moriyama, L1
Aljanati, R; Buzó, R; Chouza, C; de Medina, O; Dieguez, E; Gomensoro, J; Lisanti, N; Romero, S; Scaramelli, A1
Clissold, BG; Kempster, PA; McColl, CD; Reardon, KR; Shiff, M1
Cohen, HS; Gracies, JM; MacDougall, HG; Moore, ST; Ondo, WG1
Alves, R; Barbosa, E; Scaff, M1
Di Rocco, A; Nasser, S; Werner, P1
Ba, M; Chen, S; Kong, M; Liu, Z; Lu, G; Ma, G; Yang, H1
Al-Barghouthy, G; Jackson, MJ; Jenner, P; Rose, S; Smith, LA1
Avila, I; Bibbiani, F; Chase, TN; Collins, MA; Oh, JD; Smith, CP1
Chaná C, P; Juri C, C1
Mash, DC; Papapetropoulos, S1
Barker, RA; Kuan, WL; Lin, R; Tyers, P1
Agid, Y; Blau, N; Remy, P; Ribeiro, MJ; Saudubray, JM; Sedel, F1
Bastia, E; Benn, CL; Cha, JH; Chen, JF; Peterson, TS; Schwarzschild, MA; Xiao, D; Xu, YH1
Harn, HJ; Lin, JJ; Lin, SZ; Liu, JT; Yueh, KC1
Cao, X; Chen, Z; Guan, Q; Sun, S; Wang, L; Xu, Y1
Bartalucci, A; Biagioni, F; Ferrucci, M; Fornai, F; Fulceri, F; Galli, V; Lazzeri, G; Paparelli, A; Ruggieri, S1
Enokizono, J; Hagihara, K; Iida, K; Kashima, H; Kurokawa, M; Nonaka, H; Shimada, J; Uchida, S1
Ludin, HP; Surber, Ch1
Cenci, MA; Danysz, W; Dekundy, A; Lundblad, M1
Angel, MJ; Chen, R; Enjati, M; Gunraj, C; Lang, AE; Wagle-Shukla, A; Zadikoff, C1
Chen, L; Cox, H; Di Monte, DA; Langston, JW; Quik, M; Togasaki, DM1
Bezard, E; Bloch, B; Doudnikoff, E; Guigoni, C; Li, Q1
Carlson, NE; Carter, JH; Nutt, JG1
Grandas, F; Hernández, B1
Cenci, MA; Danysz, W; Dekundy, A; Marti, M; Mela, F; Morari, M1
Fiddian-Green, RG1
Tetrud, JW1
Brotchie, JM; Fabbrini, G; Goetz, CG; Grandas, F; Nomoto, M1
Al-Barghouthy, G; Jackson, MJ; Jenner, P; Kuoppamäki, M; Quinn, N; Smith, LA1
Björklund, A; Carlsson, T; Carta, M; Kirik, D1
Ding, Y; Hwang, DY; Kang, UJ; Kim, KS; Restrepo, J; Won, L1
Cenci, MA; Danysz, W; Dekundy, A; James, P; Krogh, M; Lundblad, M; Quack, G; Valastro, B1
Lo, N; Robinson, T; Thanvi, B1
Chen, J; Ma, L; Wang, F; Zhang, H; Zhen, X1
Choi, JK; Iris Chen, YC; Isacson, O; Jenkins, BG; Sánchez-Pernaute, R1
Borgkvist, A; Carta, M; Fisone, G; Girault, JA; Greengard, P; Hervé, D; Santini, E; Usiello, A; Valjent, E1
Karamanakos, PN; Marselos, M; Pappas, P1
Hurley, MJ; Jackson, MJ; Jenner, P; Patel, PH; Rose, S; Smith, LA1
Hauser, RA; Sullivan, KL; Zesiewicz, TA1
Cao, X; Factor, S; Greenamyre, JT; Griffith, DA; Hadcock, JR; Iredale, PA; Liang, L; Menniti, FS; Papa, SM1
Jankovic, J; Stacy, M1
Björklund, A; Carlsson, T; Carta, M; Kirik, D; Winkler, C1
Belknap, JK; Johnson, SW; Kozell, LB; Munhall, AC; Putterman, DB1
Cenci, MA; Konradi, C; Strome, EM; Vercammen, L; Westin, JE1
Duval, C; Edwards, R; Ghassemi, M; Gour, J; Jog, M; Lemieux, S1
Calon, F; Di Paolo, T; Morelli, M; Schwarzschild, MA; Wardas, J; Xiao, D1
Bédard, PJ; Di Paolo, T; Grégoire, L; Guidetti, P; Izzo, E; Rassoulpour, A; Samadi, P; Schwarcz, R1
Hauser, RA; Schapira, AH; Simonson, W1
Guan, Q; He, Y; Tan, L; Zhan, Q1
di Poggio, AB; Fornai, F; Paparelli, A; Pellegrini, A; Ruggieri, S1
Dunnett, S; Lane, E1
Cassano, T; Cuomo, V; Giuffrida, A; Morgese, MG1
Armentero, MT; Bazzini, E; Blandini, F; Levandis, G; Nappi, G1
Jackson, MJ; Jenner, P; Olanow, W; Rose, S; Smith, LA; Stockwell, KA; Tayarani-Binazir, K; Zubair, M1
Tse, W1
Chang, LJ; Furukawa, Y; Guttman, M; Hornykiewicz, O; Kish, SJ; Rajput, A; Tong, J1
Cox, H; Di Monte, D; Langston, JW; O'Leary, K; Parameswaran, N; Quik, M1
Liou, HH; Liu, HM; Su, PC; Tseng, HM; Yen, RF1
Bédard, PJ; Belanger, N; Calon, F; Di Paolo, T; Dridi, M; Hadj Tahar, A; Meltzer, LT; Morissette, M; Samadi, P1
Angela Cenci, M; Bagetta, V; Barone, I; Bernardi, G; Calabresi, P; Ghiglieri, V; Lindgren, HS; Paillé, V; Picconi, B1
Brown, P; Eusebio, A1
Bédard, PJ; Bélanger, N; Calon, F; Di Paolo, T; Dridi, M; Grégoire, L; Hadj Tahar, A; Morissette, M; Samadi, P1
Haeger, DA; Hock, K; Mueller, T; Russ, H; Woitalla, D1
Duval, C; Fenney, A; Jog, MS1
Baláz, M; Pulkrábek, J; Rektor, I1
Barker, RA; Kuan, WL; Zhao, JW1
Jeon, BS; Kim, DG; Kim, HJ; Kim, JY; Lee, JY; Paek, SH1
Alvarez-Erviti, L; Barroso-Chinea, P; Blesa, FJ; Guridi, J; Lanciego, JL; Obeso, JA; Rodríguez-Oroz, MC; Smith, Y1
Agid, Y; Brice, A; Durr, A; Fraix, V; Houeto, JL; Krack, P; Laine, S; Lesage, S; Lohmann, E; Mesnage, V; Pollak, P; Tanguy, ML; Welter, ML1
Brotchie, JM; Gomez-Ramirez, J; Johnston, TH; Lee, J; Visanji, N1
Alm, H; Andrén, PE; Bezard, E; Crossman, AR; Doudnikoff, E; Fälth, M; Guigoni, C; Kultima, K; Li, Q; Scholz, B; Sköld, K; Svensson, M1
Berger, SP; Brudney, EG; Johnson, SW; Meshul, CK; Paquette, MA; Putterman, DB1
Cenci, MA; Lindgren, HS1
Brooks, D; Rascol, O; Ross, IN; Sharma, JC1
Gardoni, F1
Guridi, J; Lozano, AA; Manrique, M; Obeso, JA; Rodriguez-Oroz, MC1
Bezard, E; Brotchie, JM; Fox, SH; Hallett, PJ; Lubin, FD; Nicholas, AP; Ravenscroft, P; Standaert, DG; Sweatt, JD; Vattem, P; Zhou, S1
Clarke, C; Ferreira, J; Gray, R; Hawker, RJ; Ives, NJ; Shah, L; Stowe, RL; van Hilten, J; Wheatley, K1
Evangelou, A; Konitsiotis, S; Marselos, M; Tsironis, C1
Encarnacion, EV; Hauser, RA1
Horstink, MW1
Lakke, JP; Staal-Schreinemachers, A; van Weerden, TW1
Bjørndal, N; Casey, D; Gerlach, J1
Itoh, H1
Bathien, N; Koutlidis, RM; Rondot, P1
Lloyd, KG; Worms, P1
Jeste, DV; Wyatt, RJ2
Hunter, KR1
Rosal-Greif, VL1
Weiner, M1
Ananth, J1
Hellemans, J; Hens, L1
Bjørndal, N; Casey, DE; Gerlach, J1
Alpert, M; Diamond, F; Friedhoff, AJ1
Shoulson, I1
Hardie, RJ; Lees, AJ; Stern, GM1
Jeste, DV; Karson, CN; LeWitt, PA; Wyatt, RJ1
Carvey, P; Goetz, CG; Klawans, HL1
Casey, DE; Gerlach, J1
Bitton, V; Melamed, E1
Andrade, LA; Bertolucci, PH; Pereira, JS1
Still, CN1
Yung, CY1
Bartholini, G2
Mejer Nielsen, B1
Giampietro, AC; Karniol, IG; Moura, DS; Oliveira, MA; Vilela, WA; Zuardi, AW1
Nakajima, Y; Narabayashi, H; Yokochi, F1
Coffey, CE; Massey, EW; Olanow, CW; Ross, DR1
Blair, RD; Lang, AE1
Ludin, HP1
Koga, I; Nishikawa, T; Tanaka, M; Tsuda, A; Uchida, Y1
Burns, R1
Morris, JG2
Katsuki, T; Mizuno, Y; Shimizu, N1
Mutani, R; Sechi, GP; Tanda, F1
Klawans, HL2
Reilly, DK; Rivera-Calimlim, L1
Jacob, RG; Szekely, BC; Turner, SM1
Matsumoto, Y; Miyamoto, T; Nakamura, S; Ohmoto, T1
Kucharski, LT; Unterwald, EM1
Agnoli, A; Baldassarre, M; Bocola, V; Del Roscio, S; Denaro, A; Ruggieri, S1
Broekkamp, CL1
Hirayama, K; Yamada, T1
Parkes, JD1
Haas, JA; Lakke, JP1
Ando, K; Mano, Y; Muramoto, O; Riku, S1
Calne, DB1
Meerwaldt, JD; Staal, A1
Calne, DB; Karson, CN; LeWitt, PA; Wyatt, RJ1
Goetz, CG; Klawans, HL; Koller, WC; Nausieda, PA; Perlik, S; Weiner, WJ1
Carvey, P; Goetz, CG; Klawans, HL; Nausieda, PA; Weiner, WJ1
Bergsrud, D; Elton, RL; Racy, A; Teychenne, PF; Vern, B1
Gil Núñez, A; Giménez-Roldán, S; Mateo, D1
Korein, J1
McKenna, P; Pratt, RT; Stern, GM; Ward, C1
Lees, AJ; Shaw, KM; Stern, GM2
Dostrovsky, JO; Duff, J; Galvez-Jimenez, N; Hutchinson, WD; Lang, AE; Lozano, AM; Miyasaki, J1
Agid, Y; Blin, J; Bonnet, AM; Durif, F; Vidailhet, M1
Cardoso, F1
Kempster, PA; Shif, M1
Lunn, V; Northcott, C; Yatham, LN1
Brown, LK1
Winn, P1
Bédard, PJ; Blanchet, PJ; Calon, F; Di Paolo, T; Goulet, M; Martel, JC; Piercey, MF1
Crossman, AR; Page, RD; Sambrook, MA1
Hamamoto, M; Ishikura, N; Miyazaki, T; Ohtsubo, K1
Kaur, S; Starr, BS; Starr, MS1
Bédard, PJ; Blanchet, P; Britton, DR; Kebabian, JW1
Chouinard, G; Miller, R1
Caligiuri, MP1
Arnold, G; Oertel, WH; Schwarz, J; Trenkwalder, C1
Radwany, SM; Rich, MW1
Agid, Y; Bonnet, AM; Gouider-Khouja, N; Marconi, R; Vidailhet, M1
Bédard, PJ; Blanchet, PJ; Boucher, R1
Bennett, JP; Dietrich, S; Landow, ER; Schuh, LA1
Ané, M; Blin, O; Fabre, N; Montastruc, JL; Poulik, J; Rascol, A; Rascol, O; Sabatini, U; Senard, JM1
Imai, T; Nakamura, Y; Ogawa, N; Tachibana, H; Takahashi, M; Yorifuji, S; Yuasa, R1
Nutt, JG4
Bennett, JP; Landow, ER; Schuh, LA1
Koller, WC; Pahwa, R1
Kondo, T; Mizuno, Y; Mori, H1
Martí, MJ; Tolosa, ES; Valldeoriola, F1
Poewe, WH1
Montastruc, JL; Rascol, A; Rascol, O; Senard, JM1
Bédard, PJ; Blanchette, P; DiPaolo, T; Falardeau, P; Gagnon, C; Gomez-Mancilla, B1
Bravi, D; Chase, TN; Davis, TL; Mouradian, MM1
Poewe, W; Schelosky, L1
Bédard, PJ; Gomez-Mancilla, B3
Caligiuri, MP; Peterson, S1
Agid, Y; Bonnet, AM; Dubois, B; Lefebvre-Caparros, D; Marconi, R; Vidailhet, M1
Mendis, L1
Bonifati, V; Cipriani, R; Fabrizio, E; Meco, G; Vanacore, N1
Deffond, D; Dordain, G; Durif, F; Tournilhac, M1
Lang, AE; Mark, MH; Sage, JI; Zimmerman, TR1
Kurisaki, H; Mizuno, T1
Poewe, W1
Akiguchi, I; Nakamura, S1
Lang, AE; Riley, DE1
Chase, TN; Dambrosia, JM; Peppe, A1
Gash, DM; Kurlan, R; McDermott, M; Smith, RD; Zhang, Z1
Blond, S; Caparros-Lefebvre, D; Guieu, JD; Pécheux, N; Petit, H; Vermersch, P1
Carter, JH; Gancher, ST; Hammerstad, JP; Nutt, JG; Woodward, W1
Kabel, JF; Kerkhof, GA; Kramer, CG; Middelkoop, HA; Roos, RA; van Hilten, JJ1
Caligiuri, MP; Lohr, JB1
Agid, Y; Bonnet, AM; Dubois, B; Marconi, R; Serre, I1
Eichhorn, TE; Kohnen, R; Oertel, WH; Poewe, W; Schrag, A; Selzer, R; Trenkwalder, C1
Di Rocco, A; Kollmeier, B; Molinari, SP; Yahr, MD1
Holford, NH; Nutt, JG1
Chase, TN; Papa, SM1
Narabayashi, H3
Facca, A; Sanchez-Ramos, J1
Andrade, LA; Borges, V; Ferraz, HB; Rocha, MS1
Hirato, M; Horikoshi, S; Ishihara, J; Ohye, C; Shibazaki, T1
Iacono, RP; Kuniyoshi, S; Lonser, RR; Maeda, G; Mandybur, G; Warner, D; Yamada, S1
Jackson, M; Jenner, P; Marsden, CD; Pearce, RK; Smith, L1
Bédard, PJ; Blanchet, PJ; Grondin, R1
Goto, I; Kanazawa, I; Kowa, H; Kuno, S; Mizuno, Y; Ogawa, N; Tashiro, K; Yanagisawa, N2
Giron, LT; Koller, WC1
Blümner, E; Danielczyk, W; Gerlach, M; Kaiser, HJ; Kraus, PH; Letzel, H; Przuntek, H; Riederer, P; Uberla, K; Welzel, D1
Gerlach, M; Klotz, P; Kuhn, W; Müller, T; Przuntek, H1
Brotchie, JM; Henry, B1
Arai, N; Isaji, M; Kojima, M; Kuno, S; Mizuta, E1
Gachoud, JP; Gasser, U; Ghika, J1
Chase, TN; Mouradian, MM1
Kołodziejczyk, K; Maj, J; Rogóz, Z; Skuza, G1
Emerich, DF; Francis, JM; Lindner, MD; Plone, MA1
Hariz, MI1
Alterman, RL; Beric, A; Eidelberg, D; Fazzini, E; Kelly, P; Perrine, K; Sterio, D1
Dostrovsky, JO; Gross, RE; Hutchison, WD; Lang, AE; Lozano, AM; Tasker, RR1
Bédard, PJ; Britton, DR; Grondin, R; Shiosaki, K1
Grandas, F; López-Ariztegui, N1
Jiménez-Jiménez, FJ; Molina, JA1
Bioulac, B; Boraud, T; Gross, C; Guehl, D; Julien, J; Rougier, A1
Albani, F; Baruzzi, A; Contin, M; Martinelli, P; Riva, R1
Barbato, L; Berardelli, A; Bonamartini, A; Manfredi, M; Patsalos, PN; Ruggieri, S; Stocchi, F1
Tolosa, E; Valldeoriola, F1
Marsden, CD2
Endo, S; Hikiji, A; Nakamura, Y; Yoshinaga, J1
Bosch, DA; de Bie, RM; Schuurman, PR; Speelman, JD1
Brooks, DJ; Piccini, P; Weeks, RA1
Busenbark, K; Hubble, J; Koller, WC; Lyons, K; McGuire, D; Michalek, D; Miyawaki, E; Pahwa, R; Smith, D; Tröster, AI1
Oertel, WH; Quinn, NP1
Alessandri, A; Bonifati, V; Fabrizio, E; Meco, G; Vanacore, N1
Bassi, A; Bernardi, G; Mazzone, P; Stanzione, P; Stefani, A; Vangelista, T1
Banerji, T; Jenner, P; Marsden, CD; Pearce, RK1
Mark, MH; Murphy, J; Sage, JI; Syed, N; Zimmerman, T1
Branston, NM; Brooks, DJ; Caputo, E; Lees, AJ; Marsden, CD; Quinn, NP; Rothwell, JC; Samuel, M; Scaravilli, T; Schrag, A; Thomas, DG1
Benabid, AL; Benazzouz, A; Hoffmann, D; Krack, P; Limousin, P; Pollak, P; Xie, J1
Brefel, C; Celsis, P; Chollet, F; Fabre, N; Montastruc, JL; Rai, S; Rascol, O; Sabatini, U; Senard, JM; Viallard, G1
de la Fuente-Fernández, R1
Seeman, P; Tallerico, T1
Kulisevsky, J1
Chase, TN1
Baas, H; Beiske, AG; Ghika, J; Jackson, M; Oertel, WH; Poewe, W; Ransmayr, G1
Chase, TN; Del Dotto, P; Fang, J; Mouradian, MM; van den Munckhof, P; Verhagen Metman, L1
Colzi, A; Lees, AJ; Turner, K1
Adipietro, A; Fattapposta, F; Pierelli, F; Pozzessere, G; Scoppetta, C; Soldati, G1
Brotchie, JM; Crossman, AR; Henry, B2
Koller, WC; Tolosa, E1
Capildeo, R1
Chase, TN; Del Dotto, P; Natté, R; van den Munckhof, P; Verhagen Metman, L1
Benabid, AL; Benazzouz, A; Hoffmann, D; Krack, P; Limousin, P; Pollak, P1
Blasko, J; Burkhart, WA; Goiney, RC; Grimm, P; Posewitz, A; Shumway-Cook, A; Vermeulen, SS; Young, RF1
Horstink, MW; Praamstra, P1
Harper, J; Vieira, B1
Wills, AJ1
Chouinard, G; Looper, KJ1
Black, KJ; Carl, JL; Hershey, T; McGee-Minnich, LA; Perlmutter, JS; Stambuk, MK1
Blanchet, PJ; Chase, TN; Konitsiotis, S1
Galvez-Jimenez, N; Kumar, R; Lang, AE; Rajput, A; Rajput, AH; Uitti, RJ1
Björklund, A; Cenci, MA; Lee, CS1
Ardouin, C; Benabid, AL; Benazzouz, A; Hoffmann, D; Krack, P; Limousin, P; Pollak, P1
Onofrj, M; Paci, C; Thomas, A2
Rinne, UK; Ruottinen, HM1
Standaert, D1
Ben-Shlomo, Y; Brown, R; Marsden, CD; Quinn, N; Schrag, A1
Dillon, LC; Hoffman, M; Hughes, AJ; O'Sullivan, JD; Said, CM1
Agid, Y; Arnulf, I; Bejjani, BP; Bonnet, AM; Cornu, P; Damier, P; Dormont, D; Marsault, C; Papadopoulos, S; Pidoux, B; Vidailhet, M1
Bassi, A; Bernardi, G; Mazzone, P; Peppe, A; Pierantozzi, M; Stanzione, P; Stefani, A1
Castro García, A; Sesar Ignacio, A1
Giladi, N; Melamed, E1
Agid, Y; Debilly, B; Durif, F; Vidailhet, M1
Bédard, PJ; Hadj Tahar, A1
Broussolle, E1
Britton, DR; Jackson, M; Jenner, P; Marsden, CD; Pearce, RK; Shiosaki, K1
Djaldetti, R; Melamed, E; Merims, D; Ziv, I1
Klockgether, T; Löschmann, PA; Spieker, S1
Caparros-Lefebvre, D; Lannuzel, A; Strobel, M; Tiberghien, F1
Benabid, AL; Benazzouz, A; Deuschl, G; Krack, P; Limousin, P; Pollak, P1
Tedroff, JM1
Marin, C; Tolosa, E1
Brefel-Courbon, C; Descombes, S; Montastruc, JL; Rascol, O1
Grossman, R; Jankovic, J; Krauss, J; Lai, EC1
Damier, P1
Carlson, JD; Iacono, RP; Kuniyoshi, SM; Mohamed, AS1
Sunohara, N1
Benabid, AL; Blond, S; Caparros-Lefebvre, D; Feltin, MP; Pollak, P2
King, DB1
Blanchet, PJ; Chase, TN; Konitsiotis, S; Whittemore, ER; Woodward, RM; Zhou, ZL1
Vale, S1
Agid, Y; Bonnet, AM; Durif, F; Marconi, R; Vidailhet, M1
Bédard, PJ; Blanchet, PJ; Calon, F; DiPaolo, T; Doucet, JP; Falardeau, P; Gomez-Mancilla, B; Goulet, M; Grondin, R; Lévesque, D; Morissette, M; Robertson, GS; Soghomonian, JJ1
Goetz, CG1
Pearce, RK1
Agid, Y; Arnulf, I; Bejjani, BP; Bonnet, AM; Clavier, I; Damier, P; Jaillon, C1
Defer, GL; Widner, H1
Nutt, J1
Giduz, T; Pact, V1
Ben-Arie, L; Grossman, R; Jankovic, J; Krauss, JK; Lai, E1
Aguglia, U; Andreoli, V; Annesi, G; Branca, D; Cittadella, R; Civitelli, D; Gambardella, A; Montesanti, R; Nicoletti, G; Oliveri, RL; Pasqua, AA; Quattrone, A; Spadafora, P; Zappia, M1
Andringa, G; Cools, AR; Stoof, JC1
Desimone, R; Fiorani, M; Oldfield, EH; Papa, SM1
Chase, TN; Del Dotto, P; Fang, J; Konitsiotis, S; LePoole, K; Metman, LV1
Gottwald, MD1
Ahlskog, JE2
Anderson, VC; Burchiel, KJ; Favre, J; Hammerstad, JP1
Finken, MJ; Ramaker, C; van de Beek, WJ; van Hilten, BJ1
Asselman, P; Brown, P; Buckwell, D; Lees, AJ; Manson, AJ; O'Sullivan, JD1
Galiano, ML; Grandas, F; Tabernero, C1
Guridi, J; Linazasoro, G; Obeso, JA; Ramos, E; Rodriguez-Oroz, MC1
Ben-Aire, L; Contant, C; Grossman, R; Jankovic, J; Lai, E; Ondo, WG1
Bédard, PJ; Doan, VD; Grondin, R; Hadj Tahar, A; Ladure, P1
Shulman, LM1
Weiner, WJ2
Jackson, MJ; Jenner, P; Kanda, T; Kase, H; Kuwana, Y; Nakamura, J; Pearce, RK; Smith, LA1
Damier, P; Féger, J; Hirsch, EC; Tremblay, L1
Iakovidou, E; Lees, AJ; Manson, AJ1
Chin, S; Dhawan, V; Eidelberg, D; Fahn, S; Frucht, S1
Kumar, R; Lang, AE; Lozano, AM; Saint-Cyr, JA; Trépanier, LL1
Ferrer, E; Molinuevo, JL; Nobbe, FA; Rumià, J; Tolosa, E; Valldeoriola, F1
Agid, Y; Arnulf, I; Bejjani, BP; Bonnet, AM; Cornu, P; Damier, P; Dormont, D; Marsault, C; Philippon, J; Pidoux, B; Yelnik, J1
Sealfon, SC1
DeLong, MR; Obeso, JA; Olanow, CW; Rodriguez, M; Rodriguez-Oroz, MC1
Filion, M1
Canales, JJ; Graybiel, AM1
Bernardi, G; Calabresi, P; Centonze, D; Giacomini, P1
Bédard, PJ; Blanchet, PJ; Calon, F; Di Paolo, T; Goulet, M; Grondin, R; Morissette, M1
Di Monte, DA; Jakowec, M; Langston, JW; Petzinger, G; Quik, M1
Hirsch, EC1
Hallett, M1
Brooks, DJ; Piccini, P; Samuel, M; Turjanski, N1
Obeso, JA; Olanow, CW1
Benabid, AL; Benazzouz, A; Koudsie, A; Krack, P; Limousin, P; Piallat, B; Pollak, P1
Lang, AE1
Jenner, P; MacKenzie, GM; Pearce, RK; Zeng, BY2
Blanchet, PJ; Chase, TN; Konitsiotis, S; Lamers, E; Verhagen, L1
Iacono, RP; Nahab, FB; Nahab, FH1
Andringa, G; Cools, AR; Drukarch, B; Lubbers, L; Stoof, JC1
Clarke C, E; Speller J, M2
Finken, MJ; Ramaker, C; Van de Beek, WJ; van Hilten, JJ1
Clarke, CE; Speller, JM2
Agid, Y; Arnulf, I; Bejjani, BP; Bonnet, AM; Damier, P; Demeret, S; Houeto, JL1
Brooks, DJ; Clarke, CE; De Deyn, PP; Korczyn, AD; Lang, AE; Rascol, O1
Di Monte, DA; Janson, AM; Langston, WJ; McCormack, A; Petzinger, G; Quik, M1
Blasucci, LM; Goetz, CG; Stebbins, GT1
Stoessl, AJ; Van Kampen, JM1
Björklund, A; Cenci, MA; Lee, CS; Schulzer, M1
Bangassoro, E; Bédard, PJ; Bélanger, N; Grégoire, L; Hadj Tahar, A1
Ferrer, E; Molinuevo, JL; Roldan, H; Rumia, J; Tolosa, E; Valldeoriola, F; Valls-Sole, J1
Becker, G; Berg, D; Reiners, K1
Busek, P; Jech, R; Roth, J; Růzicka, E1
Lees, AJ; Manson, AJ; Schrag, A1
Earnhart, M; Hiner, BC1
Frucht, S1
Yamamoto, T1
Factor, SA; Weiner, WJ1
Jenner, P; Smith, LA; Treseder, SA1
Bösch, S; Luginger, E; Poewe, W; Wenning, GK1
Emre, M; Hanağasi, HA; Kaptanoglu, G; Sahin, HA1
Nomoto, M1
Fung, VS; Hely, MA; Morris, JG1
Quinn, N; Schrag, A1
Cersósimo, MG; Micheli, FE; Scorticati, MC1
Nutt, JG; Obeso, JA; Olanow, CW1
Artieda, J; Gonzalo, N; Lanciego, JL; Obeso, JA; Olanow, CW; Rodríguez, M; Rodríguez-Oroz, MC1
Bernardi, G; Calabresi, P; Centonze, D1
Canales, JJ; Capper-Loup, C; Graybiel, AM1
Brooks, DJ1
Bédard, PJ; Blanchet, PJ; Calon, F; Di Paolo, T; Doucet, JP; Goulet, M; Grondin, R; Hadj Tahar, A; Morissette, M; Nestler, E; Robertson, GS1
Nutt, JG; Obeso, JA; Stocchi, F1
Olanow, W; Rascol, O; Schapira, AH1
Kanazawa, I; Momose, Y; Murata, M1
Saiki, H; Takeuchi, J; Yamagami, T1
Katayama, Y1
Itakura, T; Nakao, N; Uematsu, Y1
Kuno, S1
Namba, H; Sugiyama, K; Yokoyama, T1
Balakrishnan, S; Joseph, S; Kishore, A; Panikar, D; Sarma, S1
Gielen, CC; Hoff, JI; Horstink, MW; Keijsers, NL; van Hilten, JJ1
Benabid, AL; Fraix, V; Koudsie, A; Krack, P; Pollak, P; Van Blercom, N; Xie, J2
Lachenmayer, L; Reichmann, H1
Bangassoro, E; Bédard, PJ; Ekesbo, A; Grégoire, L; Hadj Tahar, A; Svensson, KA; Tedroff, J1
Cannizzaro, C; Costa, S; Iravani, MM; Jackson, MJ; Jenner, P; Pearce, RK; Tel, BC1
Blin, O; Carter, JH; Currie, LJ; Fabre, N; Giardina, WW; Goetz, CG; Nutt, JG; Rascol, O; Soubrouillard, C; Thalamas, C; Trugman, JM; Wright, S1
Baas, H1
Hoff, JI; van den Plas, AA; van Hilten, JJ; Wagemans, EA1
Hobart, J; Katzenschlager, R; Lees, AJ; Manson, AJ1
Clarke, CE; Deane, KH1
Clarke, CE; Deane, KD1
Ashby, P; Dostrovsky, JO; Levy, R; Tasker, RR; Wu, YR1
Andersson, KE; Andersson, M; Cenci, MA; Johansson, PA1
Ahlskog, JE; Muenter, MD1
Bernardini, S; Bonuccelli, U; Chase, TN; Del Dotto, P; Gambaccini, G; Metman, LV; Pavese, N1
Le Pen, C; Lilliu, H; Maurel, F1
Bonanni, L; Di Iorio, A; Iacono, D; Onofrj, M; Thomas, A1
Jackson, MJ; Jenner, P; Maratos, EC; Pearce, RK1
Brotchie, JM; Crossman, AR; Fox, SH; Henry, B; Hill, MP; Peggs, D1
Agid, Y; Arnulf, I; Bejjani, B; Bonnet, AM; Brefel-Courbon, C; Descombes, S; Fabre, N; Montastruc, JL; Peyro-Saint Paul, H; Rascol, O; Thalamas, C; Vidailhet, M1
Bezard, E; Brotchie, JM; Gross, CE1
Heikkilä, M; Jenner, P; Lindén, IB; Pearce, RK1
Di Monte, DA; Langston, JW; Protell, P; Quik, M; Tan, L; Togasaki, DM1
Benabou, R; Cubo, E; Goetz, CG; Gracies, JM; Leurgans, S; Olanow, CW; Raman, R1
Hamada, I; Hasegawa, N; Okiyama, R; Takahashi, H; Taniguchi, M; Yokochi, F1
Ben-Shlomo, Y; Head, J; Katzenschlager, R; Lees, AJ1
Becker, G; Berg, D; Naumann, M; Reiners, K1
Brotchie, JM; Crossman, AR; Dick, JP; Fox, SH; Hill, M; Sieradzan, KA1
Ohye, C1
Groenewegen, HJ; Van De Witte, SV; Voorn, P1
Albanese, A; Bentivoglio, AR; Cortelli, P; Elia, A; Ferraris, A; Ialongo, T; Montagna, P; Valente, EM1
Kostić, VS; Marinković, J; Przedborski, S; Stefanova, E; Svetel, M1
Ding, Y; Li, Y; Shao, M; Zhao, G1
Bareš, M; Hortová, H; Kanovský, P; Kubová, D; Rektor, I; Streitová, H; Znojil, V1
Bédard, PJ; Birdi, S; Calon, F; Di Paolo, T; Hornykiewicz, O; Rajput, AH1
Andersson, M; Cenci, MA; Kirik, D; Lundblad, M; Wierup, N; Winkler, C1
Boesch, SM; Poewe, W; Ransmayr, G; Wenning, GK1
Mazzoni, P1
Deuschl, G; Herzog, J; Klebe, S; Krack, P; Lorenz, D; Pohle, S; Wenzelburger, R; Wilms, H; Zhang, BR1
Brooks, DJ; Brunt, ER; Korczyn, AD; Montastruc, JL; Stocchi, F1
Djaldetti, R; Melamed, E; Merims, D; Sherki, Y; Ziv, I1
Burgunder, JM; Krauss, JK; Loher, TJ; Pohle, T; Sommerhalder, R; Weber, S1
Defebvre, L; Krystkowiak, P1
Dill, RE; Dorris, RL; Phillips-Thonnard, I1
Carroll, BJ; Curtis, GC; Kokmen, E1
Lloyd, KG1
Ringwald, E1
Costentin, J1
Marsden, CD; Parkes, JD; Price, P1
Jiang, Y; Liu, D1
Lander, CM; Lees, A; Stern, G1
Sears, ES1
Goetz, C; Klawans, HL; Nausieda, PA; Weiner, WJ2
Casey, DE2
Bédard, P; Langlier, P; Villeneuve, A1
Klawans, HL; Moskovitz, C; Nausieda, PA; Weiner, WJ1
Cotzias, GC; Tang, LC1
Godwin-Austen, RB1
Marsden, CD; Parkes, JD; Price, PA1
Lakke, JP; Lindeboom, SF1
Lance, JW; Mackenzie, RA1
Gerlach, J2
Fischer, PA; Jacobi, P; Schneider, E1
Casey, DE; Denney, D1
Hirayama, K; Kondo, T; Kuruma, I; Narabayashi, H; Yokochi, M1
Lander, CM; Lees, AJ; Stern, GM1
List, SJ; Seeman, P1
Bathien, N; Rondot, P1
Asano, T; Matsumoto, Y; Mimura, Y; Mino, S; Nishimoto, A; Ohmoto, T; Yoshimura, Y1
Durocher, AM; Graux, P1
Cotzias, GC; Lazarus, CB; Papavasiliou, PS; Tolosa, ES1
Klawans, HL; Nausieda, PA; Weiner, WJ1
Murphy, MJ1
Feuerstein, C; Gavend, M; Pellat, J; Perret, J; Serre, F; Tanche, M3
Ando, K1
Cotzias, GC; McDowell, FH; Papavasilliou, PS; Rosal, VL; Sheehan, PJ1
Granérus, AK1
Goetz, CG; Klawans, HL; Nausieda, PA; Weiner, WJ1
Bédard, P; Marsden, CD; Parkes, JD1
Agid, Y; Lhermitte, F; Signoret, JL1
Bonnet, K; Friedhoff, AJ; Rosengarten, H1
Bianchine, JR; Shaw, GM1
Comoy, E; Lhermitte, F; Rosa, A1
Galea-Debono, A; Jenner, P; Marsden, CD; Parkes, JD; Tarsy, D; Walters, J1
Bala, SP; Cohen, B; Mendoza, M; Shimizu, N; Yahr, MD1
Agid, Y; Lhermitte, F; Signoret, JL; Studler, JM1
Davis, JM; Frohman, LA; Pandey, G; Smith, RC; Tamminga, CA1
Mano, T1
Ohtomo, E1
Debono, AG; Marsden, CD; Parkes, JD1
Johnels, B; Karlsson, S; Persson, M1
Sandyk, R1
Anninos, PA; Derpapas, K; Sandyk, R; Tsagas, N1
Deleu, D1
Mark, MH; Sage, JI1
Gershanik, O; Luquin, MR; Obeso, JA; Scipioni, O; Vaamonde, J1
Baronti, F; Brughitta, G; Chase, TN; Conant, KE; Giuffra, M; Mouradian, MM1
Heinz, A; Klewin, I; Klotz, P; Kuhn, W; Przuntek, H; Suchy, I1
Koller, WC1
Rodnitzky, RL1
Bédard, PJ; Blanchette, P; Di Paolo, T; Gagnon, C; Mancilla, BG1
Page, RD1
Chen, S1
Lees, AJ; Turjanski, N1
Jenkins, JR; Pearce, JM1
de Saint Victor, JF; Gervason, CL; Perret, J; Pollak, P1
Arts, N; Horstink, M; Tacke, T; van de Vlasakker, C1
Lu, CS; Tsai, CH1
Fahn, S; Flaster, E; Giladi, N; Guillory, S; Kostic, V; McMahon, D; Przedborski, S1
Jamieson, PW1
Campbell, N; Evans, C; Franco, K; Pentz, J; Tamburrino, M1
Chaná, P; Díaz, F1
Carey, RJ1
Friedman, A; Sienkiewicz, J1
Ahlskog, JE; Wilkinson, JM1
Haba, K; Mizukawa, K; Ogawa, N; Sato, H1
Crossman, AR1
Flaster, E; Kostic, V; Przedborski, S; Sternic, N1
Marsden, CD; Quinn, NP; Steiger, MJ1
Cedarbaum, JM; Gandy, SE; McDowell, FH1
Baronti, F; Brughitta, G; Davis, TL; Mouradian, MM1
Kleedorfer, B; Lees, AJ; Stern, GM1
Boyce, S; Iversen, SD; Rupniak, NM; Steventon, MJ3
Bergen, M; Hening, WA; McHale, D; Sage, JI; Walters, AS1
Cedarbaum, JM1
Montastruc, JL; Rascol, A; Rascol, O1
Dickey, W; Morrow, JI1
Genitrini, S; Giovannini, P; Girotti, F; Piccolo, I; Scigliano, G; Suchy, I; Testa, D1
Bakay, RA; Byrd, LD; Colbassani, HJ; Herring, CJ; Iuvone, PM; Mandir, A; Sweeney, KM; Watts, RL1
Boyce, S; Iversen, SD; Rupniak, NM; Steventon, M1
Berger, HJ; Horstink, MW; Pasman, JW; van't Hof, MA; Zijlmans, JC1
Jansen, EN; van Laar, T1
Cedarbaum, JM; Kutt, H; Silvestri, M1
Ludatscher, JI1
Schneider, JS1
Iversen, SD; Miyaji, M; Naruse, T; Rupniak, NM; Tye, SJ1
Ahlskog, JE; Bell, GN; Carmichael, SW; Kelly, PJ; Stoddard, SL; van Heerden, JA1
Artieda, J; Grandas, F; Lera, G; Luquin, MR; Martinez-Lage, JM; Obeso, JA; Rodriguez, ME; Vaamonde, J1
Le, W1
Chacon, J; Chaparro, P; Iriarte, LM; Madrazo, J; Vadillo, J1
Luquin, MR; Obeso, JA; Vaamonde, J1
Baronti, F; Chase, TN; Fabbrini, G; Heuser, IJ; Juncos, JL; Mouradian, MM1
Greer, M1
Fog, R1
Bossi, L; Fournier, V; Morselli, PL; Musch, B1
Rajput, AH; Uitti, RJ1
Koller, WC; Lang, AE; Marsden, CD; Quinn, NP1
Critchley, P; Marsden, CD; Parkes, D; Quinn, N1
Casabona, J; Jankovic, J1
Engstrom, FW1
Bathien, N; Fournier, V; Morselli, PL; Rondot, P; Ziegler, M1
Boyce, S; Clarke, CE; Crossman, AR; Sambrook, MA; Stahl, SM1
Ohmoto, T1
García, S; Gershanik, OS; Scipioni, O1
Agid, Y; Bonnet, AM; Javoy-Agid, F; Ruberg, M1
Sandyk, R; Snider, SR1
Ahlskog, JE; Bailey, PA; Bell, GN; McManis, PG; Muenter, MD1
Caradoc-Davies, TH1
Mondal, BK; Mondal, KN1
Delwaide, PJ; Maertens de Noordhout, A1
Albani, C; Asper, R; Baumgartner, G1
Gershanik, OS; Luquin, MR; Obeso, JA; Scipioni, O1
Chase, TN; Fabbrini, G; Juncos, JL; Mohr, E; Mouradian, MM; Schlegel, J1
Bartko, JJ; Chase, TN; Fabbrini, G; Juncos, JL; Mouradian, MM; Schlegel, J1
Martí, MJ; Tolosa, E1
Wermuth, L1
Gibb, WR; Lees, AJ1
Lieberman, AN1
Bhatia, R; Weinrich, M1
Clarke, CE; Crossman, AR; Mitchell, IJ; Sambrook, MA1
Critchley, P; Marsden, CD; Quinn, N1
el-Awar, M; Freedman, M; Goldenberg, L; Little, J; Seeman, P; Solomon, P1
Diamond, SG; Markham, CH1
Indo, T; Takahashi, A1
von Kummer, R1
Jankovic, J; Nour, F1
Luquin, MR; Martínez Lage, JM; Obeso, JA2
Gopinathan, G; Lieberman, AN; Neophytides, A1
Glantz, RH; Goetz, CG; Klawans, HL; Tanner, CM1
Friedman, A1
Bulpitt, CJ; Clifton, P; Davies, JB; Reid, JL; Shaw, K; Stern, G1
Arlazoroff, A; Barber, Y; Bleicher, Z; Flechtir, S; Goldexberg, E1
Espadaler Medina, JM1
Kondo, T; Nakajima, Y; Narabayashi, H1

Reviews

393 review(s) available for levodopa and Dyskinesia, Drug-Induced

ArticleYear
Amantadine Revisited: A Contender for Initial Treatment in Parkinson's Disease?
    CNS drugs, 2021, Volume: 35, Issue:11

    Topics: Amantadine; Animals; Antiparkinson Agents; Confusion; Delayed-Action Preparations; Dopamine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Nausea; Parkinson Disease

2021
The effect and safety of levodopa alone versus levodopa sparing therapy for early Parkinson's disease: a systematic review and meta-analysis.
    Journal of neurology, 2022, Volume: 269, Issue:4

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2022
Amantadine in the treatment of Parkinson's disease and other movement disorders.
    The Lancet. Neurology, 2021, Volume: 20, Issue:12

    Topics: Amantadine; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2021
Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee.
    Neurology, 2021, 11-16, Volume: 97, Issue:20

    Topics: Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Motor Activity; Parkinson Disease; Practice Guidelines as Topic

2021
GOCOVRI
    Neurodegenerative disease management, 2022, Volume: 12, Issue:1

    Topics: Amantadine; Antiparkinson Agents; Catechol O-Methyltransferase; Delayed-Action Preparations; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2022
Levodopa-induced dyskinesia: a brief review of the ongoing clinical trials.
    Neurodegenerative disease management, 2022, Volume: 12, Issue:2

    Topics: Dyskinesia, Drug-Induced; Humans; Levodopa; Longitudinal Studies

2022
Levodopa-induced dyskinesia: a historical review of Parkinson's disease, dopamine, and modern advancements in research and treatment.
    Journal of neurology, 2022, Volume: 269, Issue:6

    Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2022
Neurobiological and Pharmacological Perspectives of D3 Receptors in Parkinson's Disease.
    Biomolecules, 2022, 02-01, Volume: 12, Issue:2

    Topics: Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine D1; Receptors, Dopamine D3

2022
Non-dopaminergic approaches to the treatment of motor complications in Parkinson's disease.
    Neuropharmacology, 2022, 06-01, Volume: 210

    Topics: Antiparkinson Agents; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2022
Glutamate modulation for the treatment of levodopa induced dyskinesia: a brief review of the drugs tested in the clinic.
    Neurodegenerative disease management, 2022, Volume: 12, Issue:4

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Glutamic Acid; Humans; Levodopa; N-Methylaspartate; Parkinson Disease

2022
Dyskinesia and Parkinson's disease: animal model, drug targets, and agents in preclinical testing.
    Expert opinion on therapeutic targets, 2022, Volume: 26, Issue:10

    Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Neurodegenerative Diseases; Oxidopamine; Parkinson Disease; Quality of Life

2022
Levodopa-Induced Dyskinesia in Parkinson's Disease: Pathogenesis and Emerging Treatment Strategies.
    Cells, 2022, Nov-23, Volume: 11, Issue:23

    Topics: Antiparkinson Agents; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Quality of Life

2022
Serotonin 5-HT
    Neuropharmacology, 2023, 03-15, Volume: 226

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Serotonin

2023
Role of P11 through serotonergic and glutamatergic pathways in LID.
    Molecular biology reports, 2023, Volume: 50, Issue:5

    Topics: Basal Ganglia; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2023
5-HT
    Neurodegenerative disease management, 2023, Volume: 13, Issue:2

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Serotonin; Serotonin 5-HT1 Receptor Agonists

2023
Impaired cognitive and motor function are coincident with L-DOPA-induced dyskinesia in a model of Parkinson's disease.
    Scientific reports, 2023, 10-17, Volume: 13, Issue:1

    Topics: Animals; Cognition; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley

2023
Levodopa-induced dyskinesia: interplay between the N-methyl-D-aspartic acid receptor and neuroinflammation.
    Frontiers in immunology, 2023, Volume: 14

    Topics: Aged; Dyskinesia, Drug-Induced; Glutamic Acid; Humans; Levodopa; Middle Aged; N-Methylaspartate; Neuroinflammatory Diseases; Parkinson Disease; Quality of Life; Receptors, N-Methyl-D-Aspartate

2023
Efficacy and safety of extended-release amantadine in levodopa-induced dyskinesias: a meta-analysis.
    Neurodegenerative disease management, 2019, Volume: 9, Issue:4

    Topics: Accidental Falls; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Bias; Constipation; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Randomized Controlled Trials as Topic; Severity of Illness Index; Treatment Outcome; Xerostomia

2019
Dystonia and levodopa-induced dyskinesias in Parkinson's disease: Is there a connection?
    Neurobiology of disease, 2019, Volume: 132

    Topics: Animals; Antiparkinson Agents; Brain; Dyskinesia, Drug-Induced; Dystonic Disorders; Humans; Levodopa; Parkinson Disease

2019
Can therapeutic strategies prevent and manage dyskinesia in Parkinson's disease? An update.
    Expert opinion on drug safety, 2019, Volume: 18, Issue:12

    Topics: Animals; Antiparkinson Agents; Deep Brain Stimulation; Drug Delivery Systems; Dyskinesia, Drug-Induced; Dyskinesias; Humans; Levodopa; Parkinson Disease

2019
Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson's Disease and L-DOPA-Induced Dyskinesia.
    Neurotoxicity research, 2020, Volume: 37, Issue:1

    Topics: Animals; Cannabidiol; Cannabinoids; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease

2020
Opicapone for the treatment of Parkinson's disease: an update.
    Expert opinion on pharmacotherapy, 2019, Volume: 20, Issue:18

    Topics: Administration, Oral; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catechols; Dyskinesia, Drug-Induced; Humans; Levodopa; Nitriles; Oxadiazoles; Parkinson Disease

2019
Technological prospection: patents mapping involving compounds for the treatment of L-DOPA-induced dyskinesias.
    Expert opinion on therapeutic patents, 2019, Volume: 29, Issue:12

    Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Patents as Topic

2019
MRI of Motor and Nonmotor Therapy-Induced Complications in Parkinson's Disease.
    Movement disorders : official journal of the Movement Disorder Society, 2020, Volume: 35, Issue:5

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Magnetic Resonance Imaging; Parkinson Disease

2020
Research advances on L-DOPA-induced dyskinesia: from animal models to human disease.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2020, Volume: 41, Issue:8

    Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Mice; Oxidopamine; Parkinson Disease; Rats

2020
Emerging drugs for the treatment of L-DOPA-induced dyskinesia: an update.
    Expert opinion on emerging drugs, 2020, Volume: 25, Issue:2

    Topics: Amantadine; Animals; Antiparkinson Agents; Drug Development; Drug Repositioning; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic

2020
The MPTP-lesioned marmoset model of Parkinson's disease: proposed efficacy thresholds that may potentially predict successful clinical trial results.
    Journal of neural transmission (Vienna, Austria : 1996), 2020, Volume: 127, Issue:10

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2020
Pivotal Role of Fyn Kinase in Parkinson's Disease and Levodopa-Induced Dyskinesia: a Novel Therapeutic Target?
    Molecular neurobiology, 2021, Volume: 58, Issue:4

    Topics: Animals; Dyskinesia, Drug-Induced; Humans; Levodopa; Models, Biological; Molecular Targeted Therapy; Oxidative Stress; Parkinson Disease; Proto-Oncogene Proteins c-fyn

2021
Genetic variants in levodopa-induced dyskinesia (LID): A systematic review and meta-analysis.
    Parkinsonism & related disorders, 2021, Volume: 84

    Topics: Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2021
Serotonin/dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesia: An update.
    Progress in brain research, 2021, Volume: 261

    Topics: Animals; Antiparkinson Agents; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Serotonin

2021
Mechanisms of Antiparkinsonian Anticholinergic Therapy Revisited.
    Neuroscience, 2021, 07-15, Volume: 467

    Topics: Animals; Antiparkinson Agents; Cholinergic Antagonists; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Oxidopamine; Parkinson Disease

2021
New insights into pathogenesis of l-DOPA-induced dyskinesia.
    Neurotoxicology, 2021, Volume: 86

    Topics: Animals; Antiparkinson Agents; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2021
Cortical plasticity and levodopa-induced dyskinesias in Parkinson's disease: Connecting the dots in a multicomponent network.
    Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology, 2017, Volume: 128, Issue:6

    Topics: Cerebellum; Connectome; Corpus Striatum; Dyskinesia, Drug-Induced; Humans; Levodopa; Motor Cortex; Neuronal Plasticity; Parkinson Disease

2017
Investigational drugs in Phase I and Phase II for Levodopa-induced dyskinesias.
    Expert opinion on investigational drugs, 2017, Volume: 26, Issue:7

    Topics: Animals; Antiparkinson Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Design; Drugs, Investigational; Dyskinesia, Drug-Induced; Humans; Levodopa; Molecular Targeted Therapy; Parkinson Disease

2017
Levodopa treatment and dendritic spine pathology.
    Movement disorders : official journal of the Movement Disorder Society, 2018, Volume: 33, Issue:6

    Topics: Animals; Antiparkinson Agents; Caudate Nucleus; Dendritic Spines; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Putamen

2018
PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson's Disease.
    Current neurology and neuroscience reports, 2017, Oct-03, Volume: 17, Issue:11

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Molecular Imaging; Parkinson Disease; Positron-Emission Tomography

2017
Synaptic plasticity may underlie l-DOPA induced dyskinesia.
    Current opinion in neurobiology, 2018, Volume: 48

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuronal Plasticity; Parkinson Disease

2018
Levodopa: A new look at an old friend.
    Movement disorders : official journal of the Movement Disorder Society, 2018, Volume: 33, Issue:6

    Topics: Age Factors; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Treatment Outcome

2018
Motor complications in Parkinson's disease: Striatal molecular and electrophysiological mechanisms of dyskinesias.
    Movement disorders : official journal of the Movement Disorder Society, 2018, Volume: 33, Issue:6

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2018
Understanding the role of glycogen synthase kinase-3 in L-DOPA-induced dyskinesia in Parkinson's disease.
    Expert opinion on drug metabolism & toxicology, 2018, Volume: 14, Issue:1

    Topics: Animals; Antiparkinson Agents; beta Catenin; Dopamine; Dyskinesia, Drug-Induced; Glycogen Synthase Kinase 3; Humans; Levodopa; Neurotoxicity Syndromes; Oxidative Stress; Parkinson Disease

2018
Animal models of L-DOPA-induced dyskinesia: the 6-OHDA-lesioned rat and mouse.
    Journal of neural transmission (Vienna, Austria : 1996), 2018, Volume: 125, Issue:8

    Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Mice; Oxidopamine; Parkinsonian Disorders; Rats

2018
Serotonergic targets for the treatment of L-DOPA-induced dyskinesia.
    Journal of neural transmission (Vienna, Austria : 1996), 2018, Volume: 125, Issue:8

    Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Receptors, Serotonin; Serotonin; Serotonin Receptor Agonists

2018
Levodopa-induced dyskinesia in Parkinson's disease: still no proof? A meta-analysis.
    Journal of neural transmission (Vienna, Austria : 1996), 2018, Volume: 125, Issue:9

    Topics: Antiparkinson Agents; Causality; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic; Regression Analysis

2018
Signal transduction in L-DOPA-induced dyskinesia: from receptor sensitization to abnormal gene expression.
    Journal of neural transmission (Vienna, Austria : 1996), 2018, Volume: 125, Issue:8

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; GABAergic Neurons; Gene Expression; Humans; Levodopa; Receptors, Dopamine D1; Signal Transduction

2018
Role of adenosine A
    Journal of neural transmission (Vienna, Austria : 1996), 2018, Volume: 125, Issue:8

    Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptor, Adenosine A2A

2018
Dyskinesias and levodopa therapy: why wait?
    Journal of neural transmission (Vienna, Austria : 1996), 2018, Volume: 125, Issue:8

    Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2018
The serotonergic system in L-DOPA-induced dyskinesia: pre-clinical evidence and clinical perspective.
    Journal of neural transmission (Vienna, Austria : 1996), 2018, Volume: 125, Issue:8

    Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Serotonergic Neurons

2018
Animal models of l-dopa-induced dyskinesia in Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2018, Volume: 33, Issue:6

    Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Parkinson Disease, Secondary

2018
Synaptic plasticity and levodopa-induced dyskinesia: electrophysiological and structural abnormalities.
    Journal of neural transmission (Vienna, Austria : 1996), 2018, Volume: 125, Issue:8

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuronal Plasticity

2018
The striatal cholinergic system in L-dopa-induced dyskinesias.
    Journal of neural transmission (Vienna, Austria : 1996), 2018, Volume: 125, Issue:8

    Topics: Animals; Corpus Striatum; Dyskinesia, Drug-Induced; Humans; Interneurons; Levodopa; Parkinson Disease

2018
Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia.
    Journal of neural transmission (Vienna, Austria : 1996), 2018, Volume: 125, Issue:8

    Topics: Amantadine; Animals; Antiparkinson Agents; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Humans; Levodopa; Receptors, N-Methyl-D-Aspartate

2018
Neuroinflammation in L-DOPA-induced dyskinesia: beyond the immune function.
    Journal of neural transmission (Vienna, Austria : 1996), 2018, Volume: 125, Issue:8

    Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Inflammation; Levodopa; Tumor Necrosis Factor-alpha

2018
The role of extended-release amantadine for the treatment of dyskinesia in Parkinson's disease patients.
    Neurodegenerative disease management, 2018, Volume: 8, Issue:2

    Topics: Amantadine; Analgesics, Non-Narcotic; Antiparkinson Agents; Drug Delivery Systems; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2018
mGlu receptors in the treatment of Parkinson's disease and L-DOPA-induced dyskinesia.
    Current opinion in pharmacology, 2018, Volume: 38

    Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptor, Metabotropic Glutamate 5

2018
On the neuronal circuitry mediating L-DOPA-induced dyskinesia.
    Journal of neural transmission (Vienna, Austria : 1996), 2018, Volume: 125, Issue:8

    Topics: Animals; Antiparkinson Agents; Brain; Dyskinesia, Drug-Induced; Levodopa; Neural Pathways

2018
▼ Safinamide for Parkinson's disease.
    Drug and therapeutics bulletin, 2018, Volume: 56, Issue:5

    Topics: Alanine; Benzylamines; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease

2018
A new outlook on cholinergic interneurons in Parkinson's disease and L-DOPA-induced dyskinesia.
    Neuroscience and biobehavioral reviews, 2018, Volume: 92

    Topics: Animals; Antiparkinson Agents; Cholinergic Neurons; Dyskinesia, Drug-Induced; Humans; Interneurons; Levodopa; Neurotransmitter Agents; Parkinson Disease

2018
Repurposing drugs to treat l-DOPA-induced dyskinesia in Parkinson's disease.
    Neuropharmacology, 2019, 03-15, Volume: 147

    Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Drug Repositioning; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic

2019
Levodopa-induced dyskinesia: clinical features, incidence, and risk factors.
    Journal of neural transmission (Vienna, Austria : 1996), 2018, Volume: 125, Issue:8

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Incidence; Levodopa; Parkinson Disease; Risk Factors

2018
Amantadine Extended-Release (GOCOVRI
    CNS drugs, 2018, Volume: 32, Issue:8

    Topics: Amantadine; Animals; Antiparkinson Agents; Delayed-Action Preparations; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2018
L-DOPA for Parkinson's disease-a bittersweet pill.
    The European journal of neuroscience, 2019, Volume: 49, Issue:3

    Topics: Animals; Antiparkinson Agents; Cell Transplantation; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2019
Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts.
    Annals of neurology, 2018, Volume: 84, Issue:6

    Topics: Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2018
Pharmacogenetics and levodopa induced motor complications.
    The International journal of neuroscience, 2019, Volume: 129, Issue:4

    Topics: Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Pharmacogenetics

2019
Chemical management of levodopa-induced dyskinesia in Parkinson's disease patients.
    Expert opinion on pharmacotherapy, 2019, Volume: 20, Issue:2

    Topics: Animals; Antiparkinson Agents; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic

2019
Safety and Efficacy of Levetiracetam for the Management of Levodopa- Induced Dyskinesia in Patients with Parkinson's Disease: A Systematic Review.
    CNS & neurological disorders drug targets, 2019, Volume: 18, Issue:4

    Topics: Anticonvulsants; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levetiracetam; Levodopa; Parkinson Disease; Treatment Outcome

2019
Neurosurgical Approaches to Levodopa-Induced Dyskinesia.
    World neurosurgery, 2019, Volume: 126

    Topics: Brain; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Humans; Levodopa; Neurosurgical Procedures; Parkinson Disease; Transcranial Magnetic Stimulation

2019
Extended-Release Amantadine for Levodopa-Induced Dyskinesia.
    Expert review of neurotherapeutics, 2019, Volume: 19, Issue:4

    Topics: Amantadine; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2019
Dopaminergic modulation of striatal function and Parkinson's disease.
    Journal of neural transmission (Vienna, Austria : 1996), 2019, Volume: 126, Issue:4

    Topics: Animals; Corpus Striatum; Dopamine; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2019
Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson's Disease.
    Biomolecules, 2019, 04-09, Volume: 9, Issue:4

    Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Neurotransmitter Agents; Parkinson Disease; Receptors, Neurotransmitter

2019
Evaluating ADS5102 (amantadine) for the treatment of Parkinson's disease patients with dyskinesia.
    Expert opinion on pharmacotherapy, 2019, Volume: 20, Issue:10

    Topics: Amantadine; Antiparkinson Agents; Antiviral Agents; Delayed-Action Preparations; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Patient Compliance

2019
Dyskinesia in multiple system atrophy and progressive supranuclear palsy.
    Journal of neural transmission (Vienna, Austria : 1996), 2019, Volume: 126, Issue:7

    Topics: Diagnosis, Differential; Dyskinesia, Drug-Induced; Dyskinesias; Humans; Levodopa; Multiple System Atrophy; Parkinson Disease; Supranuclear Palsy, Progressive

2019
Dysfunction of serotonergic neurons in Parkinson's disease and dyskinesia.
    International review of neurobiology, 2019, Volume: 146

    Topics: Animals; Brain; Dyskinesia, Drug-Induced; Humans; Levodopa; Models, Neurological; Parkinson Disease; Serotonergic Neurons

2019
CLINICAL TRIAL HIGHLIGHTS - DYSKINESIA.
    Journal of Parkinson's disease, 2019, Volume: 9, Issue:3

    Topics: Antiparkinson Agents; Clinical Trials as Topic; Dyskinesia, Drug-Induced; Dyskinesias; Humans; Levodopa; Parkinson Disease

2019
Drug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia?
    BMC medicine, 2013, Mar-20, Volume: 11

    Topics: Animals; Disease Management; Dyskinesia, Drug-Induced; Humans; Levodopa; Motor Skills; Parkinson Disease; Recovery of Function; Signal-To-Noise Ratio

2013
Multisite intracerebral microdialysis to study the mechanism of L-DOPA induced dopamine and serotonin release in the parkinsonian brain.
    ACS chemical neuroscience, 2013, May-15, Volume: 4, Issue:5

    Topics: Animals; Antiparkinson Agents; Brain; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Levodopa; Microdialysis; Neostriatum; Parkinson Disease; Rats; Serotonergic Neurons; Serotonin

2013
New insights into the mechanism of drug-induced dyskinesia.
    CNS spectrums, 2013, Volume: 18, Issue:1

    Topics: Antiparkinson Agents; Cerebral Cortex; Corpus Striatum; Dyskinesia, Drug-Induced; GABAergic Neurons; Glutamic Acid; Humans; Levodopa; Neural Pathways; Thalamus

2013
[Specificities of the treatment of Parkinson's disease in the elderly].
    Psychologie & neuropsychiatrie du vieillissement, 2006, Volume: 4 Spec No 1

    Topics: Aged; Antiparkinson Agents; Cognition Disorders; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2006
Mechanisms underlying cortical resonant states: implications for levodopa-induced dyskinesia.
    Reviews in the neurosciences, 2013, Volume: 24, Issue:4

    Topics: Animals; Antiparkinson Agents; Cerebral Cortex; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2013
Non-dopaminergic treatments for motor control in Parkinson's disease.
    Drugs, 2013, Volume: 73, Issue:13

    Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Dopamine Agents; Drug Resistance; Dyskinesia, Drug-Induced; Gait Disorders, Neurologic; Humans; Levodopa; Mesencephalon; Molecular Targeted Therapy; Monoamine Oxidase Inhibitors; Neurons; Off-Label Use; Parkinson Disease; Serotonin Antagonists; Tremor

2013
Levodopa-induced-dyskinesias clinical features, incidence, risk factors, management and impact on quality of life.
    Journal of Parkinson's disease, 2012, Volume: 2, Issue:3

    Topics: Antiparkinson Agents; Disease Management; Dyskinesia, Drug-Induced; Humans; Incidence; Levodopa; Parkinson Disease; Quality of Life; Risk Factors

2012
Levodopa in the treatment of Parkinson's disease: current status and new developments.
    Journal of Parkinson's disease, 2013, Jan-01, Volume: 3, Issue:3

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2013
Receptor heteromers in Parkinson's disease and L-DOPA-induced dyskinesia.
    CNS & neurological disorders drug targets, 2013, Volume: 12, Issue:8

    Topics: Animals; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Protein Multimerization; Receptors, N-Methyl-D-Aspartate

2013
Parkinson's disease.
    Handbook of clinical neurology, 2013, Volume: 116

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Evoked Potentials, Motor; Humans; Levodopa; Motor Cortex; Parkinson Disease; Transcranial Magnetic Stimulation

2013
Investigating the molecular mechanisms of L-DOPA-induced dyskinesia in the mouse.
    Parkinsonism & related disorders, 2014, Volume: 20 Suppl 1

    Topics: Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Mice; Oxidopamine; Parkinson Disease; Tyrosine 3-Monooxygenase

2014
Dopamine agonist monotherapy in Parkinson's disease and potential risk factors for dyskinesia: a meta-analysis of levodopa-controlled trials.
    European journal of neurology, 2014, Volume: 21, Issue:3

    Topics: Databases, Bibliographic; Dopamine Agonists; Double-Blind Method; Dyskinesia, Drug-Induced; Humans; Levodopa; Randomized Controlled Trials as Topic; Risk Factors; Stroke

2014
Dyskinesias in Parkinson's disease: views from positron emission tomography studies.
    European journal of neurology, 2014, Volume: 21, Issue:5

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Fluorodeoxyglucose F18; Humans; Levodopa; Parkinson Disease; Positron-Emission Tomography

2014
Effect of nicotine on L-dopa-induced dyskinesia in animal models of Parkinson's disease: a systematic review and meta-analysis.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2014, Volume: 35, Issue:5

    Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Ganglionic Stimulants; Levodopa; Nicotine; Parkinsonian Disorders

2014
[Treatment possibilities in advanced Parkinson's disease].
    Ideggyogyaszati szemle, 2013, Nov-30, Volume: 66, Issue:11-12

    Topics: Administration, Oral; Age Factors; Antiparkinson Agents; Apomorphine; Carbidopa; Cognition Disorders; Deep Brain Stimulation; Dopamine Agents; Drug Tolerance; Duodenum; Dyskinesia, Drug-Induced; Gels; Humans; Infusion Pumps, Implantable; Levodopa; Parkinson Disease; Quality of Life; Severity of Illness Index

2013
Mavoglurant as a treatment for Parkinson's disease.
    Expert opinion on investigational drugs, 2014, Volume: 23, Issue:8

    Topics: Allosteric Regulation; Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Indoles; Levodopa; Parkinson Disease; Quality of Life; Receptor, Metabotropic Glutamate 5

2014
Emerging drugs for levodopa-induced dyskinesia.
    Expert opinion on emerging drugs, 2014, Volume: 19, Issue:3

    Topics: Animals; Antiparkinson Agents; Basal Ganglia; Drug Design; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic; Receptors, Dopamine; Signal Transduction

2014
Symptomatic Models of Parkinson's Disease and L-DOPA-Induced Dyskinesia in Non-human Primates.
    Current topics in behavioral neurosciences, 2015, Volume: 22

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Primates

2015
Adenosine receptors and dyskinesia in pathophysiology.
    International review of neurobiology, 2014, Volume: 119

    Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Purinergic P1 Receptor Antagonists; Receptors, Purinergic P1

2014
Prognostic significance of weight changes in Parkinson's disease: the Park-weight phenotype.
    Neurodegenerative disease management, 2014, Volume: 4, Issue:4

    Topics: Antiparkinson Agents; Body Weight; Dyskinesia, Drug-Induced; Energy Intake; Female; Humans; Levodopa; Male; Nutritional Status; Parkinson Disease; Quality of Life; Sex Factors; Smell; Thinness; Treatment Outcome; Weight Loss

2014
Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.
    CNS drugs, 2014, Volume: 28, Issue:12

    Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Clinical Trials as Topic; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2014
Presynaptic effects of levodopa and their possible role in dyskinesia.
    Movement disorders : official journal of the Movement Disorder Society, 2015, Volume: 30, Issue:1

    Topics: Animals; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Neurons; Parkinson Disease; Presynaptic Terminals

2015
Targeting glutamatergic synapses in Parkinson's disease.
    Current opinion in pharmacology, 2015, Volume: 20

    Topics: Animals; Antiparkinson Agents; Disease Progression; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Humans; Levodopa; Molecular Targeted Therapy; Parkinson Disease; Receptors, Ionotropic Glutamate; Synaptic Transmission

2015
Targeting metabotropic glutamate receptors (mGluRs) in Parkinson's disease.
    Current opinion in pharmacology, 2015, Volume: 20

    Topics: Animals; Antiparkinson Agents; Basal Ganglia; Dopamine; Dyskinesia, Drug-Induced; Glutamic Acid; Humans; Levodopa; Molecular Targeted Therapy; Parkinson Disease; Receptors, Metabotropic Glutamate

2015
Therapeutic strategies to prevent and manage dyskinesias in Parkinson's disease.
    Expert opinion on drug safety, 2015, Volume: 14, Issue:2

    Topics: Deep Brain Stimulation; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Administration Schedule; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agents; GABA Antagonists; Humans; Levodopa; Parkinson Disease; Serotonin Antagonists; Serotonin Receptor Agonists

2015
Clinical spectrum of levodopa-induced complications.
    Movement disorders : official journal of the Movement Disorder Society, 2015, Volume: 30, Issue:1

    Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2015
Nitric oxide, a new player in L-DOPA-induced dyskinesia?
    Frontiers in bioscience (Elite edition), 2015, 01-01, Volume: 7, Issue:1

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Humans; Levodopa; Nitric Oxide; Parkinson Disease

2015
Dopamine agonists early monotherapy for the delay of development of levodopa-induced dyskinesias.
    Expert review of neurotherapeutics, 2015, Volume: 15, Issue:2

    Topics: Animals; Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Time

2015
Molecular imaging of levodopa-induced dyskinesias.
    Cellular and molecular life sciences : CMLS, 2015, Volume: 72, Issue:11

    Topics: Antiparkinson Agents; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Molecular Imaging; Parkinson Disease; Receptors, Dopamine

2015
Safety of IPX066 , an extended release carbidopa-levodopa formulation, for the treatment of Parkinson's disease.
    Expert opinion on drug safety, 2015, Volume: 14, Issue:5

    Topics: Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Dyskinesia, Drug-Induced; Half-Life; Humans; Levodopa; Parkinson Disease

2015
L-DOPA-induced dyskinesia, is striatal dopamine depletion a requisite?
    Journal of the neurological sciences, 2015, Apr-15, Volume: 351, Issue:1-2

    Topics: Animals; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Neostriatum

2015
Zooming in on the small: the plasticity of striatal dendritic spines in L-DOPA-induced dyskinesia.
    Movement disorders : official journal of the Movement Disorder Society, 2015, Volume: 30, Issue:4

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dendritic Spines; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuronal Plasticity; Neurons

2015
Neurobiology of l-DOPA induced dyskinesia and the novel therapeutic strategies.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2015, Volume: 70

    Topics: Animals; Corpus Striatum; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2015
Current treatment and future prospects of dopa-induced dyskinesias.
    Drugs of today (Barcelona, Spain : 1998), 2015, Volume: 51, Issue:5

    Topics: Amantadine; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Practice Guidelines as Topic; Treatment Outcome

2015
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease.
    Progress in neurobiology, 2015, Volume: 132

    Topics: Animals; Antiparkinson Agents; Central Nervous System; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2015
New treatments for levodopa-induced motor complications.
    Movement disorders : official journal of the Movement Disorder Society, 2015, Sep-15, Volume: 30, Issue:11

    Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2015
mGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-induced Dyskinesias.
    Current neuropharmacology, 2016, Volume: 14, Issue:5

    Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Neostriatum; Parkinsonian Disorders; Receptor, Adenosine A2A; Receptor, Metabotropic Glutamate 5; Receptors, Dopamine D2

2016
Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist.
    Current neuropharmacology, 2016, Volume: 14, Issue:4

    Topics: Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Treatment Outcome

2016
Excitotoxic Mechanisms in Non-Motor Dysfunctions and Levodopa- Induced Dyskinesia in Parkinson's Disease: The Role of the Interaction Between the Dopaminergic and the Kynurenine System.
    Current medicinal chemistry, 2016, Volume: 23, Issue:9

    Topics: Animals; Antiparkinson Agents; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Kynurenine; Levodopa; Molecular Structure; Parkinson Disease

2016
Advances in levodopa therapy for Parkinson disease: Review of RYTARY (carbidopa and levodopa) clinical efficacy and safety.
    Neurology, 2016, Apr-05, Volume: 86, Issue:14 Suppl 1

    Topics: Administration, Oral; Animals; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Treatment Outcome

2016
Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia.
    Drugs, 2016, Volume: 76, Issue:7

    Topics: Amantadine; Anti-Dyskinesia Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Quality of Life; Randomized Controlled Trials as Topic

2016
l-DOPA-induced dyskinesia in Parkinson's disease: Are neuroinflammation and astrocytes key elements?
    Synapse (New York, N.Y.), 2016, Volume: 70, Issue:12

    Topics: Animals; Antiparkinson Agents; Astrocytes; Dyskinesia, Drug-Induced; Humans; Inflammation; Levodopa; Neurons; Parkinson Disease

2016
Maladaptive Synaptic Plasticity in L-DOPA-Induced Dyskinesia.
    Frontiers in neural circuits, 2016, Volume: 10

    Topics: Animals; Antiparkinson Agents; Basal Ganglia; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Motor Cortex; Neuronal Plasticity

2016
Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update.
    The Lancet. Neurology, 2017, Volume: 16, Issue:3

    Topics: Antiparkinson Agents; Disruptive, Impulse Control, and Conduct Disorders; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2017
[Dyskinesia in Parkinson's disease: an update on new neuroimaging methods and treatment possibilities].
    Ugeskrift for laeger, 2017, Mar-06, Volume: 179, Issue:10

    Topics: Amantadine; Antiparkinson Agents; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Humans; Levodopa; Magnetic Resonance Imaging; Parkinson Disease; Positron-Emission Tomography; Tomography, Emission-Computed, Single-Photon

2017
Involvement of the serotonin system in L-dopa-induced dyskinesias.
    Parkinsonism & related disorders, 2008, Volume: 14 Suppl 2

    Topics: Animals; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Serotonin

2008
Striatal synaptic changes in experimental parkinsonism: role of NMDA receptor trafficking in PSD.
    Parkinsonism & related disorders, 2008, Volume: 14 Suppl 2

    Topics: Animals; Corpus Striatum; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuronal Plasticity; Parkinsonian Disorders; Protein Transport; Receptors, N-Methyl-D-Aspartate; Synapses

2008
Direct and indirect striatal efferent pathways are differentially influenced by low and high dyskinetic drugs: behavioural and biochemical evidence.
    Parkinsonism & related disorders, 2008, Volume: 14 Suppl 2

    Topics: Animals; Antiparkinson Agents; Behavior; Brain Chemistry; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Efferent Pathways; Gene Expression Regulation; Humans; Levodopa; Oxidopamine; Parkinson Disease; Rats

2008
Role of receptor heterodimers in the development of L-dopa-induced dyskinesias in the 6-hydroxydopamine rat model of Parkinson's disease.
    Parkinsonism & related disorders, 2008, Volume: 14 Suppl 2

    Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Models, Molecular; Oxidopamine; Parkinson Disease; Protein Subunits; Rats; Receptors, Dopamine; Receptors, N-Methyl-D-Aspartate

2008
Molecular mechanisms of L-DOPA-induced dyskinesia.
    Nature reviews. Neuroscience, 2008, Volume: 9, Issue:9

    Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Models, Neurological; Parkinson Disease

2008
Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias.
    Progress in brain research, 2008, Volume: 172

    Topics: Animals; Clinical Trials as Topic; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Parkinsonian Disorders; Presynaptic Terminals; Protein Isoforms; Receptors, Dopamine; Receptors, Serotonin; Serotonin

2008
Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.
    Progress in brain research, 2008, Volume: 172

    Topics: Animals; Basal Ganglia; Clinical Trials as Topic; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Protein Isoforms; Receptors, Serotonin; Serotonin

2008
Levodopa unresponsive symptoms in Parkinson disease.
    Movement disorders : official journal of the Movement Disorder Society, 2008, Volume: 23 Suppl 3

    Topics: Antiparkinson Agents; Anxiety; Depression; Dyskinesia, Drug-Induced; Female; Gait Disorders, Neurologic; Humans; Levodopa; Male; Parkinson Disease; Sexual Dysfunction, Physiological; Sleep Wake Disorders; Sweating; Xerostomia

2008
Therapeutic strategies to prevent motor complications in Parkinson's disease.
    Journal of neurology, 2008, Volume: 255 Suppl 4

    Topics: Antiparkinson Agents; Dopamine Agonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonia; Humans; Levodopa; Movement Disorders; Parkinson Disease

2008
Levodopa-induced dyskinesias and their management.
    Journal of neurology, 2008, Volume: 255 Suppl 4

    Topics: Antiparkinson Agents; Chorea; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Dyskinesias; Dystonia; Humans; Levodopa; Parkinson Disease; Subthalamic Nucleus

2008
Priming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease?
    Progress in neurobiology, 2009, Jan-12, Volume: 87, Issue:1

    Topics: Animals; Antiparkinson Agents; Brain; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2009
How do you treat motor complications in Parkinson's disease: Medicine, surgery, or both?
    Annals of neurology, 2008, Volume: 64 Suppl 2

    Topics: Deep Brain Stimulation; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Neurosurgical Procedures; Parkinson Disease; Quality of Life; Risk Factors; Treatment Outcome

2008
Levodopa in the early treatment of Parkinson's disease.
    Parkinsonism & related disorders, 2009, Volume: 15 Suppl 1

    Topics: Antiparkinson Agents; Disease Progression; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Time Factors

2009
The effect of onset age on the clinical features of Parkinson's disease.
    European journal of neurology, 2009, Volume: 16, Issue:4

    Topics: Adult; Age of Onset; Aged; Dementia; Disease Progression; Dyskinesia, Drug-Induced; Dyskinesias; Dystonia; Humans; Levodopa; Middle Aged; Parkinson Disease; Phenotype; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome

2009
Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    International journal of clinical practice, 2009, Volume: 63, Issue:4

    Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Dopamine Agonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Treatment Outcome

2009
Levodopa-related wearing-off in Parkinson's disease: identification and management.
    Current medical research and opinion, 2009, Volume: 25, Issue:4

    Topics: Antiparkinson Agents; Cost of Illness; Disabled Persons; Disease Progression; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Dyskinesia, Drug-Induced; Health Surveys; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Surveys and Questionnaires; Time Factors

2009
Treatment of Parkinson's disease in Thailand: review of the literature and practical recommendations.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2009, Volume: 92, Issue:1

    Topics: Antiparkinson Agents; Deep Brain Stimulation; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Thailand

2009
Optimising levodopa therapy.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2008, Volume: 29 Suppl 5

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2008
Levodopa in the treatment of Parkinson's disease.
    European journal of neurology, 2009, Volume: 16, Issue:9

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2009
[Management of Parkinson's disease in 2009].
    Revue medicale suisse, 2009, Aug-26, Volume: 5, Issue:214

    Topics: Antiparkinson Agents; Deep Brain Stimulation; Dopamine Agonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Primary Dysautonomias; Prognosis; Risk Factors

2009
[Dopamine agonist therapy in early Parkinson's disease. A survey of a Cochrane review].
    Ugeskrift for laeger, 2009, Oct-05, Volume: 171, Issue:41

    Topics: Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Evidence-Based Medicine; Humans; Levodopa; Parkinson Disease; Treatment Outcome

2009
Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders.
    The Lancet. Neurology, 2009, Volume: 8, Issue:12

    Topics: Antiparkinson Agents; Automatism; Compulsive Behavior; Disruptive, Impulse Control, and Conduct Disorders; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Gambling; Humans; Levodopa; Parkinson Disease; Psychoses, Substance-Induced; Sexual Behavior

2009
Emergencies in parkinsonism: akinetic crisis, life-threatening dyskinesias, and polyneuropathy during L-Dopa gel treatment.
    Parkinsonism & related disorders, 2009, Volume: 15 Suppl 3

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuroleptic Malignant Syndrome; Parkinsonian Disorders; Polyneuropathies

2009
Plastic effects of L-DOPA treatment in the basal ganglia and their relevance to the development of dyskinesia.
    Parkinsonism & related disorders, 2009, Volume: 15 Suppl 3

    Topics: Animals; Antiparkinson Agents; Basal Ganglia; Brain-Derived Neurotrophic Factor; Dyskinesia, Drug-Induced; Humans; Levodopa; Microvessels; Neuronal Plasticity; Parkinson Disease; Serotonin

2009
Involvement of canonical and non-canonical D1 dopamine receptor signalling pathways in L-dopa-induced dyskinesia.
    Parkinsonism & related disorders, 2009, Volume: 15 Suppl 3

    Topics: Animals; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Models, Biological; Protein Transport; Receptors, Dopamine D1; Signal Transduction

2009
The therapeutic concept of continuous dopaminergic stimulation (CDS) in the treatment of Parkinson's disease.
    Parkinsonism & related disorders, 2009, Volume: 15 Suppl 3

    Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2009
Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson's disease.
    CNS drugs, 2010, Volume: 24, Issue:2

    Topics: Administration, Oral; Clinical Protocols; Delayed-Action Preparations; Dyskinesia, Drug-Induced; Dyskinesias; Humans; Infusions, Parenteral; Levodopa; Parkinson Disease; Treatment Outcome

2010
Rodent models of treatment-induced motor complications in Parkinson's disease.
    Parkinsonism & related disorders, 2009, Volume: 15 Suppl 4

    Topics: Animals; Brain Tissue Transplantation; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Mice; Motor Skills Disorders; Parkinson Disease; Rats

2009
Dopamine receptors and L-dopa-induced dyskinesia.
    Parkinsonism & related disorders, 2009, Volume: 15 Suppl 4

    Topics: Animals; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine; Signal Transduction

2009
Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
    Clinical neuropharmacology, 2010, Volume: 33, Issue:4

    Topics: Antiparkinson Agents; Biological Availability; Carbidopa; Delayed-Action Preparations; Dopamine Agonists; Drug Combinations; Dyskinesia, Drug-Induced; Dyskinesias; Female; Humans; Hyperkinesis; Levodopa; Male; Parkinson Disease; Solubility; Time Factors

2010
Entacapone.
    Expert opinion on drug metabolism & toxicology, 2010, Volume: 6, Issue:8

    Topics: Animals; Antiparkinson Agents; Biological Availability; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Half-Life; Humans; Levodopa; Nitriles; Parkinson Disease

2010
rTMS effects on levodopa induced dyskinesias in Parkinson's disease patients: searching for effective cortical targets.
    Restorative neurology and neuroscience, 2010, Volume: 28, Issue:4

    Topics: Animals; Antiparkinson Agents; Cerebellum; Cerebral Cortex; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Prefrontal Cortex; Transcranial Magnetic Stimulation

2010
L-DOPA-induced dyskinesia in Parkinson's disease: a drug discovery perspective.
    Drug discovery today, 2010, Volume: 15, Issue:19-20

    Topics: Animals; Disease Models, Animal; Drug Discovery; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2010
Levodopa in the treatment of Parkinson's disease: an old drug still going strong.
    Clinical interventions in aging, 2010, Sep-07, Volume: 5

    Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2010
Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap.
    The Lancet. Neurology, 2010, Volume: 9, Issue:11

    Topics: Animals; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine

2010
The clinical spectrum of levodopa-induced motor complications.
    Journal of neurology, 2010, Volume: 257, Issue:Suppl 2

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2010
Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.
    European journal of neurology, 2011, Volume: 18 Suppl 1

    Topics: Animals; Antiparkinson Agents; Benzothiazoles; Catechol O-Methyltransferase Inhibitors; Catechols; Clinical Trials, Phase III as Topic; Delayed-Action Preparations; Dopamine Agonists; Drug Delivery Systems; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Nitriles; Parkinson Disease; Pramipexole

2011
Role of nitric oxide in motor control: implications for Parkinson's disease pathophysiology and treatment.
    Current pharmaceutical design, 2011, Volume: 17, Issue:5

    Topics: Animals; Brain; Disease Models, Animal; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Models, Neurological; Motor Activity; Nitric Oxide; Nitric Oxide Synthase; Parkinson Disease; Signal Transduction; Synaptic Transmission

2011
The treatment of early Parkinson's disease: levodopa rehabilitated.
    Practical neurology, 2011, Volume: 11, Issue:3

    Topics: Dopamine Agents; Drug Resistance; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2011
Contribution of pre-synaptic mechanisms to L-DOPA-induced dyskinesia.
    Neuroscience, 2011, Dec-15, Volume: 198

    Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Oxidopamine; Parkinson Disease; Positron-Emission Tomography; Presynaptic Terminals; Rats; Serotonergic Neurons; Serotonin

2011
Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.
    Journal of neural transmission (Vienna, Austria : 1996), 2011, Volume: 118, Issue:12

    Topics: Animals; Antiparkinson Agents; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuronal Plasticity; Neurotransmitter Agents; Parkinson Disease; Signal Transduction

2011
Molecular mechanisms of l-DOPA-induced dyskinesia.
    International review of neurobiology, 2011, Volume: 98

    Topics: Amantadine; Animals; Antiparkinson Agents; Basal Ganglia; Dyskinesia, Drug-Induced; Genes, Immediate-Early; Humans; Levodopa; Neurons; Parkinson Disease; Receptor, Cannabinoid, CB1; Receptors, Dopamine; Receptors, N-Methyl-D-Aspartate; Receptors, Serotonin; Signal Transduction; Sirolimus

2011
New approaches to therapy.
    International review of neurobiology, 2011, Volume: 98

    Topics: Animals; Antipsychotic Agents; Dopamine; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Humans; Levodopa; Parkinson Disease; Receptors, Biogenic Amine

2011
Surgical approach to l-dopa-induced dyskinesias.
    International review of neurobiology, 2011, Volume: 98

    Topics: Antiparkinson Agents; Basal Ganglia; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Humans; Levodopa; Neurosurgery; Parkinson Disease

2011
Motor complications in Parkinson's disease.
    The International journal of neuroscience, 2011, Volume: 121 Suppl 2

    Topics: Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Hypokinesia; Levodopa; Parkinson Disease

2011
Treatment of Parkinson disease, time and dosage: "does simple dosage facilitate compliance and therapeutic goals?".
    The neurologist, 2011, Volume: 17, Issue:6 Suppl 1

    Topics: Antiparkinson Agents; Disease Progression; Drug Administration Schedule; Dyskinesia, Drug-Induced; Goals; Humans; Levodopa; Parkinson Disease; Patient Compliance

2011
Advanced strategies for treatment of Parkinson's disease: the role of early treatment.
    The American journal of managed care, 2011, Volume: 17 Suppl 12

    Topics: Antiparkinson Agents; Cost-Benefit Analysis; Disease Progression; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Early Diagnosis; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Quality-Adjusted Life Years; Secondary Prevention

2011
Striatal plasticity in Parkinson's disease and L-dopa induced dyskinesia.
    Parkinsonism & related disorders, 2012, Volume: 18 Suppl 1

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuronal Plasticity; Parkinson Disease

2012
Serotonergic involvement in levodopa-induced dyskinesias in Parkinson's disease.
    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2012, Volume: 19, Issue:3

    Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Neurons; Parkinson Disease; Serotonin

2012
Animal models of L-DOPA-induced dyskinesia: an update on the current options.
    Neuroscience, 2012, Jun-01, Volume: 211

    Topics: Animals; Disease Models, Animal; Drug Discovery; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Reproducibility of Results

2012
Functional neuroimaging in Parkinson's disease.
    Cold Spring Harbor perspectives in medicine, 2012, Volume: 2, Issue:5

    Topics: Antiparkinson Agents; Brain Diseases, Metabolic; Cognition Disorders; Disease Progression; Dopamine; Dyskinesia, Drug-Induced; Fluorodeoxyglucose F18; Functional Neuroimaging; Humans; Levodopa; Lewy Bodies; Magnetic Resonance Imaging; Neurotransmitter Agents; Parkinson Disease; Positron-Emission Tomography; Psychomotor Disorders; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon

2012
What can we expect from the serotonergic side of L-DOPA?
    Revue neurologique, 2012, Volume: 168, Issue:12

    Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Serotonergic Neurons; Serotonin; Serotonin Agents; Serotonin Receptor Agonists; Synaptic Transmission

2012
An approach to the continuous dopaminergic stimulation in Parkinson's disease.
    The Israel Medical Association journal : IMAJ, 2012, Volume: 14, Issue:3

    Topics: Antiparkinson Agents; Delayed-Action Preparations; Dopamine Agonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2012
N-Methyl-D-Aspartate antagonists in levodopa induced dyskinesia: a meta-analysis.
    The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 2012, Volume: 39, Issue:4

    Topics: Amantadine; Databases, Factual; Disability Evaluation; Double-Blind Method; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic; Receptors, N-Methyl-D-Aspartate; Severity of Illness Index

2012
Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease.
    CNS drugs, 2012, Volume: 26, Issue:12

    Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptors, AMPA; Receptors, Glutamate; Receptors, Metabotropic Glutamate; Receptors, N-Methyl-D-Aspartate

2012
The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease.
    Pharmacological reviews, 2013, Volume: 65, Issue:1

    Topics: Animals; Antiparkinson Agents; Basal Ganglia; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Synaptic Transmission

2013
Levodopa response motor complications--GABA receptors and preproenkephalin expression in human brain.
    Parkinsonism & related disorders, 2002, Volume: 8, Issue:6

    Topics: Animals; Brain; Dyskinesia, Drug-Induced; Enkephalins; Humans; Levodopa; Protein Precursors; Receptors, GABA

2002
Acoustic analysis of parkinsonian speech I: speech characteristics and L-Dopa therapy.
    NeuroRehabilitation, 2002, Volume: 17, Issue:3

    Topics: Articulation Disorders; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Long-Term Care; Male; Parkinson Disease; Prognosis; Risk Assessment; Risk Factors; Speech Acoustics; Speech Disorders; Speech Production Measurement; Speech Therapy; Treatment Outcome

2002
Acoustic analysis of parkinsonian speech II: L-Dopa related fluctuations and methodological issues.
    NeuroRehabilitation, 2002, Volume: 17, Issue:3

    Topics: Articulation Disorders; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Long-Term Care; Male; Parkinson Disease; Prognosis; Risk Assessment; Severity of Illness Index; Speech Acoustics; Speech Production Measurement; Speech Therapy; Treatment Outcome

2002
Glutamate-mediated striatal dysregulation and the pathogenesis of motor response complications in Parkinson's disease.
    Amino acids, 2002, Volume: 23, Issue:1-3

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Glutamic Acid; Humans; Levodopa; Motor Activity; Parkinson Disease; Receptors, Cell Surface

2002
Recognition and treatment of response fluctuations in Parkinson's disease: review article.
    Amino acids, 2002, Volume: 23, Issue:1-3

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Motor Activity; Parkinson Disease; Treatment Outcome

2002
Treatment of Parkinson's disease: levodopa as the first choice.
    Journal of neurology, 2002, Volume: 249 Suppl 2

    Topics: Dyskinesia, Drug-Induced; Dystonia; Female; Humans; Levodopa; Male; Neuroprotective Agents; Parkinson Disease; Randomized Controlled Trials as Topic

2002
Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
    Journal of neurology, 2002, Volume: 249 Suppl 2

    Topics: Animals; Antiparkinson Agents; Bromocriptine; Contraindications; Disease Models, Animal; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine

2002
New drugs in the future treatment of Parkinson's disease.
    Journal of neurology, 2002, Volume: 249 Suppl 2

    Topics: Animals; Antioxidants; Antipsychotic Agents; Dopamine Agonists; Drug Therapy; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Glial Cell Line-Derived Neurotrophic Factor; Humans; Levodopa; Monoamine Oxidase Inhibitors; Nerve Growth Factors; Neuroprotective Agents; Parkinson Disease; Psychotic Disorders

2002
New insights in Parkinson's disease therapy: can levodopa-induced dyskinesia ever be manageable.
    Advances in neurology, 2003, Volume: 91

    Topics: Animals; Brain; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Neural Pathways; Parkinson Disease; Receptors, Dopamine

2003
Strategies to modify levodopa treatment.
    Advances in neurology, 2003, Volume: 91

    Topics: Antiparkinson Agents; Drug Interactions; Drug Resistance; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2003
Renaissance of amantadine in the treatment of Parkinson's disease.
    Advances in neurology, 2003, Volume: 91

    Topics: Amantadine; Animals; Antiparkinson Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Glutamic Acid; Humans; Levodopa; Parkinson Disease; Receptors, N-Methyl-D-Aspartate; Treatment Outcome

2003
Are there clinically significant differences between dopamine agonists.
    Advances in neurology, 2003, Volume: 91

    Topics: Antiparkinson Agents; Clinical Trials as Topic; Disorders of Excessive Somnolence; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine

2003
5-hydroxytryptamine (5-HT, serotonin) and Parkinson's disease - opportunities for novel therapeutics to reduce the problems of levodopa therapy.
    European journal of neurology, 2002, Volume: 9 Suppl 3

    Topics: Animals; Antiparkinson Agents; Basal Ganglia; Drug Delivery Systems; Drug Tolerance; Dyskinesia, Drug-Induced; Humans; Levodopa; Neural Pathways; Parkinson Disease; Receptor, Serotonin, 5-HT1B; Receptor, Serotonin, 5-HT2C; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Serotonin; Serotonin Agents

2002
Measuring motor complications in clinical trials for early Parkinson's disease.
    Journal of neurology, neurosurgery, and psychiatry, 2003, Volume: 74, Issue:2

    Topics: Antiparkinson Agents; Clinical Trials as Topic; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Neurologic Examination; Parkinson Disease; Risk

2003
Should levodopa be used anymore?
    Acta neurologica Belgica, 2002, Volume: 102, Issue:4

    Topics: Antiparkinson Agents; Brain; Dopamine; Dopamine Agonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuronal Plasticity; Parkinson Disease

2002
Initial agonist treatment of Parkinson disease: a critique.
    Neurology, 2003, Feb-11, Volume: 60, Issue:3

    Topics: Animals; Antiparkinson Agents; Binding, Competitive; Clinical Trials as Topic; Confounding Factors, Epidemiologic; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Humans; Levodopa; Membrane Glycoproteins; Membrane Transport Proteins; Motor Activity; Nerve Tissue Proteins; Neuroprotective Agents; Parkinson Disease; Treatment Outcome

2003
[Continuous dopaminergic stimulation, pulsatile dopaminergic stimulation].
    Revue neurologique, 2002, Volume: 158 Spec no 1

    Topics: Antiparkinson Agents; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2002
[Dyskinesia caused by L-DOPA].
    Revue neurologique, 2002, Volume: 158 Spec no 1

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2002
[Management of levodopa-induced dyskinesia].
    Revue neurologique, 2002, Volume: 158 Spec no 1

    Topics: Algorithms; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2002
Motor complications of Parkinson's disease.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2003, Volume: 24 Suppl 1

    Topics: Drug Resistance; Dyskinesia, Drug-Induced; Dyskinesias; Humans; Hypokinesia; Levodopa; Parkinson Disease; Treatment Failure

2003
[Various kinds of antiparkinson agents and their characteristics].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2003, Aug-10, Volume: 92, Issue:8

    Topics: Animals; Antiparkinson Agents; Autonomic Nervous System Diseases; Catechol O-Methyltransferase Inhibitors; Cholinergic Antagonists; Dopamine Agonists; Drug Tolerance; Dyskinesia, Drug-Induced; Humans; Levodopa; Mental Disorders; Monoamine Oxidase Inhibitors

2003
[Therapy for patients with progressive Parkinson's disease].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2003, Aug-10, Volume: 92, Issue:8

    Topics: Antiparkinson Agents; Disease Progression; Drug Tolerance; Dyskinesia, Drug-Induced; Humans; Levodopa; Life Style; Parkinson Disease

2003
The MPTP-treated primate as a model of motor complications in PD: primate model of motor complications.
    Neurology, 2003, Sep-23, Volume: 61, Issue:6 Suppl 3

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine Agonists; Drug Resistance; Dyskinesia, Drug-Induced; Levodopa; Motor Activity; Parkinsonian Disorders; Primates

2003
Clinical strategies to prevent and delay motor complications.
    Neurology, 2003, Sep-23, Volume: 61, Issue:6 Suppl 3

    Topics: Antiparkinson Agents; Benzothiazoles; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Pramipexole; Thiazoles

2003
Present and future directions in the management of motor complications in patients with advanced PD.
    Neurology, 2003, Sep-23, Volume: 61, Issue:6 Suppl 3

    Topics: Antiparkinson Agents; Chronic Disease; Disease Management; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Humans; Levodopa; Middle Aged; Neurosurgical Procedures; Parkinson Disease

2003
Adenosine A2A receptor modulation of motor systems for symptomatic therapy in Parkinson's disease.
    Neurology, 2003, Dec-09, Volume: 61, Issue:11 Suppl 6

    Topics: Animals; Basal Ganglia; Dopamine Agonists; Dyskinesia, Drug-Induced; Efferent Pathways; Enzyme Inhibitors; Humans; Levodopa; Parkinson Disease; Receptor, Adenosine A2A

2003
Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease.
    Neurology, 2003, Dec-09, Volume: 61, Issue:11 Suppl 6

    Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Clinical Trials as Topic; Corpus Striatum; Disease Models, Animal; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Globus Pallidus; Humans; Levodopa; Mice; Mice, Knockout; Motor Activity; Neurons; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Primates; Purines; Rats; Receptor, Adenosine A2A; Receptors, Dopamine D2

2003
Unmet medical needs in Parkinson's disease.
    Neurology, 2004, Jan-13, Volume: 62, Issue:1 Suppl 1

    Topics: Antiparkinson Agents; Disability Evaluation; Disease Progression; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2004
New developments in levodopa therapy.
    Neurology, 2004, Jan-13, Volume: 62, Issue:1 Suppl 1

    Topics: Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Pulse Therapy, Drug

2004
Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation.
    Neurology, 2004, Jan-13, Volume: 62, Issue:1 Suppl 1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Catechols; Disease Models, Animal; Dopamine Agonists; Drug Administration Schedule; Drug Evaluation, Preclinical; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Levodopa; Nitriles; Parkinson Disease, Secondary; Primates; Rats

2004
Continuous dopaminergic stimulation in early and advanced Parkinson's disease.
    Neurology, 2004, Jan-13, Volume: 62, Issue:1 Suppl 1

    Topics: Animals; Antiparkinson Agents; Catechols; Dopamine Agents; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Parkinson Disease

2004
COMT inhibitors in Parkinson's disease: can they prevent and/or reverse levodopa-induced motor complications?
    Neurology, 2004, Jan-13, Volume: 62, Issue:1 Suppl 1

    Topics: Animals; Antiparkinson Agents; Area Under Curve; Aromatic Amino Acid Decarboxylase Inhibitors; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Drug Administration Routes; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Parkinson Disease

2004
Comt inhibition in the treatment of Parkinson's disease: neuroprotection and future perspectives.
    Advances in experimental medicine and biology, 2004, Volume: 541

    Topics: Animals; Antiparkinson Agents; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Depression; Dyskinesia, Drug-Induced; Forecasting; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Psychoses, Substance-Induced

2004
[Pathophysiology and therapy of L-Dopa-induced dyskinesia].
    Revue neurologique, 2003, Volume: 159, Issue:12

    Topics: Animals; Basal Ganglia; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Receptors, Adrenergic; Receptors, Dopamine; Receptors, Glutamate; Receptors, Opioid; Receptors, Purinergic P1

2003
Rapid treatment of "wearing off" in Parkinson's disease.
    Neurology, 2004, Mar-23, Volume: 62, Issue:6 Suppl 4

    Topics: Antiemetics; Antiparkinson Agents; Apomorphine; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Levodopa; Nausea; Parkinson Disease; Salvage Therapy; Time Factors

2004
[Hypothesis: Parkinson's disease, reward deficiency syndrome and addictive effects of levodopa].
    Neurologia (Barcelona, Spain), 2004, Volume: 19, Issue:3

    Topics: Adult; Antiparkinson Agents; Behavior, Addictive; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Neuronal Plasticity; Parkinson Disease; Reward; Visual Cortex

2004
Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease.
    Current opinion in neurology, 2003, Volume: 16 Suppl 1

    Topics: Animals; Antiparkinson Agents; Binding, Competitive; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2

2003
DARPP-32 and modulation of cAMP signaling: involvement in motor control and levodopa-induced dyskinesia.
    Parkinsonism & related disorders, 2004, Volume: 10, Issue:5

    Topics: Animals; Cyclic AMP; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Humans; Levodopa; Motor Activity; Nerve Tissue Proteins; Phosphoproteins; Signal Transduction

2004
Recent failures of new potential symptomatic treatments for Parkinson's disease: causes and solutions.
    Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:7

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Agents; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Globus Pallidus; Humans; Levodopa; Movement Disorders; Neurons; Neurosurgical Procedures; Oxidopamine; Parkinson Disease; Treatment Failure

2004
Deep brain stimulation in the treatment of dyskinesia and dystonia.
    Neurosurgical focus, 2004, Jul-15, Volume: 17, Issue:1

    Topics: Dyskinesia, Drug-Induced; Dyskinesias; Dystonic Disorders; Electric Stimulation Therapy; Electrodes, Implanted; Globus Pallidus; Humans; Levodopa; Molecular Chaperones; Parkinson Disease; Stereotaxic Techniques; Subthalamic Nucleus; Treatment Outcome

2004
Comparison of pallidal and subthalamic deep brain stimulation for the treatment of levodopa-induced dyskinesias.
    Neurosurgical focus, 2004, Jul-15, Volume: 17, Issue:1

    Topics: Antiparkinson Agents; Combined Modality Therapy; Dyskinesia, Drug-Induced; Dyskinesias; Electric Stimulation Therapy; Electrodes, Implanted; Globus Pallidus; Humans; Levodopa; Organ Specificity; Parkinson Disease; Subthalamic Nucleus; Thalamus; Treatment Outcome

2004
Long term motor complications of levodopa: clinical features, mechanisms, and management strategies.
    Postgraduate medical journal, 2004, Volume: 80, Issue:946

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Dystonia; Forecasting; Humans; Levodopa; Parkinson Disease

2004
Levodopa in the treatment of Parkinson's disease: current controversies.
    Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:9

    Topics: Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine

2004
[Medical treatment of dyskinesia].
    Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62, Issue:9

    Topics: Dyskinesia, Drug-Induced; Dystonia; Humans; Levodopa

2004
Options in the treatment of motor fluctuations and dyskinesias in Parkinson's disease: a brief review.
    Neurologic clinics, 2004, Volume: 22, Issue:3 Suppl

    Topics: Antiparkinson Agents; Clinical Trials as Topic; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Globus Pallidus; Humans; Levodopa; Neurologic Examination; Treatment Outcome

2004
["How I do it" no. 8, dopa-resistant Parkinson's disease].
    No shinkei geka. Neurological surgery, 2004, Volume: 32, Issue:11

    Topics: Adult; Antiparkinson Agents; Brain; Drug Resistance; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Humans; Levodopa; Magnetic Resonance Imaging; Male; Parkinson Disease; Tomography, X-Ray Computed

2004
Levodopa-induced dyskinesia in Parkinson's disease.
    Journal of neural transmission (Vienna, Austria : 1996), 2005, Volume: 112, Issue:3

    Topics: Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine

2005
Striatal synaptic plasticity: implications for motor learning and Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20, Issue:4

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Learning; Levodopa; Motor Skills; Neural Pathways; Neuronal Plasticity; Parkinson Disease; Rats; Synapses

2005
Role of surgery in the treatment of motor complications.
    Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20 Suppl 11

    Topics: Antiparkinson Agents; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Globus Pallidus; Humans; Levodopa; Neurosurgical Procedures; Parkinson Disease; Subthalamic Nucleus; Thalamus

2005
Other pharmacological treatments for motor complications and dyskinesias.
    Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20 Suppl 11

    Topics: Amantadine; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Dyskinesia, Drug-Induced; Gait; Humans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Periodicity; Purinergic P1 Receptor Antagonists; Purines; Selegiline

2005
Pathophysiology of motor fluctuations in Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20 Suppl 11

    Topics: Adaptation, Physiological; Antiparkinson Agents; Basal Ganglia; Corpus Striatum; Cyclic AMP; Dyskinesia, Drug-Induced; Globus Pallidus; Humans; Hypokinesia; Levodopa; Muscle Rigidity; Neural Pathways; Parkinson Disease; Receptors, Neurotransmitter; Thalamus; Tremor

2005
Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations.
    Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20 Suppl 11

    Topics: Adult; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Risk Factors; Severity of Illness Index

2005
Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy.
    Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20 Suppl 11

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antiparkinson Agents; Coenzymes; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Indans; Levodopa; Membrane Proteins; N-Methylaspartate; Neuroprotective Agents; Parkinson Disease; Prostaglandin-Endoperoxide Synthases; Ubiquinone; Vitamin E

2005
Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors.
    Parkinsonism & related disorders, 2005, Volume: 11 Suppl 1

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3

2005
Pathological synaptic plasticity in the striatum: implications for Parkinson's disease.
    Neurotoxicology, 2005, Volume: 26, Issue:5

    Topics: Animals; Antiparkinson Agents; Cerebral Cortex; Denervation; Dyskinesia, Drug-Induced; Humans; Levodopa; Long-Term Potentiation; Neostriatum; Neuronal Plasticity; Parkinson Disease; Parkinson Disease, Secondary; Rats; Synapses

2005
Nondopaminergic mechanisms in levodopa-induced dyskinesia.
    Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20, Issue:8

    Topics: Animals; Antiparkinson Agents; Biogenic Monoamines; Brain; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Synaptic Transmission

2005
New ideas on the origin of L-dopa-induced dyskinesias: age, genes and neural plasticity.
    Trends in pharmacological sciences, 2005, Volume: 26, Issue:8

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Neuronal Plasticity; Parkinson Disease; Pharmacogenetics

2005
Optimising levodopa therapy for the management of Parkinson's disease.
    Journal of neurology, 2005, Volume: 252 Suppl 4

    Topics: Antiparkinson Agents; Clinical Trials as Topic; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2005
Advances in the delivery of treatments for Parkinson's disease.
    Expert opinion on drug delivery, 2005, Volume: 2, Issue:6

    Topics: Animals; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Chemistry, Pharmaceutical; Clinical Trials as Topic; Delayed-Action Preparations; Drug Delivery Systems; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Forecasting; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease

2005
The levodopa wearing-off phenomenon in Parkinson's disease: pharmacokinetic considerations.
    Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:10

    Topics: Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Clinical Trials as Topic; Delayed-Action Preparations; Dopa Decarboxylase; Drug Administration Schedule; Drug Therapy, Combination; Drug Tolerance; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Parkinson Disease

2006
[Role and regulation of dopamine D1 receptors in the striatum: implications for the genesis of dyskinesia in Parkinson's disease].
    Revue neurologique, 2006, Volume: 162, Issue:6-7

    Topics: Antiparkinson Agents; Corpus Striatum; Cyclic AMP; Dyskinesia, Drug-Induced; GTP-Binding Proteins; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine D1; Receptors, Dopamine D2

2006
Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications.
    The Lancet. Neurology, 2006, Volume: 5, Issue:8

    Topics: Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dopamine Agents; Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Levodopa; Neural Networks, Computer; Parkinson Disease; Receptors, Dopamine

2006
Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Nature clinical practice. Neurology, 2006, Volume: 2, Issue:7

    Topics: Antiparkinson Agents; Clinical Trials as Topic; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2006
How reliable is the behavioural evaluation of dyskinesia in animal models of Parkinson's disease?
    Behavioural pharmacology, 2006, Volume: 17, Issue:5-6

    Topics: Animals; Antiparkinson Agents; Behavior, Animal; Dopamine Agents; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; Levodopa; Motor Activity; Motor Skills; Parkinsonian Disorders; Stereotyped Behavior

2006
Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia.
    Journal of neurochemistry, 2006, Volume: 99, Issue:2

    Topics: Animals; Basal Ganglia; Blood-Brain Barrier; Dopamine; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuronal Plasticity; Synapses; Synaptic Transmission

2006
Long-term care of Parkinson's disease. Strategies for managing "wearing off" symptom re-emergence and dyskinesias.
    Geriatrics, 2006, Volume: 61, Issue:9

    Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Long-Term Care; Nitriles; Parkinson Disease

2006
Thirty five years of experience in the treatment of Parkinson's disease with levodopa and associations.
    Journal of neural transmission. Supplementum, 2006, Issue:70

    Topics: Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; History, 20th Century; Humans; Levodopa; Parkinson Disease

2006
[Levodopa for Parkinson's disease: What have we learned?].
    Revista medica de Chile, 2006, Volume: 134, Issue:7

    Topics: Antiparkinson Agents; Chile; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2006
Pathophysiology of motor complications in Parkinson disease: postsynaptic mechanisms are crucial.
    Archives of neurology, 2007, Volume: 64, Issue:1

    Topics: Animals; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Motor Activity; Parkinson Disease; Synapses

2007
[Prevention and treatment of fluctuations in patients with Parkinson's disease].
    Praxis, 2006, Dec-20, Volume: 95, Issue:51-52

    Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Catechol O-Methyltransferase Inhibitors; Deep Brain Stimulation; Dopamine Agonists; Drug Administration Routes; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Infusion Pumps, Implantable; Levodopa; Monoamine Oxidase Inhibitors; Neurologic Examination; Parkinson Disease; Treatment Outcome

2006
Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia.
    Trends in neurosciences, 2007, Volume: 30, Issue:5

    Topics: Animals; Brain; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Movement Disorders; Neuronal Plasticity; Neurons; Parkinson Disease

2007
Balancing short-term symptom control and long-term functional outcomes in patients with Parkinson's disease.
    CNS spectrums, 2007, Volume: 12, Issue:4

    Topics: Activities of Daily Living; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Long-Term Care; Parkinson Disease; Quality of Life; Risk Factors

2007
Levodopa-induced dyskinesias.
    Movement disorders : official journal of the Movement Disorder Society, 2007, Jul-30, Volume: 22, Issue:10

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; PubMed; Quality of Life; Review Literature as Topic

2007
Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment.
    Postgraduate medical journal, 2007, Volume: 83, Issue:980

    Topics: Antiparkinson Agents; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Neurosurgical Procedures; Parkinson Disease; Receptors, N-Methyl-D-Aspartate; Risk Factors

2007
Levodopa-induced dyskinesia in Parkinson's disease: epidemiology, etiology, and treatment.
    Current neurology and neuroscience reports, 2007, Volume: 7, Issue:4

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2007
Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
    CNS drugs, 2007, Volume: 21, Issue:8

    Topics: Antiparkinson Agents; Disease Progression; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2007
Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications.
    Progress in neurobiology, 2007, Volume: 83, Issue:5

    Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptor, Adenosine A2A; Receptor, Metabotropic Glutamate 5; Receptors, Dopamine D2; Receptors, Metabotropic Glutamate

2007
Role of the pharmacist in the effective management of wearing-off in Parkinson's disease.
    The Annals of pharmacotherapy, 2007, Volume: 41, Issue:11

    Topics: Antiparkinson Agents; Carbidopa; Catechols; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Monoamine Oxidase Inhibitors; Nitriles; Parkinson Disease; Patient Education as Topic; Pharmacists; Professional Role; Severity of Illness Index

2007
Noradrenaline in Parkinson's disease: from disease progression to current therapeutics.
    Current medicinal chemistry, 2007, Volume: 14, Issue:22

    Topics: Animals; Antiparkinson Agents; Disease Progression; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Locus Coeruleus; Neurons; Norepinephrine; Parkinson Disease; Receptors, Adrenergic; Receptors, Dopamine

2007
Animal models of Parkinson's disease and L-dopa induced dyskinesia: how close are we to the clinic?
    Psychopharmacology, 2008, Volume: 199, Issue:3

    Topics: Animals; Animals, Genetically Modified; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; MPTP Poisoning; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Reproducibility of Results; Sympatholytics

2008
Optimizing pharmacotherapy: strategies to manage the wearing-off phenomenon.
    Journal of the American Medical Directors Association, 2006, Volume: 7, Issue:7 Suppl 2

    Topics: Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Parkinson Disease

2006
Paradoxes of functional neurosurgery: clues from basal ganglia recordings.
    Movement disorders : official journal of the Movement Disorder Society, 2008, Volume: 23, Issue:1

    Topics: Antiparkinson Agents; Basal Ganglia; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Dystonia; Essential Tremor; Globus Pallidus; Humans; Levodopa; Movement Disorders; Neurosurgical Procedures; Parkinson Disease

2008
L-DOPA-induced dyskinesia: cellular mechanisms and approaches to treatment.
    Parkinsonism & related disorders, 2007, Volume: 13 Suppl 3

    Topics: Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinsonian Disorders

2007
Parkinson's disease: levodopa-induced dyskinesia and signal transduction.
    The FEBS journal, 2008, Volume: 275, Issue:7

    Topics: Animals; Antiparkinson Agents; Drug Delivery Systems; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Signal Transduction

2008
Advances in understanding L-DOPA-induced dyskinesia.
    Current opinion in neurobiology, 2007, Volume: 17, Issue:6

    Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Models, Neurological; Neural Pathways; Synaptic Transmission

2007
MAGUK proteins: new targets for pharmacological intervention in the glutamatergic synapse.
    European journal of pharmacology, 2008, May-06, Volume: 585, Issue:1

    Topics: Alzheimer Disease; Animals; Antiparkinson Agents; Chronic Disease; Disks Large Homolog 4 Protein; Dyskinesia, Drug-Induced; Glutamic Acid; Guanylate Kinases; Humans; Huntington Disease; Intracellular Signaling Peptides and Proteins; Levodopa; Membrane Proteins; Pain; Protein Subunits; Receptors, N-Methyl-D-Aspartate; Stroke; Synapses

2008
L-dopa-induced dyskinesia and stereotactic surgery for Parkinson's disease.
    Neurosurgery, 2008, Volume: 62, Issue:2

    Topics: Antiparkinson Agents; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Humans; Levodopa; Neurosurgical Procedures; Parkinson Disease; Stereotaxic Techniques

2008
Dopamine agonist therapy in early Parkinson's disease.
    The Cochrane database of systematic reviews, 2008, Apr-16, Issue:2

    Topics: Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic

2008
Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.
    European neurology, 2008, Volume: 60, Issue:2

    Topics: Aged; Animals; Antiparkinson Agents; Basal Ganglia; Corpus Striatum; Deep Brain Stimulation; Dopamine; Dopamine Agonists; Drug Administration Schedule; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; gamma-Aminobutyric Acid; Humans; Levodopa; Multicenter Studies as Topic; Parkinson Disease; Quality of Life; Receptors, Glutamate; Severity of Illness Index

2008
Drug-induced tardive dyskinesia.
    Current developments in psychopharmacology, 1981, Volume: 6

    Topics: Aging; Antipsychotic Agents; Basal Ganglia Diseases; Diagnosis, Differential; Dyskinesia, Drug-Induced; Humans; Huntington Disease; Levodopa; Psychotic Disorders; Racial Groups; Sex Factors

1981
Neuropharmacological actions of GABA agonists: predictability for their clinical usefulness.
    Advances in biochemical psychopharmacology, 1981, Volume: 29

    Topics: Antipsychotic Agents; Brain Chemistry; Dyskinesia, Drug-Induced; Epilepsy; gamma-Aminobutyric Acid; Humans; Huntington Disease; Levodopa; Muscular Diseases; Schizophrenia

1981
Dogma disputed: is tardive dyskinesia due to postsynaptic dopamine receptor supersensitivity?
    The Journal of clinical psychiatry, 1981, Volume: 42, Issue:12

    Topics: Antipsychotic Agents; Brain; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Neurotransmitter Agents; Receptors, Dopamine

1981
Update on antiparkinsonian agents.
    Geriatrics, 1982, Volume: 37, Issue:9

    Topics: Aged; Amantadine; Antiparkinson Agents; Blood-Brain Barrier; Bromocriptine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Gastrointestinal Diseases; Histamine H1 Antagonists; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Receptors, Dopamine; Selegiline; Vascular Resistance

1982
Current psychopathological theories of tardive dyskinesia and their implications for future research.
    Neuropsychobiology, 1982, Volume: 8, Issue:4

    Topics: Acetylcholine; Adult; Aged; Animals; Antipsychotic Agents; Brain; Dopamine; Dyskinesia, Drug-Induced; Estrogens; Female; gamma-Aminobutyric Acid; Haplorhini; Humans; Levodopa; Norepinephrine; Parkinson Disease, Secondary; Rats; Receptors, Dopamine; Tyrosine 3-Monooxygenase

1982
Animal models of tardive dyskinesia: their use in the search for new treatment methods.
    Modern problems of pharmacopsychiatry, 1983, Volume: 21

    Topics: Age Factors; Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Carbidopa; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Combinations; Drug Interactions; Dyskinesia, Drug-Induced; Guinea Pigs; Haloperidol; Haplorhini; Humans; Levodopa; Lithium; Male; Parasympatholytics; Rats; Receptors, Dopamine; Stereotyped Behavior

1983
Movement disorders with neuroleptic drug treatment.
    The Psychiatric clinics of North America, 1984, Volume: 7, Issue:3

    Topics: Acute Disease; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Diagnosis, Differential; Dopamine; Dopamine Antagonists; Dyskinesia, Drug-Induced; Humans; Huntington Disease; Levodopa; Neuroleptic Malignant Syndrome; Parasympatholytics; Parkinson Disease, Secondary; Receptors, Dopamine; Time Factors; Tourette Syndrome

1984
[Tardive dyskinesia: I. Physiopathology and treatment].
    Arquivos de neuro-psiquiatria, 1984, Volume: 42, Issue:4

    Topics: Animals; Antipsychotic Agents; Baclofen; Binding Sites; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Neurons; Receptors, Dopamine; Receptors, GABA-A; Reserpine

1984
Involuntary movement disorders.
    Neurologic clinics, 1984, Volume: 2, Issue:1

    Topics: Brain; Chorea; Dyskinesia, Drug-Induced; Dystonia Musculorum Deformans; Humans; Huntington Disease; Levodopa; Meige Syndrome; Movement Disorders; Parasympatholytics; Parkinson Disease

1984
A review of clinical trials of lithium in neurology.
    Pharmacology, biochemistry, and behavior, 1984, Volume: 21 Suppl 1

    Topics: Clinical Trials as Topic; Cluster Headache; Dyskinesia, Drug-Induced; Epilepsy; Headache; Humans; Huntington Disease; Hyperkinesis; Levodopa; Lithium; Meniere Disease; Migraine Disorders; Movement Disorders; Nervous System Diseases; Neurocognitive Disorders; Parkinson Disease; Sleep Wake Disorders; Torticollis

1984
GABA system, GABA receptor agonists and dyskinesia.
    Modern problems of pharmacopsychiatry, 1983, Volume: 21

    Topics: Basal Ganglia; Cholinergic Fibers; Dopamine; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Humans; Huntington Disease; Levodopa; Movement Disorders; Receptors, Cell Surface; Receptors, GABA-A

1983
Parkinson's disease in 1984: an update.
    Canadian Medical Association journal, 1984, Nov-01, Volume: 131, Issue:9

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Animals; Dementia; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary; Primates; Psychoses, Substance-Induced; Pyridines; Receptors, Dopamine; Time Factors

1984
[Dyskinesia (author's transl)].
    No to shinkei = Brain and nerve, 1980, Volume: 32, Issue:11

    Topics: Basal Ganglia Diseases; Dyskinesia, Drug-Induced; Humans; Hyperkinesis; Hypersensitivity, Delayed; Levodopa; Movement Disorders; Psychotropic Drugs

1980
Adverse effects of antiparkinsonian drugs.
    Drugs, 1981, Volume: 21, Issue:5

    Topics: Amantadine; Amphetamines; Antiparkinson Agents; Dyskinesia, Drug-Induced; Ergot Alkaloids; Humans; Hypotension; Levodopa; Mental Disorders; Parasympatholytics; Vomiting

1981
The management of Parkinson's disease.
    Australian and New Zealand journal of medicine, 1982, Volume: 12, Issue:2

    Topics: Adult; Aged; Amantadine; Bromocriptine; Diagnosis, Differential; Dyskinesia, Drug-Induced; Humans; Hypotension, Orthostatic; Levodopa; Middle Aged; Nausea; Parasympatholytics; Parkinson Disease

1982
[Treatment of Parkinson disease].
    Arquivos de neuro-psiquiatria, 1995, Volume: 53, Issue:1

    Topics: Antiparkinson Agents; Diagnosis, Differential; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Secondary; Treatment Failure

1995
Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia.
    Biological psychiatry, 1993, Nov-15, Volume: 34, Issue:10

    Topics: Antipsychotic Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Humans; Interneurons; Levodopa; Nerve Degeneration; Neurons; Parkinson Disease; Psychoses, Substance-Induced; Receptors, Cholinergic; Receptors, Dopamine; Schizophrenia

1993
Respiratory dyskinesia. An underrecognized phenomenon.
    Chest, 1994, Volume: 105, Issue:6

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Phenothiazines; Prevalence; Respiration Disorders; Risk Factors; Trifluoperazine

1994
Treating motor fluctuations with controlled-release levodopa preparations.
    Neurology, 1994, Volume: 44, Issue:7 Suppl 6

    Topics: Delayed-Action Preparations; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Psychomotor Performance

1994
Various aspects of motor fluctuations and their management in Parkinson's disease.
    Neurology, 1994, Volume: 44, Issue:7 Suppl 6

    Topics: Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Psychomotor Performance

1994
New and emerging strategies for improving levodopa treatment.
    Neurology, 1994, Volume: 44, Issue:7 Suppl 6

    Topics: Animals; Catechol O-Methyltransferase Inhibitors; Delayed-Action Preparations; Dyskinesia, Drug-Induced; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease

1994
Clinical aspects of motor fluctuations in Parkinson's disease.
    Neurology, 1994, Volume: 44, Issue:7 Suppl 6

    Topics: Adult; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Time Factors

1994
Current strategies in the drug treatment of advanced Parkinson's disease--new modes of dopamine substitution.
    Acta neurologica Scandinavica. Supplementum, 1993, Volume: 146

    Topics: Antiparkinson Agents; Delayed-Action Preparations; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Infusions, Intravenous; Levodopa; Parkinson Disease

1993
Clinical and pathophysiologic aspects of late levodopa failure.
    Neurology, 1993, Volume: 43, Issue:12 Suppl 6

    Topics: Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Time Factors; Treatment Failure

1993
[Oral dyskinesis, facial dystonia].
    Nihon rinsho. Japanese journal of clinical medicine, 1993, Volume: 51, Issue:11

    Topics: Dyskinesia, Drug-Induced; Dystonia; Face; Female; Humans; Levodopa; Male; Meige Syndrome; Mouth; Movement Disorders; Receptors, Dopamine D1; Sulpiride; Tiapamil Hydrochloride; Trihexyphenidyl

1993
The response to levodopa in Parkinson's disease: imposing pharmacological law and order.
    Annals of neurology, 1996, Volume: 39, Issue:5

    Topics: Circadian Rhythm; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Levodopa; Motor Activity; Parkinson Disease; Time Factors

1996
The neural mechanisms and progressive nature of symptoms of Parkinson's disease--based on clinical, neurophysiological and morphological studies.
    Journal of neural transmission. Parkinson's disease and dementia section, 1995, Volume: 10, Issue:1

    Topics: Dihydroxyphenylalanine; Disease Progression; Dyskinesia, Drug-Induced; Humans; Levodopa; Movement Disorders; Nervous System; Parkinson Disease

1995
Methods of managing levodopa-induced dyskinesias.
    Drug safety, 1996, Volume: 14, Issue:6

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa

1996
Gene therapy for Parkinson's disease: an approach to the prevention or palliation of levodopa-associated motor complications.
    Experimental neurology, 1997, Volume: 144, Issue:1

    Topics: Dyskinesia, Drug-Induced; Genetic Therapy; Humans; Levodopa; Parkinson Disease

1997
Controversies in pallidal surgery.
    Acta neurochirurgica. Supplement, 1997, Volume: 68

    Topics: Brain Mapping; Dyskinesia, Drug-Induced; Globus Pallidus; Humans; Levodopa; Neurologic Examination; Parkinson Disease; Stereotaxic Techniques

1997
[Physiopathology of the dyskinesias induced by L-dopa].
    Revista de neurologia, 1997, Volume: 25 Suppl 2

    Topics: Age of Onset; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Severity of Illness Index

1997
[Pharmacological therapy of complicated Parkinson's disease].
    Revista de neurologia, 1997, Volume: 25 Suppl 2

    Topics: Antiparkinson Agents; Ascorbic Acid; Combined Modality Therapy; Diet Therapy; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonia; Humans; Levodopa; Parkinson Disease

1997
Mid-stage parkinsonism with mild motor fluctuations.
    Clinical neuropharmacology, 1994, Volume: 17 Suppl 2

    Topics: Catechol O-Methyltransferase Inhibitors; Delayed-Action Preparations; Dopamine Agonists; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline

1994
Problems with long-term levodopa therapy for Parkinson's disease.
    Clinical neuropharmacology, 1994, Volume: 17 Suppl 2

    Topics: Cognition Disorders; Dyskinesia, Drug-Induced; Gait; Humans; Levodopa; Parkinson Disease; Speech Disorders; Time Factors

1994
Parkinson's disease: drug therapy.
    Bailliere's clinical neurology, 1997, Volume: 6, Issue:1

    Topics: Amantadine; Antiparkinson Agents; Apomorphine; Cholinergic Antagonists; Dopamine Agonists; Dyskinesia, Drug-Induced; Guidelines as Topic; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Treatment Outcome

1997
Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors.
    Molecular psychiatry, 1998, Volume: 3, Issue:2

    Topics: Antipsychotic Agents; Binding, Competitive; Cholinergic Antagonists; Clozapine; Corpus Striatum; Dopamine; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Resistance; Dyskinesia, Drug-Induced; Humans; Levodopa; Ligands; Limbic System; Nerve Tissue Proteins; Parkinson Disease, Secondary; Protein Binding; Psychoses, Substance-Induced; Psychotic Disorders; Radioligand Assay; Receptors, Dopamine D2; Receptors, Muscarinic; Receptors, Serotonin; Recurrence; Serotonin Antagonists; Tomography, Emission-Computed

1998
Levodopa therapy: consequences of the nonphysiologic replacement of dopamine.
    Neurology, 1998, Volume: 50, Issue:5 Suppl 5

    Topics: Animals; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Delayed-Action Preparations; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Parkinson Disease

1998
Effective strategies in the management of Parkinson's disease.
    Hospital medicine (London, England : 1998), 1998, Volume: 59, Issue:4

    Topics: Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Motor Skills Disorders; Parkinson Disease; Time Factors

1998
Characterization of a rodent model in which to investigate the molecular and cellular mechanisms underlying the pathophysiology of L-dopa-induced dyskinesia.
    Advances in neurology, 1998, Volume: 78

    Topics: Animals; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Rats

1998
Stereotactic surgery and Parkinson's disease.
    Stereotactic and functional neurosurgery, 1998, Volume: 70, Issue:2-4

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Globus Pallidus; Humans; Levodopa; Parkinson Disease; Stereotaxic Techniques; Thalamus

1998
COMT inhibition in the treatment of Parkinson's disease.
    Journal of neurology, 1998, Volume: 245, Issue:11 Suppl 3

    Topics: Benzophenones; Catechol O-Methyltransferase; Catechols; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease; Tolcapone

1998
Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 1998, Volume: 13, Issue:6

    Topics: Adrenergic Antagonists; Animals; Antiparkinson Agents; Cannabinoids; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Humans; Levodopa; Narcotic Antagonists; Neurons; Parkinson Disease; Selective Serotonin Reuptake Inhibitors

1998
[Long-term complications of treatment with levodopa].
    Neurologia (Barcelona, Spain), 1998, Volume: 13 Suppl 1

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Time Factors

1998
[Understanding and treating levodopa-induced dyskinesias].
    La Tunisie medicale, 1998, Volume: 76, Issue:12

    Topics: Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

1998
[Arguments in favor of the early treatment of Parkinson's disease with L-Dopa].
    Revue neurologique, 1999, Volume: 155, Issue:1

    Topics: Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Free Radicals; Humans; Levodopa; Life Expectancy; Parkinson Disease; Time Factors

1999
Functional consequences of dopaminergic degeneration in Parkinson's disease.
    Advances in neurology, 1999, Volume: 80

    Topics: Adaptation, Physiological; Brain; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Nerve Degeneration; Parkinson Disease; Receptors, Dopamine D2

1999
Advances in understanding the neural mechanisms underlying L-DOPA-induced dyskinesia.
    Advances in neurology, 1999, Volume: 80

    Topics: Amino Acids; Animals; Antiparkinson Agents; Brain; Corpus Striatum; Dopamine; Dopamine Agonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Synaptic Transmission

1999
Clinical pharmacology of levodopa-induced dyskinesia in parkinsonian patients.
    Advances in neurology, 1999, Volume: 80

    Topics: Antiparkinson Agents; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine D1; Receptors, Dopamine D2

1999
Surgical treatment of levodopa-induced dyskinesias.
    Advances in neurology, 1999, Volume: 80

    Topics: Antiparkinson Agents; Brain; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Fetal Tissue Transplantation; Globus Pallidus; Humans; Levodopa; Thalamus

1999
New aspects in the pathophysiology of dyskinesia. Salpêtrière Deep Brain Stimulation Group.
    Advances in neurology, 1999, Volume: 80

    Topics: Animals; Antiparkinson Agents; Brain; Disease Progression; Dyskinesia, Drug-Induced; Electric Stimulation; Humans; Levodopa; Neurology; Parkinson Disease

1999
[Toxic and adverse neurological effects of anti-parkinsonian drugs].
    Ryoikibetsu shokogun shirizu, 1999, Issue:27 Pt 2

    Topics: Amantadine; Antiparkinson Agents; Bromocriptine; Cholinergic Antagonists; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuroleptic Malignant Syndrome; Psychoses, Substance-Induced; Substance-Related Disorders

1999
Parkinson's disease--levodopa complications.
    The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 1999, Volume: 26 Suppl 2

    Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Hypnotics and Sedatives; Levodopa; Mental Disorders; Monoamine Oxidase Inhibitors; Parkinson Disease

1999
The phenomenology of L-dopa-induced dyskinesias in Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 1999, Volume: 14 Suppl 1

    Topics: Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Haplorhini; Levodopa; Parkinson Disease; Severity of Illness Index

1999
L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease: a clinical pharmacologic approach.
    Movement disorders : official journal of the Movement Disorder Society, 1999, Volume: 14 Suppl 1

    Topics: Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Glutamic Acid; Humans; Levodopa; Narcotics; Norepinephrine; Parkinson Disease; Receptors, Dopamine; Serotonin

1999
Pathophysiology of L-dopa-induced dyskinesias.
    Movement disorders : official journal of the Movement Disorder Society, 1999, Volume: 14 Suppl 1

    Topics: Animals; Binding, Competitive; Corpus Striatum; Dopamine; Dopamine Agonists; Dyskinesia, Drug-Induced; Globus Pallidus; Haplorhini; Humans; Levodopa; Neural Pathways; Neurons; Protein Isoforms; Proto-Oncogene Proteins c-fos; Receptors, GABA; Substantia Nigra

1999
Rating scales for dyskinesias in Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 1999, Volume: 14 Suppl 1

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Severity of Illness Index

1999
L-dopa and dyskinesias in normal monkeys.
    Movement disorders : official journal of the Movement Disorder Society, 1999, Volume: 14 Suppl 1

    Topics: Administration, Oral; Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Haplorhini; Levodopa

1999
Quantitative assessment of dyskinesias in subhuman primates.
    Movement disorders : official journal of the Movement Disorder Society, 1999, Volume: 14 Suppl 1

    Topics: Adrenergic alpha-Antagonists; Animals; Anti-Anxiety Agents; Antiparkinson Agents; Diagnosis, Differential; Dronabinol; Dyskinesia, Drug-Induced; Haplorhini; Idazoxan; Levodopa; Primates; Severity of Illness Index

1999
Medical treatment of later-stage motor problems of Parkinson disease.
    Mayo Clinic proceedings, 1999, Volume: 74, Issue:12

    Topics: Amantadine; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Cholinergic Antagonists; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Combinations; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease, Secondary; Propranolol; Randomized Controlled Trials as Topic; Selegiline; Tolcapone

1999
The efficacy and safety of adjunct bromocriptine therapy for levodopa-induced motor complications: a systematic review.
    Movement disorders : official journal of the Movement Disorder Society, 2000, Volume: 15, Issue:1

    Topics: Antiparkinson Agents; Bromocriptine; Dopamine Agonists; Double-Blind Method; Dyskinesia, Drug-Induced; Humans; Levodopa; Neurologic Examination; Parkinson Disease; Randomized Controlled Trials as Topic; Treatment Outcome

2000
[Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
    Revue neurologique, 2000, Volume: 156, Issue:3

    Topics: Animals; Antiparkinson Agents; Biological Transport, Active; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Enkephalins; Haplorhini; Humans; Levodopa; Neural Pathways; Neuronal Plasticity; Neurons, Efferent; Parkinson Disease; Receptors, Dopamine D2; Substance P; Time Factors

2000
The spectrum of levodopa-induced dyskinesias.
    Annals of neurology, 2000, Volume: 47, Issue:4 Suppl 1

    Topics: Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2000
Dopamine receptors and locomotor responses: molecular aspects.
    Annals of neurology, 2000, Volume: 47, Issue:4 Suppl 1

    Topics: Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Ion Channel Gating; Levodopa; Locomotion; Parkinson Disease; Receptors, Dopamine

2000
Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model.
    Annals of neurology, 2000, Volume: 47, Issue:4 Suppl 1

    Topics: Basal Ganglia; Brain Chemistry; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2000
Physiologic basis of dyskinesia.
    Annals of neurology, 2000, Volume: 47, Issue:4 Suppl 1

    Topics: Basal Ganglia; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2000
Patterns of gene expression and behavior induced by chronic dopamine treatments.
    Annals of neurology, 2000, Volume: 47, Issue:4 Suppl 1

    Topics: Brain Chemistry; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Gene Expression; Humans; Levodopa; Parkinson Disease

2000
Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity?
    Annals of neurology, 2000, Volume: 47, Issue:4 Suppl 1

    Topics: Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuronal Plasticity; Parkinson Disease

2000
Molecular basis of levodopa-induced dyskinesias.
    Annals of neurology, 2000, Volume: 47, Issue:4 Suppl 1

    Topics: Animals; Brain Chemistry; Dopamine Agents; Dyskinesia, Drug-Induced; Gene Expression; Humans; Levodopa; Parkinson Disease

2000
Investigating levodopa-induced dyskinesias in the parkinsonian primate.
    Annals of neurology, 2000, Volume: 47, Issue:4 Suppl 1

    Topics: Animals; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Parkinson Disease, Secondary; Primates

2000
Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates.
    Annals of neurology, 2000, Volume: 47, Issue:4 Suppl 1

    Topics: Animals; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; MPTP Poisoning; Primates

2000
The neural mechanisms underlying levodopa-induced dyskinesia in Parkinson's disease.
    Annals of neurology, 2000, Volume: 47, Issue:4 Suppl 1

    Topics: Cell Communication; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Neurons; Parkinson Disease

2000
Nigrostriatal system plasticity in Parkinson's disease: effect of dopaminergic denervation and treatment.
    Annals of neurology, 2000, Volume: 47, Issue:4 Suppl 1

    Topics: Corpus Striatum; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Nerve Degeneration; Neuronal Plasticity; Parkinson Disease; Substantia Nigra

2000
Clinical physiology of dopa dyskinesia.
    Annals of neurology, 2000, Volume: 47, Issue:4 Suppl 1

    Topics: Dopamine Agents; Dyskinesia, Drug-Induced; Electromyography; Humans; Levodopa; Parkinson Disease

2000
Neuroimaging of dyskinesia.
    Annals of neurology, 2000, Volume: 47, Issue:4 Suppl 1

    Topics: Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Tomography, Emission-Computed

2000
Clinical pharmacology of levodopa-induced dyskinesia.
    Annals of neurology, 2000, Volume: 47, Issue:4 Suppl 1

    Topics: Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2000
Preventing levodopa-induced dyskinesias.
    Annals of neurology, 2000, Volume: 47, Issue:4 Suppl 1

    Topics: Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2000
Medical treatment of levodopa-induced dyskinesias.
    Annals of neurology, 2000, Volume: 47, Issue:4 Suppl 1

    Topics: Amantadine; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2000
Dyskinesias and the subthalamic nucleus.
    Annals of neurology, 2000, Volume: 47, Issue:4 Suppl 1

    Topics: Animals; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Subthalamic Nucleus

2000
Surgery for levodopa-induced dyskinesias.
    Annals of neurology, 2000, Volume: 47, Issue:4 Suppl 1

    Topics: Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2000
Pergolide for levodopa-induced complications in Parkinson's disease.
    The Cochrane database of systematic reviews, 2000, Issue:2

    Topics: Antiparkinson Agents; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Pergolide

2000
Pergolide versus bromocriptine for levodopa-induced motor complications in Parkinson's disease.
    The Cochrane database of systematic reviews, 2000, Issue:2

    Topics: Antiparkinson Agents; Bromocriptine; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Pergolide

2000
Bromocriptine for levodopa-induced motor complications in Parkinson's disease.
    The Cochrane database of systematic reviews, 2000, Issue:2

    Topics: Antiparkinson Agents; Bromocriptine; Dyskinesia, Drug-Induced; Dystonia; Humans; Levodopa; Parkinson Disease

2000
Lisuride versus bromocriptine for levodopa-induced complications in Parkinson's disease.
    The Cochrane database of systematic reviews, 2000, Issue:2

    Topics: Antiparkinson Agents; Bromocriptine; Dyskinesia, Drug-Induced; Humans; Levodopa; Lisuride; Parkinson Disease

2000
Lisuride for levodopa-induced complications in Parkinson's disease.
    The Cochrane database of systematic reviews, 2000, Issue:2

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Lisuride; Parkinson Disease

2000
The pharmacological therapeutic management of levodopa-induced dyskinesias in patients with Parkinson's disease.
    Journal of neurology, 2000, Volume: 247 Suppl 2

    Topics: Animals; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2000
[Tardive dyskinesia and the therapeutic agents].
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2000, Volume: 115, Issue:3

    Topics: Animals; Anti-Dyskinesia Agents; Antipsychotic Agents; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa

2000
Treatment of Parkinson's disease.
    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2000, Volume: 7, Issue:6

    Topics: Age Factors; Animals; Antiparkinson Agents; Anxiety; Catechol O-Methyltransferase Inhibitors; Depression; Dopamine Agonists; Dyskinesia, Drug-Induced; Dystonia; Humans; Levodopa; Parkinson Disease

2000
Levodopa motor complications in Parkinson's disease.
    Trends in neurosciences, 2000, Volume: 23, Issue:10 Suppl

    Topics: Age of Onset; Antiparkinson Agents; Brain; Cost of Illness; Dyskinesia, Drug-Induced; Humans; Incidence; Levodopa; Male; Parkinson Disease; Receptors, Dopamine; Severity of Illness Index

2000
Pathophysiology of the basal ganglia in Parkinson's disease.
    Trends in neurosciences, 2000, Volume: 23, Issue:10 Suppl

    Topics: Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Models, Neurological; Neural Pathways; Neurons; Parkinson Disease; Pulse Therapy, Drug; Receptors, Dopamine

2000
Electrophysiology of dopamine in normal and denervated striatal neurons.
    Trends in neurosciences, 2000, Volume: 23, Issue:10 Suppl

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Electrophysiology; Glutamic Acid; Humans; Levodopa; Models, Neurological; Neurons; Parkinson Disease

2000
Levodopa-induced dyskinesias and dopamine-dependent stereotypies: a new hypothesis.
    Trends in neurosciences, 2000, Volume: 23, Issue:10 Suppl

    Topics: Animals; Antiparkinson Agents; Basal Ganglia; Cerebral Cortex; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Models, Neurological; Neural Pathways; Neuronal Plasticity; Stereotypic Movement Disorder

2000
PET studies and motor complications in Parkinson's disease.
    Trends in neurosciences, 2000, Volume: 23, Issue:10 Suppl

    Topics: Antiparkinson Agents; Brain; Corpus Striatum; Dihydroxyphenylalanine; Dyskinesia, Drug-Induced; Fluorine Radioisotopes; Humans; Levodopa; Neural Pathways; Opioid Peptides; Parkinson Disease; Pulse Therapy, Drug; Putamen; Receptors, Opioid; Tomography, Emission-Computed

2000
Continuous dopamine-receptor stimulation in advanced Parkinson's disease.
    Trends in neurosciences, 2000, Volume: 23, Issue:10 Suppl

    Topics: Antiparkinson Agents; Clinical Trials as Topic; Delayed-Action Preparations; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Tolerance; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Pulse Therapy, Drug; Receptors, Dopamine; Severity of Illness Index

2000
Continuous dopamine-receptor stimulation in early Parkinson's disease.
    Trends in neurosciences, 2000, Volume: 23, Issue:10 Suppl

    Topics: Animals; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Pulse Therapy, Drug; Receptors, Dopamine; Severity of Illness Index

2000
Why delaying levodopa is a good treatment strategy in early Parkinson's disease.
    European journal of neurology, 2000, Volume: 7 Suppl 1

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2000
[Treatment of advanced Parkinson's disease].
    Nihon rinsho. Japanese journal of clinical medicine, 2000, Volume: 58, Issue:10

    Topics: Antiparkinson Agents; Autonomic Nervous System Diseases; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Psychoses, Substance-Induced; Severity of Illness Index

2000
[Details and indications of pallidotomy and thalamotomy for Parkinson's disease].
    Nihon rinsho. Japanese journal of clinical medicine, 2000, Volume: 58, Issue:10

    Topics: Dyskinesia, Drug-Induced; Globus Pallidus; Humans; Levodopa; Muscle Rigidity; Parkinson Disease; Stereotaxic Techniques; Thalamus; Tremor

2000
[Deep brain stimulation(DBS) therapy for parkkinson,s disease].
    Nihon rinsho. Japanese journal of clinical medicine, 2000, Volume: 58, Issue:10

    Topics: Clinical Trials as Topic; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Globus Pallidus; Humans; Levodopa; Muscle Rigidity; Parkinson Disease; Subthalamic Nucleus; Tremor; Ventral Thalamic Nuclei

2000
[Cell transplantation therapy for Parkinson's disease].
    Nihon rinsho. Japanese journal of clinical medicine, 2000, Volume: 58, Issue:10

    Topics: Cell Transplantation; Clinical Trials as Topic; Dyskinesia, Drug-Induced; Ganglia, Sympathetic; Humans; Levodopa; Parkinson Disease; Stereotaxic Techniques; Transplantation, Autologous

2000
[Medical treatment of L-dopa induced dyskinesia].
    Nihon rinsho. Japanese journal of clinical medicine, 2000, Volume: 58, Issue:10

    Topics: Antiparkinson Agents; Dopamine Agonists; Dopamine Antagonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease

2000
[Neurosurgical treatment for dopamine-induced dyskinesias in Parkinson's disease patients].
    Nihon rinsho. Japanese journal of clinical medicine, 2000, Volume: 58, Issue:10

    Topics: Antiparkinson Agents; Brain Tissue Transplantation; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Fetal Tissue Transplantation; Globus Pallidus; Humans; Levodopa; Parkinson Disease; Stereotaxic Techniques; Subthalamic Nucleus; Thalamus

2000
Dyskinesia in Parkinson's disease. Pathophysiology and clinical risk factors.
    Journal of neurology, 2000, Volume: 247 Suppl 4

    Topics: Corpus Striatum; Drug Therapy; Dyskinesia, Drug-Induced; Glutamic Acid; Humans; Levodopa; Neural Pathways; Neuropeptides; Parkinson Disease; Receptors, Dopamine; Receptors, GABA; Receptors, N-Methyl-D-Aspartate; Risk Factors

2000
[Physiopathology of parkinsonism and dyskinesias: lessons from surgical observations]].
    Neurologia (Barcelona, Spain), 2001, Volume: 16, Issue:1

    Topics: Animals; Antiparkinson Agents; Basal Ganglia; Dyskinesia, Drug-Induced; Dyskinesias; Globus Pallidus; Humans; Levodopa; Models, Animal; Models, Neurological; Motor Skills; Neurons; Parkinsonian Disorders; Subthalamic Nucleus; Thalamus

2001
Cabergoline for levodopa-induced complications in Parkinson's disease.
    The Cochrane database of systematic reviews, 2001, Issue:1

    Topics: Antiparkinson Agents; Cabergoline; Dopamine Agonists; Dyskinesia, Drug-Induced; Ergolines; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic

2001
Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease.
    The Cochrane database of systematic reviews, 2001, Issue:1

    Topics: Antiparkinson Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Dyskinesia, Drug-Induced; Ergolines; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic

2001
Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature.
    Movement disorders : official journal of the Movement Disorder Society, 2001, Volume: 16, Issue:3

    Topics: Adult; Age of Onset; Aged; Antiparkinson Agents; Australia; Canada; Drug Tolerance; Dyskinesia, Drug-Induced; Europe; Humans; Hypokinesia; Levodopa; Middle Aged; Parkinson Disease; Prevalence; Risk; Time Factors; United States

2001
Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.
    Nature reviews. Neuroscience, 2001, Volume: 2, Issue:8

    Topics: Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2001
Motor fluctuations and dyskinesia in Parkinson's disease.
    Parkinsonism & related disorders, 2001, Volume: 8, Issue:2

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Dyskinesias; Humans; Levodopa; Movement; Parkinson Disease

2001
Use of selective thalamotomy for various kinds of movement disorder, based on basic studies.
    Stereotactic and functional neurosurgery, 2000, Volume: 75, Issue:2-3

    Topics: Antiparkinson Agents; Cerebral Hemorrhage; Chorea; Dyskinesia, Drug-Induced; Dyskinesias; Dystonia; Electrodes, Implanted; Electroencephalography; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Movement Disorders; Muscle Rigidity; Paresthesia; Parkinson Disease; Postoperative Complications; Stereotaxic Techniques; Surgery, Computer-Assisted; Thalamic Nuclei; Tomography, X-Ray Computed; Treatment Outcome; Tremor

2000
Neurotransmitter interactions related to central dopamine neurons.
    Essays in neurochemistry and neuropharmacology, 1978, Volume: 3

    Topics: Acetylcholine; Animals; Antipsychotic Agents; Behavior, Animal; Brain; Central Nervous System; Dopamine; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Humans; Huntington Disease; Levodopa; Mental Disorders; Neural Pathways; Neurons; Neurotransmitter Agents; Norepinephrine; Parasympathetic Nervous System; Parkinson Disease; Serotonin

1978
In search of treatment for tardive dyskinesia: review of the literature.
    Schizophrenia bulletin, 1979, Volume: 5, Issue:2

    Topics: Amantadine; Antipsychotic Agents; Diagnosis, Differential; Dyskinesia, Drug-Induced; Humans; Levodopa; Lithium; Methylphenidate; Parasympatholytics; Parasympathomimetics; Patient Dropouts; Research Design

1979
[Modulation of dopaminergic receptor sensitivity in the central nervous system: important parameters in synaptic function regulation].
    L'Encephale, 1979, Volume: 5, Issue:2

    Topics: Acetylcholine; Adenylyl Cyclases; Animals; Antipsychotic Agents; Apomorphine; Behavior; Corpus Striatum; Dogs; Dopamine; Dopamine Antagonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Homovanillic Acid; Humans; Hypothermia; Levodopa; Memory; Mice; Opioid-Related Disorders; Parkinson Disease; Psychotic Disorders; Rats; Receptors, Dopamine; Sleep; Stereotyped Behavior; Substantia Nigra; Synapses; Synaptic Transmission

1979
Deanol in the management of involuntary movement disorders: a review.
    Diseases of the nervous system, 1977, Volume: 38, Issue:12 Pt 2

    Topics: Acetylcholine; Deanol; Dopamine; Dyskinesia, Drug-Induced; Ethanolamines; Female; Humans; Huntington Disease; Levodopa; Male; Middle Aged; Models, Neurological; Movement Disorders; Parkinson Disease; Physostigmine; Research Design; Time Factors

1977
The treatment of Parkinson's disease.
    Postgraduate medical journal, 1977, Volume: 53, Issue:626

    Topics: Diagnosis, Differential; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Secondary

1977
Clinical pharmacokinetics of levodopa in parkinson's disease.
    Clinical pharmacokinetics, 1976, Volume: 1, Issue:5

    Topics: Carboxy-Lyases; Cardiovascular Diseases; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Gastric Mucosa; Gastrointestinal Diseases; Homovanillic Acid; Humans; Intestinal Absorption; Kinetics; Levodopa; Mental Disorders; Parkinson Disease; Pyridoxine; Stimulation, Chemical; Time Factors

1976
The rationale for continuous dopaminergic stimulation in patients with Parkinson's disease.
    Neurology, 1992, Volume: 42, Issue:1 Suppl 1

    Topics: Animals; Clinical Trials as Topic; Corpus Striatum; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Infusion Pumps; Infusions, Intravenous; Levodopa; Parkinson Disease; Substantia Nigra

1992
Pharmacokinetics and pharmacodynamics of levodopa.
    Neurology, 1992, Volume: 42, Issue:1 Suppl 1

    Topics: Administration, Oral; Aromatic-L-Amino-Acid Decarboxylases; Blood; Brain; Digestive System; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Receptors, Dopamine

1992
Levodopa-induced dyskinesia: facts and fancy. What does the MPTP monkey model tell us?
    The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 1992, Volume: 19, Issue:1 Suppl

    Topics: Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Haplorhini; Humans; Levodopa; MPTP Poisoning

1992
The use of thalamotomy in the treatment of levodopa-induced dyskinesia.
    Acta neurochirurgica, 1992, Volume: 114, Issue:3-4

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Mapping; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Macaca fascicularis; Male; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Stereotaxic Techniques; Thalamus

1992
Parkinson's disease.
    Lancet (London, England), 1990, Apr-21, Volume: 335, Issue:8695

    Topics: 1-Methyl-4-phenylpyridinium; Adrenal Glands; Adult; Antiparkinson Agents; Brain Chemistry; Child; Child, Preschool; Cytoplasmic Granules; Dyskinesia, Drug-Induced; Environmental Pollutants; Fetus; Humans; Levodopa; Middle Aged; Palliative Care; Parkinson Disease; Prevalence; Research; Selegiline; Substantia Nigra; Time Factors

1990
A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment.
    Movement disorders : official journal of the Movement Disorder Society, 1990, Volume: 5, Issue:2

    Topics: Brain; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

1990
Pharmacokinetic and pharmacodynamic considerations in management of motor response fluctuations in Parkinson's disease.
    Neurologic clinics, 1990, Volume: 8, Issue:1

    Topics: Delayed-Action Preparations; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

1990
Drug-induced neurological disorders.
    Progress in neurobiology, 1990, Volume: 34, Issue:4

    Topics: Antihypertensive Agents; Aspirin; Brain Diseases; Dyskinesia, Drug-Induced; Humans; Levodopa; Nervous System Diseases; Neuromuscular Diseases

1990
Levodopa-induced dyskinesia: review, observations, and speculations.
    Neurology, 1990, Volume: 40, Issue:2

    Topics: Animals; Dyskinesia, Drug-Induced; Humans; Levodopa; Receptors, Dopamine

1990
Medical treatment of Parkinson's disease.
    Comprehensive therapy, 1989, Volume: 15, Issue:3

    Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

1989
Motor complications associated with chronic levodopa therapy in Parkinson's disease.
    Neurology, 1989, Volume: 39, Issue:11 Suppl 2

    Topics: Dementia; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Psychomotor Performance; Psychoses, Substance-Induced

1989
Tardive dyskinesia: epidemiologic factors as a guide for prevention and management.
    Advances in biochemical psychopharmacology, 1985, Volume: 40

    Topics: Age Factors; Animals; Antipsychotic Agents; Bromocriptine; Diagnosis, Differential; Dyskinesia, Drug-Induced; Haplorhini; Humans; Levodopa; Parasympatholytics; Reserpine; Risk

1985
Psychiatric side effects during the treatment of Parkinson's disease.
    Journal of neural transmission. Supplementum, 1988, Volume: 27

    Topics: Dreams; Dyskinesia, Drug-Induced; Hallucinations; Humans; Levodopa; Mental Disorders; Paranoid Disorders; Parkinson Disease; Serotonin; Severity of Illness Index; Sleep Wake Disorders

1988
Blepharospasm-oromandibular dystonia syndrome (Meige's syndrome): clinical aspects.
    Advances in neurology, 1988, Volume: 49

    Topics: Basal Ganglia Diseases; Dyskinesia, Drug-Induced; Facial Muscles; Female; Humans; Levodopa; Meige Syndrome

1988
Drug treatment of hyperkinetic movement disorders.
    Seminars in neurology, 1987, Volume: 7, Issue:2

    Topics: Benzodiazepines; Botulinum Toxins; Dopamine; Dyskinesia, Drug-Induced; Humans; Hyperkinesis; Levodopa; Movement Disorders; Parasympathomimetics

1987

Trials

159 trial(s) available for levodopa and Dyskinesia, Drug-Induced

ArticleYear
Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies.
    Parkinsonism & related disorders, 2022, Volume: 96

    Topics: Amantadine; Antiparkinson Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Treatment Outcome

2022
Cerebellar continuous theta burst stimulation reduces levodopa-induced dyskinesias and decreases serum BDNF levels.
    Neuroscience letters, 2020, 01-18, Volume: 716

    Topics: Aged; Antiparkinson Agents; Brain-Derived Neurotrophic Factor; Cerebellum; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polymorphism, Single Nucleotide; Theta Rhythm; Transcranial Magnetic Stimulation

2020
EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's Disease.
    Journal of Parkinson's disease, 2020, Volume: 10, Issue:2

    Topics: Aged; Amantadine; Delayed-Action Preparations; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease

2020
Efficacy and safety of 5-Hydroxytryptophan on levodopa-induced motor complications in Parkinson's disease: A preliminary finding.
    Journal of the neurological sciences, 2020, Aug-15, Volume: 415

    Topics: 5-Hydroxytryptophan; Animals; Antiparkinson Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Rats

2020
Continuous Subcutaneous Levodopa Delivery for Parkinson's Disease: A Randomized Study.
    Journal of Parkinson's disease, 2021, Volume: 11, Issue:1

    Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Feasibility Studies; Female; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Severity of Illness Index; Single-Blind Method

2021
Effects of duloxetine on motor and mood symptoms in Parkinson's disease: An open-label clinical experience.
    Journal of the neurological sciences, 2017, 04-15, Volume: 375

    Topics: Affect; Aged; Antiparkinson Agents; Drug Therapy, Combination; Duloxetine Hydrochloride; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Serotonin and Noradrenaline Reuptake Inhibitors; Treatment Outcome

2017
Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2017, Volume: 32, Issue:6

    Topics: Aged; Antiparkinson Agents; Cross-Over Studies; Dextromethorphan; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Excitatory Amino Acid Antagonists; Female; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Pilot Projects; Quinidine

2017
ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial.
    JAMA neurology, 2017, 08-01, Volume: 74, Issue:8

    Topics: Aged; Amantadine; Antiparkinson Agents; Double-Blind Method; Drug Delivery Systems; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; North America; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Time Factors; Treatment Outcome

2017
    Neurology, 2017, Aug-01, Volume: 89, Issue:5

    Topics: Antiparkinson Agents; Benserazide; Blood Pressure; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Heart Rate; Humans; Levodopa; Male; Middle Aged; Motor Activity; Mucuna; Parkinson Disease; Phytotherapy; Powders; Seeds; Treatment Outcome

2017
Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).
    Movement disorders : official journal of the Movement Disorder Society, 2017, Volume: 32, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Delayed-Action Preparations; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Time Factors; Treatment Outcome

2017
Naftazone in advanced Parkinson's disease: An acute L-DOPA challenge randomized controlled trial.
    Parkinsonism & related disorders, 2019, Volume: 60

    Topics: Aged; Antiparkinson Agents; Cross-Over Studies; Dopamine Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Naphthoquinones; Parkinson Disease; Treatment Outcome

2019
Vision-based assessment of parkinsonism and levodopa-induced dyskinesia with pose estimation.
    Journal of neuroengineering and rehabilitation, 2018, 11-06, Volume: 15, Issue:1

    Topics: Aged; Algorithms; Antiparkinson Agents; Biomechanical Phenomena; Deep Learning; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Video Recording

2018
Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials.
    Journal of Parkinson's disease, 2019, Volume: 9, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Delayed-Action Preparations; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Prevalence

2019
The impact of levodopa therapy-induced complications on quality of life in Parkinson's disease patients in Singapore.
    Scientific reports, 2019, 06-25, Volume: 9, Issue:1

    Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Incidence; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Quality of Life; Severity of Illness Index; Singapore; Treatment Outcome

2019
The safety and tolerability of rotigotine transdermal system over a 6-year period in patients with early-stage Parkinson's disease.
    Journal of neural transmission (Vienna, Austria : 1996), 2013, Volume: 120, Issue:9

    Topics: Adolescent; Aged; Aged, 80 and over; Antiparkinson Agents; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Electrocardiography; Female; Humans; Kaplan-Meier Estimate; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Survival Analysis; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; Treatment Outcome

2013
Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2013, Volume: 28, Issue:8

    Topics: Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Kaplan-Meier Estimate; Levodopa; Male; Middle Aged; Multivariate Analysis; Outcome Assessment, Health Care; Parkinson Disease; Predictive Value of Tests; Time Factors

2013
AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Movement disorders : official journal of the Movement Disorder Society, 2013, Volume: 28, Issue:13

    Topics: Aged; Antiparkinson Agents; Cognition Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Indoles; International Cooperation; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Psychiatric Status Rating Scales; Severity of Illness Index; Time Factors

2013
Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial.
    Neurology, 2014, Jan-28, Volume: 82, Issue:4

    Topics: Aged; Amantadine; Antiparkinson Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Treatment Outcome

2014
Randomized clinical trial of topiramate for levodopa-induced dyskinesia in Parkinson's disease.
    Parkinsonism & related disorders, 2014, Volume: 20, Issue:4

    Topics: Adult; Aged; Anticonvulsants; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Fructose; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Topiramate

2014
Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients.
    The Journal of clinical investigation, 2014, Volume: 124, Issue:3

    Topics: Aged; Antiparkinson Agents; Buspirone; Case-Control Studies; Dopamine; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Putamen; Raclopride; Radionuclide Imaging; Radiopharmaceuticals; Serotonergic Neurons; Serotonin 5-HT1 Receptor Agonists; Synapses; Treatment Outcome

2014
Low-frequency repetitive transcranial magnetic stimulation for dyskinesia and motor performance in Parkinson's disease.
    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2014, Volume: 21, Issue:8

    Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Severity of Illness Index; Time Factors; Transcranial Magnetic Stimulation; Treatment Outcome; Video Recording

2014
Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial.
    The Lancet. Neurology, 2014, Volume: 13, Issue:8

    Topics: Adenosine A2 Receptor Antagonists; Aged; Antiparkinson Agents; Benzothiazoles; Cross-Over Studies; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Internationality; Levodopa; Male; Middle Aged; Parkinson Disease

2014
Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2014, Volume: 29, Issue:10

    Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; International Cooperation; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Treatment Outcome

2014
Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study).
    Movement disorders : official journal of the Movement Disorder Society, 2015, Volume: 30, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome

2015
Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.
    Brain : a journal of neurology, 2015, Volume: 138, Issue:Pt 4

    Topics: Aged; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Piperazines

2015
Memantine and reduced time with dyskinesia in Parkinson's Disease.
    Acta neurologica Scandinavica, 2016, Volume: 133, Issue:5

    Topics: Aged; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Humans; Levodopa; Male; Memantine; Middle Aged; Parkinson Disease

2016
Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
    The Lancet. Neurology, 2016, Volume: 15, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catechols; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Europe; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Outcome Assessment, Health Care; Oxadiazoles; Parkinson Disease

2016
Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients.
    Movement disorders : official journal of the Movement Disorder Society, 2016, Volume: 31, Issue:4

    Topics: Administration, Mucosal; Aged; Antiparkinson Agents; Carbidopa; Double-Blind Method; Drug Combinations; Dyskinesia, Drug-Induced; Female; Gels; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome

2016
A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia.
    Movement disorders : official journal of the Movement Disorder Society, 2016, Volume: 31, Issue:7

    Topics: Aged; alpha7 Nicotinic Acetylcholine Receptor; Antiparkinson Agents; Azabicyclo Compounds; Dopamine Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Pyridines

2016
Mavoglurant in Parkinson's patients with l-Dopa-induced dyskinesias: Two randomized phase 2 studies.
    Movement disorders : official journal of the Movement Disorder Society, 2016, Volume: 31, Issue:7

    Topics: Aged; Antiparkinson Agents; Dopamine Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease

2016
A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease.
    Movement disorders : official journal of the Movement Disorder Society, 2016, Volume: 31, Issue:9

    Topics: Aged; Dopamine Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Imidazoles; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Pyridines; Receptor, Metabotropic Glutamate 5

2016
Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations.
    Movement disorders : official journal of the Movement Disorder Society, 2008, Nov-15, Volume: 23, Issue:15

    Topics: Aged; Analysis of Variance; Antiparkinson Agents; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Purines; Severity of Illness Index; Surveys and Questionnaires; Time Factors

2008
Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
    Movement disorders : official journal of the Movement Disorder Society, 2009, Jan-15, Volume: 24, Issue:1

    Topics: Aged; Antiparkinson Agents; Benserazide; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; Gastrointestinal Diseases; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Quality of Life; Severity of Illness Index; Treatment Outcome

2009
Repetitive transcranial magnetic stimulation for levodopa-induced dyskinesias in Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2009, Jan-30, Volume: 24, Issue:2

    Topics: Aged; Antiparkinson Agents; Cross-Over Studies; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Medical Records; Middle Aged; Motor Cortex; Parkinson Disease; Severity of Illness Index; Single-Blind Method; Transcranial Magnetic Stimulation; Treatment Outcome

2009
Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis.
    Movement disorders : official journal of the Movement Disorder Society, 2009, Feb-15, Volume: 24, Issue:3

    Topics: Antiparkinson Agents; Cell Transplantation; Double-Blind Method; Dyskinesia, Drug-Induced; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Risk Factors; Severity of Illness Index; Substantia Nigra; Videotape Recording

2009
Long-term experience with continuous duodenal levodopa-carbidopa infusion (Duodopa): report of six patients.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2009, Volume: 30, Issue:1

    Topics: Aged; Antiparkinson Agents; Carbidopa; Dose-Response Relationship, Drug; Drug Administration Schedule; Duodenum; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Infusion Pumps; Levodopa; Male; Middle Aged; Parkinson Disease; Time; Time Factors; Treatment Outcome

2009
Aripiprazole in L-dopa-induced dyskinesias: a one-year open-label pilot study.
    Journal of neural transmission (Vienna, Austria : 1996), 2009, Volume: 116, Issue:7

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Antipsychotic Agents; Aripiprazole; Basal Ganglia; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Mianserin; Middle Aged; Mirtazapine; Pilot Projects; Piperazines; Quinolones; Receptors, Dopamine D2; Receptors, Serotonin; Treatment Outcome

2009
Role of an electronic armband in motor function monitoring in patients with Parkinson's disease.
    Nutrition (Burbank, Los Angeles County, Calif.), 2010, Volume: 26, Issue:2

    Topics: Arm; Basal Metabolism; Diet, Protein-Restricted; Dyskinesia, Drug-Induced; Electronics; Energy Metabolism; Humans; Levodopa; Monitoring, Ambulatory; Motor Activity; Movement; Parkinson Disease

2010
Effects of a dopamine agonist on the pharmacodynamics of levodopa in Parkinson disease.
    Archives of neurology, 2010, Volume: 67, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Benzothiazoles; Brain; Cross-Over Studies; Dopamine Agonists; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Pramipexole; Risk Assessment; Treatment Outcome

2010
Long-term antidyskinetic efficacy of amantadine in Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2010, Jul-30, Volume: 25, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Treatment Outcome

2010
Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2010, May-15, Volume: 25, Issue:7

    Topics: Adult; Age of Onset; Aged; Antiparkinson Agents; Delayed-Action Preparations; Disability Evaluation; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Surveys and Questionnaires

2010
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
    Annals of neurology, 2010, Volume: 68, Issue:1

    Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Disease Progression; Dopamine Agents; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Risk; Time Factors; Treatment Outcome

2010
Patient perception of dyskinesia in Parkinson's disease.
    Journal of neurology, neurosurgery, and psychiatry, 2010, Volume: 81, Issue:10

    Topics: Dyskinesia, Drug-Induced; Female; Health Knowledge, Attitudes, Practice; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Satisfaction; Perception

2010
Levetiracetam for levodopa-induced dyskinesia in Parkinson's disease: a randomized, double-blind, placebo-controlled trial.
    Journal of neural transmission (Vienna, Austria : 1996), 2010, Volume: 117, Issue:11

    Topics: Aged; Antiparkinson Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects; Treatment Outcome

2010
[Pharmacotherapy of motor manifestations in late stages of Parkinson's disease].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2010, Volume: 110, Issue:11 Pt 1

    Topics: Aged; Carbidopa; Catechols; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease

2010
Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2011, Feb-01, Volume: 26, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levetiracetam; Levodopa; Male; Middle Aged; Parkinson Disease; Piracetam; Treatment Outcome

2011
Botulinum toxin type A for Levodopa-induced cervical dyskinesias in Parkinson's disease: unfavorable risk-benefit ratio.
    Movement disorders : official journal of the Movement Disorder Society, 2011, Volume: 26, Issue:5

    Topics: Aged; Antiparkinson Agents; Botulinum Toxins, Type A; Dyskinesia, Drug-Induced; Electromyography; Female; Humans; Levodopa; Male; Neuromuscular Agents; Parkinson Disease; Treatment Outcome

2011
AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials.
    Movement disorders : official journal of the Movement Disorder Society, 2011, Volume: 26, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Drug Interactions; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Treatment Outcome

2011
A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2011, Volume: 26, Issue:8

    Topics: Anticonvulsants; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesia, Drug-Induced; Humans; Levetiracetam; Levodopa; Parkinson Disease; Piracetam; Severity of Illness Index; Time Factors; Video Recording

2011
Abnormal bidirectional plasticity-like effects in Parkinson's disease.
    Brain : a journal of neurology, 2011, Volume: 134, Issue:Pt 8

    Topics: Aged; Analysis of Variance; Antiparkinson Agents; Dyskinesia, Drug-Induced; Electromyography; Female; Humans; Levodopa; Long-Term Synaptic Depression; Male; Middle Aged; Motor Cortex; Muscle Contraction; Parkinson Disease; Time Factors; Transcranial Magnetic Stimulation

2011
Dyskinetic Parkinson's disease patients demonstrate motor abnormalities off medication.
    Experimental brain research, 2011, Volume: 214, Issue:3

    Topics: Aged; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Substance Withdrawal Syndrome

2011
Feasibility of home-based automated Parkinson's disease motor assessment.
    Journal of neuroscience methods, 2012, Jan-15, Volume: 203, Issue:1

    Topics: Algorithms; Antiparkinson Agents; Computers; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Monitoring, Ambulatory; Motor Activity; Parkinson Disease; Patient Compliance; Software

2012
Pardoprunox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial.
    Parkinsonism & related disorders, 2012, Volume: 18, Issue:4

    Topics: Adult; Aged; Antiparkinson Agents; Benzoxazoles; Double-Blind Method; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Pain Measurement; Parkinson Disease; Piperazines; Severity of Illness Index; Time Factors; Treatment Outcome

2012
Acute dopamine boost has a negative effect on plasticity of the primary motor cortex in advanced Parkinson's disease.
    Brain : a journal of neurology, 2012, Volume: 135, Issue:Pt 7

    Topics: Adult; Aged; Dopamine; Dyskinesia, Drug-Induced; Evoked Potentials, Motor; Female; Humans; Levodopa; Long-Term Potentiation; Long-Term Synaptic Depression; Male; Middle Aged; Motor Cortex; Neuronal Plasticity; Parkinson Disease; Transcranial Magnetic Stimulation

2012
Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study).
    Neurology, 2012, Jul-10, Volume: 79, Issue:2

    Topics: Aged; Double-Blind Method; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Humans; Imidazoles; Indans; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos; Severity of Illness Index; Treatment Outcome

2012
Psychostimulant effect of levodopa: reversing sensitisation is possible.
    Journal of neurology, neurosurgery, and psychiatry, 2013, Volume: 84, Issue:1

    Topics: Anxiety; Basal Ganglia; Deep Brain Stimulation; Depression; Dopamine Agonists; Dyskinesia, Drug-Induced; Euphoria; Female; Humans; Levodopa; Male; Middle Aged; Motivation; Parkinson Disease; Psychiatric Status Rating Scales; Severity of Illness Index; Subthalamic Nucleus

2013
Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study.
    Journal of neurology, neurosurgery, and psychiatry, 2013, Volume: 84, Issue:5

    Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Disability Evaluation; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Gait Disorders, Neurologic; Humans; Levodopa; Male; Memantine; Middle Aged; Parkinson Disease; Pilot Projects; Sample Size

2013
Simvastatin decreases levodopa-induced dyskinesia in monkeys, but not in a randomized, placebo-controlled, multiple cross-over ("n-of-1") exploratory trial of simvastatin against levodopa-induced dyskinesia in Parkinson's disease patients.
    Parkinsonism & related disorders, 2013, Volume: 19, Issue:4

    Topics: Adult; Aged; Animals; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesia, Drug-Induced; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Levodopa; Macaca; Male; Middle Aged; Parkinson Disease; Parkinsonian Disorders; Simvastatin

2013
Caffeine consumption and risk of dyskinesia in CALM-PD.
    Movement disorders : official journal of the Movement Disorder Society, 2013, Volume: 28, Issue:3

    Topics: Adenosine A2 Receptor Antagonists; Aged; Antiparkinson Agents; Benzothiazoles; Caffeine; Cohort Studies; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Kaplan-Meier Estimate; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Proportional Hazards Models; Retrospective Studies; Risk

2013
Quantitative assessment of levodopa-induced dyskinesia using automated motion sensing technology.
    Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference, 2012, Volume: 2012

    Topics: Aged; Antiparkinson Agents; Biomechanical Phenomena; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Models, Biological; Monitoring, Physiologic; Motion; Parkinson Disease; Wireless Technology

2012
Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease.
    Internal medicine (Tokyo, Japan), 2013, Volume: 52, Issue:3

    Topics: Aged; Antiparkinson Agents; Benzothiazoles; Bromocriptine; Cabergoline; Dopamine Agonists; Dyskinesia, Drug-Induced; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3

2013
Response to levodopa in parkinsonian patients with bilateral subthalamic nucleus stimulation.
    Brain : a journal of neurology, 2002, Volume: 125, Issue:Pt 11

    Topics: Adult; Antiparkinson Agents; Dose-Response Relationship, Drug; Down-Regulation; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Female; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Recovery of Function; Subthalamic Nucleus; Treatment Outcome

2002
[Pergolide: a useful agonist for the treatment of Parkinson disease].
    Revue neurologique, 2002, Volume: 158, Issue:6-7

    Topics: Antiparkinson Agents; Disease Progression; Dopamine Agonists; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide

2002
Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study.
    Journal of neurology, 2003, Volume: 250, Issue:1

    Topics: Antiparkinson Agents; Bromocriptine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Treatment Outcome

2003
Amantadine in Huntington's disease: open-label video-blinded study.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2002, Volume: 23 Suppl 2

    Topics: Aged; Amantadine; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Humans; Huntington Disease; Hyperkinesis; Levodopa; Male; Receptors, N-Methyl-D-Aspartate; Time Factors

2002
Randomized trial of pallidotomy versus medical therapy for Parkinson's disease.
    Annals of neurology, 2003, Volume: 53, Issue:5

    Topics: Antiparkinson Agents; Atrophy; Brain; Carbidopa; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Drug Combinations; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Globus Pallidus; Humans; Hypokinesia; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Muscle Rigidity; Neurosurgical Procedures; Parkinson Disease; Severity of Illness Index; Treatment Outcome; Tremor

2003
Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD.
    Neurology, 2003, Aug-12, Volume: 61, Issue:3

    Topics: Adenosine A2 Receptor Antagonists; Aged; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Chronic Disease; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Nausea; Parkinson Disease; Purines; Safety; Selegiline; Treatment Outcome

2003
Quetiapine as treatment for dopaminergic-induced dyskinesias in Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2003, Volume: 18, Issue:10

    Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Dibenzothiazepines; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Quetiapine Fumarate

2003
Low dose quetiapine for drug induced dyskinesias in Parkinson's disease: a double blind cross over study.
    Journal of neurology, neurosurgery, and psychiatry, 2004, Volume: 75, Issue:2

    Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Cross-Over Studies; Dibenzothiazepines; Double-Blind Method; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Quetiapine Fumarate

2004
Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations.
    Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:1

    Topics: Aged; Antiparkinson Agents; Benzothiazoles; Carbidopa; Double-Blind Method; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Pain Measurement; Parkinson Disease; Pramipexole; Quality of Life; Thiazoles

2004
Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study.
    Neurology, 2004, Feb-10, Volume: 62, Issue:3

    Topics: Aged; Antiparkinson Agents; Clozapine; Double-Blind Method; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Parkinson Disease; Serotonin Receptor Agonists; Treatment Outcome

2004
Further experience with extradural motor cortex stimulation for treatment of advanced Parkinson's disease. Report of 3 new cases.
    Journal of neurosurgical sciences, 2003, Volume: 47, Issue:4

    Topics: Aged; Deglutition Disorders; Dura Mater; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Electrodes; Electrodes, Implanted; Female; Gait Disorders, Neurologic; Humans; Levodopa; Magnetic Resonance Imaging; Male; Motor Cortex; Muscle Rigidity; Parkinson Disease; Treatment Outcome; Tremor

2003
The role of sigma-receptors in levodopa-induced dyskinesia in patients with advanced Parkinson disease: a positron emission tomography study.
    Journal of neurosurgery, 2004, Volume: 100, Issue:4

    Topics: Aged; Antiparkinson Agents; Cerebellum; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, sigma; Severity of Illness Index; Tomography, Emission-Computed

2004
Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:5

    Topics: Antiparkinson Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Follow-Up Studies; Humans; Levodopa; Naloxone; Narcotic Antagonists; Parkinson Disease; Videotape Recording

2004
The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    CNS drugs, 2004, Volume: 18, Issue:11

    Topics: Adult; Aged; Antiparkinson Agents; Cabergoline; Case-Control Studies; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Ergolines; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Motor Activity; Movement Disorders; Parkinson Disease; Risk Factors; Time Factors; Treatment Outcome

2004
Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
    Neurology, 2005, Jan-25, Volume: 64, Issue:2

    Topics: Administration, Oral; Adult; Aged; Antiparkinson Agents; Carbidopa; Cross-Over Studies; Drug Therapy, Combination; Duodenum; Dyskinesia, Drug-Induced; Female; Gels; Humans; Intubation; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Quality of Life; Severity of Illness Index; Single-Blind Method; Surveys and Questionnaires; Suspensions; Videotape Recording

2005
Comparison of age of onset and development of motor complications between smokers and non-smokers in Parkinson's disease.
    Journal of the neurological sciences, 2005, Apr-15, Volume: 231, Issue:1-2

    Topics: Age of Onset; Aged; Antiparkinson Agents; Case-Control Studies; Cognition Disorders; Cohort Studies; Dyskinesia, Drug-Induced; Female; Human Development; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Smoking; Time Factors

2005
Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study.
    Archives of neurology, 2005, Volume: 62, Issue:4

    Topics: Age of Onset; Aged; Antiparkinson Agents; Cohort Studies; DNA Mutational Analysis; DNA Repeat Expansion; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Genetic Predisposition to Disease; Genetic Testing; Genotype; Humans; Levodopa; Male; Multivariate Analysis; Parkinson Disease; Polymorphism, Genetic; Predictive Value of Tests; Receptors, Dopamine D2; Sex Characteristics

2005
Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up.
    Brain : a journal of neurology, 2005, Volume: 128, Issue:Pt 10

    Topics: Activities of Daily Living; Adult; Aged; Antiparkinson Agents; Brain; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Electrodes, Implanted; Female; Follow-Up Studies; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Subthalamic Nucleus; Time Factors; Treatment Outcome

2005
Neither simple nor sequential arm movements are bradykinetic in parkinsonian patients with peak-dose dyskinesias.
    Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology, 2005, Volume: 116, Issue:9

    Topics: Aged; Antiparkinson Agents; Arm; Biomechanical Phenomena; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Psychomotor Performance

2005
Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study.
    Parkinsonism & related disorders, 2005, Volume: 11, Issue:7

    Topics: Aged; Amantadine; Antiparkinson Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Placebos; Treatment Outcome

2005
Treatment of levodopa-induced dyskinesias with donepezil.
    Parkinsonism & related disorders, 2006, Volume: 12, Issue:4

    Topics: Aged; Antiparkinson Agents; Donepezil; Dyskinesia, Drug-Induced; Humans; Indans; Levodopa; Male; Middle Aged; Nootropic Agents; Piperidines

2006
Efficacy and safety of high-dose cabergoline in Parkinson's disease.
    Acta neurologica Scandinavica, 2006, Volume: 113, Issue:1

    Topics: Adolescent; Adult; Aged; Amantadine; Antiparkinson Agents; Cabergoline; Catechols; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonia; Ergolines; Humans; Levodopa; Middle Aged; Nitriles; Parkinson Disease; Piperidines; Prospective Studies; Quality of Life; Selegiline; Severity of Illness Index; Treatment Outcome

2006
Levodopa induced motor complications in Thai Parkinson's disease patients.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2006, Volume: 89, Issue:5

    Topics: Aged; Antiparkinson Agents; Disease Progression; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Hypokinesia; Levodopa; Male; Parkinson Disease; Thailand

2006
Glutamate release inhibition ineffective in levodopa-induced motor complications.
    Movement disorders : official journal of the Movement Disorder Society, 2006, Volume: 21, Issue:9

    Topics: Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Glutamic Acid; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Riluzole; Treatment Outcome

2006
Low frequency rTMS of the SMA transiently ameliorates peak-dose LID in Parkinson's disease.
    Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology, 2006, Volume: 117, Issue:9

    Topics: Aged; Analysis of Variance; Antiparkinson Agents; Chi-Square Distribution; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Cortex; Parkinson Disease; Time Factors; Transcranial Magnetic Stimulation; Treatment Outcome

2006
Direct effect of subthalamic nucleus stimulation on levodopa-induced peak-dose dyskinesia in patients with Parkinson's disease.
    Stereotactic and functional neurosurgery, 2006, Volume: 84, Issue:4

    Topics: Antiparkinson Agents; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Severity of Illness Index; Subthalamic Nucleus; Treatment Outcome

2006
Clinical features and gene analysis in Korean patients with early-onset Parkinson disease.
    Archives of neurology, 2006, Volume: 63, Issue:8

    Topics: Adult; Age of Onset; Dyskinesia, Drug-Induced; Female; Humans; Korea; Levodopa; Male; Middle Aged; Mutation; Parkinson Disease; Protein Kinases; Ubiquitin-Protein Ligases

2006
Cascade of levodopa dose and weight-related dyskinesia in Parkinson's disease (LD-WD-PD cascade).
    Parkinsonism & related disorders, 2006, Volume: 12, Issue:8

    Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Cohort Studies; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Logistic Models; Male; Parkinson Disease; Retrospective Studies; Risk Factors; Sex Factors; Weight Loss

2006
Development of dyskinesias in a 5-year trial of ropinirole and L-dopa.
    Movement disorders : official journal of the Movement Disorder Society, 2006, Volume: 21, Issue:11

    Topics: Antiparkinson Agents; Confidence Intervals; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Indoles; Levodopa; Longitudinal Studies; Parkinson Disease; Predictive Value of Tests; Proportional Hazards Models; Risk Factors; Survival Analysis

2006
Longitudinal study of the motor response to levodopa in Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2006, Volume: 21, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Disease Progression; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Motor Activity; Motor Skills; Neurologic Examination; Parkinson Disease

2006
Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial.
    Archives of neurology, 2007, Volume: 64, Issue:3

    Topics: Administration, Oral; Aged; Antiparkinson Agents; Cross-Over Studies; Dopamine Uptake Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Interactions; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Methylphenidate; Middle Aged; Parkinson Disease; Psychomotor Performance; Severity of Illness Index; Time Perception; Tremor; Walking

2007
Long-term effectiveness and quality of life improvement in entacapone-treated Parkinson's disease patients: the effects of an early therapeutic intervention.
    European journal of neurology, 2007, Volume: 14, Issue:3

    Topics: Aged; Antiparkinson Agents; Catechols; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Early Diagnosis; Female; Humans; Interviews as Topic; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Patient Compliance; Patient Satisfaction; Prospective Studies; Quality of Life; Time; Time Factors; Treatment Outcome

2007
Use of dopamine receptor agonists to reduce dopamine receptor number as treatment for tardive dyskinesia.
    Advances in neurology, 1983, Volume: 37

    Topics: Antipsychotic Agents; Clinical Trials as Topic; Disability Evaluation; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Receptors, Dopamine

1983
A review of clinical trials of lithium in neurology.
    Pharmacology, biochemistry, and behavior, 1984, Volume: 21 Suppl 1

    Topics: Clinical Trials as Topic; Cluster Headache; Dyskinesia, Drug-Induced; Epilepsy; Headache; Humans; Huntington Disease; Hyperkinesis; Levodopa; Lithium; Meniere Disease; Migraine Disorders; Movement Disorders; Nervous System Diseases; Neurocognitive Disorders; Parkinson Disease; Sleep Wake Disorders; Torticollis

1984
Tiapride in levodopa-induced involuntary movements.
    Acta neurologica Scandinavica, 1983, Volume: 67, Issue:6

    Topics: Aged; Benzamides; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Hyperkinesis; Levodopa; Male; Middle Aged; Parkinson Disease; Random Allocation; Tiapamil Hydrochloride

1983
[A double-blind study of the effect of L-dopa in psychotic patients with tardive dyskinesia].
    Acta psiquiatrica y psicologica de America latina, 1983, Volume: 29, Issue:4

    Topics: Clinical Trials as Topic; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Placebos; Psychotic Disorders

1983
Dyskinesias associated with lithium therapy in parkinsonism.
    Clinical neuropharmacology, 1984, Volume: 7, Issue:3

    Topics: Adult; Aged; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Lithium; Male; Middle Aged; Parkinson Disease; Random Allocation

1984
Bromocriptine: low-dose therapy in Parkinson disease.
    Neurology, 1982, Volume: 32, Issue:6

    Topics: Aged; Bromocriptine; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos; Tremor

1982
Effect of GPi pallidotomy on motor function in Parkinson's disease.
    Lancet (London, England), 1995, Nov-25, Volume: 346, Issue:8987

    Topics: Activities of Daily Living; Adult; Aged; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Gait; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Stereotaxic Techniques; Tremor; Videotape Recording

1995
Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 1994, Volume: 9, Issue:4

    Topics: Aged; Bromocriptine; Cross-Over Studies; Disability Evaluation; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Naltrexone; Neurologic Examination; Parkinson Disease

1994
Selegiline (L-deprenyl) and L-dopa treatment of Parkinson's disease: a double-blind trial.
    Internal medicine (Tokyo, Japan), 1994, Volume: 33, Issue:9

    Topics: Aged; Chi-Square Distribution; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline

1994
A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.
    Journal of neurology, neurosurgery, and psychiatry, 1994, Volume: 57, Issue:9

    Topics: Bromocriptine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects; Prospective Studies

1994
Treatment of Parkinson's disease with the partial dopamine agonist EMD 49980.
    Movement disorders : official journal of the Movement Disorder Society, 1993, Volume: 8, Issue:2

    Topics: Adult; Brain; Dopamine Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Neurologic Examination; Oxindoles; Parkinson Disease; Pyridines; Receptors, Dopamine

1993
Buspirone in levodopa-induced dyskinesias.
    Clinical neuropharmacology, 1994, Volume: 17, Issue:1

    Topics: Aged; Buspirone; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease

1994
A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists: application to pergolide and bromocriptine.
    Movement disorders : official journal of the Movement Disorder Society, 1995, Volume: 10, Issue:5

    Topics: Aged; Antiparkinson Agents; Bromocriptine; Dopamine Agonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Parkinson Disease; Pergolide

1995
Parkinson's disease: progression and mortality in the L-DOPA era.
    Advances in neurology, 1996, Volume: 69

    Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Antiparkinson Agents; Cause of Death; Dementia; Disease Progression; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Hypotension, Orthostatic; Levodopa; Life Expectancy; Male; Middle Aged; Parkinson Disease; Survival Analysis

1996
Eight-year follow-up study of bromocriptine monotherapy for Parkinson's disease.
    European neurology, 1996, Volume: 36 Suppl 1

    Topics: Aged; Antiparkinson Agents; Bromocriptine; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Japan; Levodopa; Male; Middle Aged; Parkinson Disease

1996
Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study.
    Journal of neural transmission (Vienna, Austria : 1996), 1996, Volume: 103, Issue:6

    Topics: Aged; Antiparkinson Agents; Bromocriptine; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Incidence; Levodopa; Longitudinal Studies; Male; Middle Aged; Motor Neurons; Parkinson Disease; Prospective Studies; Time Factors

1996
Sustained-release of levodopa: single dose study of a new formulation.
    Journal of neural transmission (Vienna, Austria : 1996), 1996, Volume: 103, Issue:6

    Topics: Aged; Antiparkinson Agents; Cross-Over Studies; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease

1996
Clinical efficacy and tolerability of a new levodopa/benserazide dual-release formulation in parkinsonian patients. L-Dopa Dual-Release Study Group.
    Clinical neuropharmacology, 1997, Volume: 20, Issue:2

    Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Drug Combinations; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nausea; Parkinson Disease; Patient Dropouts; Psychomotor Agitation

1997
The effects of pallidotomy on Parkinson's disease: study design and assessment techniques.
    Acta neurochirurgica. Supplement, 1997, Volume: 68

    Topics: Adult; Aged; Antiparkinson Agents; Brain Mapping; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Outcome Assessment, Health Care; Parkinson Disease; Postoperative Complications; Single-Blind Method; Stereotaxic Techniques; Video Recording

1997
Nine-year follow-up study of bromocriptine monotherapy for Parkinson's disease.
    European neurology, 1997, Volume: 38 Suppl 1

    Topics: Aged; Antiparkinson Agents; Bromocriptine; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease

1997
Relationship between levodopa concentration, dyskinesias, and motor effect in parkinsonian patients: a 3-year follow-up study.
    Clinical neuropharmacology, 1997, Volume: 20, Issue:5

    Topics: Adult; Aged; Antiparkinson Agents; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Individuality; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Prospective Studies; Time Factors

1997
Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Parkinson Study Group.
    Annals of neurology, 1997, Volume: 42, Issue:5

    Topics: Aged; Antiparkinson Agents; Catechols; Double-Blind Method; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Movement; Nitriles; Parkinson Disease; Patient Compliance; Substance Withdrawal Syndrome; Treatment Outcome

1997
Risperidone in levodopa induced dyskinesiae.
    Journal of neurology, neurosurgery, and psychiatry, 1998, Volume: 64, Issue:1

    Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Dopamine Antagonists; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Risperidone; Serotonin Antagonists; Severity of Illness Index

1998
[Tolcapone: a different, effective approach to improving dopaminergic treatment in Parkinson's disease].
    Neurologia (Barcelona, Spain), 1998, Volume: 13, Issue:2

    Topics: Antiparkinson Agents; Benzophenones; Dose-Response Relationship, Drug; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Nitrophenols; Parkinson Disease; Tolcapone; Treatment Outcome

1998
Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
    Neurology, 1998, Volume: 50, Issue:5 Suppl 5

    Topics: Aged; Antiparkinson Agents; Benserazide; Benzophenones; Catechol O-Methyltransferase Inhibitors; Diarrhea; Dopamine Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Europe; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Tolcapone; Treatment Outcome

1998
Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease.
    Neurology, 1998, Volume: 50, Issue:5

    Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Humans; Levodopa; Logistic Models; Male; Middle Aged; Motor Activity; Parkinson Disease; Receptors, N-Methyl-D-Aspartate; Treatment Outcome

1998
Low dosage clozapine effects on L-dopa induced dyskinesias in parkinsonian patients.
    Acta neurologica Scandinavica, 1998, Volume: 97, Issue:5

    Topics: Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Clozapine; Dopamine Antagonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Parkinson Disease; Severity of Illness Index; Treatment Outcome

1998
Implications of the 5-year CR FIRST trial. Sinemet CR Five-Year International Response Fluctuation Study.
    Neurology, 1998, Volume: 50, Issue:6 Suppl 6

    Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease

1998
Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease.
    Neurology, 1998, Volume: 51, Issue:1

    Topics: Aged; Antiparkinson Agents; Antitussive Agents; Dextromethorphan; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, N-Methyl-D-Aspartate

1998
The NMDA antagonist budipine can alleviate levodopa-induced motor fluctuations.
    Movement disorders : official journal of the Movement Disorder Society, 1999, Volume: 14, Issue:3

    Topics: Adult; Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; N-Methylaspartate; Parkinson Disease; Pilot Projects; Piperidines; Severity of Illness Index

1999
[The effect of thalamic stimulation on levodopa induced dyskinesias--evaluation of a new target: the center parafascicular median].
    Revue neurologique, 1999, Volume: 155, Issue:8

    Topics: Aged; Cerebral Ventriculography; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Electrodes; Female; Humans; Levodopa; Male; Middle Aged; Retrospective Studies; Stereotaxic Techniques; Thalamic Nuclei

1999
Dyskinesias assessment in Phase II studies.
    Movement disorders : official journal of the Movement Disorder Society, 1999, Volume: 14 Suppl 1

    Topics: Biological Transport; Brain; Clinical Protocols; Dopamine; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Levodopa; Sensitivity and Specificity

1999
Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study.
    Archives of neurology, 1999, Volume: 56, Issue:11

    Topics: Amantadine; Antiparkinson Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Severity of Illness Index

1999
Comparison of pallidal and subthalamic nucleus deep brain stimulation for advanced Parkinson's disease: results of a randomized, blinded pilot study.
    Neurosurgery, 1999, Volume: 45, Issue:6

    Topics: Adult; Aged; Double-Blind Method; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Pilot Projects; Subthalamic Nucleus; Treatment Outcome

1999
An ambulatory dyskinesia monitor.
    Journal of neurology, neurosurgery, and psychiatry, 2000, Volume: 68, Issue:2

    Topics: Adult; Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Electrophysiology; Female; Humans; Levodopa; Male; Middle Aged; Monitoring, Ambulatory; Parkinson Disease; Sensitivity and Specificity; Severity of Illness Index

2000
Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2000, Volume: 15, Issue:2

    Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adult; Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Idazoxan; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Treatment Failure

2000
A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.
    The New England journal of medicine, 2000, May-18, Volume: 342, Issue:20

    Topics: Aged; Antiparkinson Agents; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Incidence; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Risk Factors

2000
Levodopa withdrawal after bilateral subthalamic nucleus stimulation in advanced Parkinson disease.
    Archives of neurology, 2000, Volume: 57, Issue:7

    Topics: Aged; Dopamine Agents; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Electrodes, Implanted; Female; Humans; Levodopa; Male; Microelectrodes; Middle Aged; Parkinson Disease; Subthalamic Nucleus; Treatment Outcome

2000
Low-dose olanzapine for levodopa induced dyskinesias.
    Neurology, 2000, Sep-26, Volume: 55, Issue:6

    Topics: Aged; Benzodiazepines; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Olanzapine; Pirenzepine

2000
Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2000, Volume: 15, Issue:5

    Topics: Aged; Amantadine; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Treatment Outcome

2000
Evidence of functional somatotopy in GPi from results of pallidotomy.
    Brain : a journal of neurology, 2000, Volume: 123 Pt 12

    Topics: Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Globus Pallidus; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neural Pathways; Neurologic Examination; Neurosurgical Procedures; Parkinson Disease; Postoperative Complications; Severity of Illness Index; Treatment Outcome

2000
[1st long-term double-blind study of effectiveness and dyskinesia prevention of ropinirol].
    Der Nervenarzt, 2000, Volume: 71, Issue:12

    Topics: Adult; Aged; Dopamine Agonists; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Indoles; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Prospective Studies; Treatment Outcome

2000
Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease.
    Archives of neurology, 2001, Volume: 58, Issue:2

    Topics: Adult; Aged; Antiparkinson Agents; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prodrugs; Pyridines; Receptors, Dopamine D1; Tetrahydronaphthalenes

2001
Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study.
    Movement disorders : official journal of the Movement Disorder Society, 2001, Volume: 16, Issue:3

    Topics: Aged; Amantadine; Antiparkinson Agents; Dopamine Agents; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, N-Methyl-D-Aspartate; Remission Induction

2001
Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2001, Volume: 16, Issue:4

    Topics: Administration, Oral; Adrenergic alpha-Antagonists; Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Idazoxan; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Pilot Projects

2001
Amantadine for dyskinesia in patients affected by severe Parkinson's disease.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2001, Volume: 22, Issue:1

    Topics: Aged; Amantadine; Antiviral Agents; Disease Progression; Dopamine Agents; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Recovery of Function; Substance Withdrawal Syndrome; Treatment Outcome

2001
Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial.
    Neurology, 2001, Nov-13, Volume: 57, Issue:9

    Topics: Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Bromocriptine; Disability Evaluation; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Incidence; Levodopa; Male; Parkinson Disease; Selegiline; Treatment Outcome

2001
Morphine in tardive and idiopathic dystonia (short communication).
    Journal of neural transmission (Vienna, Austria : 1996), 2001, Volume: 108, Issue:8-9

    Topics: Adult; Aged; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Dystonia; Female; Humans; Levodopa; Middle Aged; Morphine; Neostriatum; Pain; Parkinson Disease; Pilot Projects; Receptors, Dopamine; Treatment Outcome

2001
Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study.
    Neurology, 2001, Dec-11, Volume: 57, Issue:11

    Topics: Aged; Animals; Cross-Over Studies; Culture Techniques; Double-Blind Method; Dronabinol; Dyskinesia, Drug-Induced; Female; gamma-Aminobutyric Acid; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, Cannabinoid; Receptors, Drug

2001
The effect of stage of Parkinson's disease at the onset of levodopa therapy on development of motor complications.
    European journal of neurology, 2002, Volume: 9, Issue:1

    Topics: Age of Onset; Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Movement; Muscle Rigidity; Parkinson Disease; Sex Characteristics; Tremor

2002
A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa.
    Journal of neural transmission (Vienna, Austria : 1996), 2002, Volume: 109, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Bromocriptine; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Hallucinations; Humans; Indoles; Levodopa; Logistic Models; Male; Middle Aged; Odds Ratio; Parkinson Disease

2002
Long-term pallidal deep brain stimulation in patients with advanced Parkinson disease: 1-year follow-up study.
    Journal of neurosurgery, 2002, Volume: 96, Issue:5

    Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Electrodes; Female; Follow-Up Studies; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Psychiatric Status Rating Scales; Treatment Outcome

2002
[Dopamine-receptor stimulators and neuroleptic-induced dyskinesia (author's transl)].
    Pharmakopsychiatrie, Neuro-Psychopharmakologie, 1978, Volume: 11, Issue:6

    Topics: Antipsychotic Agents; Bromocriptine; Clinical Trials as Topic; Dyskinesia, Drug-Induced; Humans; Levodopa; Receptors, Dopamine; Schizophrenia; Time Factors; Trihexyphenidyl

1978
Sodium valproate in the treatment of levodopa-induced dyskinesia.
    Journal of neurology, neurosurgery, and psychiatry, 1978, Volume: 41, Issue:8

    Topics: Clinical Trials as Topic; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Valerates; Valproic Acid

1978
Baclofen in Parkinson's disease.
    Journal of neurology, neurosurgery, and psychiatry, 1978, Volume: 41, Issue:8

    Topics: Aged; Aminobutyrates; Baclofen; Clinical Trials as Topic; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Parkinson Disease

1978
Deanol and physostigmine in the treatment of L-dopa-induced dyskinesias.
    Acta neurologica Scandinavica, 1978, Volume: 58, Issue:2

    Topics: Aged; Clinical Trials as Topic; Deanol; Double-Blind Method; Drug Evaluation; Dyskinesia, Drug-Induced; Ethanolamines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Physostigmine; Placebos

1978
An evaluation of bromocriptine in the treatment of Parkinson's disease.
    Clinical and experimental neurology, 1978, Volume: 15

    Topics: Aged; Bromocriptine; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Nausea; Parkinson Disease

1978
Pharmacological characterization of tardive dyskinesia.
    Psychopharmacology, 1977, Aug-31, Volume: 54, Issue:1

    Topics: Adult; Benztropine; Clinical Trials as Topic; Deanol; Dopamine; Droperidol; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Parasympatholytics; Physostigmine; Placebos; Time Factors

1977
Cyproheptadine in levodopa-induced dyskinesia in parkinsonism.
    Clinical pharmacology and therapeutics, 1978, Volume: 23, Issue:2

    Topics: Aged; Carbidopa; Cyproheptadine; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease

1978
Levodopa-induced diphasic dyskinesias improved by subcutaneous apomorphine.
    Movement disorders : official journal of the Movement Disorder Society, 1992, Volume: 7, Issue:3

    Topics: Adult; Apomorphine; Double-Blind Method; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Humans; Injections, Subcutaneous; Levodopa; Middle Aged; Single-Blind Method

1992
[Comparison of bromocriptine and levodopa as first line treatment of Parkinson's disease: results of a 3-year prospective randomized study].
    Revue neurologique, 1990, Volume: 146, Issue:2

    Topics: Bromocriptine; Dose-Response Relationship, Drug; Drug Evaluation; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Mental Disorders; Middle Aged; Parkinson Disease; Prospective Studies; Psychomotor Disorders; Randomized Controlled Trials as Topic

1990
Stable remission of tardive dyskinesia by L-dopa.
    Journal of clinical psychopharmacology, 1989, Volume: 9, Issue:1

    Topics: Adult; Aged; Antipsychotic Agents; Carbidopa; Chronic Disease; Clinical Trials as Topic; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Schizophrenia

1989
[Clinical study on the treatment of dyskinesia by L-stepholidine].
    Zhonghua shen jing jing shen ke za zhi = Chinese journal of neurology and psychiatry, 1989, Volume: 22, Issue:6

    Topics: Aged; Berberine; Berberine Alkaloids; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Multicenter Studies as Topic; Tourette Syndrome

1989
Clinical activity of GABA agonists in neuroleptic- and L-dopa-induced dyskinesia.
    Psychopharmacology. Supplementum, 1985, Volume: 2

    Topics: Antipsychotic Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Electromyography; gamma-Aminobutyric Acid; Humans; Levodopa

1985
Therapeutic response to progabide in neuroleptic- and L-dopa-induced dyskinesias.
    Clinical neuropharmacology, 1987, Volume: 10, Issue:3

    Topics: Adult; Aged; Antipsychotic Agents; Clinical Trials as Topic; Double-Blind Method; Dyskinesia, Drug-Induced; Female; gamma-Aminobutyric Acid; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Placebos

1987
Controlled-release Sinemet (CR-4): a double-blind crossover study in patients with fluctuating Parkinson's disease.
    Mayo Clinic proceedings, 1988, Volume: 63, Issue:9

    Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Consumer Behavior; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Evaluation; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Random Allocation; Time Factors

1988

Other Studies

1286 other study(ies) available for levodopa and Dyskinesia, Drug-Induced

ArticleYear
The cross-hemispheric nigrostriatal pathway prevents the expression of levodopa-induced dyskinesias.
    Neurobiology of disease, 2021, Volume: 159

    Topics: Animals; Antiparkinson Agents; Disease Progression; Dyskinesia, Drug-Induced; Levodopa; Medial Forebrain Bundle; Neostriatum; Oxidopamine; Parkinsonian Disorders; Rats; Substantia Nigra; Sympatholytics

2021
Zonisamide attenuates the severity of levodopa-induced dyskinesia via modulation of the striatal serotonergic system in a rat model of Parkinson's disease.
    Neuropharmacology, 2021, 10-15, Volume: 198

    Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; GABAergic Neurons; Levodopa; Neostriatum; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT1B; RNA-Binding Proteins; Serotonergic Neurons; Serotonin Agents; Zonisamide

2021
Evaluation of microglia in a rodent model of Parkinson's disease primed with L-DOPA after sub-anesthetic ketamine treatment.
    Neuroscience letters, 2021, 11-20, Volume: 765

    Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Humans; Ketamine; Levodopa; Male; Microglia; Parkinson Disease; Phagocytosis; Rats; Receptors, N-Methyl-D-Aspartate; Substantia Nigra

2021
Additive effects of mGluR
    Naunyn-Schmiedeberg's archives of pharmacology, 2021, Volume: 394, Issue:12

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Bridged Bicyclo Compounds; Callithrix; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Indoles; Levodopa; Male; Parkinsonian Disorders; Piperazines; Psychotic Disorders; Pyridines; Receptors, Metabotropic Glutamate; Serotonin 5-HT2 Receptor Antagonists; Sulfonamides

2021
Exome-wide association study of levodopa-induced dyskinesia in Parkinson's disease.
    Scientific reports, 2021, 10-01, Volume: 11, Issue:1

    Topics: Aged; Alleles; Biomarkers; Disease Susceptibility; Dyskinesia, Drug-Induced; Exome Sequencing; Female; Gene Frequency; Humans; Levodopa; Male; Middle Aged; Odds Ratio; Parkinson Disease; Symptom Assessment

2021
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease.
    Journal of visualized experiments : JoVE, 2021, 10-04, Issue:176

    Topics: Animals; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Rats

2021
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease.
    Journal of visualized experiments : JoVE, 2021, 10-14, Issue:176

    Topics: Animals; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Dyskinesias; Levodopa; Oxidopamine; Parkinson Disease; Rats

2021
White matter connectivity networks predict levodopa-induced dyskinesia in Parkinson's disease.
    Journal of neurology, 2022, Volume: 269, Issue:6

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; White Matter

2022
Dopamine D3 receptor ligand suppresses the expression of levodopa-induced dyskinesia in nonhuman primate model of parkinson's disease.
    Experimental neurology, 2022, Volume: 347

    Topics: Animals; Antiparkinson Agents; Callithrix; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; HEK293 Cells; Humans; Levodopa; Ligands; Parkinsonian Disorders; Primates; Protein Structure, Secondary; Quinpirole; Receptors, Dopamine D3

2022
Spontaneous Graft-Induced Dyskinesias Are Independent of 5-HT Neurons and Levodopa Priming in a Model of Parkinson's Disease.
    Movement disorders : official journal of the Movement Disorder Society, 2022, Volume: 37, Issue:3

    Topics: Animals; Antiparkinson Agents; Dopamine; Dyskinesia, Drug-Induced; Dyskinesias; Humans; Levodopa; Neurons; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin

2022
Regulator of G-Protein Signalling 4 (RGS4) negatively modulates nociceptin/orphanin FQ opioid receptor signalling: Implication for l-Dopa-induced dyskinesia.
    British journal of pharmacology, 2023, Volume: 180, Issue:7

    Topics: Analgesics, Opioid; Animals; Dyskinesia, Drug-Induced; HEK293 Cells; Humans; Levodopa; Mice; Nociceptin; Rats; Receptors, Opioid; Signal Transduction

2023
Metabolic Profile in Plasma AND CSF of LEVODOPA-induced Dyskinesia in Parkinson's Disease: Focus on Neuroinflammation.
    Molecular neurobiology, 2022, Volume: 59, Issue:2

    Topics: Antiparkinson Agents; Chromatography, Liquid; Dyskinesia, Drug-Induced; Humans; Levodopa; Metabolome; Neuroinflammatory Diseases; Parkinson Disease; Tandem Mass Spectrometry

2022
Autoradiographic labelling of 5-HT
    Neuroscience research, 2022, Volume: 177

    Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Ondansetron; Oxidopamine; Rats; Rats, Sprague-Dawley; Serotonin; Subthalamic Nucleus

2022
Amantadine treatment and delayed onset of levodopa-induced dyskinesia in patients with early Parkinson's disease.
    European journal of neurology, 2022, Volume: 29, Issue:4

    Topics: Amantadine; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Retrospective Studies

2022
Cabergoline, a long-acting dopamine agonist, attenuates L-dopa-induced dyskinesia without L-dopa sparing in a rat model of Parkinson's disease.
    Neuroscience research, 2022, Volume: 178

    Topics: Animals; Antiparkinson Agents; Cabergoline; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; RNA, Messenger

2022
Prevention of L-Dopa-Induced Dyskinesias by MPEP Blockade of Metabotropic Glutamate Receptor 5 Is Associated with Reduced Inflammation in the Brain of Parkinsonian Monkeys.
    Cells, 2022, 02-16, Volume: 11, Issue:4

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Dyskinesia, Drug-Induced; Humans; Inflammation; Levodopa; Macaca fascicularis; Parkinson Disease; Pyridines; Receptor, Metabotropic Glutamate 5

2022
Striatal Neuronal Ensembles Reveal Differential Actions of Amantadine and Clozapine to Ameliorate Mice L-DOPA-Induced Dyskinesia.
    Neuroscience, 2022, 06-01, Volume: 492

    Topics: Amantadine; Animals; Antiparkinson Agents; Calcium; Clozapine; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Mice; Neurons; Oxidopamine

2022
Phosphodiesterase 9 inhibition prolongs the antiparkinsonian action of l-DOPA in parkinsonian non-human primates.
    Neuropharmacology, 2022, 07-01, Volume: 212

    Topics: Animals; Antiparkinson Agents; Disabled Persons; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Motor Disorders; Parkinson Disease; Phosphoric Diester Hydrolases; Primates

2022
Human Embryonic Stem Cell-Derived Dopaminergic Grafts Alleviate L-DOPA Induced Dyskinesia.
    Journal of Parkinson's disease, 2022, Volume: 12, Issue:6

    Topics: Amphetamines; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Human Embryonic Stem Cells; Humans; Levodopa; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley

2022
The multimodal serotonin compound Vilazodone alone, but not combined with the glutamate antagonist Amantadine, reduces l-DOPA-induced dyskinesia in hemiparkinsonian rats.
    Pharmacology, biochemistry, and behavior, 2022, Volume: 217

    Topics: Amantadine; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Humans; Levodopa; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin; Vilazodone Hydrochloride

2022
D1/D5 Inverse Agonists Restore Striatal Cholinergic Interneuron Physiology in Dyskinetic Mice.
    Movement disorders : official journal of the Movement Disorder Society, 2022, Volume: 37, Issue:8

    Topics: Animals; Antiparkinson Agents; Cholinergic Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Interneurons; Levodopa; Mice; Oxidopamine; Parkinson Disease

2022
[Parkinson's Disease with Intolerable Painful Dyskinesia: Standard Treatment and Subsequent Tips].
    Brain and nerve = Shinkei kenkyu no shinpo, 2022, Volume: 74, Issue:5

    Topics: Amantadine; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Pain; Parkinson Disease

2022
Tetrabenazine Mitigates Aberrant Release and Clearance of Dopamine in the Nigrostriatal System, and Alleviates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease.
    Journal of Parkinson's disease, 2022, Volume: 12, Issue:5

    Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Mice; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin; Tetrabenazine

2022
Levodopa-induced dyskinesia is preceded by increased levels of anxiety and motor impairment in Parkinson's disease patients.
    The International journal of neuroscience, 2023, Volume: 133, Issue:12

    Topics: Antiparkinson Agents; Anxiety; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Motor Disorders; Parkinson Disease

2023
Cerebellar stimulation prevents Levodopa-induced dyskinesia in mice and normalizes activity in a motor network.
    Nature communications, 2022, 06-09, Volume: 13, Issue:1

    Topics: Animals; Antiparkinson Agents; Cerebellum; Dyskinesia, Drug-Induced; Humans; Levodopa; Mice; Parkinson Disease

2022
L-Dopa response, choreic dyskinesia, and dystonia in Perry syndrome.
    Parkinsonism & related disorders, 2022, Volume: 100

    Topics: Antiparkinson Agents; Depression; Dyskinesia, Drug-Induced; Dystonia; Dystonic Disorders; Humans; Hypoventilation; Levodopa; Parkinson Disease; Parkinsonian Disorders

2022
Effect of glycine transporter 1 inhibition with bitopertin on parkinsonism and L-DOPA induced dyskinesia in the 6-OHDA-lesioned rat.
    European journal of pharmacology, 2022, Aug-15, Volume: 929

    Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Glycine Plasma Membrane Transport Proteins; Levodopa; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Piperazines; Rats; Sulfones

2022
Contracted thalamic shape is associated with early development of levodopa-induced dyskinesia in Parkinson's disease.
    Scientific reports, 2022, 07-25, Volume: 12, Issue:1

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Thalamus

2022
A positive allosteric modulator of mGlu4 receptors restores striatal plasticity in an animal model of l-Dopa-induced dyskinesia.
    Neuropharmacology, 2022, 11-01, Volume: 218

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Rats

2022
Synergistic effect of serotonin 1A and serotonin 1B/D receptor agonists in the treatment of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rats.
    Experimental neurology, 2022, Volume: 358

    Topics: Amantadine; Animals; Antiparkinson Agents; Buspirone; Dyskinesia, Drug-Induced; Levodopa; Oxazolidinones; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Serotonin; Serotonin 5-HT1 Receptor Agonists; Tryptamines

2022
Discovery of levodopa-induced dyskinesia-associated genes using genomic studies in patients and Drosophila behavioral analyses.
    Communications biology, 2022, 08-25, Volume: 5, Issue:1

    Topics: Animals; Drosophila; Dyskinesia, Drug-Induced; Genome-Wide Association Study; Genomics; Levodopa; Parkinson Disease

2022
Altered dynamic functional network connectivity in levodopa-induced dyskinesia of Parkinson's disease.
    CNS neuroscience & therapeutics, 2023, Volume: 29, Issue:1

    Topics: Antiparkinson Agents; Brain; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2023
Distinctive Effects of D1 and D2 Receptor Agonists on Cortico-Basal Ganglia Oscillations in a Rodent Model of L-DOPA-Induced Dyskinesia.
    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2023, Volume: 20, Issue:1

    Topics: Animals; Basal Ganglia; Corpus Striatum; Dyskinesia, Drug-Induced; Levodopa; Rats; Rodentia

2023
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
    Cells, 2022, 11-08, Volume: 11, Issue:22

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Glycine; Levodopa; Macaca fascicularis; Neuroprotective Agents; Parkinsonian Disorders; Pilot Projects; Prodrugs; Receptors, N-Methyl-D-Aspartate

2022
Characterizing the relationship between L-DOPA-induced-dyskinesia and psychosis-like behaviors in a bilateral rat model of Parkinson's disease.
    Neurobiology of disease, 2023, Volume: 176

    Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Psychotic Disorders; Quality of Life; Rats; Rats, Sprague-Dawley

2023
Dopamine Agonist Cotreatment Alters Neuroplasticity and Pharmacology of Levodopa-Induced Dyskinesia.
    Movement disorders : official journal of the Movement Disorder Society, 2023, Volume: 38, Issue:3

    Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Rats; Rats, Sprague-Dawley

2023
Cross-Cultural Differences in Patient Perceptions of Dyskinesia in Parkinson's Disease.
    Movement disorders : official journal of the Movement Disorder Society, 2023, Volume: 38, Issue:4

    Topics: Antiparkinson Agents; Cross-Cultural Comparison; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2023
ONO-2506 Can Delay Levodopa-induced Dyskinesia in the Early Stage.
    Neuroscience, 2023, 07-15, Volume: 523

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Rats

2023
Associations between variants in levodopa metabolic pathway genes and levodopa-induced dyskinesia in Parkinson's disease.
    Neuroscience letters, 2023, 03-28, Volume: 801

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Monoamine Oxidase; Parkinson Disease; Polymorphism, Single Nucleotide

2023
Pregnenolone for the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.
    Experimental neurology, 2023, Volume: 363

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dutasteride; Dyskinesia, Drug-Induced; Levodopa; Male; Neurosteroids; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley

2023
PT320, a Sustained-Release GLP-1 Receptor Agonist, Ameliorates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease.
    International journal of molecular sciences, 2023, Feb-28, Volume: 24, Issue:5

    Topics: Animals; Antiparkinson Agents; Delayed-Action Preparations; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Glucagon-Like Peptide-1 Receptor; Levodopa; Mice; Oxidopamine; Parkinson Disease

2023
The Dynamics of Dopamine D
    Neuroscience bulletin, 2023, Volume: 39, Issue:9

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Receptors, Dopamine D2

2023
Altered amantadine effects after repetitive treatment for l-dopa-induced involuntary movements in a rat model of Parkinson's disease.
    Neuroscience letters, 2023, 05-29, Volume: 806

    Topics: Amantadine; Animals; Antiparkinson Agents; Benserazide; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley

2023
Reply to: "Epigenetic Drug Effects in Levodopa Treated Patients with Parkinson's Disease".
    Movement disorders : official journal of the Movement Disorder Society, 2023, Volume: 38, Issue:4

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Epigenesis, Genetic; Humans; Levodopa; Parkinson Disease

2023
Epigenetic Drug Effects in Levodopa-Treated Patients with Parkinson's Disease.
    Movement disorders : official journal of the Movement Disorder Society, 2023, Volume: 38, Issue:4

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Epigenesis, Genetic; Humans; Levodopa; Parkinson Disease

2023
Chronic H
    Psychopharmacology, 2023, Volume: 240, Issue:6

    Topics: Animals; Cerebral Cortex; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Male; Oxidopamine; Rats; RNA, Messenger

2023
Amphiregulin blockade decreases the levodopa-induced dyskinesia in a 6-hydroxydopamine Parkinson's disease mouse model.
    CNS neuroscience & therapeutics, 2023, Volume: 29, Issue:10

    Topics: Amphiregulin; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Mice; Oxidopamine; Parkinson Disease

2023
Eltoprazine modulated gamma oscillations on ameliorating L-dopa-induced dyskinesia in rats.
    CNS neuroscience & therapeutics, 2023, Volume: 29, Issue:10

    Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Gamma Rhythm; Levodopa; Motor Cortex; Piperazines; Rats; Serotonin Receptor Agonists

2023
7-Nitroindazole reduces L-DOPA-induced dyskinesias in non-human Parkinsonian primate.
    Open biology, 2023, Volume: 13, Issue:5

    Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Levodopa; Parkinson Disease; Parkinsonian Disorders; Primates; Quality of Life

2023
Doxycycline to treat levodopa-induced dyskinesias in Parkinson's disease: a preliminary study.
    Arquivos de neuro-psiquiatria, 2023, Volume: 81, Issue:5

    Topics: Antiparkinson Agents; Double-Blind Method; Doxycycline; Dyskinesia, Drug-Induced; Dyskinesias; Humans; Levodopa; Parkinson Disease

2023
Targeting metabotropic glutamate receptors for the treatment of Parkinson's disease.
    Neurodegenerative disease management, 2023, Volume: 13, Issue:4

    Topics: Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptors, Metabotropic Glutamate

2023
Comparison of dyskinesia profiles after L-DOPA dose challenges with or without dopamine agonist coadministration.
    Neuropharmacology, 2023, 10-01, Volume: 237

    Topics: Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Dystonia; Humans; Hyperkinesis; Levodopa; Oxidopamine; Parkinson Disease

2023
Substantia Nigra Pars Reticulata Projections to the Pedunculopontine Nucleus Modulate Dyskinesia.
    Movement disorders : official journal of the Movement Disorder Society, 2023, Volume: 38, Issue:10

    Topics: Animals; Dyskinesia, Drug-Induced; GABAergic Neurons; Halorhodopsins; Levodopa; Mice; Parkinson Disease; Pars Reticulata; Substantia Nigra

2023
BDNF/TrkB pathway activation in D1 receptor-expressing striatal projection neurons plays a protective role against L-DOPA-induced dyskinesia.
    Neurobiology of disease, 2023, Volume: 185

    Topics: Animals; Antiparkinson Agents; Brain-Derived Neurotrophic Factor; Corpus Striatum; Dopamine; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Levodopa; Mice; Mice, Transgenic; Oxidopamine; Receptor, trkB; Receptors, Dopamine D2

2023
Ropinirole Cotreatment Prevents Perivascular Glial Recruitment in a Rat Model of L-DOPA-Induced Dyskinesia.
    Cells, 2023, 07-14, Volume: 12, Issue:14

    Topics: Animals; Antiparkinson Agents; Dopamine; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Microglia; Rats

2023
Effect of the mGlu
    Psychopharmacology, 2023, Volume: 240, Issue:10

    Topics: Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Dyskinesia, Drug-Induced; Levodopa; Parkinson Disease; Parkinsonian Disorders; Psychotic Disorders; Rats

2023
Brainstem Modulates Parkinsonism-Induced Orofacial Sensorimotor Dysfunctions.
    International journal of molecular sciences, 2023, Jul-31, Volume: 24, Issue:15

    Topics: Animals; Antiparkinson Agents; Brain Stem; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Rats

2023
Shared GABA transmission pathology in dopamine agonist- and antagonist-induced dyskinesia.
    Cell reports. Medicine, 2023, 10-17, Volume: 4, Issue:10

    Topics: Animals; Antiparkinson Agents; Dopamine; Dopamine Agonists; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Levodopa; Mice; Oxidopamine; Parkinsonian Disorders

2023
Antagonism of kappa opioid receptors accelerates the development of L-DOPA-induced dyskinesia in a preclinical model of moderate dopamine depletion.
    Brain research, 2023, 12-15, Volume: 1821

    Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa

2023
Dopamine-Depleted Dopamine Transporter Knockout (DDD) Mice: Dyskinesia with L-DOPA and Dopamine D1 Agonists.
    Biomolecules, 2023, Nov-17, Volume: 13, Issue:11

    Topics: Amantadine; Animals; Dopamine; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Levodopa; Mice; Mice, Knockout; Parkinson Disease

2023
Imaging SERT Availability in a Rat Model of L-DOPA-Induced Dyskinesia.
    Molecular imaging and biology, 2020, Volume: 22, Issue:3

    Topics: Animals; Brain; Carbon Radioisotopes; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Positron-Emission Tomography; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Serotonin Plasma Membrane Transport Proteins

2020
Acute L-DOPA administration reverses changes in firing pattern and low frequency oscillatory activity in the entopeduncular nucleus from long term L-DOPA treated 6-OHDA-lesioned rats.
    Experimental neurology, 2019, Volume: 322

    Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Entopeduncular Nucleus; Levodopa; Male; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Subthalamic Nucleus

2019
Risk thresholds of levodopa dose for dyskinesia in Chinese patients with Parkinson's disease: a pilot study.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2020, Volume: 41, Issue:1

    Topics: Antiparkinson Agents; China; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects; Retrospective Studies; Risk Factors

2020
Role of striatal ΔFosB in l-Dopa-induced dyskinesias of parkinsonian nonhuman primates.
    Proceedings of the National Academy of Sciences of the United States of America, 2019, 09-10, Volume: 116, Issue:37

    Topics: Animals; Animals, Genetically Modified; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Macaca fascicularis; Male; Neostriatum; Parkinson Disease; Protein Isoforms; Proto-Oncogene Proteins c-fos; Up-Regulation

2019
Selective Regulation of 5-HT1B Serotonin Receptor Expression in the Striatum by Dopamine Depletion and Repeated L-DOPA Treatment: Relationship to L-DOPA-Induced Dyskinesias.
    Molecular neurobiology, 2020, Volume: 57, Issue:2

    Topics: Animals; Behavior, Animal; Corpus Striatum; Dopamine; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Gene Expression Regulation; Levodopa; Male; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1B; Tyrosine 3-Monooxygenase

2020
Striatal overexpression of β-arrestin2 counteracts L-dopa-induced dyskinesia in 6-hydroxydopamine lesioned Parkinson's disease rats.
    Neurochemistry international, 2019, Volume: 131

    Topics: Adenoviridae; Animals; Antiparkinson Agents; beta-Arrestin 2; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Gene Deletion; Genetic Therapy; Genetic Vectors; Levodopa; Male; MAP Kinase Signaling System; Neostriatum; Parkinson Disease, Secondary; Phosphoproteins; Rats; Rats, Sprague-Dawley; Recovery of Function; Transcription Factors

2019
Subthalamic nucleus deep brain stimulation improves dyskinesias in Parkinson's disease beyond levodopa reduction.
    Journal of neural transmission (Vienna, Austria : 1996), 2019, Volume: 126, Issue:11

    Topics: Aged; Deep Brain Stimulation; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Subthalamic Nucleus

2019
Altered brain structural topological properties in Parkinson's disease with levodopa-induced dyskinesias.
    Parkinsonism & related disorders, 2019, Volume: 67

    Topics: Aged; Antiparkinson Agents; Basal Ganglia; Brain; Case-Control Studies; Cerebral Cortex; Connectome; Diffusion Magnetic Resonance Imaging; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Neural Pathways; Parkinson Disease; Thalamus; White Matter

2019
Cerebellar connectivity in Parkinson's disease with levodopa-induced dyskinesia.
    Annals of clinical and translational neurology, 2019, Volume: 6, Issue:11

    Topics: Aged; Antiparkinson Agents; Cerebellum; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neural Pathways; Parkinson Disease; Retrospective Studies

2019
Genetic deletion of GPR88 enhances the locomotor response to L-DOPA in experimental parkinsonism while counteracting the induction of dyskinesia.
    Neuropharmacology, 2020, 01-01, Volume: 162

    Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Cholinesterase Inhibitors; Corpus Striatum; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; GABAergic Neurons; Glutamic Acid; Levodopa; Locomotion; Male; Medial Forebrain Bundle; Mice; Mice, Knockout; Movement; Neuronal Plasticity; Oxidopamine; Parkinsonian Disorders; Receptors, G-Protein-Coupled; RNA, Messenger; Serotonin; Tacrine; Tremor

2020
Targeting the cannabinoid receptor CB2 in a mouse model of l-dopa induced dyskinesia.
    Neurobiology of disease, 2020, Volume: 134

    Topics: Amantadine; Animals; Antiparkinson Agents; Camphanes; Cannabinoid Receptor Agonists; Cannabinoids; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Mice, Inbred C57BL; Parkinsonian Disorders; Pyrazoles; Receptor, Cannabinoid, CB2

2020
Tapentadol Prevents Motor Impairments in a Mouse Model of Dyskinesia.
    Neuroscience, 2020, 01-01, Volume: 424

    Topics: Adrenergic Uptake Inhibitors; Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Motor Disorders; Oxidopamine; Parkinsonian Disorders; Tapentadol

2020
The increased gray matter volumes of precentral gyri in Parkinson's disease patients with diphasic dyskinesia.
    Aging, 2019, 11-07, Volume: 11, Issue:21

    Topics: Adult; Age of Onset; Case-Control Studies; Dyskinesia, Drug-Induced; Female; Frontal Lobe; Gray Matter; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease

2019
Complex dyskinesias in Parkinson patients on levodopa/carbidopa intestinal gel.
    Parkinsonism & related disorders, 2019, Volume: 69

    Topics: Aged; Antiparkinson Agents; Carbidopa; Case-Control Studies; Cross-Sectional Studies; Drug Combinations; Dyskinesia, Drug-Induced; Female; Gels; Humans; Intestines; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Retrospective Studies

2019
Pallidal versus subthalamic nucleus deep brain stimulation for levodopa-induced dyskinesia.
    Annals of clinical and translational neurology, 2020, Volume: 7, Issue:1

    Topics: Aged; Antiparkinson Agents; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Retrospective Studies; Subthalamic Nucleus

2020
Reply to: "Parkinson disease-associated dyskinesia in countries with low access to levodopa-sparing Regimens".
    Movement disorders : official journal of the Movement Disorder Society, 2019, Volume: 34, Issue:12

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2019
Neuroinflammation: Fanning the fire of l-dopa-induced dyskinesia.
    Movement disorders : official journal of the Movement Disorder Society, 2019, Volume: 34, Issue:12

    Topics: Animals; Antiparkinson Agents; Cytokines; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Inflammation; Levodopa; Nervous System Diseases; Tumor Necrosis Factor-alpha

2019
Dyskinesia matters.
    Movement disorders : official journal of the Movement Disorder Society, 2020, Volume: 35, Issue:3

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Quality of Life

2020
Simultaneous mass spectrometry imaging of multiple neuropeptides in the brain and alterations induced by experimental parkinsonism and L-DOPA therapy.
    Neurobiology of disease, 2020, Volume: 137

    Topics: Animals; Brain; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Globus Pallidus; Levodopa; Male; Neostriatum; Parkinsonian Disorders; Rats, Wistar

2020
Selective metabotropic glutamate receptor 2 positive allosteric modulation alleviates L-DOPA-induced psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset.
    European journal of pharmacology, 2020, Apr-15, Volume: 873

    Topics: Animals; Antiparkinson Agents; Antipsychotic Agents; Behavior, Animal; Callithrix; Dyskinesia, Drug-Induced; Female; GABA Modulators; Levodopa; Male; MPTP Poisoning; Parkinson Disease; Psychoses, Substance-Induced; Pyridines; Receptors, Metabotropic Glutamate; Sulfonamides

2020
Gene polymorphisms and motor levodopa-induced complications in Parkinson's disease.
    Brain and behavior, 2020, Volume: 10, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Alleles; Antiparkinson Agents; Brain-Derived Neurotrophic Factor; Catechol O-Methyltransferase; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Female; Genotype; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pharmacogenetics; Polymorphism, Single Nucleotide

2020
White matter hyperintensities and risk of levodopa-induced dyskinesia in Parkinson's disease.
    Annals of clinical and translational neurology, 2020, Volume: 7, Issue:2

    Topics: Aged; Comorbidity; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Humans; Leukoaraiosis; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Proportional Hazards Models; Retrospective Studies; Risk

2020
The Dopamine D5 receptor contributes to activation of cholinergic interneurons during L-DOPA induced dyskinesia.
    Scientific reports, 2020, 02-13, Volume: 10, Issue:1

    Topics: Animals; Cholinergic Neurons; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Interneurons; Levodopa; MAP Kinase Signaling System; Mice; Mice, Knockout; Oxidopamine; Parkinson Disease; Receptors, Dopamine D5

2020
Distinct anti-dyskinetic effects of amantadine and group II metabotropic glutamate receptor agonist LY354740 in a rodent model: An electrophysiological perspective.
    Neurobiology of disease, 2020, Volume: 139

    Topics: Amantadine; Animals; Antiparkinson Agents; Bridged Bicyclo Compounds; Corpus Striatum; Dyskinesia, Drug-Induced; Electrophysiology; Levodopa; Male; Motor Cortex; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate

2020
Ameliorative effects of a phosphodiesterase 10A inhibitor, MR1916 on L-DOPA-induced dyskinesia in parkinsonian rats.
    Pharmacological reports : PR, 2020, Volume: 72, Issue:2

    Topics: Administration, Oral; Amantadine; Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Rats, Sprague-Dawley

2020
Highly-selective µ-opioid receptor antagonism does not block L-DOPA-induced dyskinesia in a rodent model.
    BMC research notes, 2020, Mar-12, Volume: 13, Issue:1

    Topics: Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Glycopeptides; Levodopa; Male; Morphine; Narcotic Antagonists; Nociception; Rats, Sprague-Dawley; Receptors, Opioid, mu

2020
Intraventricular dopamine infusion alleviates motor symptoms in a primate model of Parkinson's disease.
    Neurobiology of disease, 2020, Volume: 139

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dopamine Agonists; Dyskinesia, Drug-Induced; Infusions, Intraventricular; Levodopa; Macaca; Male; Motor Activity; Parkinson Disease; Parkinsonian Disorders; Pilot Projects

2020
Genetic lack of histamine upregulates dopamine neurotransmission and alters rotational behavior but not levodopa-induced dyskinesia in a mouse model of Parkinson's disease.
    Neuroscience letters, 2020, 06-11, Volume: 729

    Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Levodopa; Mice; Oxidopamine; Parkinson Disease; Synaptic Transmission; Up-Regulation

2020
Striatal Nurr1 Facilitates the Dyskinetic State and Exacerbates Levodopa-Induced Dyskinesia in a Rat Model of Parkinson's Disease.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2020, 04-29, Volume: 40, Issue:18

    Topics: Aged; Animals; Corpus Striatum; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Nuclear Receptor Subfamily 4, Group A, Member 2; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Inbred F344; Rats, Inbred Lew; Rats, Sprague-Dawley

2020
Antiparkinsonian Effects of a Metabotropic Glutamate Receptor 4 Agonist in MPTP-Treated Marmosets.
    Journal of Parkinson's disease, 2020, Volume: 10, Issue:3

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Disabled Persons; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; Motor Disorders; Parkinson Disease; Receptors, Metabotropic Glutamate

2020
L-DOPA-elicited abnormal involuntary movements in the rats damaged severely in substantia nigra by 6-hydroxydopamine.
    Annals of palliative medicine, 2020, Volume: 9, Issue:3

    Topics: Animals; Apomorphine; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Rats; Substantia Nigra

2020
Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson's disease.
    Arquivos de neuro-psiquiatria, 2020, Volume: 78, Issue:4

    Topics: Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Polymorphism, Single Nucleotide

2020
Striatal Kir2 K+ channel inhibition mediates the antidyskinetic effects of amantadine.
    The Journal of clinical investigation, 2020, 05-01, Volume: 130, Issue:5

    Topics: Amantadine; Animals; Antiparkinson Agents; CHO Cells; Corpus Striatum; Cricetulus; Dyskinesia, Drug-Induced; Humans; Levodopa; Long-Term Potentiation; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Parkinson Disease; Parkinsonian Disorders; Potassium Channel Blockers; Potassium Channels, Inwardly Rectifying; Receptors, N-Methyl-D-Aspartate; Synaptic Potentials

2020
Predicting levodopa-induced dyskinesia.
    Arquivos de neuro-psiquiatria, 2020, Volume: 78, Issue:4

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Dyskinesias; Humans; Levodopa; Parkinson Disease

2020
Analysis of factors associated with brittle response in patients with Parkinson's disease.
    Annals of clinical and translational neurology, 2020, Volume: 7, Issue:5

    Topics: Adult; Body Mass Index; Body Weight; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Risk Factors; Sex Factors; Time Factors

2020
Striatal Nurr1, but not FosB expression links a levodopa-induced dyskinesia phenotype to genotype in Fisher 344 vs. Lewis hemiparkinsonian rats.
    Experimental neurology, 2020, Volume: 330

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Genotype; Levodopa; Male; Nuclear Receptor Subfamily 4, Group A, Member 2; Parkinsonian Disorders; Phenotype; Proto-Oncogene Proteins c-fos; Rats; Rats, Inbred F344; Rats, Inbred Lew

2020
Arachidonyl-2'-chloroethylamide (ACEA), a synthetic agonist of cannabinoid receptor, increases CB
    Pharmacology, biochemistry, and behavior, 2020, Volume: 194

    Topics: Animals; Arachidonic Acids; Cannabinoid Receptor Agonists; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Gene Expression; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; RNA, Messenger

2020
Dyskinesia Matters: But Not as Much as It Used to.
    Movement disorders : official journal of the Movement Disorder Society, 2020, Volume: 35, Issue:5

    Topics: Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2020
RasGRP1 is a causal factor in the development of l-DOPA-induced dyskinesia in Parkinson's disease.
    Science advances, 2020, Volume: 6, Issue:18

    Topics: Animals; Corpus Striatum; Disease Models, Animal; DNA-Binding Proteins; Dyskinesia, Drug-Induced; Guanine Nucleotide Exchange Factors; Humans; Levodopa; Mammals; Parkinson Disease; TOR Serine-Threonine Kinases

2020
Sex-specific association of urate and levodopa-induced dyskinesia in Parkinson's disease.
    European journal of neurology, 2020, Volume: 27, Issue:10

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Parkinson Disease; Uric Acid

2020
High levodopa plasma concentration after oral administration predicts levodopa-induced dyskinesia in Parkinson's disease.
    Parkinsonism & related disorders, 2020, Volume: 75

    Topics: Aged; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prognosis; Retrospective Studies

2020
Pain and dyskinesia in Parkinson's disease may share common pathophysiological mechanisms - An fMRI study.
    Journal of the neurological sciences, 2020, Sep-15, Volume: 416

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Magnetic Resonance Imaging; Pain; Parkinson Disease

2020
GABA storage and release in the medial globus pallidus in L-DOPA-induced dyskinesia priming.
    Neurobiology of disease, 2020, Volume: 143

    Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Globus Pallidus; Levodopa; Male; Neuronal Plasticity; Neurons; Parkinsonian Disorders; Rats; Rats, Wistar; Synaptic Transmission

2020
Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmoset.
    Naunyn-Schmiedeberg's archives of pharmacology, 2020, Volume: 393, Issue:11

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Callithrix; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Moclobemide; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Motor Activity; Parkinsonian Disorders; Psychoses, Substance-Induced

2020
Preclinical evidence in support of repurposing sub-anesthetic ketamine as a treatment for L-DOPA-induced dyskinesia.
    Experimental neurology, 2020, Volume: 333

    Topics: Anesthetics, Dissociative; Animals; Antiparkinson Agents; Brain-Derived Neurotrophic Factor; Dendritic Spines; Depression; Drug Repositioning; Dyskinesia, Drug-Induced; Ketamine; Levodopa; Male; MAP Kinase Signaling System; Neurons; Rats; Rats, Sprague-Dawley; TOR Serine-Threonine Kinases

2020
Transcriptomic approach predicts a major role for transforming growth factor beta type 1 pathway in L-Dopa-induced dyskinesia in parkinsonian rats.
    Genes, brain, and behavior, 2020, Volume: 19, Issue:8

    Topics: Animals; Antiparkinson Agents; Brain; Dyskinesia, Drug-Induced; Gene Regulatory Networks; Inhibin-beta Subunits; Levodopa; Male; Rats; Rats, Sprague-Dawley; Receptors, Neurotransmitter; Signal Transduction; Tachykinins; Tissue Inhibitor of Metalloproteinase-1; Transcriptome; Transforming Growth Factor beta1; Up-Regulation

2020
Lack of correlation between dyskinesia and pallidal serotonin transporter expression-induced by L-Dopa and Pramipexole in hemiparkinsonian rats.
    Pharmacology, biochemistry, and behavior, 2020, Volume: 197

    Topics: Animals; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Globus Pallidus; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Pramipexole; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Plasma Membrane Transport Proteins; Signal Transduction

2020
Levodopa partially rescues microglial numerical, morphological, and phagolysosomal alterations in a monkey model of Parkinson's disease.
    Brain, behavior, and immunity, 2020, Volume: 90

    Topics: Animals; Dyskinesia, Drug-Induced; Humans; Levodopa; Macaca fascicularis; Microglia; Parkinson Disease

2020
Globus pallidus, but not entopeduncular nucleus, 6-OHDA-induced lesion attenuates L-Dopa-induced dyskinesia in the rat model of Parkinson's disease.
    Pharmacology, biochemistry, and behavior, 2020, Volume: 197

    Topics: Animals; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Entopeduncular Nucleus; Globus Pallidus; Levodopa; Male; Medial Forebrain Bundle; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Plasma Membrane Transport Proteins; Signal Transduction

2020
A Retrospective Imaging Evaluation of Presynaptic Dopaminergic Degeneration in Multiple System Atrophy with Levodopa Induced Dyskinesia.
    Tremor and other hyperkinetic movements (New York, N.Y.), 2020, 06-15, Volume: 10

    Topics: Aged; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Multiple System Atrophy; Neostriatum; Neurodegenerative Diseases; Presynaptic Terminals; Retrospective Studies; Tomography, Emission-Computed, Single-Photon; Tropanes

2020
Parkinsonian Symptoms, Not Dyskinesia, Negatively Affect Active Life Participation of Dyskinetic Patients with Parkinson's Disease.
    Tremor and other hyperkinetic movements (New York, N.Y.), 2020, 07-08, Volume: 10

    Topics: Activities of Daily Living; Aged; Cross-Sectional Studies; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Social Participation

2020
Endocannabinoid levels in patients with Parkinson's disease with and without levodopa-induced dyskinesias.
    Journal of neural transmission (Vienna, Austria : 1996), 2020, Volume: 127, Issue:10

    Topics: Antiparkinson Agents; Chromatography, High Pressure Liquid; Dyskinesia, Drug-Induced; Endocannabinoids; Humans; Levodopa; Parkinson Disease

2020
Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats.
    Neurobiology of disease, 2020, Volume: 144

    Topics: Allosteric Regulation; Animals; Dopamine Agents; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Microdialysis; Muscarinic Antagonists; Neostriatum; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Rats; Receptor, Muscarinic M1; Receptor, Muscarinic M4; Substantia Nigra; Sympatholytics

2020
Angiotensin AT
    Journal of neuroinflammation, 2020, Aug-17, Volume: 17, Issue:1

    Topics: Animals; Calcium; Corpus Striatum; Cyclic AMP; Dyskinesia, Drug-Induced; HEK293 Cells; Humans; Levodopa; Mice; Phosphorylation; Rats; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin-Angiotensin System; Signal Transduction; Substantia Nigra

2020
Rapid drug increase and early onset of levodopa-induced dyskinesia in Parkinson's disease.
    PloS one, 2020, Volume: 15, Issue:8

    Topics: Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Linear Models; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Risk Factors; Sex Factors

2020
GraphNet-based imaging biomarker model to explain levodopa-induced dyskinesia in Parkinson's disease.
    Computer methods and programs in biomedicine, 2020, Volume: 196

    Topics: Antiparkinson Agents; Biomarkers; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2020
The selective 5-HT
    Parkinsonism & related disorders, 2020, Volume: 78

    Topics: Amantadine; Animals; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Piperidines; Pyridines; Serotonin 5-HT1 Receptor Agonists

2020
Rho kinase inhibitor fasudil reduces l-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
    British journal of pharmacology, 2020, Volume: 177, Issue:24

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Rats; rho-Associated Kinases

2020
The Vasomotor Response to Dopamine Is Altered in the Rat Model of l-dopa-Induced Dyskinesia.
    Movement disorders : official journal of the Movement Disorder Society, 2021, Volume: 36, Issue:4

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Oxidopamine; Parkinson Disease; Rats

2021
Inhaled Levodopa as a Potential Treatment for Diphasic Dyskinesia.
    Movement disorders : official journal of the Movement Disorder Society, 2021, Volume: 36, Issue:1

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2021
The BDNF Val66Met polymorphism (rs6265) enhances dopamine neuron graft efficacy and side-effect liability in rs6265 knock-in rats.
    Neurobiology of disease, 2021, Volume: 148

    Topics: Animals; Antiparkinson Agents; Brain-Derived Neurotrophic Factor; Cell Transplantation; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Dyskinesias; Embryo, Mammalian; Gene Knock-In Techniques; Levodopa; Mesencephalon; Oxidopamine; Parkinson Disease, Secondary; Rats; Sympatholytics; Vesicular Glutamate Transport Protein 2

2021
Levodopa-Induced Dyskinesia Are Mediated by Cortical Gamma Oscillations in Experimental Parkinsonism.
    Movement disorders : official journal of the Movement Disorder Society, 2021, Volume: 36, Issue:4

    Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Rats

2021
Genetic suppression of the dopamine D3 receptor in striatal D1 cells reduces the development of L-DOPA-induced dyskinesia.
    Experimental neurology, 2021, Volume: 336

    Topics: Animals; Behavior, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Genetic Therapy; Hydroxydopamines; Levodopa; Male; MicroRNAs; Neostriatum; Psychomotor Performance; Rats; Receptors, Dopamine D1; Receptors, Dopamine D3

2021
Granisetron, a selective 5-HT3 antagonist, reduces L-3,4-dihydroxyphenylalanine-induced abnormal involuntary movements in the 6-hydroxydopamine-lesioned rat.
    Behavioural pharmacology, 2021, 02-01, Volume: 32, Issue:1

    Topics: Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Granisetron; Levodopa; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Serotonin 5-HT3 Receptor Antagonists

2021
Cognitive impairment and levodopa induced dyskinesia in Parkinson's disease: a longitudinal study from the PACOS cohort.
    Scientific reports, 2021, 01-13, Volume: 11, Issue:1

    Topics: Aged; Attention; Cognitive Dysfunction; Cohort Studies; Dyskinesia, Drug-Induced; Executive Function; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Proportional Hazards Models; Severity of Illness Index

2021
Involvement of Autophagy in Levodopa-Induced Dyskinesia.
    Movement disorders : official journal of the Movement Disorder Society, 2021, Volume: 36, Issue:5

    Topics: Animals; Antiparkinson Agents; Autophagy; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Mice; Oxidopamine; Parkinsonian Disorders

2021
Bilateral subthalamic nucleus deep brain stimulation is an effective treatment for diphasic dyskinesia.
    European journal of neurology, 2021, Volume: 28, Issue:5

    Topics: Antiparkinson Agents; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Humans; Levodopa; Subthalamic Nucleus; Treatment Outcome

2021
Mass spectrometry imaging identifies abnormally elevated brain l-DOPA levels and extrastriatal monoaminergic dysregulation in l-DOPA-induced dyskinesia.
    Science advances, 2021, Volume: 7, Issue:2

    Topics: Animals; Brain; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Mass Spectrometry

2021
Texture-based markers from structural imaging correlate with motor handicap in Parkinson's disease.
    Scientific reports, 2021, 02-01, Volume: 11, Issue:1

    Topics: Aged; Antiparkinson Agents; Biomarkers; Brain; Dyskinesia, Drug-Induced; Female; Gray Matter; Humans; Image Processing, Computer-Assisted; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Nerve Degeneration; Parkinson Disease

2021
Exercise decreases aberrant corticostriatal plasticity in an animal model of l-DOPA-induced dyskinesia.
    American journal of physiology. Regulatory, integrative and comparative physiology, 2021, 04-01, Volume: 320, Issue:4

    Topics: Animals; Antiparkinson Agents; Benserazide; Cerebral Cortex; Corpus Striatum; Dihydroxyphenylalanine; Disease Models, Animal; Dyskinesia, Drug-Induced; Exercise Therapy; Levodopa; Long-Term Potentiation; Long-Term Synaptic Depression; Male; Mice, Inbred C57BL; Motor Activity; Neuronal Plasticity; Parkinsonian Disorders; Running; Time Factors

2021
Abnormal Cortico-Basal Ganglia Neurotransmission in a Mouse Model of l-DOPA-Induced Dyskinesia.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2021, 03-24, Volume: 41, Issue:12

    Topics: Animals; Basal Ganglia; Cerebral Cortex; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Mice, Inbred ICR; Motor Activity; Synaptic Transmission

2021
Spectral signatures of L-DOPA-induced dyskinesia depend on L-DOPA dose and are suppressed by ketamine.
    Experimental neurology, 2021, Volume: 340

    Topics: Analgesics; Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Gamma Rhythm; Ketamine; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley

2021
Interferon-γ Involvement in the Neuroinflammation Associated with Parkinson's Disease and L-DOPA-Induced Dyskinesia.
    Neurotoxicity research, 2021, Volume: 39, Issue:3

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Inflammation Mediators; Interferon-gamma; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidopamine; Parkinsonian Disorders

2021
Striatal ΔFosB gene suppression inhibits the development of abnormal involuntary movements induced by L-Dopa in rats.
    Gene therapy, 2021, Volume: 28, Issue:12

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Oxidopamine; Rats

2021
Doxycycline and its derivative, COL-3, decrease dyskinesia induced by l-DOPA in hemiparkinsonian rats.
    British journal of pharmacology, 2021, Volume: 178, Issue:13

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Doxycycline; Dyskinesia, Drug-Induced; Levodopa; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 3; Matrix Metalloproteinase 9; Oxidopamine; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Tetracyclines

2021
A novel phosphodiesterase 1 inhibitor reverses L-dopa-induced dyskinesia, but not motivation deficits, in monkeys.
    Pharmacology, biochemistry, and behavior, 2021, Volume: 205

    Topics: Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine Antagonists; Dyskinesia, Drug-Induced; Levodopa; Macaca mulatta; Male; Motivation; Motor Activity; Parkinsonian Disorders; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases

2021
Dyskinesia estimation during activities of daily living using wearable motion sensors and deep recurrent networks.
    Scientific reports, 2021, 04-12, Volume: 11, Issue:1

    Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Wearable Electronic Devices

2021
Differential roles of two isoforms of dopamine D2 receptors in l-dopa-induced abnormal involuntary movements in mice.
    Neuroreport, 2021, 05-05, Volume: 32, Issue:7

    Topics: Animals; Dopamine Agonists; Dopamine Antagonists; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Mice, Knockout; Motor Activity; Protein Isoforms; Quinpirole; Receptors, Dopamine D2; Salicylamides

2021
Levodopa-Induced Dyskinesia Is Mediated by Cortical Gamma Oscillations in Experimental Parkinsonism.
    Movement disorders : official journal of the Movement Disorder Society, 2021, Volume: 36, Issue:4

    Topics: Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinsonian Disorders

2021
Reply to: "Levodopa-Induced Dyskinesia Is Mediated by Cortical Gamma Oscillations in Experimental Parkinsonism".
    Movement disorders : official journal of the Movement Disorder Society, 2021, Volume: 36, Issue:4

    Topics: Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinsonian Disorders

2021
Beneficial effects of dipeptidyl peptidase-4 inhibitors in diabetic Parkinson's disease.
    Brain : a journal of neurology, 2021, 05-07, Volume: 144, Issue:4

    Topics: Aged; Antiparkinson Agents; Brain; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Female; Humans; Hypoglycemic Agents; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies

2021
The p75 neurotrophin receptor as a novel intermediate in L-dopa-induced dyskinesia in experimental Parkinson's disease.
    Experimental neurology, 2021, Volume: 342

    Topics: Animals; Dyskinesia, Drug-Induced; Levodopa; Male; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Growth Factor

2021
Subregion-Specific Regulation of Dopamine D1 Receptor Signaling in the Striatum: Implication for L-DOPA-Induced Dyskinesia.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2021, 07-28, Volume: 41, Issue:30

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Mice, Inbred C57BL; Parkinsonian Disorders; Receptors, Dopamine D1; Signal Transduction

2021
Neuropsychiatric Burden Is a Predictor of Early Freezing and Motor Progression in Drug-Naïve Parkinson's Disease.
    Journal of Parkinson's disease, 2021, Volume: 11, Issue:4

    Topics: Disease Progression; Dyskinesia, Drug-Induced; Gait Disorders, Neurologic; Humans; Levodopa; Parkinson Disease

2021
Riluzole Administration to Rats with Levodopa-Induced Dyskinesia Leads to Loss of DNA Methylation in Neuronal Genes.
    Cells, 2021, 06-09, Volume: 10, Issue:6

    Topics: Animals; Corpus Striatum; DNA Methylation; Dyskinesia, Drug-Induced; Levodopa; Rats; Rats, Wistar; Riluzole

2021
Neuroinflammation and L-dopa-induced abnormal involuntary movements in 6-hydroxydopamine-lesioned rat model of Parkinson's disease are counteracted by combined administration of a 5-HT
    Neuropharmacology, 2021, 09-15, Volume: 196

    Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Calcium-Binding Proteins; Caudate Nucleus; Dyskinesia, Drug-Induced; Glial Fibrillary Acidic Protein; Interleukin-10; Interleukin-1beta; Levodopa; Microfilament Proteins; Neuroinflammatory Diseases; Oxidopamine; Parkinsonian Disorders; Pars Compacta; Piperazines; Putamen; Pyrimidines; Rats; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT1B; Serotonin 5-HT1 Receptor Agonists; Triazoles; Tumor Necrosis Factor-alpha

2021
White matter alterations in Parkinson's disease with levodopa-induced dyskinesia.
    Parkinsonism & related disorders, 2021, Volume: 90

    Topics: Aged; Antiparkinson Agents; Biomarkers; Case-Control Studies; Diffusion Magnetic Resonance Imaging; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Nerve Fibers; Odds Ratio; Parkinson Disease; Temporal Lobe; White Matter

2021
Multivariable clinical-genetic model for predicting dyskinesia in early-onset Parkinson's disease.
    Translational neurodegeneration, 2021, 07-29, Volume: 10, Issue:1

    Topics: Adult; Age of Onset; Antiparkinson Agents; Cohort Studies; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Models, Genetic; Multivariate Analysis; Parkinson Disease; Predictive Value of Tests

2021
Severe Dyskinesia After Administration of SARS-CoV2 mRNA Vaccine in Parkinson's Disease.
    Movement disorders : official journal of the Movement Disorder Society, 2021, Volume: 36, Issue:10

    Topics: COVID-19; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; RNA, Messenger; RNA, Viral; SARS-CoV-2; Vaccines

2021
Human COMT over-expression confers a heightened susceptibility to dyskinesia in mice.
    Neurobiology of disease, 2017, Volume: 102

    Topics: Animals; Antiparkinson Agents; Armadillo Domain Proteins; Catechol O-Methyltransferase; Cell Adhesion Molecules; Corpus Striatum; Disease Models, Animal; Disease Susceptibility; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Mice, Inbred C57BL; Mice, Transgenic; Motor Activity; Oxidopamine; Parkinsonian Disorders; Phosphoproteins; Proto-Oncogene Proteins c-fos; Serotonin; Thioredoxin Reductase 2

2017
A novel framework for understanding reduced awareness of dyskinesias in Parkinson's Disease.
    Parkinsonism & related disorders, 2017, Volume: 39

    Topics: Aged; Awareness; Dyskinesia, Drug-Induced; Executive Function; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Neuropsychological Tests; Parkinson Disease; Psychiatric Status Rating Scales; Regression Analysis; Theory of Mind

2017
A Web Resource for Levodopa-Induced Dyskinesia Genetics in Parkinson's Disease.
    Neuroinformatics, 2017, Volume: 15, Issue:3

    Topics: Antiparkinson Agents; Computer Communication Networks; Dyskinesia, Drug-Induced; Health Resources; Humans; Levodopa; Parkinson Disease

2017
Effects of a combination treatment of KD5040 and
    BMC complementary and alternative medicine, 2017, Apr-19, Volume: 17, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cyclic AMP Response Element-Binding Protein; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Enkephalins; Extracellular Signal-Regulated MAP Kinases; Levodopa; Magnoliopsida; Male; Mice, Inbred C57BL; Movement; Parkinson Disease; Phytotherapy; Plant Extracts; Proto-Oncogene Proteins c-fos; Substance P

2017
What would Dr. James Parkinson think today? parcelling out the circuitry of levodopa-induced dyskinesias.
    Movement disorders : official journal of the Movement Disorder Society, 2017, Volume: 32, Issue:4

    Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2017
Altered somatosensory cortex neuronal activity in a rat model of Parkinson's disease and levodopa-induced dyskinesias.
    Experimental neurology, 2017, Volume: 294

    Topics: Action Potentials; Animals; Antiparkinson Agents; Apomorphine; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Glutamate Decarboxylase; Levodopa; Motor Cortex; Nerve Tissue Proteins; Neurons; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, GABA; RNA, Messenger; Sympatholytics; Tandem Mass Spectrometry

2017
Common Myths in the Use of Levodopa in Parkinson Disease: When Clinical Trials Misinform Clinical Practice.
    JAMA neurology, 2017, 06-01, Volume: 74, Issue:6

    Topics: Antiparkinson Agents; Clinical Trials as Topic; Dopamine Agonists; Dyskinesia, Drug-Induced; Dyskinesias; Humans; Levodopa; Parkinson Disease

2017
Liquid levodopa-carbidopa in advanced Parkinson's disease with motor complications.
    Journal of the neurological sciences, 2017, Jun-15, Volume: 377

    Topics: Aged; Antiparkinson Agents; Ascorbic Acid; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Kaplan-Meier Estimate; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Treatment Outcome

2017
Involvement of the bed nucleus of the stria terminalis in L-Dopa induced dyskinesia.
    Scientific reports, 2017, 05-24, Volume: 7, Issue:1

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Daunorubicin; Disease Models, Animal; Dyskinesia, Drug-Induced; Gene Expression; Levodopa; Male; Neurons; Parkinson Disease; Proto-Oncogene Proteins c-fos; Rats, Sprague-Dawley; Septal Nuclei

2017
Zonisamide ameliorates levodopa-induced dyskinesia and reduces expression of striatal genes in Parkinson model rats.
    Neuroscience research, 2017, Volume: 122

    Topics: Animals; Anticonvulsants; Corpus Striatum; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Gene Expression; Isoxazoles; Levodopa; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Receptor, Cannabinoid, CB1; Receptors, Dopamine D1; Receptors, Dopamine D2; Zonisamide

2017
Altered adenosine 2A and dopamine D2 receptor availability in the 6-hydroxydopamine-treated rats with and without levodopa-induced dyskinesia.
    NeuroImage, 2017, 08-15, Volume: 157

    Topics: Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Oxidopamine; Parkinson Disease, Secondary; Positron-Emission Tomography; Rats; Rats, Wistar; Receptor, Adenosine A2A; Receptors, Dopamine D2; Sympatholytics

2017
Changes in kynurenine pathway metabolism in Parkinson patients with L-DOPA-induced dyskinesia.
    Journal of neurochemistry, 2017, Volume: 142, Issue:5

    Topics: Adult; Aged; Antiparkinson Agents; Biomarkers; Denmark; Dyskinesia, Drug-Induced; Female; Humans; Kynurenine; Levodopa; Male; Middle Aged; Parkinson Disease; Signal Transduction; Single-Blind Method

2017
Ceftriaxone reduces L-dopa-induced dyskinesia severity in 6-hydroxydopamine parkinson's disease model.
    Movement disorders : official journal of the Movement Disorder Society, 2017, Volume: 32, Issue:11

    Topics: Animals; Anti-Bacterial Agents; Ceftriaxone; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Transporter 2; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Sympatholytics

2017
Opioid K receptor variant is associated with a delayed onset of dyskinesias in Parkinson's disease.
    Journal of neurology, neurosurgery, and psychiatry, 2018, Volume: 89, Issue:3

    Topics: Adult; Aged; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Linear Models; Male; Middle Aged; Multivariate Analysis; Parkinson Disease; Pharmacogenomic Variants; Receptors, Opioid, kappa; Time Factors

2018
Choreiform dyskinesias following levodopa treatment of parkinsonism due to osmotic demyelination syndrome.
    Parkinsonism & related disorders, 2017, Volume: 43

    Topics: Aged; Antiparkinson Agents; Demyelinating Diseases; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Osmosis; Parkinsonian Disorders

2017
Psychostimulant effect of dopaminergic treatment and addictions in Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2017, Volume: 32, Issue:11

    Topics: Aged; Behavior, Addictive; Central Nervous System Stimulants; Depressive Disorder; Dopamine Agents; Dyskinesia, Drug-Induced; Euphoria; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Substance-Related Disorders

2017
A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinson's disease.
    European journal of pharmacology, 2017, Oct-15, Volume: 813

    Topics: Animals; Antiparkinson Agents; Behavior, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Motor Activity; Parkinson Disease; Piperazines; Time Factors

2017
BDNF over-expression induces striatal serotonin fiber sprouting and increases the susceptibility to l-DOPA-induced dyskinesia in 6-OHDA-lesioned rats.
    Experimental neurology, 2017, Volume: 297

    Topics: Animals; Antiparkinson Agents; Brain-Derived Neurotrophic Factor; Corpus Striatum; Dyskinesia, Drug-Induced; Gene Expression; HEK293 Cells; Humans; Levodopa; Male; Oxidopamine; Rats; Rats, Sprague-Dawley; Serotonergic Neurons

2017
ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study.
    Journal of Parkinson's disease, 2017, Volume: 7, Issue:3

    Topics: Aged; Amantadine; Double-Blind Method; Drug Delivery Systems; Dyskinesia, Drug-Induced; Female; Humans; Kaplan-Meier Estimate; Levodopa; Male; Middle Aged; Treatment Outcome

2017
Teaching Video Neuro
    Neurology, 2017, 08-15, Volume: 89, Issue:7

    Topics: Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Videotape Recording

2017
Rabphilin 3A: A novel target for the treatment of levodopa-induced dyskinesias.
    Neurobiology of disease, 2017, Volume: 108

    Topics: Adaptor Proteins, Signal Transducing; Aged; Aged, 80 and over; Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Macaca mulatta; Male; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Post-Synaptic Density; Protein Binding; Rabphilin-3A; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Synapses; Tissue Culture Techniques; Vesicular Transport Proteins

2017
The Kinase Fyn As a Novel Intermediate in L-DOPA-Induced Dyskinesia in Parkinson's Disease.
    Molecular neurobiology, 2018, Volume: 55, Issue:6

    Topics: Animals; Benzodioxoles; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Mice, Inbred C57BL; Mice, Knockout; Models, Biological; Movement; Neostriatum; Parkinson Disease; Phosphorylation; Protein Subunits; Proto-Oncogene Proteins c-fyn; Quinazolines; Receptors, N-Methyl-D-Aspartate; Tyrosine 3-Monooxygenase

2018
The effect of mianserin on the severity of psychosis and dyskinesia in the parkinsonian marmoset.
    Progress in neuro-psychopharmacology & biological psychiatry, 2018, 02-02, Volume: 81

    Topics: Animals; Antidepressive Agents, Second-Generation; Callithrix; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Mianserin; MPTP Poisoning; Psychotic Disorders; Severity of Illness Index; Time Factors; Treatment Outcome

2018
The plasmalogen precursor analog PPI-1011 reduces the development of L-DOPA-induced dyskinesias in de novo MPTP monkeys.
    Behavioural brain research, 2018, Jan-30, Volume: 337

    Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; MPTP Poisoning; Ovariectomy; Plasmalogens; Time Factors

2018
L-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life: the COPARK survey.
    European journal of neurology, 2017, Volume: 24, Issue:12

    Topics: Activities of Daily Living; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Quality of Life; Severity of Illness Index

2017
Impulse control disorders in advanced Parkinson's disease with dyskinesia: The ALTHEA study.
    Movement disorders : official journal of the Movement Disorder Society, 2017, Volume: 32, Issue:11

    Topics: Aged; Comorbidity; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index

2017
Chemogenetic modulation of cholinergic interneurons reveals their regulating role on the direct and indirect output pathways from the striatum.
    Neurobiology of disease, 2018, Volume: 109, Issue:Pt A

    Topics: Animals; Choline O-Acetyltransferase; Cholinergic Neurons; Corpus Striatum; Dopamine; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Female; Interneurons; Levodopa; Locomotion; Male; Parkinson Disease; Rats, Long-Evans; Rats, Sprague-Dawley; Rats, Transgenic; Receptors, Dopamine D1; Receptors, Dopamine D2; Tyrosine 3-Monooxygenase

2018
Metformin Inhibits the Development of L-DOPA-Induced Dyskinesia in a Murine Model of Parkinson's Disease.
    Molecular neurobiology, 2018, Volume: 55, Issue:7

    Topics: Amantadine; Animals; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Metformin; Mice, Inbred C57BL; Parkinson Disease; Signal Transduction

2018
Increased putamen hypercapnic vasoreactivity in levodopa-induced dyskinesia.
    JCI insight, 2017, 10-19, Volume: 2, Issue:20

    Topics: Aged; Antiparkinson Agents; Cerebrovascular Circulation; Dyskinesia, Drug-Induced; Dyskinesias; Female; Humans; Hypercapnia; Levodopa; Male; Middle Aged; Neuroimaging; Parkinson Disease; Putamen; Sensorimotor Cortex

2017
Automated vision-based analysis of levodopa-induced dyskinesia with deep learning.
    Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference, 2017, Volume: 2017

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Machine Learning; Parkinson Disease

2017
Factors associated with motor complications in Parkinson's disease.
    Brain and behavior, 2017, Volume: 7, Issue:10

    Topics: Age of Onset; Aged; Antiparkinson Agents; Cross-Sectional Studies; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Logistic Models; Long Term Adverse Effects; Male; Middle Aged; Parkinson Disease; Time-to-Treatment; Treatment Outcome

2017
CK2 Oppositely Modulates l-DOPA-Induced Dyskinesia via Striatal Projection Neurons Expressing D1 or D2 Receptors.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2017, 12-06, Volume: 37, Issue:49

    Topics: Animals; Casein Kinase II; Corpus Striatum; Dopamine Agonists; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Female; Gene Expression; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Neurons; Receptors, Dopamine D1; Receptors, Dopamine D2

2017
The effects of cysteamine in a mouse model of levodopa-induced dyskinesias.
    Neuroscience letters, 2018, Jan-01, Volume: 662

    Topics: Animals; Cysteamine; Cystine Depleting Agents; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Mice

2018
Lipoic acid alleviates L‑DOPA‑induced dyskinesia in 6‑OHDA parkinsonian rats via anti‑oxidative stress.
    Molecular medicine reports, 2018, Volume: 17, Issue:1

    Topics: Animals; Antioxidants; Caspase 3; Disease Models, Animal; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Female; Levodopa; Oxidative Stress; Parkinson Disease; Poly(ADP-ribose) Polymerases; Rats; Reactive Oxygen Species; Substantia Nigra; Thioctic Acid

2018
Extended-release amantadine (Gocovri) for dyskinesia in Parkinson's disease.
    The Medical letter on drugs and therapeutics, 2017, 12-04, Volume: 59, Issue:1535

    Topics: Amantadine; Antiparkinson Agents; Delayed-Action Preparations; Drug Compounding; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Treatment Outcome

2017
Dopamine receptors and BDNF-haplotypes predict dyskinesia in Parkinson's disease.
    Parkinsonism & related disorders, 2018, Volume: 47

    Topics: Aged; Brain-Derived Neurotrophic Factor; Case-Control Studies; Community Health Planning; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Genetic Association Studies; Haplotypes; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Dopamine; Retrospective Studies

2018
DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.
    Neuropharmacology, 2018, 03-15, Volume: 131

    Topics: Adrenergic Agents; Analgesics, Opioid; Animals; Benzamides; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Guinea Pigs; Levodopa; Macaca; Male; Mice; Mice, Inbred C57BL; Movement; Narcotic Antagonists; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Piperazines; Rats, Sprague-Dawley; Receptors, Opioid, delta; Receptors, Opioid, mu; Vas Deferens

2018
Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists.
    British journal of pharmacology, 2018, Volume: 175, Issue:5

    Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Acetamides; Animals; Antiparkinson Agents; Corpus Striatum; Cricetinae; Dyskinesia, Drug-Induced; Extracellular Signal-Regulated MAP Kinases; Levodopa; Male; Nociceptin Receptor; Oxidopamine; Phosphorylation; Piperidines; Radioligand Assay; Rats; Receptors, Opioid

2018
Regulation of Pleiotrophin and Fyn in the striatum of rats undergoing L-DOPA-induced dyskinesia.
    Neuroscience letters, 2018, 02-14, Volume: 666

    Topics: Animals; Carrier Proteins; Corpus Striatum; Cytokines; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Male; Neurons; Parkinson Disease; Proto-Oncogene Proteins c-fyn; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate

2018
Trazodone alleviates both dyskinesia and psychosis in the parkinsonian marmoset model of Parkinson's disease.
    Journal of neural transmission (Vienna, Austria : 1996), 2018, Volume: 125, Issue:9

    Topics: Animals; Antiparkinson Agents; Antipsychotic Agents; Behavior, Animal; Callithrix; Disorders of Excessive Somnolence; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; MPTP Poisoning; Parkinsonian Disorders; Serotonin Receptor Agonists; Trazodone

2018
Striatal norepinephrine efflux in l-DOPA-induced dyskinesia.
    Neurochemistry international, 2018, Volume: 114

    Topics: Animals; Corpus Striatum; Dyskinesia, Drug-Induced; Levodopa; Male; Microdialysis; Norepinephrine; Rats; Rats, Sprague-Dawley

2018
Glutamatergic mechanisms in L-DOPA-induced dyskinesia and therapeutic implications.
    Journal of neural transmission (Vienna, Austria : 1996), 2018, Volume: 125, Issue:8

    Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Glutamic Acid; Humans; Levodopa; Neurons; Receptors, Glutamate

2018
A Subpopulation of Striatal Neurons Mediates Levodopa-Induced Dyskinesia.
    Neuron, 2018, 02-21, Volume: 97, Issue:4

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Mice, Inbred C57BL; Mice, Transgenic; Motor Cortex; Neural Pathways; Neurons; Optogenetics; Parkinson Disease

2018
CaMKII inhibition ameliorated levodopa-induced dyskinesia by downregulating tyrosine hydroxylase activity in an experimental model of Parkinson's disease.
    Brain research, 2018, 05-15, Volume: 1687

    Topics: Animals; Antiparkinson Agents; Benzylamines; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Male; Mice, Inbred C57BL; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; PC12 Cells; Protein Kinase Inhibitors; Rats; Signal Transduction; Sulfonamides; Sympatholytics; Tyrosine 3-Monooxygenase

2018
Motor fluctuations and levodopa-induced dyskinesias in dopa-responsive dystonia.
    Parkinsonism & related disorders, 2018, Volume: 50

    Topics: Carbidopa; Dopamine Agonists; Drug Combinations; Dyskinesia, Drug-Induced; Dystonic Disorders; Female; GTP Cyclohydrolase; Humans; Levodopa; Middle Aged

2018
Effects of antidyskinetic nicotine treatment on dopamine release in dorsal and ventral striatum.
    Neuroscience letters, 2018, 04-13, Volume: 672

    Topics: Animals; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Mice; Nicotine; Nicotinic Agonists; Synaptosomes

2018
A Selective Phosphodiesterase 10A Inhibitor Reduces L-Dopa-Induced Dyskinesias in Parkinsonian Monkeys.
    Movement disorders : official journal of the Movement Disorder Society, 2018, Volume: 33, Issue:5

    Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Male; MPTP Poisoning; Organic Chemicals; Phosphodiesterase Inhibitors

2018
Correlation between dopamine receptor D2 expression and presence of abnormal involuntary movements in Wistar rats with hemiparkinsonism and dyskinesia.
    Neurologia, 2021, Volume: 36, Issue:3

    Topics: Animals; Dyskinesia, Drug-Induced; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Rats, Wistar

2021
Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements.
    Behavioural brain research, 2018, 07-16, Volume: 347

    Topics: Animals; Antiparkinson Agents; Benserazide; Cytoskeletal Proteins; Disease Models, Animal; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enkephalins; Levodopa; Male; Movement; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats, Sprague-Dawley; RNA, Messenger; Selegiline; Time Factors

2018
Genetic disruption of the nuclear receptor Nur77 (Nr4a1) in rat reduces dopamine cell loss and l-Dopa-induced dyskinesia in experimental Parkinson's disease.
    Experimental neurology, 2018, Volume: 304

    Topics: Animals; Antiparkinson Agents; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Gene Knockout Techniques; Levodopa; Mice; Nuclear Receptor Subfamily 4, Group A, Member 1; Parkinsonian Disorders; Rats

2018
Identification of metabolite biomarkers for L-DOPA-induced dyskinesia in a rat model of Parkinson's disease by metabolomic technology.
    Behavioural brain research, 2018, 07-16, Volume: 347

    Topics: Animals; Antiparkinson Agents; Apomorphine; Arachidonic Acids; Biomarkers; Cannabinoid Receptor Agonists; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Endocannabinoids; Glycerides; Levodopa; Male; Metabolome; Metabolomics; Motor Activity; Oxidopamine; Parkinsonian Disorders; Polyunsaturated Alkamides; Rats, Sprague-Dawley

2018
Nociceptive Response to L-DOPA-Induced Dyskinesia in Hemiparkinsonian Rats.
    Neurotoxicity research, 2018, Volume: 34, Issue:4

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Inflammation; Levodopa; Male; Nociceptive Pain; Oxidopamine; Parkinsonian Disorders; Pars Compacta; Rats, Wistar

2018
Levodopa-Induced Dyskinesia: "TRAP"ping the Culprit.
    Movement disorders : official journal of the Movement Disorder Society, 2018, Volume: 33, Issue:5

    Topics: Corpus Striatum; Dyskinesia, Drug-Induced; Humans; Levodopa; Neurons

2018
Automated assessment of levodopa-induced dyskinesia: Evaluating the responsiveness of video-based features.
    Parkinsonism & related disorders, 2018, Volume: 53

    Topics: Aged; Antiparkinson Agents; Biomechanical Phenomena; Deep Learning; Dyskinesia, Drug-Induced; Female; Humans; Image Interpretation, Computer-Assisted; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Reported Outcome Measures; Sensitivity and Specificity; Severity of Illness Index; Video Recording

2018
Inhaling xenon ameliorates l-dopa-induced dyskinesia in experimental parkinsonism.
    Movement disorders : official journal of the Movement Disorder Society, 2018, Volume: 33, Issue:10

    Topics: Administration, Inhalation; Animals; Antiparkinson Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Gait Disorders, Neurologic; Green Fluorescent Proteins; Levodopa; Mice; Mice, Transgenic; MPTP Poisoning; Oxidopamine; Parkinsonian Disorders; Rats; Sensation Disorders; Sympatholytics; Time Factors; Xenon

2018
Association of metals with the risk and clinical characteristics of Parkinson's disease.
    Parkinsonism & related disorders, 2018, Volume: 55

    Topics: Aged; Copper; Dyskinesia, Drug-Induced; Female; Humans; Iron; Levodopa; Logistic Models; Male; Middle Aged; Parkinson Disease; Sex Characteristics

2018
Aberrant Striatal Activity in Parkinsonism and Levodopa-Induced Dyskinesia.
    Cell reports, 2018, 06-19, Volume: 23, Issue:12

    Topics: Action Potentials; Animals; Behavior, Animal; Corpus Striatum; Dopamine; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Mice, Inbred C57BL; Mice, Transgenic; Motor Activity; Neurons; Optogenetics; Parkinsonian Disorders; Receptors, Dopamine

2018
Attenuated dopaminergic neurodegeneration and motor dysfunction in hemiparkinsonian mice lacking the α5 nicotinic acetylcholine receptor subunit.
    Neuropharmacology, 2018, Volume: 138

    Topics: Amphetamine; Animals; Antiparkinson Agents; Brain; Central Nervous System Stimulants; Dopamine; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Female; Functional Laterality; Levodopa; Male; Mice, Inbred C57BL; Mice, Knockout; Motor Activity; Neurodegenerative Diseases; Oxidopamine; Parkinsonian Disorders; Receptors, Dopamine; Receptors, Nicotinic; RNA, Messenger

2018
Striatonigral neurons divide into two distinct morphological-physiological phenotypes after chronic L-DOPA treatment in parkinsonian rats.
    Scientific reports, 2018, 07-03, Volume: 8, Issue:1

    Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Female; Levodopa; Mice; Mice, Transgenic; Neostriatum; Neurons; Parkinson Disease; Phenotype; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Striatonigral Degeneration

2018
Dysfunctional inhibitory control in Parkinson's disease patients with levodopa-induced dyskinesias.
    Journal of neurology, 2018, Volume: 265, Issue:9

    Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Impulsive Behavior; Levodopa; Male; Motor Activity; Parkinson Disease; Reaction Time

2018
MTOR Pathway-Based Discovery of Genetic Susceptibility to L-DOPA-Induced Dyskinesia in Parkinson's Disease Patients.
    Molecular neurobiology, 2019, Volume: 56, Issue:3

    Topics: Alleles; Dyskinesia, Drug-Induced; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Levodopa; Parkinson Disease; Polymorphism, Single Nucleotide; Retrospective Studies; Signal Transduction; TOR Serine-Threonine Kinases

2019
Effects of histone acetyltransferase inhibitors on L-DOPA-induced dyskinesia in a murine model of Parkinson's disease.
    Journal of neural transmission (Vienna, Austria : 1996), 2018, Volume: 125, Issue:9

    Topics: Anacardic Acids; Animals; Antiparkinson Agents; Curcumin; Cytoskeletal Proteins; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Fos-Related Antigen-2; Gene Expression Regulation; Histone Acetyltransferases; Histone Code; Levodopa; Male; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Specific Pathogen-Free Organisms; Substantia Nigra; Terpenes

2018
Dyskinesia in Parkinson's disease: a clinical complication and an open scientific question.
    Journal of neural transmission (Vienna, Austria : 1996), 2018, Volume: 125, Issue:8

    Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2018
Repurposing an established drug: an emerging role for methylene blue in L-DOPA-induced dyskinesia.
    The European journal of neuroscience, 2019, Volume: 49, Issue:6

    Topics: Animals; Antiparkinson Agents; Drug Repositioning; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Quinoxalines; Rats, Wistar; Signal Transduction

2019
Does Late Levodopa Administration Delay the Development of Dyskinesia in Patients with De Novo Parkinson's Disease?
    CNS drugs, 2018, Volume: 32, Issue:10

    Topics: Aged; Antiparkinson Agents; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Female; Humans; Kaplan-Meier Estimate; Levodopa; Male; Middle Aged; Parkinson Disease; Proportional Hazards Models; Retrospective Studies

2018
Acupuncture Alleviates Levodopa-Induced Dyskinesia via Melanin-Concentrating Hormone in Pitx3-Deficient aphakia and 6-Hydroxydopamine-Lesioned Mice.
    Molecular neurobiology, 2019, Volume: 56, Issue:4

    Topics: Acupuncture Therapy; Animals; Aphakia; Dyskinesia, Drug-Induced; Gene Expression Regulation; Homeodomain Proteins; Hypothalamic Hormones; Hypothalamus; Levodopa; Melanins; Mice, Inbred C57BL; Neostriatum; Oxidopamine; Pituitary Hormones; Reproducibility of Results; RNA, Messenger; Transcription Factors; Up-Regulation

2019
Treadmill Exercise Attenuates L-DOPA-Induced Dyskinesia and Increases Striatal Levels of Glial Cell-Derived Neurotrophic Factor (GDNF) in Hemiparkinsonian Mice.
    Molecular neurobiology, 2019, Volume: 56, Issue:4

    Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Glial Cell Line-Derived Neurotrophic Factor; Levodopa; Male; Mice, Inbred C57BL; Motor Activity; Parkinson Disease; Physical Conditioning, Animal; Tyrosine 3-Monooxygenase

2019
Polymorphisms of Catechol-O-Methyl Transferase (COMT) Gene in Vulnerability to Levodopa-Induced Dyskinesia.
    Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 2018, Volume: 21, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Catechol O-Methyltransferase; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polymorphism, Single Nucleotide; Regression Analysis

2018
Nefazodone reduces dyskinesia, but not psychosis-like behaviours, in the parkinsonian marmoset.
    Naunyn-Schmiedeberg's archives of pharmacology, 2018, Volume: 391, Issue:12

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Parkinsonian Disorders; Piperazines; Psychoses, Substance-Induced; Triazoles

2018
Pathophysiology of levodopa-induced dyskinesia: Insights from multimodal imaging and immunohistochemistry in non-human primates.
    NeuroImage, 2018, Volume: 183

    Topics: Animals; Brain; Diffusion Tensor Imaging; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Immunohistochemistry; Levodopa; Macaca fascicularis; MPTP Poisoning; Multimodal Imaging; N-Methyl-3,4-methylenedioxyamphetamine; Nerve Fibers; Parkinson Disease, Secondary; Positron-Emission Tomography; Serotonin Agents; Serotonin Plasma Membrane Transport Proteins

2018
Cortical response to levodopa in Parkinson's disease patients with dyskinesias.
    The European journal of neuroscience, 2018, Volume: 48, Issue:6

    Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Brain; Drug Combinations; Dyskinesia, Drug-Induced; Electroencephalography; Female; Humans; Levodopa; Male; Middle Aged; Motor Cortex; Parkinson Disease; Transcranial Magnetic Stimulation

2018
Tat-Src reduced NR2B tyrosine phosphorylation and its interaction with NR2B in levodopa-induced dyskinetic rats model.
    Behavioural brain research, 2019, 01-01, Volume: 356

    Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Parkinson Disease; Peptides; Phosphorylation; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; src-Family Kinases

2019
Modulation of CaMKIIa-GluN2B interaction in levodopa-induced dyskinesia in 6-OHDA-lesioned Parkinson's rats.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2018, Volume: 107

    Topics: Animals; Behavior, Animal; Benzylamines; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Corpus Striatum; Dizocilpine Maleate; Dyskinesia, Drug-Induced; Levodopa; Male; Neurons; Oxidopamine; Parkinson Disease; Phosphorylation; Protein Binding; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Sulfonamides

2018
The combination of the opioid glycopeptide MMP-2200 and a NMDA receptor antagonist reduced l-DOPA-induced dyskinesia and MMP-2200 by itself reduced dopamine receptor 2-like agonist-induced dyskinesia.
    Neuropharmacology, 2018, Volume: 141

    Topics: Animals; Antiparkinson Agents; Benzazepines; Dizocilpine Maleate; Drug Synergism; Dyskinesia, Drug-Induced; Glycopeptides; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Quinpirole; Rats

2018
An mGlu4-Positive Allosteric Modulator Alleviates Parkinsonism in Primates.
    Movement disorders : official journal of the Movement Disorder Society, 2018, Volume: 33, Issue:10

    Topics: Allosteric Regulation; Animals; Antiparkinson Agents; Cognition Disorders; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Positron-Emission Tomography; Receptors, Metabotropic Glutamate; Time Factors

2018
Genetic Knockdown of mGluR5 in Striatal D1R-Containing Neurons Attenuates L-DOPA-Induced Dyskinesia in Aphakia Mice.
    Molecular neurobiology, 2019, Volume: 56, Issue:6

    Topics: Allosteric Regulation; Animals; Aphakia; Biomarkers; Corpus Striatum; Down-Regulation; Dyskinesia, Drug-Induced; Female; Gene Knockdown Techniques; Levodopa; Male; Mice, Inbred C57BL; Models, Biological; Neurons; Nicotine; Receptor, Metabotropic Glutamate 5; Receptors, Dopamine D1

2019
NMDA receptor GluN2D subunit participates to levodopa-induced dyskinesia pathophysiology.
    Neurobiology of disease, 2019, Volume: 121

    Topics: Animals; Cholinergic Neurons; Corpus Striatum; Disease Models, Animal; Disks Large Homolog 4 Protein; Dyskinesia, Drug-Induced; Interneurons; Levodopa; Macaca mulatta; Male; Neurons; Parkinson Disease; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Synapses

2019
Viewpoint: Developing drugs for levodopa-induced dyskinesia in PD: Lessons learnt, what does the future hold?
    The European journal of neuroscience, 2019, Volume: 49, Issue:3

    Topics: Animals; Drug Development; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Translational Research, Biomedical

2019
Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia.
    The Journal of pharmacology and experimental therapeutics, 2018, Volume: 367, Issue:3

    Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agents; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Signal Transduction

2018
DAT gene polymorphisms (rs28363170, rs393795) and levodopa-induced dyskinesias in Parkinson's disease.
    Neuroscience letters, 2019, 01-18, Volume: 690

    Topics: Aged; Alleles; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Female; Genetic Predisposition to Disease; Genotype; Haplotypes; Humans; Italy; Levodopa; Male; Minisatellite Repeats; Parkinson Disease; Polymorphism, Genetic; Prevalence

2019
Levodopa-induced dyskinesia in Parkinson disease: Sleep matters.
    Annals of neurology, 2018, Volume: 84, Issue:6

    Topics: Actigraphy; Adult; Aged; Antiparkinson Agents; Depression; Dyskinesia, Drug-Induced; Electroencephalography; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polysomnography; Psychiatric Status Rating Scales; Sleep Wake Disorders; Statistics, Nonparametric

2018
Levodopa-induced dyskinesia in Parkinson disease: A population-based cohort study.
    Neurology, 2018, 12-11, Volume: 91, Issue:24

    Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index

2018
Evaluation of D1/D5 Partial Agonist PF-06412562 in Parkinson's Disease following Oral Administration.
    Neuro-degenerative diseases, 2018, Volume: 18, Issue:5-6

    Topics: Administration, Oral; Aged; Antiparkinson Agents; Carbidopa; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome

2018
Riluzole Attenuates L-DOPA-Induced Abnormal Involuntary Movements Through Decreasing CREB1 Activity: Insights from a Rat Model.
    Molecular neurobiology, 2019, Volume: 56, Issue:7

    Topics: Animals; Cyclic AMP Response Element-Binding Protein; Disease Models, Animal; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Levodopa; Male; Oxidopamine; Protein Interaction Maps; Random Allocation; Rats; Rats, Wistar; Riluzole

2019
The treatment of levodopa-induced dyskinesias: Surfing the serotoninergic wave.
    Movement disorders : official journal of the Movement Disorder Society, 2018, Volume: 33, Issue:11

    Topics: Animals; Dyskinesia, Drug-Induced; Dyskinesias; Levodopa; Rats; Serotonin; Vilazodone Hydrochloride

2018
Diverse serotonin actions of vilazodone reduce l-3,4-dihidroxyphenylalanine-induced dyskinesia in hemi-parkinsonian rats.
    Movement disorders : official journal of the Movement Disorder Society, 2018, Volume: 33, Issue:11

    Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Gene Expression Regulation; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Piperazines; Protein Precursors; Proto-Oncogene Proteins c-fos; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; RNA, Messenger; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists; Time Factors; Vilazodone Hydrochloride

2018
Dyskinesia and brain-derived neurotrophic factor levels after long-term levodopa and nicotinic receptor agonist treatments in female mice with near-total unilateral dopaminergic denervation.
    BMC neuroscience, 2018, Nov-29, Volume: 19, Issue:1

    Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Brain; Brain-Derived Neurotrophic Factor; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Furans; Levodopa; Mice, Inbred C57BL; Nicotine; Nicotinic Agonists; Parkinsonian Disorders; Quinuclidines; Random Allocation

2018
Eltoprazine prevents levodopa-induced dyskinesias by reducing causal interactions for theta oscillations in the dorsolateral striatum and substantia nigra pars reticulate.
    Neuropharmacology, 2019, Volume: 148

    Topics: Animals; Corpus Striatum; Dyskinesia, Drug-Induced; Levodopa; Male; Piperazines; Rats; Substantia Nigra; Theta Rhythm

2019
The effects of zonisamide on L-DOPA-induced dyskinesia in Parkinson's disease model mice.
    Neurochemistry international, 2019, Volume: 124

    Topics: Animals; Anticonvulsants; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Mice, Inbred ICR; Oxidopamine; Parkinsonian Disorders; Treatment Outcome; Zonisamide

2019
Regulation of dopamine neurotransmission from serotonergic neurons by ectopic expression of the dopamine D2 autoreceptor blocks levodopa-induced dyskinesia.
    Acta neuropathologica communications, 2019, 01-15, Volume: 7, Issue:1

    Topics: Animals; Autoreceptors; Dopamine; Dorsal Raphe Nucleus; Dyskinesia, Drug-Induced; Ectopic Gene Expression; HEK293 Cells; Humans; Levodopa; Male; Rats, Inbred F344; Receptors, Dopamine D2; Serotonergic Neurons; Synaptic Transmission

2019
Sitagliptin and Liraglutide Modulate L-dopa Effect and Attenuate Dyskinetic Movements in Rotenone-Lesioned Rats.
    Neurotoxicity research, 2019, Volume: 35, Issue:3

    Topics: Animals; Antiparkinson Agents; Carbidopa; Corpus Striatum; Dopamine; Drug Combinations; Dyskinesia, Drug-Induced; Levodopa; Liraglutide; Male; Motor Activity; Parkinsonian Disorders; Pars Compacta; Random Allocation; Rats, Wistar; Rotenone; Sitagliptin Phosphate

2019
Deep Brain Stimulation as a Rescue When Duodenal Levodopa Infusion Fails.
    The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 2019, Volume: 46, Issue:1

    Topics: Antiparkinson Agents; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Parkinson Disease

2019
Does the Side Onset of Parkinson's Disease Influence the Time to Develop Levodopa-Induced Dyskinesia?
    Journal of Parkinson's disease, 2019, Volume: 9, Issue:1

    Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Neuronal Plasticity; Parkinson Disease; Risk Factors; Time Factors

2019
Striatal spreading depolarization: Possible implication in levodopa-induced dyskinetic-like behavior.
    Movement disorders : official journal of the Movement Disorder Society, 2019, Volume: 34, Issue:6

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antiparkinson Agents; Corpus Striatum; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Levodopa; Neurons; Nitrogen Mustard Compounds; Parkinsonian Disorders; Prednisolone; Procarbazine; Rats; Rats, Wistar; Synaptic Transmission; Vincristine

2019
Time dependent degeneration of the nigrostriatal tract in mice with 6-OHDA lesioned medial forebrain bundle and the effect of activin A on L-Dopa induced dyskinesia.
    BMC neuroscience, 2019, Feb-13, Volume: 20, Issue:1

    Topics: Activins; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antiparkinson Agents; Disease Progression; Dyskinesia, Drug-Induced; Levodopa; Male; Medial Forebrain Bundle; Mice, Inbred C57BL; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Random Allocation; Treatment Failure

2019
Chronic administration of the histamine H
    Psychopharmacology, 2019, Volume: 236, Issue:6

    Topics: Animals; Corpus Striatum; Dyskinesia, Drug-Induced; Histamine Agonists; Imidazoles; Levodopa; Male; Oxidopamine; Piperidines; Rats; Rats, Wistar; Receptors, Histamine H3; Substantia Nigra

2019
Levodopa-induced dyskinesia is closely linked to progression of frontal dysfunction in PD.
    Neurology, 2019, 03-26, Volume: 92, Issue:13

    Topics: Aged; Antiparkinson Agents; Cognitive Dysfunction; Cohort Studies; Dementia; Disease Progression; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Proportional Hazards Models; Retrospective Studies

2019
Optostimulation of striatonigral terminals in substantia nigra induces dyskinesia that increases after L-DOPA in a mouse model of Parkinson's disease.
    British journal of pharmacology, 2019, Volume: 176, Issue:13

    Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Lasers; Levodopa; Mice, Inbred C57BL; Optogenetics; Oxidopamine; Parkinsonian Disorders; Photic Stimulation; Substantia Nigra

2019
Should there be less emphasis on levodopa-induced dyskinesia in Parkinson's disease?
    Movement disorders : official journal of the Movement Disorder Society, 2019, Volume: 34, Issue:6

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2019
Genetic silencing of striatal CaV1.3 prevents and ameliorates levodopa dyskinesia.
    Movement disorders : official journal of the Movement Disorder Society, 2019, Volume: 34, Issue:5

    Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Calcium Channels; Disease Models, Animal; Dyskinesia, Drug-Induced; Green Fluorescent Proteins; Levodopa; Luminescent Agents; Medial Forebrain Bundle; Neostriatum; Oxidopamine; Parkinsonian Disorders; Rats; RNA Interference; RNA, Small Interfering; Substantia Nigra; Tyrosine 3-Monooxygenase

2019
l-Dopa-free learned dyskinetic behavior in a Parkinson's primate model.
    Movement disorders : official journal of the Movement Disorder Society, 2019, Volume: 34, Issue:8

    Topics: Animals; Antiparkinson Agents; Conditioning, Psychological; Disease Models, Animal; Dyskinesia, Drug-Induced; Dyskinesias; Levodopa; Macaca; Parkinsonian Disorders

2019
Assessment of plasma creatine kinase as biomarker for levodopa-induced dyskinesia in Parkinson's disease.
    Journal of neural transmission (Vienna, Austria : 1996), 2019, Volume: 126, Issue:6

    Topics: Aged; Animals; Antiparkinson Agents; Biomarkers; Creatine Kinase; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Macaca; Middle Aged; Parkinson Disease; Randomized Controlled Trials as Topic; Severity of Illness Index

2019
Predictors of motor complications in early Parkinson's disease: A prospective cohort study.
    Movement disorders : official journal of the Movement Disorder Society, 2019, Volume: 34, Issue:8

    Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Antiparkinson Agents; Anxiety; Cohort Studies; Depression; Drug-Related Side Effects and Adverse Reactions; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Proportional Hazards Models; Prospective Studies; Risk Assessment; Severity of Illness Index

2019
Late aging-associated increases in L-DOPA-induced dyskinesia are accompanied by heightened neuroinflammation in the hemi-parkinsonian rat.
    Neurobiology of aging, 2019, Volume: 81

    Topics: Aging; Animals; Dyskinesia, Drug-Induced; Gene Expression; Inflammation; Interleukin-1beta; Interleukin-6; Levodopa; Male; Parkinson Disease; Rats; Rats, Inbred F344; Risk Factors

2019
Pharmacological antagonism of histamine H2R ameliorated L-DOPA-induced dyskinesia via normalization of GRK3 and by suppressing FosB and ERK in PD.
    Neurobiology of aging, 2019, Volume: 81

    Topics: Animals; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; G-Protein-Coupled Receptor Kinase 3; Histamine H2 Antagonists; Levodopa; MAP Kinase Signaling System; Mice, Inbred C57BL; Parkinson Disease; Proto-Oncogene Proteins c-fos; Ranitidine; Receptors, Histamine H2

2019
Recent Clinical Advances in Pharmacotherapy for Levodopa-Induced Dyskinesia.
    Drugs, 2019, Volume: 79, Issue:13

    Topics: Amantadine; Animals; Antiparkinson Agents; Antiviral Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Quality of Life

2019
Immunomodulatory drugs alleviate l-dopa-induced dyskinesia in a rat model of Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2019, Volume: 34, Issue:12

    Topics: Angiogenesis Inhibitors; Animals; Antiparkinson Agents; Cytokines; Dyskinesia, Drug-Induced; Immunologic Factors; Interleukin-10; Levodopa; Male; Neostriatum; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Substantia Nigra; Thalidomide; Tumor Necrosis Factor-alpha

2019
Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys.
    Parkinsonism & related disorders, 2013, Volume: 19, Issue:5

    Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Dose-Response Relationship, Drug; Drug Synergism; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Treatment Outcome

2013
l-dopa-induced dyskinesias in unilateral 6-hydroxydopamine-lesioned rats are not modified by excitotoxic lesion of the entopeduncular nucleus and substantia nigra pars reticulata.
    Synapse (New York, N.Y.), 2013, Volume: 67, Issue:7

    Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Entopeduncular Nucleus; Levodopa; Male; Movement; Neurons; Oxidopamine; Quinolinic Acid; Rats; Rats, Sprague-Dawley; Substantia Nigra

2013
Anti-dyskinetic effect of the neuronal nitric oxide synthase inhibitor is linked to decrease of FosB/deltaFosB expression.
    Neuroscience letters, 2013, Apr-29, Volume: 541

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Indazoles; Levodopa; Male; Microinjections; Motor Activity; Nitric Oxide Synthase Type I; Oxidopamine; Proto-Oncogene Proteins c-fos; Rats; Rats, Wistar

2013
A cup of coffee a day keeps dyskinesia away?
    Movement disorders : official journal of the Movement Disorder Society, 2013, Volume: 28, Issue:3

    Topics: Adenosine A2 Receptor Antagonists; Antiparkinson Agents; Benzothiazoles; Caffeine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Pramipexole

2013
[PSD-95 expression controls L-Dopa dyskinesia].
    Medecine sciences : M/S, 2013, Volume: 29, Issue:2

    Topics: Animals; Disks Large Homolog 4 Protein; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Gene Expression; Humans; Intracellular Signaling Peptides and Proteins; Levodopa; Membrane Proteins; Models, Genetic; Parkinson Disease; Protein Transport; Receptors, Dopamine D1

2013
Cerebellar sensory processing alterations impact motor cortical plasticity in Parkinson's disease: clues from dyskinetic patients.
    Cerebral cortex (New York, N.Y. : 1991), 2014, Volume: 24, Issue:8

    Topics: Adult; Aged; Antiparkinson Agents; Cerebellum; Dyskinesia, Drug-Induced; Electromyography; Evoked Potentials, Motor; Female; Follow-Up Studies; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Motor Cortex; Muscle, Skeletal; Neuronal Plasticity; Parkinson Disease; Severity of Illness Index; Transcranial Magnetic Stimulation

2014
Exercise attenuates levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned mice.
    Neuroscience, 2013, Jul-23, Volume: 243

    Topics: Animals; Antiparkinson Agents; Chromatography, High Pressure Liquid; Corpus Striatum; Dyskinesia, Drug-Induced; Immunohistochemistry; Levodopa; Male; Mice; Mice, Inbred C57BL; Oxidopamine; Parkinsonian Disorders; Physical Conditioning, Animal

2013
NMDA receptor regulation of levodopa-induced behavior and changes in striatal G protein-coupled receptor kinase 6 and β-arrestin-1 expression in parkinsonian rats.
    Clinical interventions in aging, 2013, Volume: 8

    Topics: Analysis of Variance; Animals; Antiparkinson Agents; Arrestins; Behavior, Animal; Blotting, Western; Corpus Striatum; Down-Regulation; Dyskinesia, Drug-Induced; G-Protein-Coupled Receptor Kinases; Levodopa; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Statistics, Nonparametric

2013
α4β2 Nicotinic receptors play a role in the nAChR-mediated decline in L-dopa-induced dyskinesias in parkinsonian rats.
    Neuropharmacology, 2013, Volume: 71

    Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Azabicyclo Compounds; Corpus Striatum; Cyclopropanes; Disease Models, Animal; Dopamine Agonists; Drug Tolerance; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Nerve Tissue Proteins; Neurons; Nicotinic Agonists; Parkinson Disease; Protein Subunits; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic; Synaptosomes

2013
GluN2A and GluN2B NMDA receptor subunits differentially modulate striatal output pathways and contribute to levodopa-induced abnormal involuntary movements in dyskinetic rats.
    ACS chemical neuroscience, 2013, May-15, Volume: 4, Issue:5

    Topics: Animals; Corpus Striatum; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Globus Pallidus; Glutamic Acid; Levodopa; Male; Microdialysis; Neostriatum; Oxidopamine; Phenols; Piperidines; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Substantia Nigra

2013
The K(V)7.2/3 preferring channel opener ICA 27243 attenuates L-DOPA-induced dyskinesia in hemiparkinsonian rats.
    Neuroscience letters, 2013, Jun-17, Volume: 545

    Topics: Animals; Benzamides; Dyskinesia, Drug-Induced; Female; Ion Channel Gating; KCNQ2 Potassium Channel; KCNQ3 Potassium Channel; Levodopa; Parkinsonian Disorders; Pyridines; Rats; Rats, Sprague-Dawley; Treatment Outcome

2013
Valproic acid-induced parkinsonism: levodopa responsiveness with dyskinesia.
    Parkinsonism & related disorders, 2013, Volume: 19, Issue:8

    Topics: Adult; Aged; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Valproic Acid

2013
Do tardive dyskinesia and L-dopa induced dyskinesia share common genetic risk factors? An exploratory study.
    Journal of molecular neuroscience : MN, 2013, Volume: 51, Issue:2

    Topics: Aged; Case-Control Studies; Dyskinesia, Drug-Induced; Female; Genetic Predisposition to Disease; Humans; Israel; Italy; Jews; Levodopa; Male; Middle Aged; Polymorphism, Single Nucleotide

2013
Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
    Neuropharmacology, 2013, Volume: 73

    Topics: 2-Amino-5-phosphonovalerate; Amino Acids; Animals; Basal Ganglia; Corpus Striatum; Dyskinesia, Drug-Induced; Female; Imidazoles; Levodopa; Macaca fascicularis; Oximes; Parkinsonian Disorders; Phenols; Piperidines; Pyridines; Quinazolines; Radioligand Assay; Receptor, Metabotropic Glutamate 5; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Tritium; Xanthenes

2013
L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice.
    Biological psychiatry, 2014, May-01, Volume: 75, Issue:9

    Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Cerebral Cortex; Corpus Striatum; Dendritic Spines; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Male; Membrane Potentials; Mice, Inbred C57BL; Mice, Transgenic; Neurons; Oxidopamine; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Receptors, Dopamine D1; Receptors, Dopamine D2

2014
Age at onset influences neurodegenerative processes underlying PD with levodopa-induced dyskinesias.
    Parkinsonism & related disorders, 2013, Volume: 19, Issue:10

    Topics: Age of Onset; Aged; Antiparkinson Agents; Cerebral Cortex; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Frontal Lobe; Humans; Image Processing, Computer-Assisted; Levodopa; Linear Models; Magnetic Resonance Imaging; Male; Middle Aged; Motor Cortex; Neurodegenerative Diseases; Normal Distribution; Parkinson Disease; Substantia Nigra

2013
TC-8831, a nicotinic acetylcholine receptor agonist, reduces L-DOPA-induced dyskinesia in the MPTP macaque.
    Neuropharmacology, 2013, Volume: 73

    Topics: Amantadine; Animals; Azabicyclo Compounds; Cyclopropanes; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; MPTP Poisoning; Nicotinic Agonists

2013
Levodopa-induced dyskinesias in the absence of nigrostriatal degeneration.
    Movement disorders : official journal of the Movement Disorder Society, 2013, Volume: 28, Issue:8

    Topics: Dopamine Agents; Dyskinesia, Drug-Induced; Dystonic Disorders; Humans; Levodopa

2013
Counteraction by nitric oxide synthase inhibitor of neurochemical alterations of dopaminergic system in 6-OHDA-lesioned rats under L-DOPA treatment.
    Neurotoxicity research, 2014, Volume: 25, Issue:1

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Indazoles; Levodopa; Male; Nitric Oxide Synthase; Oxidopamine; Rats; Rats, Wistar; Substantia Nigra

2014
Nicotine reduces established levodopa-induced dyskinesias in a monkey model of Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2013, Volume: 28, Issue:10

    Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Cotinine; Data Interpretation, Statistical; Dyskinesia, Drug-Induced; Female; Levodopa; Male; MPTP Poisoning; Nicotine; Nicotinic Agonists; Parkinson Disease, Secondary; Saimiri

2013
A2A receptor antagonists do not induce dyskinesias in drug-naive or L-dopa sensitized rats.
    Brain research bulletin, 2013, Volume: 98

    Topics: Adenosine A2 Receptor Antagonists; Adrenergic Agents; Analysis of Variance; Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Catalepsy; Disease Models, Animal; Dyskinesia, Drug-Induced; Haloperidol; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Time Factors

2013
Aberrant restoration of spines and their synapses in L-DOPA-induced dyskinesia: involvement of corticostriatal but not thalamostriatal synapses.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2013, Jul-10, Volume: 33, Issue:28

    Topics: Animals; Cerebral Cortex; Corpus Striatum; Dendritic Spines; Dyskinesia, Drug-Induced; Levodopa; Male; Random Allocation; Rats; Rats, Sprague-Dawley; Synapses; Thalamus

2013
Commentary.
    Movement disorders : official journal of the Movement Disorder Society, 2013, Volume: 28, Issue:9

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Parkinsonian Disorders; Substantia Nigra

2013
Wearing-off phenomena and levodopa-induced dyskinesias in posttraumatic hemiparkinsonism.
    Movement disorders : official journal of the Movement Disorder Society, 2013, Volume: 28, Issue:9

    Topics: Aged; Antiparkinson Agents; Craniocerebral Trauma; Dyskinesia, Drug-Induced; Humans; Levodopa; Magnetic Resonance Imaging; Male; Parkinsonian Disorders; Radiography; Substantia Nigra; Tomography Scanners, X-Ray Computed

2013
Poor self-awareness of levodopa-induced dyskinesias in Parkinson's disease: clinical features and mechanisms.
    Parkinsonism & related disorders, 2013, Volume: 19, Issue:11

    Topics: Aged; Aged, 80 and over; Awareness; Diagnostic Self Evaluation; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Video Recording

2013
Nicotinic receptor agonists reduce L-DOPA-induced dyskinesias in a monkey model of Parkinson's disease.
    The Journal of pharmacology and experimental therapeutics, 2013, Volume: 347, Issue:1

    Topics: Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Nicotine; Nicotinic Agonists; Parkinson Disease; Receptors, Nicotinic; Saimiri

2013
Putaminal upregulation of FosB/ΔFosB-like immunoreactivity in Parkinson's disease patients with dyskinesia.
    Journal of Parkinson's disease, 2011, Volume: 1, Issue:4

    Topics: Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Autoradiography; Basal Ganglia; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Neurons; Parkinson Disease; Postmortem Changes; Proto-Oncogene Proteins c-fos; Putamen; Up-Regulation

2011
Amphetamine-induced dyskinesia in the transplanted hemi-Parkinsonian mouse.
    Journal of Parkinson's disease, 2012, Volume: 2, Issue:2

    Topics: Adrenergic Agents; Amphetamine; Animals; Antiparkinson Agents; Cell Transplantation; Corpus Striatum; Disease Models, Animal; Dopamine Uptake Inhibitors; Dyskinesia, Drug-Induced; Embryo, Mammalian; Functional Laterality; Levodopa; Male; Mesencephalon; Mice; Mice, Inbred C57BL; Neurons; Oxidopamine; Parkinson Disease; Stereotyped Behavior

2012
mTOR inhibition alleviates L-DOPA-induced dyskinesia in parkinsonian rats.
    Journal of Parkinson's disease, 2013, Volume: 3, Issue:1

    Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Parkinson Disease; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases

2013
Activation of metabotropic glutamate 4 receptors decreases L-DOPA-induced dyskinesia in a mouse model of Parkinson's disease.
    Journal of Parkinson's disease, 2011, Volume: 1, Issue:4

    Topics: Adrenergic Agents; Aminobutyrates; Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agonists; Gene Expression Regulation; Levodopa; Male; Mice; Mice, Inbred C57BL; Oxidopamine; Parkinson Disease; Phosphinic Acids; Receptors, Metabotropic Glutamate; Time Factors

2011
Objective motion sensor assessment highly correlated with scores of global levodopa-induced dyskinesia in Parkinson's disease.
    Journal of Parkinson's disease, 2013, Jan-01, Volume: 3, Issue:3

    Topics: Adult; Aged; Algorithms; Antiparkinson Agents; Biomechanical Phenomena; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Linear Models; Male; Middle Aged; Movement; Neurologic Examination; Parkinson Disease; Tremor; Wrist

2013
Risk factors and predictors of levodopa-induced dyskinesia among multiethnic Malaysians with Parkinson's disease.
    The International journal of neuroscience, 2014, Volume: 124, Issue:3

    Topics: Aged; Antiparkinson Agents; Cross-Sectional Studies; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Malaysia; Male; Middle Aged; Parkinson Disease; Predictive Value of Tests; Risk Factors; Severity of Illness Index

2014
Basal ganglia serotonin 1B receptors in parkinsonian monkeys with L-DOPA-induced dyskinesia.
    Biochemical pharmacology, 2013, Oct-01, Volume: 86, Issue:7

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Basal Ganglia; Behavior, Animal; Benzamides; Brain; Case-Control Studies; Dyskinesia, Drug-Induced; Levodopa; Macaca fascicularis; Parkinson Disease; Pyridines; Receptor, Serotonin, 5-HT1B; Serotonin; Sulfonamides; Thiazoles

2013
Cholinergic manipulation of motor disability and L-DOPA-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated common marmosets.
    Journal of neural transmission (Vienna, Austria : 1996), 2014, Volume: 121, Issue:2

    Topics: Animals; Antiparkinson Agents; Callithrix; Carbidopa; Cholinergic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; MPTP Poisoning; Statistics, Nonparametric

2014
5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
    Neurobiology of disease, 2013, Volume: 60

    Topics: 5-Hydroxytryptophan; Adrenergic Agents; Animals; Caudate Nucleus; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Female; Levodopa; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Serotonin

2013
Influence of single nucleotide polymorphisms in COMT, MAO-A and BDNF genes on dyskinesias and levodopa use in Parkinson's disease.
    Neuro-degenerative diseases, 2014, Volume: 13, Issue:1

    Topics: Aged; Antiparkinson Agents; Brain-Derived Neurotrophic Factor; Catechol O-Methyltransferase; Cohort Studies; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase; Parkinson Disease; Polymorphism, Single Nucleotide; Prevalence; Time Factors

2014
Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: effects of combined treatment and possible mechanisms of action.
    Experimental neurology, 2013, Volume: 250

    Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Dopamine Agonists; Drug Synergism; Dyskinesia, Drug-Induced; Levodopa; Parkinsonian Disorders; Pyridines; Rats; Receptor, Metabotropic Glutamate 5; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT1B; Receptors, Dopamine D1; Serotonin Receptor Agonists; Thiazoles

2013
Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats.
    Neuropharmacology, 2014, Volume: 77

    Topics: Animals; Citalopram; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Paroxetine; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors

2014
Immediate-early gene expression in structures outside the basal ganglia is associated to l-DOPA-induced dyskinesia.
    Neurobiology of disease, 2014, Volume: 62

    Topics: Animals; Antiparkinson Agents; Basal Ganglia; Brain; Cytoskeletal Proteins; Dyskinesia, Drug-Induced; Early Growth Response Protein 1; Fos-Related Antigen-2; Immediate-Early Proteins; Levodopa; Male; Nerve Tissue Proteins; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley

2014
The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation.
    Neurobiology of disease, 2014, Volume: 62

    Topics: Amphetamine; Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Benzazepines; Buspirone; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Female; Indoles; Levodopa; Mesencephalon; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Salicylamides; Serotonin Receptor Agonists

2014
Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia.
    Neuroscience research, 2013, Volume: 77, Issue:4

    Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Piperidines; Pyridines; Rats; Rats, Sprague-Dawley; Serotonin 5-HT1 Receptor Agonists

2013
The relationship between the phenotype of Parkinson's disease and levodopa-induced dyskinesia.
    Neuroscience letters, 2013, Nov-27, Volume: 556

    Topics: Adult; Age of Onset; Aged; Antiparkinson Agents; Cross-Sectional Studies; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Risk Factors

2013
Subthalamic 6-OHDA-induced lesion attenuates levodopa-induced dyskinesias in the rat model of Parkinson's disease.
    Experimental neurology, 2013, Volume: 250

    Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; In Situ Hybridization; Levodopa; Male; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Subthalamic Nucleus

2013
Oleoylethanolamide reduces L-DOPA-induced dyskinesia via TRPV1 receptor in a mouse model of Parkinson´s disease.
    Neurobiology of disease, 2014, Volume: 62

    Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Endocannabinoids; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Oleic Acids; Oxidopamine; Parkinson Disease; TRPV Cation Channels

2014
Abnormal structure-specific peptide transmission and processing in a primate model of Parkinson's disease and l-DOPA-induced dyskinesia.
    Neurobiology of disease, 2014, Volume: 62

    Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Enkephalins; Female; Globus Pallidus; Levodopa; Macaca mulatta; Neuropeptides; Parkinsonian Disorders; Protein Precursors; Putamen; Tachykinins

2014
Buspirone anti-dyskinetic effect is correlated with temporal normalization of dysregulated striatal DRD1 signalling in L-DOPA-treated rats.
    Neuropharmacology, 2014, Volume: 79

    Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Buspirone; Corpus Striatum; Cyclic AMP Response Element-Binding Protein; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Mitogen-Activated Protein Kinase 1; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D3; Serotonin 5-HT1 Receptor Agonists; Severity of Illness Index; Signal Transduction

2014
Serotonergic nerve fibers in L-DOPA-derived dopamine release and dyskinesia.
    Neuroscience, 2014, Feb-28, Volume: 260

    Topics: Animals; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Female; Fluoxetine; Levodopa; Nerve Fibers; Rats; Rats, Sprague-Dawley; Serotonergic Neurons; Serotonin Plasma Membrane Transport Proteins

2014
Amantadine's role in the treatment of levodopa-induced dyskinesia.
    Neurology, 2014, Jan-28, Volume: 82, Issue:4

    Topics: Amantadine; Antiparkinson Agents; Antiviral Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2014
Factors predictive of the development of levodopa-induced dyskinesia and Wearing-Off in Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2014, Volume: 29, Issue:3

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male

2014
Effect of Tianqi antitremor granules on behavioral manifestations and expression of G protein-coupled receptor kinase 6 and β-arrestin1 in levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Drug design, development and therapy, 2013, Volume: 7

    Topics: Animals; Antiparkinson Agents; Arrestins; Behavior, Animal; beta-Arrestins; Blotting, Western; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Dyskinesia, Drug-Induced; Female; G-Protein-Coupled Receptor Kinases; Immunohistochemistry; Levodopa; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley

2013
Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulat
    Journal of medicinal chemistry, 2014, Feb-13, Volume: 57, Issue:3

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Allosteric Regulation; Animals; Antiparkinson Agents; Biological Availability; Cell Membrane Permeability; Dogs; Dyskinesia, Drug-Induced; HEK293 Cells; Humans; Hypersensitivity, Delayed; Levodopa; Macaca fascicularis; Madin Darby Canine Kidney Cells; Male; Microsomes, Liver; Models, Molecular; Parkinson Disease; Pyrazines; Pyrazoles; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Structure-Activity Relationship

2014
Morphological and electrophysiological changes in intratelencephalic-type pyramidal neurons in the motor cortex of a rat model of levodopa-induced dyskinesia.
    Neurobiology of disease, 2014, Volume: 64

    Topics: Animals; Antiparkinson Agents; Dendritic Spines; Dyskinesia, Drug-Induced; Excitatory Postsynaptic Potentials; Levodopa; Male; Motor Cortex; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Pyramidal Cells; Rats; Rats, Wistar; Telencephalon

2014
The effects of the β-lactam antibiotic, ceftriaxone, on forepaw stepping and L-DOPA-induced dyskinesia in a rodent model of Parkinson's disease.
    Psychopharmacology, 2014, Volume: 231, Issue:12

    Topics: Animals; Anti-Bacterial Agents; Antiparkinson Agents; Ceftriaxone; Central Nervous System Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Transporter 2; Forelimb; Kainic Acid; Levodopa; Male; Medial Forebrain Bundle; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats, Long-Evans

2014
Initiating levodopa therapy for Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2014, Volume: 29, Issue:3

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male

2014
UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset.
    Neuropharmacology, 2014, Volume: 82

    Topics: Animals; Antiparkinson Agents; Behavior, Animal; Benzodioxoles; Callithrix; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Mental Disorders; Methylamines; Molecular Structure; Motor Activity; Parkinsonian Disorders; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Time Factors

2014
Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
    Neuropharmacology, 2014, Volume: 79

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Corpus Striatum; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Excitatory Amino Acid Antagonists; Female; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Levodopa; Macaca fascicularis; MAP Kinase Signaling System; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-akt; Pyridines; Receptor, Metabotropic Glutamate 5; Receptors, Dopamine D1; Receptors, Dopamine D2; RNA, Messenger

2014
Overexpression of the dopamine D3 receptor in the rat dorsal striatum induces dyskinetic behaviors.
    Behavioural brain research, 2014, Apr-15, Volume: 263

    Topics: Animals; Antiparkinson Agents; Benserazide; Benzopyrans; Corpus Striatum; Dependovirus; Dopamine; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Genetic Vectors; Green Fluorescent Proteins; Immunohistochemistry; Levodopa; Mastication; Motor Activity; Neurons; Oxazines; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D3; Transfection

2014
Chinese culture permeation in the treatment of Parkinson disease: a cross-sectional study in four regions of China.
    BMC research notes, 2014, Jan-30, Volume: 7

    Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Asian People; China; Cross-Sectional Studies; Cultural Characteristics; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Logistic Models; Male; Middle Aged; Multivariate Analysis; Parkinson Disease; Treatment Outcome

2014
ABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2014, Volume: 29, Issue:4

    Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Male; MPTP Poisoning; Nicotinic Agonists; Pyridines; Pyrrolidines; Saimiri; Treatment Outcome

2014
Striatal cholinergic cell ablation attenuates L-DOPA induced dyskinesia in Parkinsonian mice.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2014, Feb-19, Volume: 34, Issue:8

    Topics: Adenoviridae; Animals; Antiparkinson Agents; Behavior, Animal; Denervation; Diphtheria Toxin; DNA, Complementary; Dyskinesia, Drug-Induced; Hydroxydopamines; Image Processing, Computer-Assisted; Immunohistochemistry; Levodopa; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neostriatum; Parasympathetic Nervous System; Parkinsonian Disorders

2014
Effects of L-tryptophan on L-DOPA-induced dyskinesia in the L-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson's disease.
    Neuroscience letters, 2014, Apr-30, Volume: 566

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Motor Activity; Parkinson Disease; Tryptophan

2014
Morphologic changes of dendritic spines of striatal neurons in the levodopa-induced dyskinesia model.
    Movement disorders : official journal of the Movement Disorder Society, 2014, Volume: 29, Issue:3

    Topics: Animals; Corpus Striatum; Dendritic Spines; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Neostriatum; Neurites; Neurons; Parkinson Disease; Rats, Wistar; Synapses

2014
Targeting metabotropic glutamate receptors as a new strategy against levodopa-induced dyskinesia in Parkinson's disease?
    Movement disorders : official journal of the Movement Disorder Society, 2014, Volume: 29, Issue:6

    Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptors, Metabotropic Glutamate

2014
Molecular adaptations of striatal spiny projection neurons during levodopa-induced dyskinesia.
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Mar-25, Volume: 111, Issue:12

    Topics: Animals; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Gene Expression; Homeostasis; Levodopa; Mice

2014
Genome-wide microarray analysis identifies a potential role for striatal retrograde endocannabinoid signaling in the pathogenesis of experimental L-DOPA-induced dyskinesia.
    Synapse (New York, N.Y.), 2014, Volume: 68, Issue:8

    Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Endocannabinoids; Gene Expression; Gene Ontology; Levodopa; Male; Microarray Analysis; Motor Activity; Oxidopamine; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction

2014
Profile of levodopa-induced dyskinesia in patients of Parkinson's disease: a record based study.
    Neurological research, 2014, Volume: 36, Issue:9

    Topics: Adult; Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Periodicity; Retrospective Studies; Severity of Illness Index

2014
Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2014, Volume: 29, Issue:6

    Topics: Amantadine; Analysis of Variance; Animals; Antiparkinson Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Imidazoles; Levodopa; Macaca fascicularis; MPTP Poisoning

2014
Differential dopamine receptor occupancy underlies L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
    PloS one, 2014, Volume: 9, Issue:3

    Topics: Animals; Benzamides; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Extracellular Space; Female; Levodopa; Microdialysis; Neostriatum; Nomifensine; Parkinson Disease; Positron-Emission Tomography; Proto-Oncogene Proteins c-fos; Pyrrolidines; Rats, Sprague-Dawley; Receptors, Dopamine; Serotonin

2014
Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson's disease.
    Journal of molecular neuroscience : MN, 2014, Volume: 53, Issue:2

    Topics: Adult; Aged; Brain-Derived Neurotrophic Factor; Case-Control Studies; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Female; Gene Frequency; Humans; Levodopa; Male; Middle Aged; Minisatellite Repeats; Parkinson Disease; Polymorphism, Single Nucleotide; Receptors, Dopamine D2

2014
The NK1 receptor antagonist N-acetyl-L-tryptophan reduces dyskinesia in a hemi-parkinsonian rodent model.
    Parkinsonism & related disorders, 2014, Volume: 20, Issue:5

    Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Functional Laterality; Levodopa; Male; Medial Forebrain Bundle; Motor Activity; Oxidopamine; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Time Factors; Tryptophan; Tyrosine 3-Monooxygenase

2014
Parkinson disease: A role for serotonergic neurons in levodopa-induced dyskinesia.
    Nature reviews. Neurology, 2014, Volume: 10, Issue:4

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Parkinson Disease; Serotonergic Neurons

2014
Gastrodia elata Blume alleviates L-DOPA-induced dyskinesia by normalizing FosB and ERK activation in a 6-OHDA-lesioned Parkinson's disease mouse model.
    BMC complementary and alternative medicine, 2014, Mar-20, Volume: 14

    Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Gastrodia; Levodopa; Male; MAP Kinase Signaling System; Mice, Inbred C57BL; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Phytotherapy; Plant Extracts; Proto-Oncogene Proteins c-fos

2014
Presynaptic dopamine depletion predicts levodopa-induced dyskinesia in de novo Parkinson disease.
    Neurology, 2014, May-06, Volume: 82, Issue:18

    Topics: Aged; Antiparkinson Agents; Chi-Square Distribution; Cohort Studies; Corpus Striatum; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Predictive Value of Tests; Proportional Hazards Models; Tropanes

2014
Predicting the development of levodopa-induced dyskinesias: a presynaptic mechanism?
    Neurology, 2014, May-06, Volume: 82, Issue:18

    Topics: Amantadine; Antiparasitic Agents; Dyskinesia, Drug-Induced; Fluorodeoxyglucose F18; Humans; Levodopa; Parkinson Disease; Positron-Emission Tomography; Presynaptic Terminals

2014
The thorny problem of dyskinesias: dendritic spines, synaptic plasticity, and striatal dysfunction.
    Biological psychiatry, 2014, May-01, Volume: 75, Issue:9

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dendritic Spines; Dyskinesia, Drug-Induced; Levodopa; Male; Neurons

2014
Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
    Experimental neurology, 2014, Volume: 257

    Topics: Adrenergic Agents; Adrenergic Neurons; Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Benzylamines; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Motor Activity; Nerve Degeneration; Oxidopamine; Parkinson Disease; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Ribosome Inactivating Proteins, Type 1; Saporins; Stereotyped Behavior

2014
Widespread Monoaminergic Dysregulation of Both Motor and Non-Motor Circuits in Parkinsonism and Dyskinesia.
    Cerebral cortex (New York, N.Y. : 1991), 2015, Volume: 25, Issue:9

    Topics: Analysis of Variance; Animals; Antiparkinson Agents; Biogenic Monoamines; Brain; Chromatography, High Pressure Liquid; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca mulatta; MPTP Poisoning; Neural Pathways; Time Factors

2015
Novel transgenic technology reveals several molecular adaptations and potential therapeutic targets in the direct pathway in levodopa-induced dyskinesia.
    Movement disorders : official journal of the Movement Disorder Society, 2014, Volume: 29, Issue:6

    Topics: Animals; Corpus Striatum; Dyskinesia, Drug-Induced; Levodopa

2014
Effects of noradrenergic denervation by anti-DBH-saporin on behavioral responsivity to L-DOPA in the hemi-parkinsonian rat.
    Behavioural brain research, 2014, Aug-15, Volume: 270

    Topics: Animals; Corpus Striatum; Denervation; Disease Models, Animal; Dopamine; Dopamine Agonists; Dopamine beta-Hydroxylase; Dyskinesia, Drug-Induced; Levodopa; Male; Medial Forebrain Bundle; Motor Activity; Neurons; Norepinephrine; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Ribosome Inactivating Proteins, Type 1; Saporins

2014
Derangement of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) and extracellular signal-regulated kinase (ERK) dependent striatal plasticity in L-DOPA-induced dyskinesia.
    Biological psychiatry, 2015, Jan-15, Volume: 77, Issue:2

    Topics: Animals; Antiparkinson Agents; Butadienes; Cerebral Cortex; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Extracellular Signal-Regulated MAP Kinases; Levodopa; Mice, Knockout; Neuronal Plasticity; Neurons; Nitriles; Oxidopamine; Parkinsonian Disorders; Protein Kinase Inhibitors; ras-GRF1; Tissue Culture Techniques

2015
Activation of DREAM (downstream regulatory element antagonistic modulator), a calcium-binding protein, reduces L-DOPA-induced dyskinesias in mice.
    Biological psychiatry, 2015, Jan-15, Volume: 77, Issue:2

    Topics: Acetylation; Animals; Antiparkinson Agents; Blotting, Western; Corpus Striatum; Dynorphins; Dyskinesia, Drug-Induced; Endorphins; Histones; Immunohistochemistry; Kv Channel-Interacting Proteins; Levodopa; Mice, Knockout; Motor Activity; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Proto-Oncogene Proteins c-fos; Receptors, AMPA; Repressor Proteins; Rotarod Performance Test

2015
The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model.
    Movement disorders : official journal of the Movement Disorder Society, 2014, Volume: 29, Issue:8

    Topics: Analysis of Variance; Animals; Antiparkinson Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Imidazoles; Levodopa; Macaca mulatta; Male; Motor Activity; MPTP Poisoning; Pyridines; Receptor, Metabotropic Glutamate 5; Severity of Illness Index; Time Factors

2014
The acute brain response to levodopa heralds dyskinesias in Parkinson disease.
    Annals of neurology, 2014, Volume: 75, Issue:6

    Topics: Aged; Antiparkinson Agents; Brain; Brain Mapping; Decision Making; Dyskinesia, Drug-Induced; Female; Head Movements; Humans; Image Processing, Computer-Assisted; Levodopa; Male; Middle Aged; Neuropsychological Tests; Oxygen; Parkinson Disease; Psychomotor Performance; Reaction Time; Time Factors

2014
Cellular and behavioral outcomes of dorsal striatonigral neuron ablation: new insights into striatal functions.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2014, Volume: 39, Issue:11

    Topics: Animals; Antiparkinson Agents; Anxiety; Cholinergic Neurons; Cocaine; Corpus Striatum; Diphtheria Toxin; Dopamine Uptake Inhibitors; Dyskinesia, Drug-Induced; Heparin-binding EGF-like Growth Factor; Humans; Interneurons; Levodopa; Mice, Transgenic; Monosaccharide Transport Proteins; Movement; Neural Pathways; Neurotoxins; Promoter Regions, Genetic; Substantia Nigra

2014
(6aR)-11-amino-N-propyl-noraporphine, a new dopamine D2 and serotonin 5-HT1A dual agonist, elicits potent antiparkinsonian action and attenuates levodopa-induced dyskinesia in a 6-OHDA-lesioned rat model of Parkinson's disease.
    Pharmacology, biochemistry, and behavior, 2014, Volume: 124

    Topics: Animals; Antiparkinson Agents; Aporphines; Base Sequence; Disease Models, Animal; DNA Primers; Dopamine Agonists; Drug Interactions; Dyskinesia, Drug-Induced; Levodopa; Male; Oxidopamine; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Reverse Transcriptase Polymerase Chain Reaction; Serotonin Receptor Agonists

2014
RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat model of Parkinson's disease.
    Neurobiology of disease, 2014, Volume: 70

    Topics: Animals; Antiparkinson Agents; Cells, Cultured; Corpus Striatum; Dyskinesia, Drug-Induced; Enkephalins; Functional Laterality; Gene Expression; Genetic Therapy; Levodopa; Male; Oligonucleotides, Antisense; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats, Sprague-Dawley; RGS Proteins; RNA, Messenger; Up-Regulation

2014
L-DOPA-induced dyskinesia in a rat model of Parkinson's disease is associated with the fluctuational release of norepinephrine in the sensorimotor striatum.
    Journal of neuroscience research, 2014, Volume: 92, Issue:12

    Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Benzylamines; Chromatography, High Pressure Liquid; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Idazoxan; Levodopa; Male; Microdialysis; Neurotransmitter Agents; Norepinephrine; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Time Factors; Tyrosine 3-Monooxygenase

2014
Adenosine A2A receptor antagonists in Parkinson's disease: still in the running.
    The Lancet. Neurology, 2014, Volume: 13, Issue:8

    Topics: Adenosine A2 Receptor Antagonists; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Parkinson Disease

2014
[Influence of hemantane in injectable dosage form on levodopa-induced dyskinesia in rats with model parkinsonian syndrome].
    Eksperimental'naia i klinicheskaia farmakologiia, 2014, Volume: 77, Issue:5

    Topics: Adamantane; Adrenergic Agents; Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats

2014
The α7 nicotinic receptor agonist ABT-107 decreases L-Dopa-induced dyskinesias in parkinsonian monkeys.
    The Journal of pharmacology and experimental therapeutics, 2014, Volume: 351, Issue:1

    Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Indoles; Levodopa; Male; MPTP Poisoning; Nicotinic Agonists; Quinuclidines; Saimiri

2014
The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa.
    Brain : a journal of neurology, 2014, Volume: 137, Issue:Pt 10

    Topics: Adult; Africa South of the Sahara; Age of Onset; Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Cohort Studies; Cross-Sectional Studies; Data Interpretation, Statistical; Disease Progression; Dyskinesia, Drug-Induced; Female; Ghana; Humans; Italy; Levodopa; Longitudinal Studies; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Prospective Studies; Young Adult

2014
Effect of a chronic treatment with an mGlu5 receptor antagonist on brain serotonin markers in parkinsonian monkeys.
    Progress in neuro-psychopharmacology & biological psychiatry, 2015, Jan-02, Volume: 56

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide; Brain; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Combinations; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Homovanillic Acid; Levodopa; Macaca fascicularis; Ovariectomy; Parkinsonian Disorders; Protein Binding; Pyridines; Serotonin

2015
Self-unawareness of levodopa induced dyskinesias in patients with Parkinson's disease.
    Brain and cognition, 2014, Volume: 90

    Topics: Aged; Awareness; Dopamine Agents; Dyskinesia, Drug-Induced; Executive Function; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Self Concept

2014
Lack of depotentiation at basal ganglia output neurons in PD patients with levodopa-induced dyskinesia.
    Neurobiology of disease, 2014, Volume: 71

    Topics: Action Potentials; Aged; Antiparkinson Agents; Basal Ganglia; Biophysical Phenomena; Dyskinesia, Drug-Induced; Electric Stimulation; Female; Humans; Levodopa; Male; Microelectrodes; Middle Aged; Nerve Net; Neurons; Parkinson Disease; Severity of Illness Index; Statistics as Topic

2014
Selective Inactivation of Striatal FosB/ΔFosB-Expressing Neurons Alleviates L-DOPA-Induced Dyskinesia.
    Biological psychiatry, 2016, Mar-01, Volume: 79, Issue:5

    Topics: Animals; Antiparkinson Agents; Daunorubicin; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Macaca fascicularis; Male; Neostriatum; Neurons; Oxidopamine; Parkinson Disease; Patch-Clamp Techniques; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1

2016
The H3 receptor agonist immepip does not affect l-dopa-induced abnormal involuntary movements in 6-OHDA-lesioned rats.
    European journal of pharmacology, 2014, Oct-15, Volume: 741

    Topics: Animals; Dyskinesia, Drug-Induced; Dyskinesias; Histamine Agonists; Imidazoles; Levodopa; Male; Oxidopamine; Piperidines; Rats; Rats, Wistar

2014
Angiotensin type 1 receptor blockage reduces l-dopa-induced dyskinesia in the 6-OHDA model of Parkinson's disease. Involvement of vascular endothelial growth factor and interleukin-1β.
    Experimental neurology, 2014, Volume: 261

    Topics: Adrenergic Agents; Angiotensin II Type 1 Receptor Blockers; Animals; Antiparkinson Agents; Benzimidazoles; Biphenyl Compounds; Disease Models, Animal; Dyskinesia, Drug-Induced; In Vitro Techniques; Interleukin-1beta; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Oxidopamine; Parkinson Disease; Tetrazoles; Vascular Endothelial Growth Factor A

2014
Inhibition of adenylyl cyclase type 5 prevents L-DOPA-induced dyskinesia in an animal model of Parkinson's disease.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2014, Aug-27, Volume: 34, Issue:35

    Topics: Adenylyl Cyclase Inhibitors; Adenylyl Cyclases; Animals; Antiparkinson Agents; Blotting, Western; Disease Models, Animal; Dyskinesia, Drug-Induced; Immunohistochemistry; Levodopa; Mice; Mice, Inbred C57BL; Mice, Knockout; Parkinsonian Disorders; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction

2014
A new quantitative rating scale for dyskinesia in nonhuman primates.
    Behavioural pharmacology, 2015, Volume: 26, Issue:1-2

    Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Macaca mulatta; Male; Observer Variation; Parkinsonian Disorders; Reproducibility of Results; Severity of Illness Index; Video Recording

2015
Selective loss of bi-directional synaptic plasticity in the direct and indirect striatal output pathways accompanies generation of parkinsonism and l-DOPA induced dyskinesia in mouse models.
    Neurobiology of disease, 2014, Volume: 71

    Topics: Animals; Animals, Newborn; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Postsynaptic Potentials; Functional Laterality; Green Fluorescent Proteins; In Vitro Techniques; Levodopa; Mice; Mice, Transgenic; Neural Pathways; Neuronal Plasticity; Oxidopamine; Parkinsonian Disorders; Purinergic Agents; Receptor, Adenosine A2A; Receptors, Dopamine D1

2014
AQW051, a novel and selective nicotinic acetylcholine receptor α7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys.
    Parkinsonism & related disorders, 2014, Volume: 20, Issue:11

    Topics: alpha7 Nicotinic Acetylcholine Receptor; Analysis of Variance; Animals; Antiparkinson Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Motor Activity; MPTP Poisoning; Nicotinic Agonists; Ovariectomy; Time Factors

2014
Adenosine A1 receptor stimulation reduces D1 receptor-mediated GABAergic transmission from striato-nigral terminals and attenuates l-DOPA-induced dyskinesia in dopamine-denervated mice.
    Experimental neurology, 2014, Volume: 261

    Topics: Action Potentials; Age Factors; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Inhibitory Postsynaptic Potentials; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Neurons; Parkinson Disease; Pars Reticulata; Receptor, Adenosine A1; Receptors, Dopamine D1; Xanthines

2014
Side effect profile of 5-HT treatments for Parkinson's disease and L-DOPA-induced dyskinesia in rats.
    British journal of pharmacology, 2015, Volume: 172, Issue:1

    Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Buspirone; Citalopram; Dyskinesia, Drug-Induced; Levodopa; Male; Parkinson Disease; Psychomotor Performance; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin 5-HT1 Receptor Agonists

2015
Interaction of adenosine receptors with other receptors from therapeutic perspective in Parkinson's disease.
    International review of neurobiology, 2014, Volume: 119

    Topics: Animals; Antiparkinson Agents; Basal Ganglia; Dyskinesia, Drug-Induced; GABAergic Neurons; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine; Receptors, Metabotropic Glutamate; Receptors, Purinergic P1

2014
A Role for Mitogen- and Stress-Activated Kinase 1 in L-DOPA-Induced Dyskinesia and ∆FosB Expression.
    Biological psychiatry, 2016, Mar-01, Volume: 79, Issue:5

    Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Extracellular Signal-Regulated MAP Kinases; Histones; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neostriatum; Neurons; Oxidopamine; Parkinson Disease; Phosphorylation; Proto-Oncogene Proteins c-fos; Ribosomal Protein S6 Kinases, 90-kDa

2016
Effects of prolonged neuronal nitric oxide synthase inhibition on the development and expression of L-DOPA-induced dyskinesia in 6-OHDA-lesioned rats.
    Neuropharmacology, 2015, Volume: 89

    Topics: Animals; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Indazoles; Levodopa; Male; Nitric Oxide Synthase Type I; Oxidopamine; Rats; Rats, Wistar

2015
Norepinephrine transporter inhibition with desipramine exacerbates L-DOPA-induced dyskinesia: role for synaptic dopamine regulation in denervated nigrostriatal terminals.
    Molecular pharmacology, 2014, Volume: 86, Issue:6

    Topics: Animals; Corpus Striatum; Denervation; Desipramine; Dopamine; Dyskinesia, Drug-Induced; Extracellular Signal-Regulated MAP Kinases; Levodopa; Male; Norepinephrine Plasma Membrane Transport Proteins; Phosphorylation; Rats; Rats, Sprague-Dawley; Substantia Nigra; Synapses

2014
Serotonergic antidepressant drugs and L-dopa-induced dyskinesias in Parkinson's disease.
    Acta neurologica Scandinavica, 2015, Volume: 131, Issue:3

    Topics: Adult; Aged; Antidepressive Agents; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Selective Serotonin Reuptake Inhibitors

2015
Nitric oxide synthase inhibition decreases l-DOPA-induced dyskinesia and the expression of striatal molecular markers in Pitx3(-/-) aphakia mice.
    Neurobiology of disease, 2015, Volume: 73

    Topics: Animals; Antiparkinson Agents; Benserazide; Cell Count; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Gene Expression Regulation; Homeodomain Proteins; Indazoles; Levodopa; Mice; Mice, Knockout; Molsidomine; Nitric Oxide Donors; Parkinson Disease; Signal Transduction; Time Factors; Transcription Factors

2015
L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat.
    Behavioural pharmacology, 2015, Volume: 26, Issue:1-2

    Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Levodopa; Oxidopamine; Parkinsonian Disorders; Pyridines; Pyrroles; Rats; Rats, Sprague-Dawley; Species Specificity

2015
AFQ056/mavoglurant, a novel clinically effective mGluR5 antagonist: identification, SAR and pharmacological characterization.
    Bioorganic & medicinal chemistry, 2014, Nov-01, Volume: 22, Issue:21

    Topics: Animals; Brain; Dyskinesia, Drug-Induced; Half-Life; High-Throughput Screening Assays; Humans; Hyperthermia, Induced; Indoles; Levodopa; Male; Mice; Protein Binding; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Structure-Activity Relationship

2014
Effects of dopamine uptake inhibitor MRZ-9547 in animal models of Parkinson's disease.
    Journal of neural transmission (Vienna, Austria : 1996), 2015, Volume: 122, Issue:6

    Topics: Acetamides; Animals; Brain; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Haloperidol; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Pyrrolidinones; Rats, Sprague-Dawley

2015
Stronger Dopamine D1 Receptor-Mediated Neurotransmission in Dyskinesia.
    Molecular neurobiology, 2015, Volume: 52, Issue:3

    Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Caudate Nucleus; Corpus Striatum; Dimerization; Dominance, Cerebral; Dopamine; Dopamine Agonists; Dyskinesia, Drug-Induced; Gene Expression Regulation; Levodopa; Macaca fascicularis; Male; Oxidopamine; Parkinsonian Disorders; Putamen; Radioligand Assay; Rats; Rats, Wistar; Receptors, Dopamine D1; Receptors, Dopamine D3

2015
A network centred on the inferior frontal cortex is critically involved in levodopa-induced dyskinesias.
    Brain : a journal of neurology, 2015, Volume: 138, Issue:Pt 2

    Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Efferent Pathways; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Prefrontal Cortex; Theta Rhythm; Transcranial Magnetic Stimulation

2015
Inhibiting Lateral Habenula Improves L-DOPA-Induced Dyskinesia.
    Biological psychiatry, 2016, Mar-01, Volume: 79, Issue:5

    Topics: Animals; Corpus Striatum; Daunorubicin; Deoxyglucose; Disease Models, Animal; Dyskinesia, Drug-Induced; Electrophysiology; Female; Genes, Immediate-Early; Habenula; Levodopa; Macaca fascicularis; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley

2016
Glial activation is associated with l-DOPA induced dyskinesia and blocked by a nitric oxide synthase inhibitor in a rat model of Parkinson's disease.
    Neurobiology of disease, 2015, Volume: 73

    Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Indazoles; Inflammation; Levodopa; Male; Neuroglia; Neuroprotective Agents; Nitric Oxide; Nitric Oxide Synthase; Parkinson Disease; Rats; Rats, Wistar; Up-Regulation

2015
L-DOPA-induced behavioral sensitization of motor activity in the MPTP-treated common marmoset as a Parkinson's disease model.
    Pharmacology, biochemistry, and behavior, 2014, Volume: 127

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callithrix; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Parkinsonian Disorders; Random Allocation

2014
Levodopa-induced dyskinesias are associated with transient down-regulation of cAMP and cGMP in the caudate-putamen of hemiparkinsonian rats: reduced synthesis or increased catabolism?
    Neurochemistry international, 2014, Volume: 79

    Topics: Animals; Antiparkinson Agents; Caudate Nucleus; Cyclic AMP; Cyclic GMP; Down-Regulation; Dyskinesia, Drug-Induced; Levodopa; Male; Parkinsonian Disorders; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Putamen; Rats; Rats, Wistar

2014
Dyskinesias and motor symptoms onset in Parkinson disease.
    Parkinsonism & related disorders, 2014, Volume: 20, Issue:12

    Topics: Age of Onset; Aged; Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Movement; Parkinson Disease; Retrospective Studies

2014
Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats.
    Neurobiology of disease, 2015, Volume: 74

    Topics: Animals; Anti-Dyskinesia Agents; Corpus Striatum; Dopamine; Dynorphins; Dyskinesia, Drug-Induced; Early Growth Response Protein 1; Extracellular Signal-Regulated MAP Kinases; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Phosphorylation; PPAR gamma; Rats, Sprague-Dawley; Rats, Wistar; Rosiglitazone; Thiazolidinediones

2015
Pioglitazone may impair L-DOPA anti-parkinsonian efficacy in the MPTP-lesioned macaque: results of a pilot study.
    Synapse (New York, N.Y.), 2015, Volume: 69, Issue:3

    Topics: Animals; Antiparkinson Agents; Drug Combinations; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; MPTP Poisoning; Pilot Projects; Pioglitazone; Thiazolidinediones

2015
Postsynaptic density protein 95-regulated NR2B tyrosine phosphorylation and interactions of Fyn with NR2B in levodopa-induced dyskinesia rat models.
    Drug design, development and therapy, 2015, Volume: 9

    Topics: Animals; Disease Models, Animal; Disks Large Homolog 4 Protein; Dyskinesia, Drug-Induced; Female; Intracellular Signaling Peptides and Proteins; Levodopa; Membrane Proteins; Oxidopamine; Parkinson Disease; Phosphorylation; Proto-Oncogene Proteins c-fyn; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate

2015
Gene expression analyses identify Narp contribution in the development of L-DOPA-induced dyskinesia.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2015, Jan-07, Volume: 35, Issue:1

    Topics: Animals; Antiparkinson Agents; C-Reactive Protein; Dyskinesia, Drug-Induced; Female; Gene Expression Regulation; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Nerve Tissue Proteins

2015
NR2B antagonist CP-101,606 inhibits NR2B phosphorylation at tyrosine-1472 and its interactions with Fyn in levodopa-induced dyskinesia rat model.
    Behavioural brain research, 2015, Apr-01, Volume: 282

    Topics: Animals; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Phosphorylation; Piperidines; Proto-Oncogene Proteins c-fyn; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Tyrosine

2015
Dyskinesias during levodopa-carbidopa intestinal gel (LCIG) infusion: Management inclinical practice.
    Parkinsonism & related disorders, 2015, Volume: 21, Issue:3

    Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Gels; Humans; Jejunum; Levodopa; Parkinson Disease

2015
Evidence of an association between sleep and levodopa-induced dyskinesia in an animal model of Parkinson's disease.
    Neurobiology of aging, 2015, Volume: 36, Issue:3

    Topics: Animals; Disease Models, Animal; Disease Progression; Dyskinesia, Drug-Induced; Homeostasis; Levodopa; Male; Neuronal Plasticity; Parkinson Disease; Rats, Sprague-Dawley; Sleep; Sleep Deprivation

2015
Can levodopa-induced dyskinesias go beyond the motor circuit?
    Brain : a journal of neurology, 2015, Volume: 138, Issue:Pt 2

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Prefrontal Cortex

2015
Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
    Neuropharmacology, 2015, Volume: 93

    Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; Neurotransmitter Agents; Oxidopamine; Parkinson Disease; Piperidines; Psychomotor Performance; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin; Serotonin 5-HT1 Receptor Agonists; Tyrosine 3-Monooxygenase

2015
Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias.
    Movement disorders : official journal of the Movement Disorder Society, 2015, Volume: 30, Issue:6

    Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Biomarkers; Case-Control Studies; Caudate Nucleus; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dorsal Raphe Nucleus; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Parkinson Disease; Putamen; Serotonin; Serotonin Plasma Membrane Transport Proteins; Substantia Nigra

2015
Assessment of Parkinson's disease levodopa-induced dyskinesia: a qualitative research study.
    Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2015, Volume: 24, Issue:8

    Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Caregivers; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychometrics; Qualitative Research; Quality of Life; Severity of Illness Index; Surveys and Questionnaires

2015
Enhanced histamine H2 excitation of striatal cholinergic interneurons in L-DOPA-induced dyskinesia.
    Neurobiology of disease, 2015, Volume: 76

    Topics: Action Potentials; Animals; Cholinergic Neurons; Corpus Striatum; Dicyclomine; Disease Models, Animal; Dyskinesia, Drug-Induced; Famotidine; Histamine H2 Antagonists; Interneurons; Levodopa; Mice; Mice, Inbred C57BL; Parkinson Disease; Receptors, Histamine H2

2015
Could the serotonin theory give rise to a treatment for levodopa-induced dyskinesia in Parkinson's disease?
    Brain : a journal of neurology, 2015, Volume: 138, Issue:Pt 4

    Topics: Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Parkinson Disease; Piperazines

2015
Overexpression of GRK6 rescues L-DOPA-induced signaling abnormalities in the dopamine-depleted striatum of hemiparkinsonian rats.
    Experimental neurology, 2015, Volume: 266

    Topics: Animals; Cell Nucleus; Cytosol; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; G-Protein-Coupled Receptor Kinases; Levodopa; Mitogen-Activated Protein Kinases; Neostriatum; Parkinson Disease, Secondary; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Signal Transduction

2015
Quantitative motor assessment of dyskinesias in Parkinson's disease.
    Journal of neural transmission (Vienna, Austria : 1996), 2015, Volume: 122, Issue:9

    Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Area Under Curve; Cohort Studies; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Neurologic Examination; Parkinson Disease; ROC Curve; Severity of Illness Index

2015
[Experience with levodopa/carbidopa intestinal gel in the treatment of advanced Parkinson's disease in Hungary].
    Ideggyogyaszati szemle, 2014, Nov-30, Volume: 67, Issue:11-12

    Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Gels; Humans; Hungary; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Selection; Quality of Life; Retrospective Studies; Time Factors; Treatment Outcome

2014
Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist.
    Neuropharmacology, 2015, Volume: 95

    Topics: Aminobutyrates; Animals; Antiparkinson Agents; Catalepsy; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agents; Haloperidol; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Phosphinic Acids; Picolinic Acids; Random Allocation; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate

2015
Chronic L-DOPA induces hyperactivity, normalization of gait and dyskinetic behavior in MitoPark mice.
    Genes, brain, and behavior, 2015, Volume: 14, Issue:3

    Topics: Animals; Behavior, Animal; Benserazide; Disease Models, Animal; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Gait; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Parkinson Disease; Random Allocation

2015
Interrogating the aged striatum: robust survival of grafted dopamine neurons in aging rats produces inferior behavioral recovery and evidence of impaired integration.
    Neurobiology of disease, 2015, Volume: 77

    Topics: Aging; Amphetamine; Animals; Corpus Striatum; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Embryo, Mammalian; Functional Laterality; Levodopa; Neurites; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-fos; Rats; Rats, Inbred F344; Recovery of Function; Stem Cell Transplantation; Substance P

2015
Plasmalogen precursor analog treatment reduces levodopa-induced dyskinesias in parkinsonian monkeys.
    Behavioural brain research, 2015, Jun-01, Volume: 286

    Topics: Animals; Anti-Dyskinesia Agents; Docosahexaenoic Acids; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Ovariectomy; Parkinsonian Disorders; Phosphatidylethanolamines; Plasmalogens

2015
Effect of simvastatin on L-DOPA-induced abnormal involuntary movements of hemiparkinsonian rats.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2015, Volume: 36, Issue:8

    Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Levodopa; Male; MAP Kinase Signaling System; Oncogene Proteins v-fos; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Simvastatin; Time Factors

2015
Evidence for a role for α6(∗) nAChRs in l-dopa-induced dyskinesias using Parkinsonian α6(∗) nAChR gain-of-function mice.
    Neuroscience, 2015, Jun-04, Volume: 295

    Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Cocaine; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Mice, Transgenic; Nicotine; Nicotinic Agonists; Oxidopamine; Parkinsonian Disorders; Protein Binding; Receptors, Nicotinic

2015
Modulation of L-DOPA's antiparkinsonian and dyskinetic effects by α2-noradrenergic receptors within the locus coeruleus.
    Neuropharmacology, 2015, Volume: 95

    Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Animals; Antiparkinson Agents; Clonidine; Dyskinesia, Drug-Induced; Imidazoles; Levodopa; Locus Coeruleus; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2

2015
Dual κ-agonist/μ-antagonist opioid receptor modulation reduces levodopa-induced dyskinesia and corrects dysregulated striatal changes in the nonhuman primate model of Parkinson disease.
    Annals of neurology, 2015, Volume: 77, Issue:6

    Topics: Analgesics, Opioid; Animals; Antiparkinson Agents; Disease Models, Animal; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca; Male; Nalbuphine; Neostriatum; Parkinson Disease; Receptors, Opioid, kappa; Receptors, Opioid, mu

2015
Effects of the beta-adrenergic receptor antagonist Propranolol on dyskinesia and L-DOPA-induced striatal DA efflux in the hemi-parkinsonian rat.
    Journal of neurochemistry, 2015, Volume: 134, Issue:2

    Topics: Adrenergic beta-Antagonists; Animals; Antiparkinson Agents; Chromatography, High Pressure Liquid; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Male; Microdialysis; Motor Activity; Parkinsonian Disorders; Propranolol; Rats; Rats, Sprague-Dawley

2015
Is there a role for ADORA2A polymorphisms in levodopa-induced dyskinesia in Parkinson's disease patients?
    Pharmacogenomics, 2015, Volume: 16, Issue:6

    Topics: Aged; Aged, 80 and over; Dyskinesia, Drug-Induced; Female; Genetic Association Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polymorphism, Single Nucleotide; Receptor, Adenosine A2A

2015
Abnormal dopaminergic modulation of striato-cortical networks underlies levodopa-induced dyskinesias in humans.
    Brain : a journal of neurology, 2015, Volume: 138, Issue:Pt 6

    Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Female; Functional Neuroimaging; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Motor Cortex; Neural Pathways; Psychomotor Performance; Putamen

2015
Striatal tyrosine hydroxylase-positive neurons are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
    Neuroscience, 2015, Jul-09, Volume: 298

    Topics: Amphetamine; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Functional Laterality; Levodopa; Male; Medial Forebrain Bundle; Mice; Mice, Inbred C57BL; Neurons; Oxidopamine; Parkinson Disease; Phosphopyruvate Hydratase; Proto-Oncogene Proteins c-fos; Serotonin Plasma Membrane Transport Proteins; Statistics, Nonparametric; Tyrosine 3-Monooxygenase

2015
Gypenosides attenuate the development of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    BMC neuroscience, 2015, Apr-21, Volume: 16

    Topics: Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Ethanol; Gynostemma; Levodopa; Locomotion; Male; MAP Kinase Signaling System; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Phytotherapy; Plant Extracts; Proto-Oncogene Proteins c-fos; Random Allocation; Rats, Sprague-Dawley; Solvents

2015
Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
    Neuroscience, 2015, Jul-09, Volume: 298

    Topics: Analysis of Variance; Animals; Antiparkinson Agents; Citalopram; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Male; MPTP Poisoning; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Time Factors; Tyrosine 3-Monooxygenase

2015
Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.
    Proceedings of the National Academy of Sciences of the United States of America, 2015, May-12, Volume: 112, Issue:19

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Arrestins; Behavior, Animal; beta-Arrestins; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Dyskinesias; Gene Deletion; Levodopa; Macaca; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neurons; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Signal Transduction; Up-Regulation

2015
Roles of Ca(2+)/calmodulin-dependent protein kinase II in subcellular expression of striatal N-methyl-D-aspartate receptors in l-3, 4-dihydroxyphenylalanine-induced dyskinetic rats.
    Drug design, development and therapy, 2015, Volume: 9

    Topics: Animals; Antiparkinson Agents; Benzylamines; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Neostriatum; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Structure-Activity Relationship; Sulfonamides

2015
Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy.
    Journal of neurosurgery, 2015, Volume: 123, Issue:6

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca; Parkinsonian Disorders; Receptors, Glutamate; Subthalamic Nucleus

2015
Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Experimental neurology, 2015, Volume: 271

    Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Apomorphine; Disease Models, Animal; Dopamine; Dopamine Agonists; Drug Administration Schedule; Dyskinesia, Drug-Induced; Gene Expression Regulation; Indoles; Levodopa; Male; MAP Kinase Signaling System; Motor Activity; Neurokinin-1 Receptor Antagonists; Oxidopamine; Parkinson Disease; Piperidines; Rats; Rats, Sprague-Dawley; Substantia Nigra; Time Factors

2015
Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: The Barcelona registry.
    Parkinsonism & related disorders, 2015, Volume: 21, Issue:8

    Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Duodenum; Dyskinesia, Drug-Induced; Dyskinesias; Female; Follow-Up Studies; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Registries; Spain; Treatment Outcome

2015
Are cyclooxygenase-2 and nitric oxide involved in the dyskinesia of Parkinson's disease induced by L-DOPA?
    Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 2015, Jul-05, Volume: 370, Issue:1672

    Topics: Animals; Calbindins; Cyclooxygenase 2; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Immunohistochemistry; Levodopa; Male; Nitric Oxide; Nitric Oxide Synthase; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar

2015
NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.
    Experimental neurology, 2015, Volume: 271

    Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Brain; Catalepsy; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Female; Haloperidol; Levodopa; Movement; Neurotransmitter Agents; Oxidopamine; Piperidines; Psychomotor Performance; Pyridines; Rats; Rats, Sprague-Dawley; Serotonin 5-HT1 Receptor Agonists; Serotonin Syndrome; Swimming; Vocalization, Animal

2015
The highly-selective 5-HT(1A) agonist F15599 reduces L-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque.
    Neuropharmacology, 2015, Volume: 97

    Topics: Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Motor Activity; MPTP Poisoning; Piperidines; Pyrimidines; Serotonin 5-HT1 Receptor Agonists; Severity of Illness Index

2015
Motor complications in an incident Parkinson's disease cohort.
    European journal of neurology, 2016, Volume: 23, Issue:2

    Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Incidence; Levodopa; Male; Middle Aged; Parkinson Disease; Scotland

2016
L-Dopa induced dyskinesias in Parkinsonian mice: Disease severity or L-Dopa history.
    Brain research, 2015, Aug-27, Volume: 1618

    Topics: Animals; Antidiarrheals; Benserazide; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Locomotion; Mice; Parkinson Disease; Receptors, Neurotransmitter; Severity of Illness Index; Time Factors

2015
From unilateral to bilateral parkinsonism: Effects of lateralization on dyskinesias and associated molecular mechanisms.
    Neuropharmacology, 2015, Volume: 97

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Functional Laterality; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats, Sprague-Dawley; RNA, Messenger

2015
Respiratory dyskinesia in a patient with Parkinson disease successfully treated with STN DBS.
    Neurology, 2015, Aug-04, Volume: 85, Issue:5

    Topics: Deep Brain Stimulation; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Respiratory Distress Syndrome; Subthalamic Nucleus; Treatment Outcome

2015
Parkinson's disease related dyskinesia in a Tanzanian population.
    Parkinsonism & related disorders, 2015, Volume: 21, Issue:9

    Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tanzania

2015
Dyskinesia detection and monitoring by a single sensor in patients with Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2015, Volume: 30, Issue:9

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Parkinson Disease; Posture; Psychomotor Performance; Reproducibility of Results; Severity of Illness Index; Signal Detection, Psychological

2015
Loss of glutamic acid decarboxylase (Gad67) in striatal neurons expressing the Drdr1a dopamine receptor prevents L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned mice.
    Neuroscience, 2015, Sep-10, Volume: 303

    Topics: Animals; Antiparkinson Agents; Benzazepines; Corpus Striatum; Disease Models, Animal; Dopamine Antagonists; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Glutamate Decarboxylase; Levodopa; Medial Forebrain Bundle; Mice; Mice, Inbred C57BL; Mice, Transgenic; Motor Activity; Oxidopamine; Parkinson Disease; Psychomotor Performance; Receptors, Dopamine D1; Receptors, G-Protein-Coupled

2015
Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.
    Movement disorders : official journal of the Movement Disorder Society, 2015, Volume: 30, Issue:13

    Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Functional Laterality; gamma-Aminobutyric Acid; Gene Expression Regulation; Glutamic Acid; Levodopa; Male; MAP Kinase Signaling System; Motor Activity; Oxidopamine; Parkinson Disease; Piperazines; Rats; Rats, Sprague-Dawley; Serotonin Receptor Agonists; Time Factors

2015
Contribution of brain serotonin subtype 1B receptors in levodopa-induced motor complications.
    Neuropharmacology, 2015, Volume: 99

    Topics: Aged; Aged, 80 and over; Animals; Antiparkinson Agents; Brain; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Humans; Levodopa; Macaca fascicularis; Male; MPTP Poisoning; Ovariectomy; Parkinson Disease; Pyridines; Receptor, Metabotropic Glutamate 5; Receptor, Serotonin, 5-HT1B

2015
Effect of Subthalamic Deep Brain Stimulation on Levodopa-Induced Dyskinesia in Parkinson's Disease.
    Yonsei medical journal, 2015, Volume: 56, Issue:5

    Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Postoperative Period; Retrospective Studies; Subthalamic Nucleus; Treatment Outcome

2015
The motor inhibition system in Parkinson's disease with levodopa-induced dyskinesias.
    Movement disorders : official journal of the Movement Disorder Society, 2015, Volume: 30, Issue:14

    Topics: Aged; Antiparkinson Agents; Brain; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neural Inhibition; Parkinson Disease

2015
Alterations in primary motor cortex neurotransmission and gene expression in hemi-parkinsonian rats with drug-induced dyskinesia.
    Neuroscience, 2015, Dec-03, Volume: 310

    Topics: AIDS-Related Complex; Animals; Benzazepines; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Functional Laterality; Gene Expression; Levodopa; Male; Medial Forebrain Bundle; Motor Cortex; Oxidopamine; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Synaptic Transmission

2015
Effects of fibroblast transplantation into the internal pallidum on levodopa-induced dyskinesias in parkinsonian non-human primates.
    Neuroscience bulletin, 2015, Volume: 31, Issue:6

    Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Fibroblasts; Globus Pallidus; Levodopa; Macaca mulatta; Parkinsonian Disorders

2015
Risk of Disabling Response Fluctuations and Dyskinesias for Dopamine Agonists Versus Levodopa in Parkinson's Disease.
    Journal of Parkinson's disease, 2015, Volume: 5, Issue:4

    Topics: Aged; Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors

2015
Amelioration of L-Dopa-Associated Dyskinesias with Triterpenoic Acid in a Parkinsonian Rat Model.
    Neurotoxicity research, 2016, Volume: 29, Issue:1

    Topics: Adrenergic Agents; Age Factors; Animals; Animals, Newborn; Antiparkinson Agents; Catalase; Disease Models, Animal; Dyskinesia, Drug-Induced; Extremities; Female; Glutathione; Levodopa; Male; Movement; Oleanolic Acid; Oxidopamine; Parkinsonian Disorders; Pregnancy; Rats; Rats, Sprague-Dawley; Statistics, Nonparametric

2016
Striatal NELF-mediated RNA polymerase II stalling controls L-dopa induced dyskinesia.
    Neurobiology of disease, 2016, Volume: 85

    Topics: Animals; Antiparkinson Agents; Cell Culture Techniques; Corpus Striatum; Cytoskeletal Proteins; Disease Models, Animal; Dyskinesia, Drug-Induced; Early Growth Response Protein 1; Levodopa; Male; Nerve Tissue Proteins; Neurons; Proto-Oncogene Proteins c-fos; Rats, Sprague-Dawley; RNA Polymerase II; Transcription Factors

2016
Dopamine D3 Receptor Modulates l-DOPA-Induced Dyskinesia by Targeting D1 Receptor-Mediated Striatal Signaling.
    Cerebral cortex (New York, N.Y. : 1991), 2017, 01-01, Volume: 27, Issue:1

    Topics: Animals; Corpus Striatum; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Mice; Mice, Knockout; Parkinsonian Disorders; Receptors, Dopamine D1; Receptors, Dopamine D3

2017
Genetic deletion of Rhes or pharmacological blockade of mTORC1 prevent striato-nigral neurons activation in levodopa-induced dyskinesia.
    Neurobiology of disease, 2016, Volume: 85

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Glutamic Acid; GTP-Binding Proteins; Levodopa; Male; Mechanistic Target of Rapamycin Complex 1; Mice, Inbred C57BL; Mice, Knockout; Motor Activity; Multiprotein Complexes; Neurons; Neuroprotective Agents; Sirolimus; Substantia Nigra; TOR Serine-Threonine Kinases

2016
[The use of piribedil in early and late stages of Parkinson's disease].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2015, Volume: 115, Issue:10

    Topics: Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Middle Aged; Parkinson Disease; Piribedil

2015
[Pain fluctuations in Parkinson's disease].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2015, Volume: 115, Issue:9

    Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Disease Progression; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Pain; Pain Measurement; Parkinson Disease

2015
Cerebellar and Motor Cortical Transcranial Stimulation Decrease Levodopa-Induced Dyskinesias in Parkinson's Disease.
    Cerebellum (London, England), 2016, Volume: 15, Issue:1

    Topics: Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Cerebellum; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Cortex; Parkinson Disease; Severity of Illness Index; Transcranial Direct Current Stimulation; Treatment Outcome

2016
Loss of VGLUT3 Produces Circadian-Dependent Hyperdopaminergia and Ameliorates Motor Dysfunction and l-Dopa-Mediated Dyskinesias in a Model of Parkinson's Disease.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2015, Nov-11, Volume: 35, Issue:45

    Topics: Amino Acid Transport Systems, Acidic; Animals; Circadian Rhythm; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Mice; Mice, 129 Strain; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Motor Skills Disorders; Parkinsonian Disorders

2015
α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage.
    Movement disorders : official journal of the Movement Disorder Society, 2015, Volume: 30, Issue:14

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha7 Nicotinic Acetylcholine Receptor; Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Nicotinic Agonists; Parkinsonian Disorders; Saimiri; Substantia Nigra

2015
[An implication of serotonergic fibers which goes beyond Levodopa-induced dyskinesia].
    Medecine sciences : M/S, 2015, Volume: 31, Issue:11

    Topics: Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Macaca; Parkinson Disease; Serotonergic Neurons

2015
Risk and course of motor complications in a population-based incident Parkinson's disease cohort.
    Parkinsonism & related disorders, 2016, Volume: 22

    Topics: Age Factors; Aged; Antiparkinson Agents; Cohort Studies; Disease Progression; Dyskinesia, Drug-Induced; Dyskinesias; Female; Humans; Incidence; Kaplan-Meier Estimate; Levodopa; Male; Middle Aged; Movement Disorders; Norway; Parkinson Disease; Proportional Hazards Models; Prospective Studies; Risk Factors; Sex Factors; Superior Sagittal Sinus

2016
Effects of L-dopa priming on cortical high beta and high gamma oscillatory activity in a rodent model of Parkinson's disease.
    Neurobiology of disease, 2016, Volume: 86

    Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Benzazepines; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Gamma Rhythm; Levodopa; Male; Motor Activity; Motor Cortex; Neurons; Oxidopamine; Parkinsonian Disorders; Quinpirole; Rats; Rats, Sprague-Dawley; Serotonin Receptor Agonists

2016
Bridging the Gap: Muscarinic M4 Receptors Promote Striatal Plasticity in Health and Disease.
    Neuron, 2015, Nov-18, Volume: 88, Issue:4

    Topics: Animals; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Neostriatum; Neuronal Plasticity; Parkinsonian Disorders; Receptor, Muscarinic M4; RGS Proteins

2015
M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia.
    Neuron, 2015, Nov-18, Volume: 88, Issue:4

    Topics: Allosteric Regulation; Animals; Cerebral Cortex; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Glutamic Acid; Levodopa; Long-Term Potentiation; Long-Term Synaptic Depression; Macaca mulatta; Mice; Mice, Transgenic; Neostriatum; Neuronal Plasticity; Neurons; Parkinsonian Disorders; Receptor, Muscarinic M4; RGS Proteins; Signal Transduction

2015
Levodopa-Induced Motor and Dopamine Receptor Changes in Caenorhabditis elegans Overexpressing Human Alpha-Synuclein.
    Neuro-degenerative diseases, 2016, Volume: 16, Issue:3-4

    Topics: Actigraphy; alpha-Synuclein; Animals; Animals, Genetically Modified; Antiparkinson Agents; Caenorhabditis elegans; Dyskinesia, Drug-Induced; Humans; Levodopa; Microscopy, Confocal; Motor Activity; Motor Neurons; Parkinsonian Disorders; Pattern Recognition, Automated; Receptors, Dopamine

2016
Modulation of serotonergic transmission by eltoprazine in L-DOPA-induced dyskinesia: Behavioral, molecular, and synaptic mechanisms.
    Neurobiology of disease, 2016, Volume: 86

    Topics: Animals; Behavior, Animal; Corpus Striatum; Dyskinesia, Drug-Induced; Levodopa; Male; MAP Kinase Signaling System; Motor Activity; Neuronal Plasticity; Neurons; Oxidopamine; Parkinsonian Disorders; Piperazines; Rats; Rats, Wistar; Serotonin Receptor Agonists; Synapses; Synaptic Transmission; TOR Serine-Threonine Kinases

2016
Long-term effect of sub-anesthetic ketamine in reducing L-DOPA-induced dyskinesias in a preclinical model.
    Neuroscience letters, 2016, Jan-26, Volume: 612

    Topics: Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Ketamine; Levodopa; Male; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Receptors, Opioid; Time Factors

2016
Buspirone requires the intact nigrostriatal pathway to reduce the activity of the subthalamic nucleus via 5-HT1A receptors.
    Experimental neurology, 2016, Volume: 277

    Topics: Action Potentials; Adrenergic Agents; Adrenergic Uptake Inhibitors; Animals; Buspirone; Desipramine; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Neurons; Neurotoxicity Syndromes; Oxidopamine; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin Receptor Agonists; Subthalamic Nucleus

2016
Role of the atypical vesicular glutamate transporter VGLUT3 in l-DOPA-induced dyskinesia.
    Neurobiology of disease, 2016, Volume: 87

    Topics: Amino Acid Transport Systems, Acidic; Animals; Antiparkinson Agents; Cell Count; Cell Size; Choline O-Acetyltransferase; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Mice, Inbred C57BL; Mice, Transgenic; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neurons; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Receptors, AMPA; Ribosomal Protein S6; Vesicular Acetylcholine Transport Proteins

2016
Comment: Increased D3 binding-A substrate for levodopa-induced dyskinesias?
    Neurology, 2016, Jan-19, Volume: 86, Issue:3

    Topics: Dopamine Agents; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Humans; Levodopa; Male; Parkinson Disease; Positron-Emission Tomography; Receptors, Dopamine D3

2016
D3 dopamine receptor-preferring [11C]PHNO PET imaging in Parkinson patients with dyskinesia.
    Neurology, 2016, Jan-19, Volume: 86, Issue:3

    Topics: Aged; Carbon Radioisotopes; Case-Control Studies; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Neostriatum; Parkinson Disease; Positron-Emission Tomography; Receptors, Dopamine D2; Receptors, Dopamine D3; Up-Regulation; Ventral Striatum

2016
Coherence of neuronal firing of the entopeduncular nucleus with motor cortex oscillatory activity in the 6-OHDA rat model of Parkinson's disease with levodopa-induced dyskinesias.
    Experimental brain research, 2016, Volume: 234, Issue:4

    Topics: Action Potentials; Animals; Dyskinesia, Drug-Induced; Entopeduncular Nucleus; Levodopa; Male; Motor Cortex; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley

2016
Detection of Levodopa Induced Dyskinesia in Parkinson's Disease patients based on activity classification.
    Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference, 2015, Volume: 2015

    Topics: Accelerometry; Activities of Daily Living; Aged; Algorithms; Antiparkinson Agents; Diagnosis, Computer-Assisted; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease

2015
A novel method for assessing the severity of levodopa-induced dyskinesia using wearable sensors.
    Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference, 2015, Volume: 2015

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Movement; Parkinson Disease; Wearable Electronic Devices

2015
Systems-level neurophysiological state characteristics for drug evaluation in an animal model of levodopa-induced dyskinesia.
    Journal of neurophysiology, 2016, Volume: 115, Issue:3

    Topics: Animals; Antiparkinson Agents; Brain Waves; Disease Models, Animal; Dopaminergic Neurons; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; Electroencephalography; Female; Levodopa; Rats; Rats, Sprague-Dawley

2016
On the Effect of Eltoprazine in Dyskinetic Hemiparkinsonian Rats.
    Movement disorders : official journal of the Movement Disorder Society, 2016, Volume: 31, Issue:1

    Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Parkinson Disease; Piperazines; Rats; Serotonin Receptor Agonists

2016
Coffee consumption and risk of levodopa-induced dyskinesia in Parkinson's disease: The FRAGAMP study.
    Movement disorders : official journal of the Movement Disorder Society, 2015, Volume: 30, Issue:13

    Topics: Aged; Analysis of Variance; Antiparkinson Agents; Case-Control Studies; Coffee; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease

2015
The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements.
    Neuropharmacology, 2016, Volume: 105

    Topics: Animals; Anti-Dyskinesia Agents; Corpus Striatum; Cross-Over Studies; Dopamine; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Male; Microdialysis; Oxidopamine; Parkinsonian Disorders; Piperidines; Pyridines; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin; Serotonin 5-HT1 Receptor Agonists

2016
Bilateral low frequency rTMS of the primary motor cortex may not be a suitable treatment for levodopa-induced dyskinesias in late stage Parkinson's disease.
    Parkinsonism & related disorders, 2016, Volume: 22

    Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Cortex; Parkinson Disease; Transcranial Magnetic Stimulation

2016
The acute and long-term L-DOPA effects are independent from changes in the activity of dorsal raphe serotonergic neurons in 6-OHDA lesioned rats.
    British journal of pharmacology, 2016, Volume: 173, Issue:13

    Topics: Animals; Dopamine Agents; Dorsal Raphe Nucleus; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Rats; Rats, Sprague-Dawley; Serotonergic Neurons; Serotonin

2016
Unraveling the Mechanism of Dyskinesia One Transcription Factor at a Time.
    Biological psychiatry, 2016, Mar-01, Volume: 79, Issue:5

    Topics: Dyskinesia, Drug-Induced; Humans; Levodopa; Transcription Factors

2016
Chronic L-DOPA administration increases the firing rate but does not reverse enhanced slow frequency oscillatory activity and synchronization in substantia nigra pars reticulata neurons from 6-hydroxydopamine-lesioned rats.
    Neurobiology of disease, 2016, Volume: 89

    Topics: Action Potentials; Animals; Brain; Brain Waves; Cerebral Cortex; Disease Models, Animal; Dyskinesia, Drug-Induced; GABAergic Neurons; Levodopa; Neurons; Oxidopamine; Parkinsonian Disorders; Pars Reticulata; Rats; Rats, Sprague-Dawley; Subthalamic Nucleus

2016
Altered inhibitory interaction among inferior frontal and motor cortex in l-dopa-induced dyskinesias.
    Movement disorders : official journal of the Movement Disorder Society, 2016, Volume: 31, Issue:5

    Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Frontal Lobe; Humans; Levodopa; Male; Middle Aged; Motor Cortex; Parkinson Disease; Transcranial Magnetic Stimulation

2016
Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2016, Volume: 31, Issue:4

    Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Male; Parkinson Disease; Piperazines; Pyrimidines; Rats; Rats, Sprague-Dawley; Serotonin Receptor Agonists; Triazoles

2016
Gadd45β ameliorates L-DOPA-induced dyskinesia in a Parkinson's disease mouse model.
    Neurobiology of disease, 2016, Volume: 89

    Topics: Animals; Antigens, Differentiation; Cyclic AMP-Dependent Protein Kinases; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; MAP Kinase Signaling System; Mice; Mice, Knockout; Motor Activity; Oxidopamine; Parkinsonian Disorders; Receptors, Dopamine D1; RNA, Messenger; Substantia Nigra

2016
Targeting the D1-N-methyl-D-aspartate receptor complex reduces L-dopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson's rats.
    Drug design, development and therapy, 2016, Volume: 10

    Topics: Animals; Dyskinesia, Drug-Induced; Female; Levodopa; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, N-Methyl-D-Aspartate

2016
Shp-2 knockdown prevents l-dopa-induced dyskinesia in a rat model of Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2016, Volume: 31, Issue:4

    Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Down-Regulation; Dyskinesia, Drug-Induced; Levodopa; Male; Neostriatum; Parkinson Disease; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Rats; Rats, Wistar

2016
Serotonin-to-dopamine transporter ratios in Parkinson disease: Relevance for dyskinesias.
    Neurology, 2016, Mar-22, Volume: 86, Issue:12

    Topics: Aged; Biomarkers; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Serotonin Plasma Membrane Transport Proteins; Tomography, Emission-Computed, Single-Photon

2016
Optogenetic activation of striatal cholinergic interneurons regulates L-dopa-induced dyskinesias.
    Neurobiology of disease, 2016, Volume: 91

    Topics: Animals; Choline O-Acetyltransferase; Corpus Striatum; Dyskinesia, Drug-Induced; Interneurons; Levodopa; Mice; Neostriatum; Nicotine; Nicotinic Agonists; Optogenetics

2016
Transcranial Non-Invasive Brain Stimulation in Parkinson's Disease Patients with Dyskinesias. Where is the Optimal Target?
    Cerebellum (London, England), 2017, Volume: 16, Issue:1

    Topics: Cerebellum; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2017
A combined pharmacokinetic/pharmacodynamic model of levodopa motor response and dyskinesia in Parkinson's disease patients.
    European journal of clinical pharmacology, 2016, Volume: 72, Issue:4

    Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Models, Biological; Parkinson Disease; Prospective Studies

2016
Continuous leg dyskinesia assessment in Parkinson's disease -clinical validity and ecological effect.
    Parkinsonism & related disorders, 2016, Volume: 26

    Topics: Aged; Antiparkinson Agents; Cohort Studies; Dyskinesia, Drug-Induced; Female; Humans; Leg; Levodopa; Male; Middle Aged; Parkinson Disease; Reproducibility of Results; Severity of Illness Index; Video Recording

2016
Resting-state connectivity predicts levodopa-induced dyskinesias in Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2016, Volume: 31, Issue:4

    Topics: Aged; Antiparkinson Agents; Connectome; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Prefrontal Cortex; Prognosis; Putamen; Sensorimotor Cortex

2016
Optogenetic Inhibition of the Subthalamic Nucleus Reduces Levodopa-Induced Dyskinesias in a Rat Model of Parkinson's Disease.
    Stereotactic and functional neurosurgery, 2016, Volume: 94, Issue:1

    Topics: Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Optogenetics; Parkinson Disease; Rats; Subthalamic Nucleus

2016
Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson's disease.
    Journal of neurology, 2016, Volume: 263, Issue:5

    Topics: Age Factors; Aged; Antiparkinson Agents; Case-Control Studies; Dyskinesia, Drug-Induced; Female; Humans; Interviews as Topic; Italy; Levodopa; Logistic Models; Male; Middle Aged; Multivariate Analysis; Parkinson Disease; Phenotype; Risk; Severity of Illness Index; Time Factors

2016
L-DOPA Reverses the Increased Free Amino Acids Tissue Levels Induced by Dopamine Depletion and Rises GABA and Tyrosine in the Striatum.
    Neurotoxicity research, 2016, Volume: 30, Issue:1

    Topics: Amino Acids; Animals; Aspartic Acid; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Forelimb; gamma-Aminobutyric Acid; Glutamic Acid; Glycine; Levodopa; Mice; Oxidopamine; Rotarod Performance Test; Taurine; Tyrosine

2016
Striatal mRNA expression patterns underlying peak dose L-DOPA-induced dyskinesia in the 6-OHDA hemiparkinsonian rat.
    Neuroscience, 2016, Jun-02, Volume: 324

    Topics: Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Cytoskeleton; Drug Combinations; Dyskinesia, Drug-Induced; Functional Laterality; Gene Expression; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Random Allocation; Rats, Wistar; RNA, Messenger; Tyrosine 3-Monooxygenase

2016
Inhibition of Glycogen Synthase Kinase-3β (GSK-3β) as potent therapeutic strategy to ameliorates L-dopa-induced dyskinesia in 6-OHDA parkinsonian rats.
    Scientific reports, 2016, Mar-21, Volume: 6

    Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Cyclic AMP-Dependent Protein Kinases; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Glycogen Synthase Kinase 3 beta; Levodopa; Mitogen-Activated Protein Kinase 3; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Rats; Receptors, Dopamine D1; tau Proteins; Thiadiazoles; Tyrosine 3-Monooxygenase

2016
Ibuprofen or piroxicam protects nigral neurons and delays the development of l-dopa induced dyskinesia in rats with experimental Parkinsonism: Influence on angiogenesis.
    Neuropharmacology, 2016, Volume: 107

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Dyskinesia, Drug-Induced; Female; Ibuprofen; Levodopa; Neovascularization, Physiologic; Neurons; Neuroprotective Agents; Parkinsonian Disorders; Piroxicam; Random Allocation; Rats; Substantia Nigra; Time Factors

2016
Brain α7 nicotinic acetylcholine receptors in MPTP-lesioned monkeys and parkinsonian patients.
    Biochemical pharmacology, 2016, 06-01, Volume: 109

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Aged, 80 and over; alpha7 Nicotinic Acetylcholine Receptor; Animals; Antiparkinson Agents; Bungarotoxins; Case-Control Studies; Caudate Nucleus; Corpus Striatum; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Gene Expression; Humans; Iodine Radioisotopes; Levodopa; Macaca fascicularis; Male; Organ Specificity; Ovariectomy; Parkinson Disease; Parkinson Disease, Secondary; Putamen; Pyridines; Signal Transduction

2016
Antidyskinetic Effect of 7-Nitroindazole and Sodium Nitroprusside Associated with Amantadine in a Rat Model of Parkinson's Disease.
    Neurotoxicity research, 2016, Volume: 30, Issue:1

    Topics: Amantadine; Animals; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Indazoles; Levodopa; Male; Medial Forebrain Bundle; Microinjections; Nitroprusside; Oxidopamine; Parkinson Disease; Rats

2016
Enkephalin and dynorphin neuropeptides are differently correlated with locomotor hypersensitivity and levodopa-induced dyskinesia in parkinsonian rats.
    Experimental neurology, 2016, Volume: 280

    Topics: Analysis of Variance; Animals; Antiparkinson Agents; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Female; Gene Expression Regulation; Levodopa; Oxidopamine; Parkinson Disease; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; RNA, Messenger; Statistics as Topic; Sympatholytics; Tyrosine 3-Monooxygenase

2016
Restoration of the Dopamine Transporter through Cell Therapy Improves Dyskinesia in a Rat Model of Parkinson's Disease.
    PloS one, 2016, Volume: 11, Issue:4

    Topics: Animals; Behavior, Animal; Brain; Cell Line; Cell- and Tissue-Based Therapy; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Neural Stem Cells; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar

2016
Effect of the C-terminal domain of the heavy chain of tetanus toxin on dyskinesia caused by levodopa in 6-hydroxydopamine-lesioned rats.
    Pharmacology, biochemistry, and behavior, 2016, Volume: 145

    Topics: Animals; Cell Death; Corpus Striatum; Dopaminergic Neurons; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Oxidopamine; Peptide Fragments; Protein Domains; Proto-Oncogene Proteins c-fos; Rats; Substantia Nigra; Tetanus Toxin; Tyrosine 3-Monooxygenase

2016
Dementia with Lewy bodies presenting marked tongue protrusion and bite due to lingual dystonia: A case report.
    Rinsho shinkeigaku = Clinical neurology, 2016, 06-22, Volume: 56, Issue:6

    Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Bites and Stings; Drug Interactions; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonia; Female; Humans; Indoles; Laryngeal Diseases; Levodopa; Lewy Body Disease; Middle Aged; Olanzapine; Receptors, Dopamine D1; Tetrahydronaphthalenes; Thiophenes; Tongue Diseases

2016
Dynamic DNA Methylation Regulates Levodopa-Induced Dyskinesia.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2016, 06-15, Volume: 36, Issue:24

    Topics: Analysis of Variance; Animals; Antiparkinson Agents; Corpus Striatum; Dioxygenases; Disease Models, Animal; DNA Methylation; Dopamine; Dyskinesia, Drug-Induced; Enzyme Inhibitors; GADD45 Proteins; Gene Expression Regulation; Immunoprecipitation; Intracellular Signaling Peptides and Proteins; Levodopa; Male; Medial Forebrain Bundle; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Phthalimides; Rats; Rats, Sprague-Dawley; Tryptophan

2016
Dramatic differences in susceptibility to l-DOPA-induced dyskinesia between mice that are aged before or after a nigrostriatal dopamine lesion.
    Neurobiology of disease, 2016, Volume: 94

    Topics: Aging; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Mice, Inbred C57BL; Motor Activity; Oxidopamine; Parkinson Disease

2016
l-DOPA-induced dyskinesia is associated with a deficient numerical downregulation of striatal tyrosine hydroxylase mRNA-expressing neurons.
    Neuroscience, 2016, 09-07, Volume: 331

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Down-Regulation; Dyskinesia, Drug-Induced; Enkephalins; Levodopa; Male; Medial Forebrain Bundle; Mice, Inbred C57BL; Neuronal Plasticity; Neurons; Oxidopamine; Protein Precursors; RNA, Messenger; Tyrosine 3-Monooxygenase

2016
Using epigenetic networks for the analysis of movement associated with levodopa therapy for Parkinson's disease.
    Bio Systems, 2016, Volume: 146

    Topics: Accelerometry; Antiparkinson Agents; Data Mining; Dyskinesia, Drug-Induced; Epigenomics; Gene Regulatory Networks; Humans; Levodopa; Movement; Neural Networks, Computer; Parkinson Disease

2016
Co-administration of cannabidiol and capsazepine reduces L-DOPA-induced dyskinesia in mice: Possible mechanism of action.
    Neurobiology of disease, 2016, Volume: 94

    Topics: Animals; Anti-Dyskinesia Agents; Arachidonic Acids; Brain; Cannabidiol; Capsaicin; Cyclooxygenase 2; Dyskinesia, Drug-Induced; Endocannabinoids; Extracellular Signal-Regulated MAP Kinases; Histones; Levodopa; Male; Mice, Inbred C57BL; NF-kappa B; Oxidopamine; Parkinsonian Disorders; Polyunsaturated Alkamides; PPAR gamma; Receptor, Cannabinoid, CB1; TRPV Cation Channels; Tyrosine 3-Monooxygenase

2016
Effects and molecular mechanism of chitosan-coated levodopa nanoliposomes on behavior of dyskinesia rats.
    Biological research, 2016, Jul-04, Volume: 49, Issue:1

    Topics: Animals; Biocompatible Materials; Blotting, Western; Chitosan; Corpus Striatum; Dopamine Agents; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Extracellular Signal-Regulated MAP Kinases; Immunohistochemistry; Levodopa; Liposomes; Male; MAP Kinase Signaling System; Nanoparticles; Parkinson Disease; Phosphorylation; Proto-Oncogene Proteins c-fos; Random Allocation; Rats, Sprague-Dawley; Reproducibility of Results; Treatment Outcome

2016
[Motor levodopa-induced complications in Parkinson's disease].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2016, Volume: 40, Issue:240

    Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Risk Factors

2016
Parkinsonian monkeys with prior levodopa-induced dyskinesias followed by fetal dopamine precursor grafts do not display graft-induced dyskinesias.
    The Journal of comparative neurology, 2017, 02-15, Volume: 525, Issue:3

    Topics: Animals; Antiparkinson Agents; Calbindins; Caudate Nucleus; Cerebellum; Chlorocebus aethiops; Dopamine; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Fetal Tissue Transplantation; G Protein-Coupled Inwardly-Rectifying Potassium Channels; Levodopa; Male; Mesencephalon; Microglia; MPTP Poisoning; Neurons; Putamen; Tyrosine 3-Monooxygenase

2017
An evaluation of istradefylline treatment on Parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque models.
    Neuropharmacology, 2016, Volume: 110, Issue:Pt A

    Topics: Adenosine A2 Receptor Antagonists; Animals; Cognition Disorders; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Hypokinesia; Levodopa; Macaca fascicularis; Motor Skills Disorders; MPTP Poisoning; Purines; Treatment Outcome

2016
Benefits of subthalamic stimulation for elderly parkinsonian patients aged 70 years or older.
    Clinical neurology and neurosurgery, 2016, Volume: 149

    Topics: Aged; Antiparkinson Agents; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Subthalamic Nucleus; Tremor

2016
Paradoxical facilitation after depotentiation protocol can precede dyskinesia onset in early Parkinson's disease.
    Experimental brain research, 2016, Volume: 234, Issue:12

    Topics: Aged; Analysis of Variance; Antiparkinson Agents; Biophysics; Case-Control Studies; Dyskinesia, Drug-Induced; Evoked Potentials, Motor; Female; Humans; Levodopa; Long-Term Synaptic Depression; Male; Middle Aged; Motor Cortex; Parkinson Disease; Theta Rhythm; Transcranial Magnetic Stimulation

2016
Unilateral Subthalamic Nucleus Stimulation in the Treatment of Asymmetric Parkinson"s Disease with Early Motor Complications.
    Turkish neurosurgery, 2017, Volume: 27, Issue:2

    Topics: Aftercare; Aged; Antiparkinson Agents; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Subthalamic Nucleus; Treatment Outcome

2017
Validation of an improved scale for rating l-DOPA-induced dyskinesia in the mouse and effects of specific dopamine receptor antagonists.
    Neurobiology of disease, 2016, Volume: 96

    Topics: Analysis of Variance; Animals; Disease Models, Animal; Dopamine Agents; Dopamine Antagonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Exploratory Behavior; Levodopa; Male; Mice; Mice, Inbred C57BL; Movement; Outcome Assessment, Health Care; Oxidopamine; Parkinson Disease; Reproducibility of Results; Time Factors

2016
L-DOPA Oppositely Regulates Synaptic Strength and Spine Morphology in D1 and D2 Striatal Projection Neurons in Dyskinesia.
    Cerebral cortex (New York, N.Y. : 1991), 2016, 10-17, Volume: 26, Issue:11

    Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Postsynaptic Potentials; Female; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neurons; Oxidopamine; Parkinson Disease, Secondary; Receptors, Dopamine D1; Receptors, Dopamine D2; Spine; Sympatholytics

2016
Repetitive transcranial magnetic stimulation (rTMS) improves behavioral and biochemical deficits in levodopa-induced dyskinetic rats model.
    Oncotarget, 2016, 09-13, Volume: 7, Issue:37

    Topics: Animals; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Female; Glial Cell Line-Derived Neurotrophic Factor; Humans; Levodopa; Parkinson Disease; Problem Behavior; Proto-Oncogene Proteins c-fyn; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Transcranial Magnetic Stimulation; Tyrosine 3-Monooxygenase

2016
The impact of l-dopa on attentional impairments in a rat model of Parkinson's disease.
    Neuroscience, 2016, Nov-19, Volume: 337

    Topics: Animals; Antiparkinson Agents; Attention; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Male; Medial Forebrain Bundle; Motor Activity; Oxidopamine; Parkinson Disease; Rats, Sprague-Dawley

2016
Subthalamic oscillatory activity in parkinsonian patients with off-period dystonia.
    Acta neurologica Scandinavica, 2016, Volume: 134, Issue:5

    Topics: Adult; Aged; Dyskinesia, Drug-Induced; Dystonia; Electroencephalography; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Subthalamic Nucleus

2016
Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson's disease.
    Experimental neurology, 2016, Volume: 286

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Cytokines; Disease Models, Animal; Drug Delivery Systems; Dyskinesia, Drug-Induced; Encephalitis; Functional Laterality; Gene Expression Regulation; Levodopa; Lipopolysaccharides; Male; Nerve Tissue Proteins; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sympatholytics; Tumor Necrosis Factor-alpha

2016
Flow-metabolism dissociation in the pathogenesis of levodopa-induced dyskinesia.
    JCI insight, 2016, 09-22, Volume: 1, Issue:15

    Topics: Aged; Antiparkinson Agents; Brain; Cerebrovascular Circulation; Dopamine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Vasomotor System

2016
Pallidal stimulation in Parkinson's patients with contraindications to subthalamic target: A 3 years follow-up.
    Parkinsonism & related disorders, 2017, Volume: 34

    Topics: Aged; Antiparkinson Agents; Cognition Disorders; Contraindications; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Neuropsychological Tests; Neurosurgery; Parkinson Disease; Quality of Life; Severity of Illness Index; Subthalamic Nucleus; Time Factors; Treatment Outcome; Visual Analog Scale

2017
Intrastriatal injection of ionomycin profoundly changes motor response to l-DOPA and its underlying molecular mechanisms.
    Neuroscience, 2017, 01-06, Volume: 340

    Topics: Animals; Antiparkinson Agents; Calcineurin; Calcium Ionophores; Corpus Striatum; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Glutamic Acid; Ionomycin; Levodopa; Male; MAP Kinase Signaling System; Parkinsonian Disorders; Phosphorylation; Proto-Oncogene Proteins c-fos; Random Allocation; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate

2017
Axial levodopa-induced dyskinesias and neuronal activity in the dorsal striatum.
    Neuroscience, 2017, 02-20, Volume: 343

    Topics: Action Potentials; Animals; Antiparkinson Agents; Automation, Laboratory; Corpus Striatum; Delta Rhythm; Dyskinesia, Drug-Induced; Electrodes, Implanted; Functional Laterality; Levodopa; Male; Mice, Inbred C57BL; Neurons; Pattern Recognition, Automated

2017
Motor cortex plasticity can indicate vulnerability to motor fluctuation and high L-DOPA need in drug-naïve Parkinson's disease.
    Parkinsonism & related disorders, 2017, Volume: 35

    Topics: Adult; Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Evoked Potentials, Motor; Female; Follow-Up Studies; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Motor Cortex; Neuronal Plasticity; Parkinson Disease; Transcranial Magnetic Stimulation

2017
The impact of early versus late levodopa administration.
    Journal of neural transmission (Vienna, Austria : 1996), 2017, Volume: 124, Issue:4

    Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Multivariate Analysis; Parkinson Disease; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Time Factors

2017
Diphasic dyskinesias during levodopa-carbidopa intestinal gel (LCIG) infusion in Parkinson's disease.
    Parkinsonism & related disorders, 2017, Volume: 37

    Topics: Aged; Antiparkinson Agents; Carbidopa; Disability Evaluation; Drug Combinations; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Gels; Humans; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index

2017
Long-term treatment of Parkinson's disease with levodopa and other adjunctive drugs.
    Journal of neural transmission (Vienna, Austria : 1996), 2018, Volume: 125, Issue:1

    Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome; Tremor

2018
Dyskinesias in levodopa-carbidopa intestinal gel infusion era: New challenges, new features.
    Movement disorders : official journal of the Movement Disorder Society, 2017, Volume: 32, Issue:4

    Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Parkinson Disease

2017
The effect of mirtazapine on dopaminergic psychosis and dyskinesia in the parkinsonian marmoset.
    Psychopharmacology, 2017, Volume: 234, Issue:6

    Topics: Animals; Antidepressive Agents, Tricyclic; Antiparkinson Agents; Behavior, Animal; Callithrix; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Mianserin; Mirtazapine; Motor Activity; MPTP Poisoning; Parkinsonian Disorders; Psychoses, Substance-Induced

2017
Disability in Activities of Daily Living and Severity of Dyskinesias Determine the Handicap of Parkinson's Disease Patients in Advanced Stage Selected to DBS.
    Journal of Parkinson's disease, 2017, Volume: 7, Issue:2

    Topics: Activities of Daily Living; Deep Brain Stimulation; Disability Evaluation; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Severity of Illness Index

2017
Side effects induced by the acute levodopa challenge in Parkinson's Disease and atypical parkinsonisms.
    PloS one, 2017, Volume: 12, Issue:2

    Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Nausea; Parkinson Disease; Retrospective Studies; Vomiting

2017
Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia.
    Journal of neurochemistry, 2017, Volume: 141, Issue:4

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Aging; Antiparkinson Agents; Catecholamines; Dopamine; Dyskinesia, Drug-Induced; Female; Homovanillic Acid; Humans; Levodopa; Male; Middle Aged; Norepinephrine; Parkinson Disease

2017
Differential effects of gaseous versus injectable anesthetics on changes in regional cerebral blood flow and metabolism induced by l-DOPA in a rat model of Parkinson's disease.
    Experimental neurology, 2017, Volume: 292

    Topics: Anesthetics; Animals; Basal Ganglia; Cerebrovascular Circulation; Dyskinesia, Drug-Induced; Dyskinesias; Gases; Isoflurane; Ketamine; Levodopa; Parkinson Disease; Rats

2017
Dysregulation of BET proteins in levodopa-induced dyskinesia.
    Neurobiology of disease, 2017, Volume: 102

    Topics: Animals; Antiparkinson Agents; Azepines; Chromatin Immunoprecipitation; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Protein Domains; Proteins; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; RNA, Messenger; Transcription, Genetic; Triazoles

2017
A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model.
    Pharmacology, biochemistry, and behavior, 2008, Volume: 90, Issue:4

    Topics: Animals; Data Interpretation, Statistical; Dopamine Agents; Dyskinesia, Drug-Induced; Jaw; Levodopa; Macaca fascicularis; Male; MPTP Poisoning; Piperidines; Rats; Rats, Sprague-Dawley; Serotonin 5-HT2 Receptor Agonists; Serotonin Receptor Agonists; Tremor; Urea

2008
Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on L-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat.
    Psychopharmacology, 2008, Volume: 199, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Corpus Striatum; Dizocilpine Maleate; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Hydroxyindoleacetic Acid; Injections, Intraperitoneal; Levodopa; Male; Medial Forebrain Bundle; Motor Activity; Motor Skills; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptors, N-Methyl-D-Aspartate; Serotonin; Serotonin Receptor Agonists; Stereotyped Behavior

2008
Levodopa/DDCI and entacapone is the preferred treatment for Parkinson's disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort.
    European journal of neurology, 2008, Volume: 15, Issue:7

    Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Catechols; Dopa Decarboxylase; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; France; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Practice Patterns, Physicians'; Retrospective Studies

2008
Cabergoline and pramipexole fail to modify already established dyskinesias in an animal model of parkinsonism.
    Behavioural brain research, 2008, Dec-01, Volume: 194, Issue:1

    Topics: Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Benzothiazoles; Cabergoline; Disease Models, Animal; Dopamine Antagonists; Drug Interactions; Dyskinesia, Drug-Induced; Ergolines; Female; Levodopa; Mesencephalon; Oxidopamine; Parkinsonian Disorders; Pramipexole; Rats; Rats, Wistar; Stereotyped Behavior; Tyrosine 3-Monooxygenase

2008
Continuous and intermittent nicotine treatment reduces L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson's disease.
    The Journal of pharmacology and experimental therapeutics, 2008, Volume: 327, Issue:1

    Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Infusion Pumps; Levodopa; Male; Nicotine; Parkinson Disease; Rats; Rats, Sprague-Dawley

2008
Exogenous corticosterone reduces L-DOPA-induced dyskinesia in the hemi-parkinsonian rat: role for interleukin-1beta.
    Neuroscience, 2008, Sep-22, Volume: 156, Issue:1

    Topics: Animals; Anti-Inflammatory Agents; Corpus Striatum; Corticosterone; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Encephalitis; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Levodopa; Male; Medial Forebrain Bundle; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; RNA, Messenger; Substantia Nigra; Sympatholytics; Up-Regulation

2008
Investigation on tolerance development to subchronic blockade of mGluR5 in models of learning, anxiety, and levodopa-induced dyskinesia in rats.
    Journal of neural transmission (Vienna, Austria : 1996), 2008, Volume: 115, Issue:12

    Topics: Animals; Antiparkinson Agents; Anxiety Disorders; Brain; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Glutamic Acid; Learning Disabilities; Levodopa; Male; Maze Learning; Memory Disorders; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Synaptic Transmission; Thiazoles

2008
Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms.
    The European journal of neuroscience, 2008, Volume: 28, Issue:5

    Topics: Animals; Animals, Newborn; Brain; Cerebral Cortex; Cyclic AMP; Cyclic GMP; Dopamine; Dopamine Agents; Down-Regulation; Dyskinesia, Drug-Induced; Globus Pallidus; Levodopa; Male; Neostriatum; Oxidopamine; Parkinsonian Disorders; Phosphodiesterase Inhibitors; Phosphorylation; Purinones; Rats; Rats, Sprague-Dawley; Second Messenger Systems; Substantia Nigra; Sympatholytics; Synaptic Transmission

2008
Oral creatine supplementation attenuates L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rats.
    Behavioural brain research, 2009, Jan-30, Volume: 197, Issue:1

    Topics: Administration, Oral; Analysis of Variance; Animals; Creatine; Dietary Supplements; Disease Models, Animal; Dyskinesia, Drug-Induced; Energy Metabolism; Enkephalins; Female; In Vitro Techniques; Levodopa; Neostriatum; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Phosphocreatine; Protein Precursors; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; RNA, Messenger; Statistics, Nonparametric

2009
Antagonizing L-type Ca2+ channel reduces development of abnormal involuntary movement in the rat model of L-3,4-dihydroxyphenylalanine-induced dyskinesia.
    Biological psychiatry, 2009, Mar-15, Volume: 65, Issue:6

    Topics: Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Cerebrum; Dendritic Spines; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Enkephalins; Isradipine; Levodopa; Male; Motor Activity; Nimodipine; Oxidopamine; Protein Precursors; Rats; Rats, Wistar; RNA, Messenger; Sympatholytics

2009
Use of clozapine in Brazilian patients with Parkinson's disease.
    Arquivos de neuro-psiquiatria, 2008, Volume: 66, Issue:3B

    Topics: Adult; Aged; Antiparkinson Agents; Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychoses, Substance-Induced; Retrospective Studies

2008
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Brain : a journal of neurology, 2008, Volume: 131, Issue:Pt 12

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Drug Administration Schedule; Drug Evaluation, Preclinical; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Motor Activity; Parkinson Disease; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Pyridines; Receptors, N-Methyl-D-Aspartate; Serotonin 5-HT1 Receptor Agonists; Serotonin Receptor Agonists; Treatment Outcome

2008
BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease.
    Journal of neurology, neurosurgery, and psychiatry, 2009, Volume: 80, Issue:2

    Topics: Adult; Aged; Alleles; Antiparkinson Agents; Brain-Derived Neurotrophic Factor; Corpus Striatum; Dyskinesia, Drug-Induced; Female; Gene Expression; Genotype; Humans; Levodopa; Male; Middle Aged; Neuronal Plasticity; Parkinson Disease; Polymorphism, Genetic; Receptor, trkB; Risk Factors; Synapses; Time Factors

2009
Implanted reuptake-deficient or wild-type dopaminergic neurons improve ON L-dopa dyskinesias without OFF-dyskinesias in a rat model of Parkinson's disease.
    Brain : a journal of neurology, 2008, Volume: 131, Issue:Pt 12

    Topics: Animals; Antiparkinson Agents; Brain Tissue Transplantation; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Enkephalins; Female; Fetal Tissue Transplantation; Gene Expression Regulation; Graft Survival; Levodopa; Mesencephalon; Microdialysis; Neurons; Parkinson Disease; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate; RNA, Messenger

2008
The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway: positive interaction with L-DOPA.
    Journal of neurochemistry, 2008, Volume: 107, Issue:6

    Topics: Animals; Antiparkinson Agents; Benzimidazoles; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Functional Laterality; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Mice; Mice, Inbred C57BL; Mice, Knockout; Microdialysis; Motor Activity; Narcotic Antagonists; Neural Pathways; Nociceptin Receptor; Oxidopamine; Parkinsonian Disorders; Psychomotor Performance; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Opioid; Substantia Nigra; Thalamus; Time Factors

2008
Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
    Brain : a journal of neurology, 2009, Volume: 132, Issue:Pt 2

    Topics: Animals; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Female; Immunohistochemistry; Levodopa; Models, Animal; Nerve Degeneration; Neurons; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin; Substantia Nigra

2009
Genetic, temporal and diurnal influences on L-dopa-induced dyskinesia in the 6-OHDA model.
    Brain research bulletin, 2009, Mar-16, Volume: 78, Issue:4-5

    Topics: Animals; Antiparkinson Agents; Circadian Rhythm; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Injections, Intraperitoneal; Levodopa; Microinjections; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Inbred Lew; Rats, Sprague-Dawley; Risk Factors; Rotation; Species Specificity; Sympatholytics; Time Factors; Treatment Outcome

2009
Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats.
    Journal of neuroscience research, 2009, May-15, Volume: 87, Issue:7

    Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Corpus Striatum; Dynorphins; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Piperazines; Protein Precursors; Proto-Oncogene Proteins c-fos; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; RNA, Messenger; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT1 Receptor Antagonists; Serotonin Antagonists; Serotonin Receptor Agonists

2009
Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
    Neurobiology of disease, 2009, Volume: 35, Issue:2

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benzopyrans; Callithrix; Corpus Striatum; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Dopamine Antagonists; Dyskinesia, Drug-Induced; Enkephalins; Female; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; RNA, Messenger

2009
Parkinson's disease with and without REM sleep behaviour disorder: are there any clinical differences?
    European neurology, 2009, Volume: 61, Issue:3

    Topics: Age Factors; Aged; Antiparkinson Agents; Brain; Brain Mapping; Constipation; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Logistic Models; Male; Odds Ratio; Parkinson Disease; REM Sleep Behavior Disorder; Sex Factors; Tomography, Emission-Computed, Single-Photon

2009
Comparison of intrastriatal administration of noradrenaline and l-DOPA on dyskinetic movements: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine-lesioned rats.
    Neuroscience, 2009, Mar-03, Volume: 159, Issue:1

    Topics: Analysis of Variance; Animals; Benserazide; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Microdialysis; Norepinephrine; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Severity of Illness Index

2009
A new perspective on brain derived neurotrophin factor polymorphism in L-dopa induced dyskinesia.
    Journal of neurology, neurosurgery, and psychiatry, 2009, Volume: 80, Issue:2

    Topics: Antiparkinson Agents; Brain-Derived Neurotrophic Factor; Corpus Striatum; Dyskinesia, Drug-Induced; Genetic Markers; Genotype; Humans; Levodopa; Neuronal Plasticity; Parkinson Disease; Polymorphism, Genetic

2009
Serpentine tongue: A rare manifestation following initiation of levodopa therapy in a patient with Parkinson's disease.
    Parkinsonism & related disorders, 2009, Volume: 15, Issue:9

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tongue; Trihexyphenidyl

2009
Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats.
    Psychopharmacology, 2009, Volume: 204, Issue:2

    Topics: Animals; Apomorphine; Benserazide; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Immunohistochemistry; Levodopa; Male; Microinjections; Organic Chemicals; Oxidopamine; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Rotation; Serotonin Receptor Agonists; Stereotyped Behavior; Subthalamic Nucleus; Sympathectomy, Chemical; Sympatholytics

2009
Quantifying drug induced dyskinesia in Parkinson's disease patients using standardized videos.
    Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference, 2008, Volume: 2008

    Topics: Analysis of Variance; Antiparkinson Agents; Biomedical Engineering; Diagnosis, Computer-Assisted; Dyskinesia, Drug-Induced; Humans; Levodopa; Movement; Parkinson Disease; Tremor; Video Recording

2008
L-dopa-induced desensitization depends on 5-hydroxytryptamine imbalance in hemiparkinsonian rats.
    Neuroreport, 2009, Feb-18, Volume: 20, Issue:3

    Topics: Animals; Brain; Brain Chemistry; Corpus Striatum; Dopamine Agents; Drug Interactions; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Movement Disorders; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Rotation; Serotonin; Sympatholytics; Tryptophan Hydroxylase

2009
Chronic intermittent L-DOPA treatment induces changes in dopamine release.
    Journal of neurochemistry, 2009, Volume: 108, Issue:4

    Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agonists; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Levodopa; Parkinson Disease; Potassium; Presynaptic Terminals; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Plasma Membrane Transport Proteins; Synaptic Transmission

2009
Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.
    Parkinsonism & related disorders, 2009, Volume: 15, Issue:6

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Organic Chemicals; Ovariectomy; Parkinsonian Disorders; Serotonin Receptor Agonists

2009
Levodopa-induced dyskinesia and striatal signaling pathways.
    Proceedings of the National Academy of Sciences of the United States of America, 2009, Mar-03, Volume: 106, Issue:9

    Topics: Animals; Dyskinesia, Drug-Induced; Humans; Levodopa; Signal Transduction

2009
The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism.
    Psychopharmacology, 2009, Volume: 204, Issue:4

    Topics: Animals; Buspirone; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Parkinson Disease; Piperazines; Pyridines; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptors, sigma; Serotonin 5-HT1 Receptor Agonists; Serotonin Antagonists; Serotonin Receptor Agonists; Sigma-1 Receptor

2009
Metabotropic glutamate receptor II in the brains of Parkinsonian patients.
    Journal of neuropathology and experimental neurology, 2009, Volume: 68, Issue:4

    Topics: Aged; Aged, 80 and over; Amino Acids; Antiparkinson Agents; Brain; Cocaine; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Humans; Iodine Radioisotopes; Levodopa; Male; Parkinsonian Disorders; Postmortem Changes; Radioligand Assay; Receptors, Metabotropic Glutamate; Tritium; Xanthenes

2009
Nitric oxide synthase inhibition attenuates L-DOPA-induced dyskinesias in a rodent model of Parkinson's disease.
    Neuroscience, 2009, Mar-31, Volume: 159, Issue:3

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Indazoles; Levodopa; Male; Motor Activity; Nitric Oxide Synthase; Nitroarginine; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Substantia Nigra

2009
The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats.
    Synapse (New York, N.Y.), 2009, Volume: 63, Issue:7

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Hydroxyindoleacetic Acid; Levodopa; Male; Medial Forebrain Bundle; Motor Activity; Neurons; Raphe Nuclei; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin; Serotonin Agents

2009
Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling.
    The Journal of pharmacology and experimental therapeutics, 2009, Volume: 330, Issue:1

    Topics: Animals; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Female; Glutamic Acid; Levodopa; Motor Activity; Rats; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate; Synaptic Transmission

2009
Pharmacological analysis demonstrates dramatic alteration of D1 dopamine receptor neuronal distribution in the rat analog of L-DOPA-induced dyskinesia.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2009, Apr-15, Volume: 29, Issue:15

    Topics: Animals; Dyskinesia, Drug-Induced; Levodopa; Male; Neurons; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptor Cross-Talk; Receptors, Dopamine D1; Receptors, Dopamine D3

2009
Continuous dopaminergic stimulation achieved by duodenal levodopa infusion.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2008, Volume: 29 Suppl 5

    Topics: Antiparkinson Agents; Dopamine Agonists; Duodenum; Dyskinesia, Drug-Induced; Humans; Intestinal Absorption; Intubation, Gastrointestinal; Levodopa; Parkinson Disease; Suspensions

2008
Priming for L-DOPA-induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats.
    Experimental neurology, 2009, Volume: 219, Issue:1

    Topics: Amphetamine; Animals; Antiparkinson Agents; Brain Tissue Transplantation; Central Nervous System Stimulants; Corpus Striatum; Disease Models, Animal; Drug Synergism; Dyskinesia, Drug-Induced; Female; Levodopa; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Stem Cell Transplantation; Sympatholytics

2009
Effect of levodopa priming on dopamine neuron transplant efficacy and induction of abnormal involuntary movements in parkinsonian rats.
    The Journal of comparative neurology, 2009, Jul-01, Volume: 515, Issue:1

    Topics: Animals; Antiparkinson Agents; Brain; Brain Tissue Transplantation; Disease Models, Animal; Dopamine; Drug Administration Schedule; Dyskinesia, Drug-Induced; Graft Survival; Levodopa; Male; Neurons; Parkinsonian Disorders; Rats; Rats, Inbred F344; Treatment Outcome

2009
Increased vulnerability to 6-hydroxydopamine lesion and reduced development of dyskinesias in mice lacking CB1 cannabinoid receptors.
    Neurobiology of aging, 2011, Volume: 32, Issue:4

    Topics: Amphetamine; Analysis of Variance; Animals; Benserazide; Brain; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; In Situ Hybridization; Levodopa; Lipid Peroxidation; Male; Mice; Mice, Knockout; Motor Activity; Neurons; Oxidopamine; Receptor, Cannabinoid, CB1; Severity of Illness Index

2011
Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2009, Volume: 16, Issue:8

    Topics: Adult; Age Factors; Aged; Antiparkinson Agents; China; Cross-Sectional Studies; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Risk Factors; Severity of Illness Index; Time Factors

2009
Striatal overexpression of DeltaJunD resets L-DOPA-induced dyskinesia in a primate model of Parkinson disease.
    Biological psychiatry, 2009, Sep-15, Volume: 66, Issue:6

    Topics: Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Drug Combinations; Dyskinesia, Drug-Induced; Female; Gene Expression Regulation; Genetic Therapy; Genetic Vectors; Green Fluorescent Proteins; Humans; Iodine Radioisotopes; Levodopa; Linear Models; Macaca fascicularis; Male; MPTP Poisoning; Nortropanes; Protein Binding; Proto-Oncogene Proteins c-jun; Radionuclide Imaging; RNA, Messenger

2009
Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model.
    Experimental neurology, 2009, Volume: 219, Issue:1

    Topics: Animals; Apomorphine; Brain; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT1B; Receptors, Serotonin; Serotonin; Serotonin 5-HT1 Receptor Agonists; Serotonin Receptor Agonists

2009
The blood-brain barrier is intact after levodopa-induced dyskinesias in parkinsonian primates--evidence from in vivo neuroimaging studies.
    Neurobiology of disease, 2009, Volume: 35, Issue:3

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Blood-Brain Barrier; Brain; Dyskinesia, Drug-Induced; Gadolinium DTPA; Levodopa; Macaca fascicularis; Magnetic Resonance Imaging; Male; Parkinsonian Disorders; Time Factors

2009
Why are some Parkinson disease patients unaware of their dyskinesias?
    Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology, 2009, Volume: 22, Issue:2

    Topics: Aged; Antiparkinson Agents; Awareness; Dyskinesia, Drug-Induced; Feedback, Psychological; Female; Humans; Levodopa; Male; Neuropsychological Tests; Parkinson Disease; Photic Stimulation; Psychomotor Performance; Self Concept

2009
Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation.
    Biological psychiatry, 2009, Sep-15, Volume: 66, Issue:6

    Topics: Acetylation; Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Extracellular Signal-Regulated MAP Kinases; Functional Laterality; Gene Expression Regulation; Histones; Levodopa; Mice; Mice, Knockout; Motor Activity; Neurons; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Proto-Oncogene Proteins c-fos; Receptors, Dopamine D1; Receptors, Dopamine D2; Statistics as Topic; Tyrosine 3-Monooxygenase

2009
Agonist or levodopa for Parkinson disease? Ultimately, it doesn't matter; neither is good enough.
    Neurology, 2009, Jun-16, Volume: 72, Issue:24

    Topics: Bromocriptine; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Follow-Up Studies; Humans; Indoles; Levodopa; Parkinson Disease; Practice Patterns, Physicians'; Prevalence; Randomized Controlled Trials as Topic; Time; Treatment Outcome

2009
Reduced levodopa-induced complications after 5 years of subthalamic stimulation in Parkinson's disease: a second honeymoon.
    Journal of neurology, 2009, Volume: 256, Issue:10

    Topics: Antiparkinson Agents; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Dystonia; Follow-Up Studies; Humans; Levodopa; Parkinson Disease; Severity of Illness Index; Subthalamic Nucleus

2009
Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.
    Neuropharmacology, 2010, Volume: 58, Issue:1

    Topics: Animals; Antiparkinson Agents; Benzoxazoles; Cocaine; Corpus Striatum; Disease Models, Animal; Docosahexaenoic Acids; Dopamine; Dopamine Uptake Inhibitors; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Female; Iodine Isotopes; Levodopa; Macaca fascicularis; Naltrexone; Neuropeptides; Ovariectomy; Parkinsonian Disorders; Piperidines; Protein Precursors; RNA, Messenger; Sulfonamides; Tachykinins; Thiazoles; Time Factors

2010
[Long term experience with Stalevo in Szeged, Hungary].
    Ideggyogyaszati szemle, 2009, May-30, Volume: 62, Issue:5-6

    Topics: Aged; Antiparkinson Agents; Carbidopa; Catechols; Drug Combinations; Drug Resistance; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Pain Measurement; Parkinson Disease; Quality of Life; Severity of Illness Index; Time Factors; Treatment Outcome

2009
Cerebellar magnetic stimulation decreases levodopa-induced dyskinesias in Parkinson disease.
    Neurology, 2009, Jul-14, Volume: 73, Issue:2

    Topics: Aged; Analysis of Variance; Cerebellum; Dyskinesia, Drug-Induced; Evoked Potentials, Motor; Humans; Levodopa; Middle Aged; Motor Cortex; Neural Inhibition; Neural Pathways; Neuronal Plasticity; Parkinson Disease; Severity of Illness Index; Thalamus; Transcranial Magnetic Stimulation

2009
Different functional basal ganglia subcircuits associated with anti-akinetic and dyskinesiogenic effects of antiparkinsonian therapies.
    Neurobiology of disease, 2009, Volume: 36, Issue:1

    Topics: Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Electric Stimulation; Electrodes, Implanted; Electron Transport Complex IV; Gene Expression Regulation; Levodopa; Male; Nerve Net; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Protein Subunits; Rats; Rats, Wistar; RNA, Messenger

2009
Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction.
    Experimental neurology, 2009, Volume: 219, Issue:2

    Topics: Analysis of Variance; Animals; Antiparkinson Agents; Callithrix; Disease Models, Animal; Drug Administration Schedule; Drug Delivery Systems; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; Motor Skills; MPTP Poisoning; Tetrahydronaphthalenes; Thiophenes

2009
Inhibition of mTOR signaling in Parkinson's disease prevents L-DOPA-induced dyskinesia.
    Science signaling, 2009, Jul-21, Volume: 2, Issue:80

    Topics: Animals; Antiparkinson Agents; Carrier Proteins; Dyskinesia, Drug-Induced; Levodopa; Male; Mechanistic Target of Rapamycin Complex 1; Mice; Multiprotein Complexes; Parkinsonian Disorders; Phosphotransferases (Alcohol Group Acceptor); Proteins; Receptors, Dopamine D1; Signal Transduction; TOR Serine-Threonine Kinases; Transcription Factors

2009
Serotonin 1B receptor stimulation reduces D1 receptor agonist-induced dyskinesia.
    Neuroreport, 2009, Sep-23, Volume: 20, Issue:14

    Topics: Adrenergic Agents; Animals; Benzazepines; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Serotonin 5-HT1 Receptor Agonists; Serotonin Receptor Agonists; Severity of Illness Index; Time Factors

2009
Nur77 mRNA levels and L-Dopa-induced dyskinesias in MPTP monkeys treated with docosahexaenoic acid.
    Neurobiology of disease, 2009, Volume: 36, Issue:1

    Topics: Acetylcholinesterase; Analysis of Variance; Animals; Antiparkinson Agents; Autoradiography; Brain; Cocaine; Disease Models, Animal; Docosahexaenoic Acids; Drug Interactions; Dyskinesia, Drug-Induced; Female; Iodine Isotopes; Levodopa; Macaca fascicularis; MPTP Poisoning; Nuclear Receptor Subfamily 4, Group A, Member 1; Protein Binding; RNA, Messenger; Statistics as Topic

2009
Effect of the metabotropic glutamate antagonist MPEP on striatal expression of the Homer family proteins in levodopa-treated hemiparkinsonian rats.
    Psychopharmacology, 2009, Volume: 206, Issue:2

    Topics: Animals; Antiparkinson Agents; Carrier Proteins; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Gene Expression Regulation; Homer Scaffolding Proteins; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Pyridines; Rats; Rats, Sprague-Dawley; Tyrosine 3-Monooxygenase

2009
Metabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movements and the increases in glutamic acid decarboxylase mRNA levels induced by l-DOPA in striatal neurons of 6-hydroxydopamine-lesioned rats.
    Neuroscience, 2009, Nov-10, Volume: 163, Issue:4

    Topics: Adrenergic Agents; Animals; Corpus Striatum; Dopamine Agents; Dynorphins; Dyskinesia, Drug-Induced; Dystonia; Excitatory Amino Acid Antagonists; Glutamate Decarboxylase; Levodopa; Male; Neurons; Oxidopamine; Protein Precursors; Pyridines; Random Allocation; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; RNA, Messenger

2009
Onset and spread of dyskinesias and motor symptoms in Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2009, Oct-30, Volume: 24, Issue:14

    Topics: Age of Onset; Aged; Antiparkinson Agents; Disease Progression; Dyskinesia, Drug-Induced; Female; Functional Laterality; Hand Strength; Humans; Italy; Levodopa; Male; Middle Aged; Motor Skills; Movement; Movement Disorders; Parkinson Disease; Retrospective Studies

2009
Effect of the additional noradrenergic neurodegeneration to 6-OHDA-lesioned rats in levodopa-induced dyskinesias and in cognitive disturbances.
    Journal of neural transmission (Vienna, Austria : 1996), 2009, Volume: 116, Issue:10

    Topics: Animals; Benzylamines; Cognition Disorders; Dyskinesia, Drug-Induced; Levodopa; Locus Coeruleus; Male; Maze Learning; Medial Forebrain Bundle; Memory, Short-Term; Motor Activity; Neurodegenerative Diseases; Oxidopamine; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Substantia Nigra; Time Factors

2009
The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats.
    Neuropharmacology, 2010, Volume: 58, Issue:2

    Topics: Animals; Antiparkinson Agents; Benzopyrans; Disability Evaluation; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Hypokinesia; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D3; Time Factors; Treatment Outcome

2010
Expression of catechol-O-methyltransferase in the brain and periphery of normal and MPTP-treated common marmosets.
    Journal of neural transmission (Vienna, Austria : 1996), 2010, Volume: 117, Issue:1

    Topics: Animals; Antiparkinson Agents; Brain; Callithrix; Catechol O-Methyltransferase; Cell Membrane; Cerebral Cortex; Corpus Striatum; Dyskinesia, Drug-Induced; Female; Levodopa; Liver; Male; MPTP Poisoning; Neuroglia; Neurons; RNA, Messenger

2010
The selective alpha1 adrenoceptor antagonist HEAT reduces L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
    Synapse (New York, N.Y.), 2010, Volume: 64, Issue:2

    Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Antiparkinson Agents; Brain; Cerebrospinal Fluid; Disease Models, Animal; Dyskinesia, Drug-Induced; Idazoxan; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Plasma; Propranolol; Random Allocation; Rats; Rats, Wistar; Receptors, Adrenergic, alpha-1; Tetralones

2010
The dopamine D(2) receptor partial agonist aplindore improves motor deficits in MPTP-treated common marmosets alone and combined with L-dopa.
    Journal of neural transmission (Vienna, Austria : 1996), 2010, Volume: 117, Issue:1

    Topics: Animals; Antiparkinson Agents; Callithrix; Disability Evaluation; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Indoles; Levodopa; Locomotion; Male; MPTP Poisoning; Receptors, Dopamine D2; Time Factors; Treatment Outcome

2010
Continuous rotigotine administration reduces dyskinesia resulting from pulsatile treatment with rotigotine or L-DOPA in MPTP-treated common marmosets.
    Experimental neurology, 2010, Volume: 221, Issue:1

    Topics: Animals; Callithrix; Disability Evaluation; Disease Models, Animal; Dopamine Agents; Drug Administration Schedule; Drug Delivery Systems; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; MPTP Poisoning; Statistics, Nonparametric; Tetrahydronaphthalenes; Thiophenes; Time Factors

2010
Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate.
    Synapse (New York, N.Y.), 2010, Volume: 64, Issue:2

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Cell Membrane; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca mulatta; Neostriatum; Neurons; Parkinsonian Disorders; Receptors, AMPA; Synapses; Synaptic Vesicles

2010
Levodopa-induced dyskinesias detection based on the complexity of involuntary movements.
    Journal of neuroscience methods, 2010, Jan-30, Volume: 186, Issue:1

    Topics: Aged; Antiparkinson Agents; Biological Clocks; Biomechanical Phenomena; Brain; Cognition; Diagnosis, Differential; Dyskinesia, Drug-Induced; Dyskinesias; Entropy; Evoked Potentials; Female; Humans; Levodopa; Male; Middle Aged; Neural Networks, Computer; Neuropsychological Tests; Predictive Value of Tests; Signal Processing, Computer-Assisted; Time Factors

2010
The alpha(2) adrenoceptor antagonist idazoxan alleviates L-DOPA-induced dyskinesia by reduction of striatal dopamine levels: an in vivo microdialysis study in 6-hydroxydopamine-lesioned rats.
    Journal of neurochemistry, 2010, Volume: 112, Issue:2

    Topics: Adrenergic Agents; Adrenergic alpha-Antagonists; Analysis of Variance; Animals; Antiparkinson Agents; Chromatography, High Pressure Liquid; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Idazoxan; Levodopa; Male; Microdialysis; Neurotoxicity Syndromes; Oxidopamine; Rats; Rats, Wistar; Tandem Mass Spectrometry

2010
NMDA antagonist memantine improves levodopa-induced dyskinesias and "on-off" phenomena in Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2010, Mar-15, Volume: 25, Issue:4

    Topics: Aged; Antiparkinson Agents; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Humans; Incidence; Levodopa; Male; Memantine; N-Methylaspartate; Parkinson Disease

2010
BDNF levels are not related with levodopa-induced dyskinesias in MPTP monkeys.
    Movement disorders : official journal of the Movement Disorder Society, 2010, Jan-15, Volume: 25, Issue:1

    Topics: Animals; Antiparkinson Agents; Brain; Brain-Derived Neurotrophic Factor; Disease Models, Animal; Dyskinesia, Drug-Induced; Enzyme-Linked Immunosorbent Assay; Female; Levodopa; Macaca fascicularis; MPTP Poisoning

2010
Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys.
    Progress in neuro-psychopharmacology & biological psychiatry, 2010, Apr-16, Volume: 34, Issue:3

    Topics: Animals; Antiparkinson Agents; Benzoxazoles; Cabergoline; Corpus Striatum; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Ergolines; Female; Glycogen Synthase Kinase 3; Levodopa; Macaca fascicularis; Oncogene Protein v-akt; Parkinsonian Disorders; Phosphorylation; Piperidines; Serine; Signal Transduction; Statistics as Topic

2010
Site-specific action of L-3,4-dihydroxyphenylalanine in the striatum but not globus pallidus and substantia nigra pars reticulata evokes dyskinetic movements in chronic L-3,4-dihydroxyphenylalanine-treated 6-hydroxydopamine-lesioned rats.
    Neuroscience, 2010, Mar-17, Volume: 166, Issue:2

    Topics: Animals; Corpus Striatum; Dyskinesia, Drug-Induced; Globus Pallidus; Levodopa; Male; Microdialysis; Oxidopamine; Rats; Rats, Wistar; Substantia Nigra

2010
Metabotropic glutamate receptor type 5 in levodopa-induced motor complications.
    Neurobiology of aging, 2011, Volume: 32, Issue:7

    Topics: Aged; Aged, 80 and over; Animals; Antiparkinson Agents; Cohort Studies; Corpus Striatum; Dyskinesia, Drug-Induced; Female; Glutamic Acid; Humans; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Up-Regulation

2011
L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.
    Journal of neurochemistry, 2010, Volume: 112, Issue:6

    Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Female; Levodopa; Microdialysis; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Substantia Nigra; Time Factors

2010
Striatal inhibition of PKA prevents levodopa-induced behavioural and molecular changes in the hemiparkinsonian rat.
    Neurobiology of disease, 2010, Volume: 38, Issue:1

    Topics: Animals; Behavior, Animal; Biomarkers; Corpus Striatum; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Disease Models, Animal; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Gait Disorders, Neurologic; Infusion Pumps, Implantable; Levodopa; Locomotion; Male; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Signal Transduction; Thionucleotides

2010
Levodopa-induced dyskinesias in spinocerebellar ataxia type 2.
    Archives of neurology, 2010, Volume: 67, Issue:1

    Topics: Antiparkinson Agents; Atrophy; Depressive Disorder; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Magnetic Resonance Imaging; Middle Aged; Parkinsonian Disorders; Rhombencephalon; Spinocerebellar Ataxias

2010
Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys.
    Neuropharmacology, 2010, Volume: 58, Issue:7

    Topics: Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Levodopa; Locomotion; Macaca fascicularis; Parkinsonian Disorders; Pyridines; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Severity of Illness Index; Thiazoles; Time Factors; Treatment Outcome

2010
MK-801 inhibits L-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonism.
    Neuropharmacology, 2010, Volume: 58, Issue:7

    Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dizocilpine Maleate; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotation; Time Factors

2010
Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson's disease.
    The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 2010, Volume: 37, Issue:1

    Topics: Animals; Antiparkinson Agents; Behavioral Symptoms; Callithrix; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Hyperkinesis; Levodopa; Parkinsonian Disorders; Reproducibility of Results

2010
Nicotinic receptor-mediated reduction in L-DOPA-induced dyskinesias may occur via desensitization.
    The Journal of pharmacology and experimental therapeutics, 2010, Volume: 333, Issue:3

    Topics: Amphetamine; Animals; Antiparkinson Agents; Autoradiography; Behavior, Animal; Bridged Bicyclo Compounds, Heterocyclic; Calcium Channel Blockers; Central Nervous System Stimulants; Cocaine; Conotoxins; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Functional Laterality; Levodopa; Male; Mecamylamine; Neostriatum; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic; Stereotyped Behavior

2010
Intra- and inter-limb coherency during stance in non-dyskinetic and dyskinetic patients with Parkinson's disease.
    Clinical neurology and neurosurgery, 2010, Volume: 112, Issue:5

    Topics: Aged; Antiparkinson Agents; Biomechanical Phenomena; Chorea; Dyskinesia, Drug-Induced; Extremities; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prevalence; Severity of Illness Index

2010
Objective measurement of dyskinesia in Parkinson's disease using a force plate.
    Movement disorders : official journal of the Movement Disorder Society, 2010, Apr-15, Volume: 25, Issue:5

    Topics: Aged; Antiparkinson Agents; Biomechanical Phenomena; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Postural Balance; Posture; Pressure; Psychomotor Performance; Reproducibility of Results; Severity of Illness Index

2010
Dyskinesia and the antiparkinsonian response always temporally coincide: a retrospective study.
    Neurology, 2010, Apr-13, Volume: 74, Issue:15

    Topics: Aged; Antiparkinson Agents; Disease Progression; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Time Factors

2010
Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
    The Journal of pharmacology and experimental therapeutics, 2010, Volume: 333, Issue:3

    Topics: Animals; Antiparkinson Agents; Behavior, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Male; Motor Activity; MPTP Poisoning; Parkinson Disease, Secondary; Piperidines; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Thiazoles

2010
The roles of striatal serotonin and L -amino-acid decarboxylase on L-DOPA-induced Dyskinesia in a Hemiparkinsonian rat model.
    Cellular and molecular neurobiology, 2010, Volume: 30, Issue:6

    Topics: Animals; Aromatic-L-Amino-Acid Decarboxylases; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Movement; Neostriatum; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin; Tyrosine 3-Monooxygenase

2010
Relief of parkinsonism and dyskinesia: one and the same dopaminergic mechanism?
    Neurology, 2010, Apr-13, Volume: 74, Issue:15

    Topics: Antiparkinson Agents; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2010
Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias.
    Neuroscience, 2010, Jun-02, Volume: 167, Issue:4

    Topics: Animals; Antiparkinson Agents; Autoradiography; Benzoxazoles; Brain; Cabergoline; Drug Interactions; Dyskinesia, Drug-Induced; Ergolines; Female; Imidazoles; Levodopa; Ligands; Macaca fascicularis; MPTP Poisoning; Piperidines; Quinazolines; Receptors, AMPA; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate

2010
Age of Parkinson's disease onset as a predictor for the development of dyskinesia.
    Movement disorders : official journal of the Movement Disorder Society, 2010, Jul-15, Volume: 25, Issue:9

    Topics: Adult; Age Factors; Age of Onset; Aged; Aged, 80 and over; Dyskinesia, Drug-Induced; Female; Humans; Kaplan-Meier Estimate; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinsonian Disorders; Predictive Value of Tests; Proportional Hazards Models; Risk Factors

2010
Direct relief of levodopa-induced dyskinesia by stimulation in the area above the subthalamic nucleus in a patient with Parkinson's disease--case report.
    Neurologia medico-chirurgica, 2010, Volume: 50, Issue:3

    Topics: Aged; Antiparkinson Agents; Deep Brain Stimulation; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Parkinson Disease; Subthalamic Nucleus; Treatment Outcome

2010
Pre-treatment with dopamine agonists influence L-dopa mediated rotations without affecting abnormal involuntary movements in the 6-OHDA lesioned rat.
    Behavioural brain research, 2010, Nov-12, Volume: 213, Issue:1

    Topics: Animals; Antiparkinson Agents; Bromocriptine; Corpus Striatum; Dopamine Agonists; Dyskinesia, Drug-Induced; Enkephalins; Female; Indoles; Levodopa; Oxidopamine; Parkinsonian Disorders; Piribedil; Protein Precursors; Rats; Rats, Sprague-Dawley; RNA, Messenger; Rotation; Time Factors

2010
A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys.
    Neurobiology of disease, 2010, Volume: 39, Issue:3

    Topics: Analysis of Variance; Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Imidazoles; Levodopa; Macaca mulatta; Male; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate

2010
Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.
    Journal of neurochemistry, 2010, Volume: 114, Issue:2

    Topics: Adamantane; Animals; Antiparkinson Agents; Behavior, Animal; Benserazide; Brain; Calcium; Callithrix; Dyskinesia, Drug-Induced; Enkephalins; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, AMPA

2010
Effect of cdk5 antagonist on L-dopa-induced dyskinesias in a rat model of Parkinson's disease.
    The International journal of neuroscience, 2010, Volume: 120, Issue:6

    Topics: Animals; Antiparasitic Agents; Corpus Striatum; Cyclin-Dependent Kinase 5; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Protein Kinase Inhibitors; Purines; Random Allocation; Rats; Rats, Sprague-Dawley; Roscovitine; Severity of Illness Index; Treatment Outcome

2010
[Optimal time for beginning treatment with levodopa].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2010, Volume: 110, Issue:4

    Topics: Aged; Antiparkinson Agents; Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors

2010
Locomotor response to L-DOPA in reserpine-treated rats following central inhibition of aromatic L-amino acid decarboxylase: further evidence for non-dopaminergic actions of L-DOPA and its metabolites.
    Neuroscience research, 2010, Volume: 68, Issue:1

    Topics: Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Brain Chemistry; Disease Models, Animal; Dopamine Agents; Drug Combinations; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Hydrazines; Hyperkinesis; Levodopa; Male; Motor Activity; Rats; Rats, Sprague-Dawley; Reserpine; Serotonin Receptor Agonists

2010
5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA.
    Neurobiology of aging, 2012, Volume: 33, Issue:1

    Topics: Animals; Autoradiography; Brain; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; MPTP Poisoning; Receptor, Serotonin, 5-HT2A; Serotonin 5-HT2 Receptor Antagonists; Synaptic Transmission

2012
Long-term effect of unilateral pallidotomy on levodopa-induced dyskinesia.
    Movement disorders : official journal of the Movement Disorder Society, 2010, Jul-30, Volume: 25, Issue:10

    Topics: Antiparkinson Agents; Child; Child, Preschool; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Female; Functional Laterality; Humans; Levodopa; Longitudinal Studies; Male; Pallidotomy; Parkinson Disease; Severity of Illness Index; Statistics, Nonparametric

2010
mTORC1 signaling in Parkinson's disease and L-DOPA-induced dyskinesia: A sensitized matter.
    Cell cycle (Georgetown, Tex.), 2010, Jul-15, Volume: 9, Issue:14

    Topics: Animals; Anti-Bacterial Agents; Antiparkinson Agents; Basal Ganglia; Dyskinesia, Drug-Induced; Levodopa; Mechanistic Target of Rapamycin Complex 1; Mice; Multiprotein Complexes; Parkinson Disease; Proteins; Receptors, Dopamine D1; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases

2010
Movement disorders ii: chorea, dystonia, myoclonus, and tremor.
    Pediatrics in review, 2010, Volume: 31, Issue:7

    Topics: Child; Chorea; Dopamine Agents; Dyskinesia, Drug-Induced; Dyskinesias; Dystonia; Humans; Levodopa; Lupus Erythematosus, Systemic; Myoclonus; Tremor

2010
Presynaptic dopaminergic compartment determines the susceptibility to L-DOPA-induced dyskinesia in rats.
    Proceedings of the National Academy of Sciences of the United States of America, 2010, Jul-20, Volume: 107, Issue:29

    Topics: Animals; Apomorphine; Chromatography, High Pressure Liquid; Dependovirus; Disease Susceptibility; Dopamine; Down-Regulation; Dyskinesia, Drug-Induced; Female; Gene Knockdown Techniques; Levodopa; Microdialysis; Neostriatum; Neurons; Presynaptic Terminals; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Recombination, Genetic; RNA, Small Interfering; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase

2010
Direct and indirect pathways in levodopa-induced dyskinesia: a more complex matter than a network imbalance.
    Movement disorders : official journal of the Movement Disorder Society, 2010, Aug-15, Volume: 25, Issue:11

    Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Neural Pathways; Parkinson Disease

2010
Aberrant striatal plasticity is specifically associated with dyskinesia following levodopa treatment.
    Movement disorders : official journal of the Movement Disorder Society, 2010, Aug-15, Volume: 25, Issue:11

    Topics: Action Potentials; Animals; Antiparkinson Agents; Behavior, Animal; Cholera Toxin; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Fluorescent Dyes; Levodopa; Long-Term Potentiation; Neuronal Plasticity; Neurons; Oxidopamine; Parkinson Disease; Rats; Substantia Nigra; Tyrosine 3-Monooxygenase

2010
Neuronal intranuclear inclusion disease: two cases of dopa-responsive juvenile parkinsonism with drug-induced dyskinesia.
    Movement disorders : official journal of the Movement Disorder Society, 2010, Jul-15, Volume: 25, Issue:9

    Topics: Adolescent; Antiparkinson Agents; Child; Dyskinesia, Drug-Induced; Female; Humans; Intranuclear Inclusion Bodies; Levodopa; Male; Neurons; Parkinsonian Disorders; Peptides; Taiwan; Ubiquitin

2010
Levodopa/benserazide-loaded biodegradable microspheres reduce dyskinesia in rats.
    Neuroreport, 2010, Aug-23, Volume: 21, Issue:12

    Topics: Animals; Antiparkinson Agents; Benserazide; Biocompatible Materials; Disease Models, Animal; Disease Progression; Drug Combinations; Drug Synergism; Dyskinesia, Drug-Induced; Female; Lameness, Animal; Levodopa; Microspheres; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Treatment Outcome

2010
Deuterium substitutions in the L-DOPA molecule improve its anti-akinetic potency without increasing dyskinesias.
    Experimental neurology, 2010, Volume: 225, Issue:2

    Topics: Analysis of Variance; Animals; Autoradiography; Brain; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Immunohistochemistry; Levodopa; Motor Activity; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Rotarod Performance Test; Statistics, Nonparametric; Treatment Outcome; Tyrosine 3-Monooxygenase

2010
Juvenile levodopa-responsive Parkinsonism with early orobuccolingual dyskinesias and cognitive impairment.
    Movement disorders : official journal of the Movement Disorder Society, 2010, Sep-15, Volume: 25, Issue:12

    Topics: Adolescent; Brain; Cognition Disorders; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Female; Humans; Intranuclear Inclusion Bodies; Levodopa; Magnetic Resonance Imaging; Neurodegenerative Diseases; Parkinsonian Disorders; Young Adult

2010
Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors.
    Proceedings of the National Academy of Sciences of the United States of America, 2010, Aug-17, Volume: 107, Issue:33

    Topics: Animals; Catalepsy; Cocaine; Corpus Striatum; Dopamine Agents; Dopamine and cAMP-Regulated Phosphoprotein 32; Dopamine Uptake Inhibitors; Dyskinesia, Drug-Induced; Female; Fluorescent Antibody Technique; Green Fluorescent Proteins; Haloperidol; Immunohistochemistry; Levodopa; Long-Term Potentiation; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Motor Activity; Neuronal Plasticity; Neurons; Synaptic Potentials

2010
Maladaptive striatal plasticity in L-DOPA-induced dyskinesia.
    Progress in brain research, 2010, Volume: 183

    Topics: Animals; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuronal Plasticity; Parkinson Disease; Rats; Signal Transduction

2010
Morphological changes in serotoninergic neurites in the striatum and globus pallidus in levodopa primed MPTP treated common marmosets with dyskinesia.
    Neurobiology of disease, 2010, Volume: 40, Issue:3

    Topics: Animals; Antiparkinson Agents; Callithrix; Corpus Striatum; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Immunohistochemistry; Levodopa; Male; Neurites; Parkinsonian Disorders; Serotonin; Tryptophan Hydroxylase

2010
Striatal dopaminergic fiber recovery after acute L-DOPA treatment in 6-hydroxydopamine (6-OHDA) lesioned rats.
    Cell biochemistry and biophysics, 2011, Volume: 59, Issue:1

    Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Female; Levodopa; Medial Forebrain Bundle; Nerve Fibers; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Substantia Nigra

2011
L-DOPA-induced dyskinesia in hemiparkinsonian rats is associated with up-regulation of adenylyl cyclase type V/VI and increased GABA release in the substantia nigra reticulata.
    Neurobiology of disease, 2011, Volume: 41, Issue:1

    Topics: Adenylyl Cyclases; Animals; Dyskinesia, Drug-Induced; Enzyme Inhibitors; gamma-Aminobutyric Acid; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Severity of Illness Index; Substantia Nigra; Up-Regulation

2011
Mitochondrial abnormalities in the putamen in Parkinson's disease dyskinesia.
    Acta neuropathologica, 2010, Volume: 120, Issue:5

    Topics: Animals; Antiparkinson Agents; Chromatography, High Pressure Liquid; DNA, Mitochondrial; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Mitochondria; Neurons; Oligonucleotide Array Sequence Analysis; Parkinson Disease; Putamen; Rats; Reverse Transcriptase Polymerase Chain Reaction; RNA; RNA, Mitochondrial

2010
The α₂ adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates.
    Movement disorders : official journal of the Movement Disorder Society, 2010, Oct-15, Volume: 25, Issue:13

    Topics: Adrenergic alpha-2 Receptor Antagonists; Analysis of Variance; Animals; Disability Evaluation; Disease Models, Animal; Dopamine Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Imidazoles; Indans; Levodopa; Macaca fascicularis; Male; Motor Activity; Parkinsonian Disorders; Time Factors

2010
Deletion of adenosine A₁ or A(₂A) receptors reduces L-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease.
    Brain research, 2011, Jan-07, Volume: 1367

    Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Caffeine; Corpus Striatum; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Gene Expression Regulation; Levodopa; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidopamine; Parkinson Disease; Protein Precursors; Purinergic P1 Receptor Antagonists; Receptor, Adenosine A1; Receptor, Adenosine A2A; RNA, Messenger; Statistics, Nonparametric; Time Factors

2011
Effects of piclozotan (SUN N4057), a partial serotonin 1A receptor agonist, on motor complications induced by repeated administration of levodopa in parkinsonian rats.
    European journal of pharmacology, 2010, Dec-15, Volume: 649, Issue:1-3

    Topics: Animals; Antiparkinson Agents; Behavior, Animal; Benserazide; Corpus Striatum; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Drug Partial Agonism; Dyskinesia, Drug-Induced; Hyperkinesis; Levodopa; Male; Microdialysis; Motor Activity; Oxazepines; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin 5-HT1 Receptor Agonists

2010
Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia.
    Annals of neurology, 2010, Volume: 68, Issue:5

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Animals; Brain-Derived Neurotrophic Factor; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Macaca fascicularis; Male; Neuronal Plasticity; Oxidopamine; Parkinson Disease; Presynaptic Terminals; Radioligand Assay; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Plasma Membrane Transport Proteins

2010
The effects of cannabinoid drugs on abnormal involuntary movements in dyskinetic and non-dyskinetic 6-hydroxydopamine lesioned rats.
    Brain research, 2010, Dec-02, Volume: 1363

    Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dronabinol; Dyskinesia, Drug-Induced; Levodopa; Male; Parkinsonian Disorders; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant

2010
Differential genetic susceptibility in diphasic and peak-dose dyskinesias in Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2011, Volume: 26, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Cohort Studies; Dyskinesia, Drug-Induced; Female; Genetic Predisposition to Disease; Genome-Wide Association Study; Genotype; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polymorphism, Genetic; Probability; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate; Serotonin Plasma Membrane Transport Proteins; Young Adult

2011
Fatty acid amide hydrolase (FAAH) inhibition reduces L-3,4-dihydroxyphenylalanine-induced hyperactivity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned non-human primate model of Parkinson's disease.
    The Journal of pharmacology and experimental therapeutics, 2011, Volume: 336, Issue:2

    Topics: Amides; Amidohydrolases; Animals; Benzamides; Callithrix; Carbamates; Disease Models, Animal; Dyskinesia, Drug-Induced; Endocannabinoids; Enzyme Inhibitors; Ethanolamines; Female; Levodopa; Motor Activity; MPTP Poisoning; Oleic Acids; Palmitic Acids; Psychoses, Substance-Induced

2011
L-3,4-dihydroxyphenylalanine-induced sprouting of serotonin axon terminals: A useful biomarker for dyskinesias?
    Annals of neurology, 2010, Volume: 68, Issue:5

    Topics: Biomarkers, Pharmacological; Dyskinesia, Drug-Induced; Levodopa; Models, Neurological; Presynaptic Terminals; Serotonin

2010
Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaque.
    Neurobiology of aging, 2012, Volume: 33, Issue:1

    Topics: Animals; Autoradiography; Caudate Nucleus; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Motor Cortex; Parkinsonian Disorders; Receptor, Serotonin, 5-HT1A; Serotonin 5-HT1 Receptor Agonists

2012
Involvement of the subthalamic nucleus in impulse control disorders associated with Parkinson's disease.
    Brain : a journal of neurology, 2011, Volume: 134, Issue:Pt 1

    Topics: Adult; Aged; Analysis of Variance; Antiparkinson Agents; Brain Waves; Deep Brain Stimulation; Disruptive, Impulse Control, and Conduct Disorders; Dyskinesia, Drug-Induced; Electrodes, Implanted; Electrophysiology; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Subthalamic Nucleus

2011
Dyskinesias do not develop after chronic intermittent levodopa therapy in clinically hemiparkinsonian rhesus monkeys.
    Parkinsonism & related disorders, 2011, Volume: 17, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Carotid Arteries; Conditioning, Operant; Corpus Striatum; Dihydroxyphenylalanine; Dopamine Agents; Dyskinesia, Drug-Induced; Dystonia; Female; Injections, Intravenous; Levodopa; Macaca mulatta; MPTP Poisoning; Parkinson Disease, Secondary; Psychomotor Performance; Radionuclide Imaging; Radiopharmaceuticals; Substantia Nigra

2011
An improved model to investigate the efficacy of antidyskinetic agents in hemiparkinsonian rats.
    Fundamental & clinical pharmacology, 2011, Volume: 25, Issue:5

    Topics: Adenosine A2 Receptor Antagonists; Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Benserazide; Biological Assay; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Drug Administration Schedule; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Placebos; Purines; Random Allocation; Rats; Reproducibility of Results; Rotation; Sample Size; Single-Blind Method; Sympatholytics

2011
Levodopa-induced dyskinesia is associated with increased thyrotropin releasing hormone in the dorsal striatum of hemi-parkinsonian rats.
    PloS one, 2010, Nov-10, Volume: 5, Issue:11

    Topics: Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Immunohistochemistry; Levodopa; Male; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; Thyrotropin-Releasing Hormone

2010
Lack of tolerance for the anti-dyskinetic effects of 7-nitroindazole, a neuronal nitric oxide synthase inhibitor, in rats.
    Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2010, Volume: 43, Issue:11

    Topics: Animals; Anti-Dyskinesia Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Indazoles; Levodopa; Male; Nitric Oxide Synthase; Rats; Rats, Wistar; Substantia Nigra

2010
Automated Levodopa-induced dyskinesia assessment.
    Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference, 2010, Volume: 2010

    Topics: Acceleration; Algorithms; Antiparkinson Agents; Automation; Biosensing Techniques; Dyskinesia, Drug-Induced; Equipment Design; Humans; Levodopa; Models, Statistical; Monitoring, Ambulatory; Parkinson Disease; Programming Languages; Reproducibility of Results; Signal Processing, Computer-Assisted

2010
The role of apolipoprotein E polymorphisms in levodopa-induced dyskinesia.
    Acta neurologica Scandinavica, 2011, Volume: 123, Issue:2

    Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Apolipoproteins E; Dyskinesia, Drug-Induced; Female; Gene Frequency; Genotype; Humans; Kaplan-Meier Estimate; Levodopa; Male; Middle Aged; Parkinson Disease; Polymorphism, Genetic; Retrospective Studies

2011
Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia.
    Proceedings of the National Academy of Sciences of the United States of America, 2010, Dec-14, Volume: 107, Issue:50

    Topics: Animals; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Extracellular Signal-Regulated MAP Kinases; Humans; Levodopa; Mice; Mice, Knockout; Neurons; ras-GRF1; Signal Transduction

2010
BN82451 attenuates L-dopa-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
    Neuropharmacology, 2011, Volume: 60, Issue:4

    Topics: Animals; Area Under Curve; Behavior, Animal; Chromatography, High Pressure Liquid; Corpus Striatum; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Gene Expression; Levodopa; Male; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thiazoles

2011
Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on L: -DOPA-induced dyskinesia.
    Journal of neural transmission (Vienna, Austria : 1996), 2011, Volume: 118, Issue:12

    Topics: Adrenergic Agents; Allosteric Regulation; Analysis of Variance; Animals; Brain; Calcium; Cognition Disorders; Conditioning, Psychological; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Fear; In Vitro Techniques; Levodopa; Male; Maze Learning; Microdialysis; Monoamine Oxidase Inhibitors; Motor Activity; Oxidopamine; Pain Measurement; Parkinson Disease, Secondary; Picolinic Acids; Psychomotor Performance; Quinolones; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Rotarod Performance Test; Tandem Mass Spectrometry; Time Factors

2011
Positive association between striatal serotonin level and abnormal involuntary movements in chronic L-DOPA-treated hemiparkinsonian rats.
    Brain research bulletin, 2011, Feb-01, Volume: 84, Issue:2

    Topics: Animals; Benserazide; Corpus Striatum; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Medial Forebrain Bundle; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin

2011
Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia.
    Brain : a journal of neurology, 2011, Volume: 134, Issue:Pt 2

    Topics: Animals; Corpus Striatum; Cyclic GMP; Dyskinesia, Drug-Induced; Levodopa; Long-Term Synaptic Depression; Male; Microinjections; Neurons; Oxidopamine; Parkinsonian Disorders; Phosphodiesterase Inhibitors; Piperazines; Purinones; Pyrimidinones; Rats; Rats, Wistar

2011
Transcriptional alterations under continuous or pulsatile dopaminergic treatment in dyskinetic rats.
    Journal of neural transmission (Vienna, Austria : 1996), 2011, Volume: 118, Issue:12

    Topics: Analysis of Variance; Animals; Brain; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Functional Laterality; Gene Expression Profiling; Gene Expression Regulation; Levodopa; Male; Nerve Tissue Proteins; Neurotrophin 3; Oligonucleotide Array Sequence Analysis; Oxidopamine; Parkinsonian Disorders; Pulsatile Flow; Rats; Rats, Sprague-Dawley; RNA, Messenger

2011
CSC counteracts l-DOPA-induced overactivity of the corticostriatal synaptic ultrastructure and function in 6-OHDA-lesioned rats.
    Brain research, 2011, Feb-28, Volume: 1376

    Topics: Adenosine A2 Receptor Antagonists; Animals; Blotting, Western; Brain; Caffeine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Levodopa; Male; Microscopy, Electron, Transmission; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Synapses

2011
Context-driven changes in L-DOPA-induced behaviours in the 6-OHDA lesioned rat.
    Neurobiology of disease, 2011, Volume: 42, Issue:1

    Topics: Animals; Conditioning, Psychological; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley

2011
Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats.
    Neuropharmacology, 2011, Volume: 60, Issue:6

    Topics: Animals; Antiparkinson Agents; Azetidines; Benzazepines; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Levodopa; Male; Nicotinic Agonists; Oxidopamine; Parkinson Disease; Quinoxalines; Rats; Rats, Sprague-Dawley; Varenicline

2011
Role of dopamine D3 and serotonin 5-HT 1A receptors in L: -DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Journal of neural transmission (Vienna, Austria : 1996), 2011, Volume: 118, Issue:12

    Topics: Analysis of Variance; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Dyskinesia, Drug-Induced; Levodopa; Male; Organic Chemicals; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D3; Serotonin 5-HT1 Receptor Agonists; Time Factors

2011
Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
    Neurobiology of disease, 2011, Volume: 42, Issue:3

    Topics: Analysis of Variance; Animals; Behavior, Animal; Cell Count; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Immunohistochemistry; Levodopa; Mice; Motor Activity; Neural Pathways; Neurons; Oxidopamine; Parkinson Disease; Substantia Nigra

2011
The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys.
    Parkinsonism & related disorders, 2011, Volume: 17, Issue:4

    Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate

2011
Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats.
    Experimental neurology, 2011, Volume: 229, Issue:2

    Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Benserazide; Benzazepines; Chromatography, High Pressure Liquid; Corpus Striatum; Dopamine Agonists; Dyskinesia, Drug-Induced; Glutamic Acid; Levodopa; Male; Microdialysis; Neurons; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin Receptor Agonists

2011
Generation of a model of L-DOPA-induced dyskinesia in two different mouse strains.
    Journal of neuroscience methods, 2011, Apr-30, Volume: 197, Issue:2

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Efferent Pathways; Levodopa; Mice; Mice, Inbred C57BL; Mice, Transgenic

2011
Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias.
    Brain : a journal of neurology, 2011, Volume: 134, Issue:Pt 4

    Topics: Aged; Analysis of Variance; Brain; Brain Mapping; Dyskinesia, Drug-Induced; Female; Humans; Image Processing, Computer-Assisted; Levodopa; Male; Middle Aged; Parkinson Disease; Radionuclide Imaging; Receptors, N-Methyl-D-Aspartate

2011
Increased prefrontal volume in PD with levodopa-induced dyskinesias: a voxel-based morphometry study.
    Movement disorders : official journal of the Movement Disorder Society, 2011, Volume: 26, Issue:5

    Topics: Aged; Antiparkinson Agents; Brain Mapping; Dyskinesia, Drug-Induced; Female; Humans; Imaging, Three-Dimensional; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Prefrontal Cortex; Statistics, Nonparametric

2011
Stalevo reduction in dyskinesia evaluation in Parkinson's disease results were expected from a pharmacokinetic viewpoint.
    Annals of neurology, 2011, Volume: 69, Issue:2

    Topics: Antiparkinson Agents; Catechols; Dyskinesia, Drug-Induced; Humans; Levodopa; Nitriles; Parkinson Disease

2011
Behavioral and cellular modulation of L-DOPA-induced dyskinesia by beta-adrenoceptor blockade in the 6-hydroxydopamine-lesioned rat.
    The Journal of pharmacology and experimental therapeutics, 2011, Volume: 337, Issue:3

    Topics: Adrenergic beta-Antagonists; Animals; Antiparkinson Agents; Benzoxazines; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Medial Forebrain Bundle; Molecular Targeted Therapy; Motor Activity; Oxazines; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, beta; Time Factors

2011
Three year follow up of levodopa plus carbidopa treatment in a prevalent cohort of patients with Parkinson's disease in Hai, Tanzania.
    Journal of neurology, 2011, Volume: 258, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Cohort Studies; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prevalence; Retrospective Studies; Tanzania

2011
The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2011, Volume: 26, Issue:7

    Topics: Animals; Antiparkinson Agents; CHO Cells; Cricetinae; Cricetulus; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Macaca fascicularis; Male; Naltrexone; Narcotic Antagonists; Parkinsonian Disorders; Receptors, Opioid, mu

2011
The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl) pyridine decreases striatal VGlut2 expression in association with an attenuation of L-DOPA-induced dyskinesias.
    Synapse (New York, N.Y.), 2011, Volume: 65, Issue:10

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Down-Regulation; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Levodopa; Male; Parkinsonian Disorders; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Vesicular Glutamate Transport Protein 2

2011
Rhabdomyolysis induced by severe levodopa induced dyskinesia in a patient with Parkinson's disease.
    Journal of neurology, 2011, Volume: 258, Issue:10

    Topics: Aged; Anesthetics, Intravenous; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Midazolam; Parkinson Disease; Rhabdomyolysis

2011
Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias.
    The European journal of neuroscience, 2011, Volume: 33, Issue:10

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Biogenic Amines; Brain; Cabergoline; Dopamine Agents; Dyskinesia, Drug-Induced; Ergolines; Female; Humans; Ketanserin; Levodopa; Macaca; Parkinsonian Disorders; Receptor, Serotonin, 5-HT2A

2011
Pallidothalamic-projecting neurons in Macaca fascicularis co-express GABAergic and glutamatergic markers as seen in control, MPTP-treated and dyskinetic monkeys.
    Brain structure & function, 2011, Volume: 216, Issue:4

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Colorimetry; DNA Primers; Dopamine; Dyskinesia, Drug-Induced; Fluorescent Antibody Technique; GABAergic Neurons; Globus Pallidus; Glutamate Decarboxylase; Immunohistochemistry; In Situ Hybridization; In Situ Hybridization, Fluorescence; Levodopa; Macaca fascicularis; Male; Neurons, Efferent; Parkinsonian Disorders; Polymerase Chain Reaction; Statistics, Nonparametric; Thalamus; Vesicular Glutamate Transport Protein 1

2011
Gender effect on time to levodopa-induced dyskinesias.
    Journal of neurology, 2011, Volume: 258, Issue:11

    Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Proportional Hazards Models; Risk Factors; Sex Factors

2011
Dopamine release from serotonergic nerve fibers is reduced in L-DOPA-induced dyskinesia.
    Journal of neurochemistry, 2011, Volume: 118, Issue:1

    Topics: Adrenergic Agents; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopa Decarboxylase; Dopamine; Dyskinesia, Drug-Induced; Electrochemistry; Female; Functional Laterality; Levodopa; Oxidopamine; Potassium Chloride; Presynaptic Terminals; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Plasma Membrane Transport Proteins; Severity of Illness Index; Stereotyped Behavior; Tyrosine 3-Monooxygenase

2011
Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2011, May-11, Volume: 31, Issue:19

    Topics: Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Brain; Callithrix; Dyskinesia, Drug-Induced; Female; Levodopa; Motor Activity; MPTP Poisoning; N-Methyl-3,4-methylenedioxyamphetamine; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Stereoisomerism

2011
Changes in the mRNA levels of α2A and α2C adrenergic receptors in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
    Journal of molecular neuroscience : MN, 2012, Volume: 46, Issue:1

    Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Basal Ganglia; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Locus Coeruleus; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; RNA, Messenger

2012
Identification of N-propylnoraporphin-11-yl 5-(1,2-dithiolan-3-yl)pentanoate as a new anti-Parkinson's agent possessing a dopamine D2 and serotonin 5-HT1A dual-agonist profile.
    Journal of medicinal chemistry, 2011, Jul-14, Volume: 54, Issue:13

    Topics: Animals; Antiparkinson Agents; Aporphines; Binding, Competitive; CHO Cells; Corpus Striatum; Cricetinae; Cricetulus; Dyskinesia, Drug-Induced; HEK293 Cells; Humans; Levodopa; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-fos; Radioligand Assay; Rats; Receptors, Adrenergic; Receptors, Dopamine D2; Serotonin 5-HT1 Receptor Agonists; Stereoisomerism; Structure-Activity Relationship; Thioctic Acid

2011
Impact of dopamine to serotonin cell ratio in transplants on behavioral recovery and L-DOPA-induced dyskinesia.
    Neurobiology of disease, 2011, Volume: 43, Issue:3

    Topics: Animals; Antiparkinson Agents; Behavior, Animal; Cell Count; Combined Modality Therapy; Dopamine; Dyskinesia, Drug-Induced; Female; Fetal Tissue Transplantation; Levodopa; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Recovery of Function; Serotonin; Sympatholytics

2011
Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease.
    Neurology, 2011, May-24, Volume: 76, Issue:21

    Topics: Adenosine; Adenosine A2 Receptor Antagonists; Aged; Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Pyrazoles; Pyrimidines; Receptor, Adenosine A2A

2011
Role of the primary motor cortex in L-Dopa-induced dyskinesia and its modulation by 5-HT1A receptor stimulation.
    Neuropharmacology, 2011, Volume: 61, Issue:4

    Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Cortex; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin 5-HT1 Receptor Agonists

2011
Nicotine reduces L-DOPA-induced dyskinesias by acting at beta2* nicotinic receptors.
    The Journal of pharmacology and experimental therapeutics, 2011, Volume: 338, Issue:3

    Topics: Animals; Antiparkinson Agents; Autoradiography; Bridged Bicyclo Compounds, Heterocyclic; Corpus Striatum; Cotinine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Functional Laterality; Levodopa; Mice; Mice, Inbred C57BL; Mice, Knockout; Nicotine; Nicotinic Agonists; Oxidopamine; Pyridines; Receptors, Nicotinic; Substantia Nigra; Sympatholytics

2011
A case of parkinsonism and dopa-induced severe dyskinesia associated with novel mutation in the GTP cyclohydrolase I gene.
    Parkinsonism & related disorders, 2011, Volume: 17, Issue:10

    Topics: Adult; Aged; Base Sequence; Dopamine Agonists; Dyskinesia, Drug-Induced; Dystonic Disorders; Female; GTP Cyclohydrolase; Humans; Levodopa; Male; Mutation; Parkinsonian Disorders; Pedigree

2011
L-DOPA-induced dyskinesia is associated with regional increase of striatal dynorphin peptides as elucidated by imaging mass spectrometry.
    Molecular & cellular proteomics : MCP, 2011, Volume: 10, Issue:10

    Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Female; Humans; Levodopa; Mice; Neostriatum; Parkinson Disease; Protein Precursors; Rats; Rats, Sprague-Dawley; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

2011
Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels.
    Journal of neurochemistry, 2011, Volume: 118, Issue:6

    Topics: Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Data Interpretation, Statistical; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Globus Pallidus; Glutamates; Hydroxydopamines; Levodopa; Male; Mice; Microdialysis; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Substantia Nigra; Sympatholytics; Tyrosine 3-Monooxygenase

2011
Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia.
    Brain : a journal of neurology, 2011, Volume: 134, Issue:Pt 8

    Topics: Aged; Aged, 80 and over; Analysis of Variance; Animals; Antigens, CD; Antigens, Surface; Antiparkinson Agents; Astrocytes; Behavior, Animal; Benserazide; Blood Vessels; Blood-Brain Barrier; Brain; Bromodeoxyuridine; Cell Count; Cells, Cultured; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Embryo, Mammalian; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Female; Humans; Laminin; Levodopa; Male; Neovascularization, Pathologic; Nerve Tissue Proteins; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; RNA, Messenger; Time Factors; Up-Regulation; Vascular Endothelial Growth Factor A

2011
Targeting NR2A-containing NMDA receptors reduces L-DOPA-induced dyskinesias.
    Neurobiology of aging, 2012, Volume: 33, Issue:9

    Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Disease Models, Animal; Disks Large Homolog 4 Protein; Dyskinesia, Drug-Induced; Gene Expression Regulation; Intracellular Signaling Peptides and Proteins; Levodopa; Male; Medial Forebrain Bundle; Membrane Proteins; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Subcellular Fractions; Time Factors

2012
Resting tremor in Parkinson disease: a negative predictor of levodopa-induced dyskinesia.
    Archives of neurology, 2011, Volume: 68, Issue:8

    Topics: Aged; Antiparkinson Agents; Cohort Studies; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Predictive Value of Tests; Risk Assessment; Risk Factors; Tremor

2011
An autoradiographic study on the pathogenesis of levodopa-induced dyskinesia: regulation of dopamine transporter by levodopa in a rat model of Parkinson's disease.
    Neuro-degenerative diseases, 2012, Volume: 9, Issue:1

    Topics: Animals; Antiparkinson Agents; Autoradiography; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Levodopa; Male; Parkinson Disease; Rats; Rats, Sprague-Dawley

2012
Unilateral GPi-DBS as a treatment for levodopa-induced respiratory dyskinesia in Parkinson disease.
    The neurologist, 2011, Volume: 17, Issue:5

    Topics: Aged; Antiparkinson Agents; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Female; Functional Laterality; Globus Pallidus; Humans; Levodopa; Parkinson Disease; Respiration Disorders

2011
[Comparative study of amantadine and hemantane effects on development of levodopa-induced dyskinesia in rat model of parkinsonian syndrome].
    Eksperimental'naia i klinicheskaia farmakologiia, 2011, Volume: 74, Issue:7

    Topics: Adamantane; Amantadine; Animals; Behavior, Animal; Benserazide; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Substantia Nigra

2011
Experimental Models of l-DOPA-Induced Dyskinesia.
    International review of neurobiology, 2011, Volume: 98

    Topics: Animals; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Parkinsonian Disorders

2011
Metabolic changes induced by theta burst stimulation of the cerebellum in dyskinetic Parkinson's disease patients.
    Parkinsonism & related disorders, 2012, Volume: 18, Issue:1

    Topics: Aged; Cerebellum; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Nerve Net; Parkinson Disease; Positron-Emission Tomography; Theta Rhythm; Transcranial Magnetic Stimulation

2012
Higher free D-aspartate and N-methyl-D-aspartate levels prevent striatal depotentiation and anticipate L-DOPA-induced dyskinesia.
    Experimental neurology, 2011, Volume: 232, Issue:2

    Topics: Action Potentials; Animals; Antiparkinson Agents; Corpus Striatum; D-Aspartate Oxidase; D-Aspartic Acid; Dyskinesia, Drug-Induced; Extracellular Signal-Regulated MAP Kinases; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; N-Methylaspartate; Neuronal Plasticity; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Sympatholytics; Synapses

2011
Extent of pre-operative L-DOPA-induced dyskinesia predicts the severity of graft-induced dyskinesia after fetal dopamine cell transplantation.
    Experimental neurology, 2011, Volume: 232, Issue:2

    Topics: Amphetamines; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dopamine Agonists; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Dyskinesias; Female; Fetal Tissue Transplantation; Levodopa; Oxidopamine; Postoperative Complications; Predictive Value of Tests; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Substantia Nigra; Sympatholytics

2011
Unilateral nigrostriatal 6-hydroxydopamine lesions in mice II: predicting l-DOPA-induced dyskinesia.
    Behavioural brain research, 2012, Jan-01, Volume: 226, Issue:1

    Topics: Adrenergic Agents; Animals; Apomorphine; Corpus Striatum; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Mice; Motor Activity; Neurons; Oxidopamine; Rotarod Performance Test; Substantia Nigra

2012
MPTP-induced models of Parkinson's disease in mice and non-human primates.
    Current protocols in pharmacology, 2005, Volume: Chapter 5

    Topics: Animals; Callithrix; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Mice, Inbred C57BL; MPTP Poisoning

2005
Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2011, Volume: 26, Issue:13

    Topics: Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Disease Models, Animal; Dopamine Agonists; Drug Synergism; Dyskinesia, Drug-Induced; Fructose; Levodopa; Male; MPTP Poisoning; Neuroprotective Agents; Parkinson Disease; Rats; Rats, Sprague-Dawley; Topiramate

2011
The involvement of RGS9 in l-3,4-dihydroxyphenylalanine-induced dyskinesias in unilateral 6-OHDA lesion rat model.
    Brain research bulletin, 2011, Nov-25, Volume: 86, Issue:5-6

    Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Benserazide; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; RGS Proteins

2011
Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by α- and β-adrenergic receptor antagonists in hemiparkinsonian rats.
    Pharmacology, biochemistry, and behavior, 2012, Volume: 100, Issue:3

    Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adrenergic Neurons; Animals; Behavior, Animal; Corpus Striatum; Desipramine; Disease Models, Animal; Dyskinesia, Drug-Induced; Hippocampus; Idazoxan; Levodopa; Male; Molecular Targeted Therapy; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Propranolol; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Sympathectomy, Chemical

2012
In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels.
    Neurobiology of disease, 2012, Volume: 45, Issue:1

    Topics: Animals; Benzazepines; Corpus Striatum; Dopamine Antagonists; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Male; Microdialysis; Raclopride; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Substantia Nigra

2012
Striatal inhibition of calpains prevents levodopa-induced neurochemical changes and abnormal involuntary movements in the hemiparkinsonian rat model.
    Neurobiology of disease, 2012, Volume: 45, Issue:1

    Topics: Animals; Antiparkinson Agents; Behavior, Animal; Calpain; Corpus Striatum; Cyclin-Dependent Kinase 5; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley

2012
Lees' syndrome: a case series.
    Arquivos de neuro-psiquiatria, 2011, Volume: 69, Issue:5

    Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Dopamine; Dopamine Agents; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Syndrome

2011
Mechanisms underlying and medical management of L-Dopa-associated motor complications.
    Journal of neural transmission (Vienna, Austria : 1996), 2011, Volume: 118, Issue:12

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa

2011
Prefrontal alterations in Parkinson's disease with levodopa-induced dyskinesia during fMRI motor task.
    Movement disorders : official journal of the Movement Disorder Society, 2012, Volume: 27, Issue:3

    Topics: Adult; Antiparkinson Agents; Brain Mapping; Dyskinesia, Drug-Induced; Female; Functional Laterality; Humans; Image Processing, Computer-Assisted; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Motor Activity; Oxygen; Parkinson Disease; Prefrontal Cortex; Regression Analysis; Severity of Illness Index

2012
Serotonergic modulation of receptor occupancy in rats treated with L-DOPA after unilateral 6-OHDA lesioning.
    Journal of neurochemistry, 2012, Volume: 120, Issue:5

    Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Antiparkinson Agents; Autoradiography; Carbon Isotopes; Cocaine; Disease Models, Animal; Dopamine; Dopamine Uptake Inhibitors; Dyskinesia, Drug-Induced; Female; Functional Laterality; Levodopa; Microdialysis; Motor Activity; Oxidopamine; Parkinson Disease; Positron-Emission Tomography; Protein Binding; Raclopride; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Receptors, Serotonin; Serotonergic Neurons; Serotonin Receptor Agonists

2012
Rhes, a striatal-enriched small G protein, mediates mTOR signaling and L-DOPA-induced dyskinesia.
    Nature neuroscience, 2011, Dec-18, Volume: 15, Issue:2

    Topics: Adaptor Proteins, Signal Transducing; Adrenergic Agents; Animals; Antiparkinson Agents; Cell Line, Transformed; Corpus Striatum; Culture Media, Serum-Free; Disability Evaluation; Disease Models, Animal; Dyskinesia, Drug-Induced; Functional Laterality; Gene Expression Regulation; GTP-Binding Proteins; Humans; Immunosuppressive Agents; Levodopa; Mice; Mice, Knockout; Movement; Mutation; Neurons; Neurotoxicity Syndromes; Oxidopamine; Phosphorylation; Protein Binding; Radioligand Assay; Ribosomal Protein S6 Kinases; Signal Transduction; Sirolimus; Time Factors; TOR Serine-Threonine Kinases; Transfection

2011
The cannabinoid agonist WIN55212-2 decreases L-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats.
    Neuroscience research, 2012, Volume: 72, Issue:3

    Topics: Animals; Behavior, Animal; Benzoxazines; Cannabinoids; Cyclic AMP-Dependent Protein Kinases; Dopamine Agents; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Levodopa; Male; Morpholines; Motor Activity; Naphthalenes; Oxidopamine; Parkinson Disease, Secondary; Phosphorylation; Rats; Rats, Wistar

2012
L-DOPA impairs proteasome activity in parkinsonism through D1 dopamine receptor.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2012, Jan-11, Volume: 32, Issue:2

    Topics: Animals; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca mulatta; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Organ Culture Techniques; Parkinsonian Disorders; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1

2012
Dyskinetic patients show rebound worsening of affect after an acute L-dopa challenge.
    Parkinsonism & related disorders, 2012, Volume: 18, Issue:5

    Topics: Aged; Analysis of Variance; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Mental Status Schedule; Middle Aged; Mood Disorders; Parkinson Disease; Regression Analysis; Severity of Illness Index; Time Factors

2012
Investigation of the antidyskinetic site of action of metabotropic and ionotropic glutamate receptor antagonists. Intracerebral infusions in 6-hydroxydopamine-lesioned rats with levodopa-induced dyskinesia.
    European journal of pharmacology, 2012, May-15, Volume: 683, Issue:1-3

    Topics: Animals; Anti-Dyskinesia Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Infusions, Intraventricular; Levodopa; Male; Oxidopamine; Phenols; Piperidines; Putamen; Quinoxalines; Rats; Rats, Wistar; Receptor, Metabotropic Glutamate 5; Receptors, AMPA; Receptors, Metabotropic Glutamate; Receptors, N-Methyl-D-Aspartate; Substantia Nigra; Subthalamic Nucleus; Thiazoles

2012
Is executive control used to compensate for involuntary movements in levodopa-induced dyskinesia?
    Movement disorders : official journal of the Movement Disorder Society, 2012, Volume: 27, Issue:3

    Topics: Antiparkinson Agents; Brain Mapping; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Motor Activity; Parkinson Disease; Prefrontal Cortex

2012
Comparing movement patterns associated with Huntington's chorea and Parkinson's dyskinesia.
    Experimental brain research, 2012, Volume: 218, Issue:4

    Topics: Aged; Analysis of Variance; Antiparkinson Agents; Case-Control Studies; Dyskinesia, Drug-Induced; Electromyography; Entropy; Evoked Potentials, Motor; Female; Forearm; Functional Laterality; Human Body; Humans; Huntington Disease; Levodopa; Male; Middle Aged; Movement; Parkinson Disease

2012
Patient and caregiver perceptions of the social impact of advanced Parkinson's disease and dyskinesias.
    Journal of neural transmission (Vienna, Austria : 1996), 2012, Volume: 119, Issue:11

    Topics: Aged; Antiparkinson Agents; Caregivers; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Regression Analysis; Social Change; Social Perception; Surveys and Questionnaires

2012
Neuronal nitric oxide synthase inhibition attenuates the development of L-DOPA-induced dyskinesia in hemi-Parkinsonian rats.
    European journal of pharmacology, 2012, May-15, Volume: 683, Issue:1-3

    Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Indazoles; Levodopa; Male; Neostriatum; Nerve Tissue Proteins; Neurons; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase Type I; Parkinsonian Disorders; Protein Subunits; Proto-Oncogene Proteins c-fos; Random Allocation; Rats; Rats, Wistar; Receptors, AMPA; Signal Transduction

2012
Amphetamine-induced rotation and L-DOPA-induced dyskinesia in the rat 6-OHDA model: a correlation study.
    Neuroscience research, 2012, Volume: 73, Issue:2

    Topics: Amphetamine; Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Oxidopamine; Rats; Rats, Sprague-Dawley; Rotation

2012
An automated methodology for levodopa-induced dyskinesia: assessment based on gyroscope and accelerometer signals.
    Artificial intelligence in medicine, 2012, Volume: 55, Issue:2

    Topics: Aged; Automation; Biosensing Techniques; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Monitoring, Ambulatory; Parkinson Disease; Predictive Value of Tests; Severity of Illness Index

2012
Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson's disease treatment and dyskinesia.
    Neuropharmacology, 2013, Volume: 66

    Topics: Allosteric Regulation; Aminobutyrates; Anilides; Animals; Catalepsy; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agonists; Excitatory Postsynaptic Potentials; Haloperidol; Levodopa; Male; Oxidopamine; Parkinson Disease; Phosphinic Acids; Rats; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate; Synaptic Transmission

2013
Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours.
    Brain : a journal of neurology, 2012, Volume: 135, Issue:Pt 5

    Topics: Aged; Antiparkinson Agents; Cohort Studies; Deep Brain Stimulation; Disruptive, Impulse Control, and Conduct Disorders; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motivation; Neuropsychological Tests; Parkinson Disease; Psychiatric Status Rating Scales; Severity of Illness Index; Statistics, Nonparametric; Subthalamic Nucleus

2012
Gα(olf) mutation allows parsing the role of cAMP-dependent and extracellular signal-regulated kinase-dependent signaling in L-3,4-dihydroxyphenylalanine-induced dyskinesia.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2012, Apr-25, Volume: 32, Issue:17

    Topics: Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Brain; Corpus Striatum; Drug Interactions; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Functional Laterality; GTP-Binding Protein alpha Subunits; Histones; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Movement; Mutation; Oxidopamine; Psychomotor Performance; Receptors, AMPA; Signal Transduction; Sympatholytics; Time Factors; Tyrosine 3-Monooxygenase

2012
The 5-HT1A-receptor agonist flibanserin reduces drug-induced dyskinesia in RGS9-deficient mice.
    Journal of neural transmission (Vienna, Austria : 1996), 2012, Volume: 119, Issue:11

    Topics: Animals; Benzimidazoles; Buspirone; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Dyskinesia, Drug-Induced; Exploratory Behavior; Female; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Quinolines; RGS Proteins; Serotonin Antagonists; Serotonin Receptor Agonists

2012
Influence of corticostriatal δ-opioid receptors on abnormal involuntary movements induced by L-DOPA in hemiparkinsonian rats.
    Experimental neurology, 2012, Volume: 236, Issue:2

    Topics: Animals; Cerebral Cortex; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Enkephalin, D-Penicillamine (2,5)-; Levodopa; Male; Neurons; Parkinsonian Disorders; Protein Binding; Rats; Rats, Sprague-Dawley; Receptors, Opioid, delta

2012
Role for α6 nicotinic receptors in l-dopa-induced dyskinesias in parkinsonian mice.
    Neuropharmacology, 2012, Volume: 63, Issue:3

    Topics: Animals; Antiparkinson Agents; Autoradiography; Benserazide; Cotinine; Dopamine; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Hydroxydopamines; Levodopa; Mice; Mice, Inbred C57BL; Mice, Knockout; Nicotine; Nicotinic Agonists; Parkinsonian Disorders; Receptors, Nicotinic

2012
Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease.
    Neurobiology of disease, 2012, Volume: 47, Issue:3

    Topics: 5,6-Dihydroxytryptamine; Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Antiparkinson Agents; Buspirone; Cell Count; Creatinine; Disease Models, Animal; Dopamine Agonists; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Female; Indoles; Levodopa; Motor Activity; Oxidopamine; Parkinson Disease; Pyridines; Rats; Rats, Sprague-Dawley; Serotonergic Neurons; Serotonin Receptor Agonists; Time Factors

2012
The effect of piribedil on L-DOPA-induced dyskinesias in a rat model of Parkinson's disease: differential role of α(2) adrenergic mechanisms.
    Journal of neural transmission (Vienna, Austria : 1996), 2013, Volume: 120, Issue:1

    Topics: Adrenergic Agents; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Animals; Antiparkinson Agents; Benserazide; Clonidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Dystonia; Facial Asymmetry; Idazoxan; Levodopa; Locomotion; Oxidopamine; Parkinson Disease; Piribedil; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Statistics, Nonparametric; Upper Extremity

2013
Controlled-release levodopa methyl ester/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats.
    International journal of nanomedicine, 2012, Volume: 7

    Topics: Animals; Antiparkinson Agents; Benserazide; Brain; Dopamine and cAMP-Regulated Phosphoprotein 32; Drug Carriers; Drug Delivery Systems; Dynorphins; Dyskinesia, Drug-Induced; Levodopa; Male; Microscopy, Electron, Scanning; Mitogen-Activated Protein Kinase Kinases; Nanomedicine; Nanoparticles; Particle Size; Phosphorylation; Proto-Oncogene Proteins c-fos; Rats; tau Proteins

2012
Treatment patterns and associated costs with Parkinson's disease levodopa induced dyskinesia.
    Journal of the neurological sciences, 2012, Aug-15, Volume: 319, Issue:1-2

    Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Databases, Factual; Dyskinesia, Drug-Induced; Female; Health Care Costs; Humans; Insurance, Health; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Treatment Outcome; United States

2012
Rehabilitation improves dyskinesias in Parkinsonian patients: a pilot study comparing two different rehabilitative treatments.
    NeuroRehabilitation, 2012, Volume: 30, Issue:4

    Topics: Antiparkinson Agents; Disability Evaluation; Dyskinesia, Drug-Induced; Exercise Test; Exercise Therapy; Female; Humans; Levodopa; Male; Movement; Parkinson Disease; Physical Therapy Modalities; Pilot Projects; Treatment Outcome

2012
Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation.
    Parkinsonism & related disorders, 2012, Volume: 18, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; DNA Mutational Analysis; Dyskinesia, Drug-Induced; Female; Gene Frequency; Genetic Predisposition to Disease; Glycine; Humans; Israel; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Levodopa; Longitudinal Studies; Male; Middle Aged; Mutation; Parkinson Disease; Protein Serine-Threonine Kinases; Retrospective Studies; Serine; Statistics, Nonparametric; Young Adult

2012
Treatment of Parkinson disease: a 64-year-old man with motor complications of advanced Parkinson disease.
    JAMA, 2012, Jun-06, Volume: 307, Issue:21

    Topics: Amantadine; Antiparasitic Agents; Carbidopa; Catechols; Decision Making; Deep Brain Stimulation; Disease Progression; Dyskinesia, Drug-Induced; Gait Disorders, Neurologic; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Quality of Life; Subthalamus

2012
L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease.
    Neuropharmacology, 2012, Volume: 63, Issue:5

    Topics: Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Benserazide; Biological Availability; Caudate Nucleus; Chromatography, High Pressure Liquid; Dopamine Agents; Drug Combinations; Dyskinesia, Drug-Induced; Female; Half-Life; Levodopa; Macaca fascicularis; Metabolic Clearance Rate; Parkinsonian Disorders; Severity of Illness Index; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Tissue Distribution

2012
Dyskinesia in Parkinson disease - an unmet therapeutic challenge.
    The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 2012, Volume: 39, Issue:4

    Topics: Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Humans; Levodopa; Parkinson Disease; Receptors, N-Methyl-D-Aspartate

2012
Prefrontal thickening in PD with levodopa-induced dyskinesias: new evidence from cortical thickness measurement.
    Parkinsonism & related disorders, 2013, Volume: 19, Issue:1

    Topics: Aged; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neuroimaging; Parkinson Disease; Prefrontal Cortex

2013
Foot dystonia heralding levodopa-induced dyskinesias in Parkinson disease.
    Clinical neurology and neurosurgery, 2013, Volume: 115, Issue:2

    Topics: Antiparkinson Agents; Carbidopa; Catechols; Dyskinesia, Drug-Induced; Dystonia; Female; Foot Diseases; Humans; Levodopa; Middle Aged; Neurologic Examination; Nitriles; Parkinson Disease

2013
Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats.
    The European journal of neuroscience, 2012, Volume: 36, Issue:6

    Topics: Animals; Antiparkinson Agents; Apomorphine; Biogenic Monoamines; Citalopram; Corpus Striatum; Dyskinesia, Drug-Induced; Fluoxetine; Levodopa; Male; Parkinsonian Disorders; Paroxetine; Raphe Nuclei; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors

2012
Imaging DA release in a rat model of L-DOPA-induced dyskinesias: a longitudinal in vivo PET investigation of the antidyskinetic effect of MDMA.
    NeuroImage, 2012, Oct-15, Volume: 63, Issue:1

    Topics: Adrenergic Uptake Inhibitors; Animals; Brain; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Male; N-Methyl-3,4-methylenedioxyamphetamine; Positron-Emission Tomography; Rats; Rats, Sprague-Dawley

2012
NMDA receptor genotypes associated with the vulnerability to develop dyskinesia.
    Translational psychiatry, 2012, Jan-10, Volume: 2

    Topics: Age of Onset; Alleles; Antiparkinson Agents; Antipsychotic Agents; Dyskinesia, Drug-Induced; Dyskinesias; Gene Expression; Genetic Predisposition to Disease; Genotype; Humans; Huntington Disease; Levodopa; Long-Term Care; Motor Cortex; Movement Disorders; Polymorphism, Single Nucleotide; Receptors, N-Methyl-D-Aspartate; Schizophrenia

2012
Recurrent bilateral metatarsal "stress-and-insufficiency" fractures in a levodopa-treated young woman with Parkinson's disease.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2013, Volume: 24, Issue:3

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Fractures, Stress; Humans; Levodopa; Metatarsal Bones; Middle Aged; Osteoporotic Fractures; Parkinson Disease; Radiography; Recurrence

2013
The role of the subthalamic nucleus in L-DOPA induced dyskinesia in 6-hydroxydopamine lesioned rats.
    PloS one, 2012, Volume: 7, Issue:8

    Topics: Animals; Dyskinesia, Drug-Induced; Electrophysiological Phenomena; Levodopa; Neostriatum; Neurons; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Regression Analysis; Subthalamic Nucleus

2012
MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates.
    Neuropharmacology, 2013, Volume: 66

    Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; Drug Administration Schedule; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Levodopa; Macaca fascicularis; Oximes; Parkinsonian Disorders; Putamen; Pyridines; Radioligand Assay; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate

2013
RGFP109, a histone deacetylase inhibitor attenuates L-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: a proof-of-concept study.
    Parkinsonism & related disorders, 2013, Volume: 19, Issue:2

    Topics: Animals; Antiparkinson Agents; Callithrix; Dyskinesia, Drug-Induced; Female; Histone Deacetylase Inhibitors; Levodopa; Parkinsonian Disorders

2013
Non-homogeneous effect of levodopa on inhibitory circuits in Parkinson's disease and dyskinesia.
    Parkinsonism & related disorders, 2013, Volume: 19, Issue:2

    Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Cortex; Parkinson Disease; Transcranial Magnetic Stimulation

2013
Nicotine-mediated improvement in L-dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal function.
    Neurobiology of disease, 2013, Volume: 50

    Topics: Animals; Corpus Striatum; Dopamine; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Levodopa; Male; MPTP Poisoning; Nicotine; Nicotinic Agonists; Presynaptic Terminals; Receptors, Nicotinic; Saimiri

2013
PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking.
    The Journal of clinical investigation, 2012, Volume: 122, Issue:11

    Topics: Animals; Corpus Striatum; Disks Large Homolog 4 Protein; Dyskinesia, Drug-Induced; HEK293 Cells; Humans; Intracellular Signaling Peptides and Proteins; Levodopa; Macaca; Male; Membrane Proteins; Parkinson Disease; Protein Transport; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Synapses

2012
Comparison of rating scales used to evaluate L-DOPA-induced dyskinesia in the 6-OHDA lesioned rat.
    Neurobiology of disease, 2013, Volume: 50

    Topics: Adrenergic Agents; Amantadine; Animals; Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Severity of Illness Index

2013
Potentiation of response to low doses of levodopa in MPTP-injected monkeys by chemical unilateral subthalamotomy.
    Journal of neurosurgery, 2013, Volume: 118, Issue:1

    Topics: Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Ibotenic Acid; Levodopa; Macaca fascicularis; MPTP Poisoning; Subthalamic Nucleus

2013
1-Hz repetitive transcranial magnetic stimulation and diphasic dyskinesia in Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2013, Volume: 28, Issue:2

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Middle Aged; Parkinson Disease; Transcranial Magnetic Stimulation

2013
Nociceptin/orphanin FQ receptor agonists attenuate L-DOPA-induced dyskinesias.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2012, Nov-14, Volume: 32, Issue:46

    Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Autoradiography; Behavior, Animal; Dyskinesia, Drug-Induced; Electrophysiological Phenomena; Excitatory Postsynaptic Potentials; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Macaca; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Microdialysis; Microinjections; Nociceptin; Opioid Peptides; Oxidopamine; Postural Balance; Rats; Rats, Sprague-Dawley; Rats, Wistar

2012
DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson's disease patients.
    Pharmacogenomics, 2012, Volume: 13, Issue:15

    Topics: Adult; Aged; Aged, 80 and over; Dyskinesia, Drug-Induced; Female; Genetic Predisposition to Disease; Haplotypes; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polymorphism, Genetic; Protein Serine-Threonine Kinases; Receptors, Dopamine D2

2012
Overweight is more prevalent in patients with Parkinson's disease.
    Arquivos de neuro-psiquiatria, 2012, Volume: 70, Issue:11

    Topics: Aged; Antiparkinson Agents; Body Mass Index; Case-Control Studies; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Mexico; Middle Aged; Obesity; Overweight; Parkinson Disease; Prevalence; Severity of Illness Index; Thinness

2012
Levodopa-induced dyskinesia is strongly associated with resonant cortical oscillations.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2012, Nov-21, Volume: 32, Issue:47

    Topics: Algorithms; Animals; Antiparkinson Agents; Cerebral Cortex; Dyskinesia, Drug-Induced; Electrodes, Implanted; Electroencephalography; Evoked Potentials; Female; Fluorescent Antibody Technique; Levodopa; Microelectrodes; Neostriatum; Neurons; Oxidopamine; Parkinson Disease, Secondary; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Tyrosine 3-Monooxygenase

2012
Validating an objective video-based dyskinesia severity score in Parkinson's disease patients.
    Parkinsonism & related disorders, 2013, Volume: 19, Issue:2

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Observer Variation; Parkinson Disease; Severity of Illness Index; Video Recording

2013
Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats.
    Drug design, development and therapy, 2012, Volume: 6

    Topics: Animals; Antiparkinson Agents; Benserazide; Blotting, Western; Delayed-Action Preparations; Disease Models, Animal; Down-Regulation; Drug Carriers; Drug Combinations; Dyskinesia, Drug-Induced; Female; Lactic Acid; Levodopa; Microspheres; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Receptors, AMPA

2012
Rebalance of striatal NMDA/AMPA receptor ratio underlies the reduced emergence of dyskinesia during D2-like dopamine agonist treatment in experimental Parkinson's disease.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2012, Dec-05, Volume: 32, Issue:49

    Topics: Animals; Benzothiazoles; Corpus Striatum; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Excitatory Postsynaptic Potentials; Levodopa; Male; Neurons; Oxidopamine; Parkinsonian Disorders; Pramipexole; Rats; Rats, Wistar; Receptors, AMPA; Receptors, Dopamine D3; Receptors, N-Methyl-D-Aspartate

2012
Drebrin immunoreactivity in the striatum of a rat model of levodopa-induced dyskinesia.
    Neuropathology : official journal of the Japanese Society of Neuropathology, 2013, Volume: 33, Issue:4

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dendritic Spines; Dyskinesia, Drug-Induced; Immunohistochemistry; Levodopa; Male; Microscopy, Immunoelectron; Neuropeptides; Parkinsonian Disorders; Rats; Rats, Wistar

2013
Use of catechol-O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque.
    The European journal of neuroscience, 2013, Volume: 37, Issue:5

    Topics: Animals; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catechols; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Male; MPTP Poisoning; Nitriles

2013
The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques.
    Progress in neuro-psychopharmacology & biological psychiatry, 2013, Jun-03, Volume: 43

    Topics: Animals; Antiparkinson Agents; Behavior, Animal; Butyrophenones; Cloning, Molecular; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Male; MPTP Poisoning; Parkinson Disease, Secondary; Psychoses, Substance-Induced

2013
Unexpected improvement in levodopa-induced dyskinesia and on-off phenomena after introduction of memantine for treatment of Parkinson's disease dementia.
    Journal of the American Geriatrics Society, 2013, Volume: 61, Issue:1

    Topics: Aged, 80 and over; Antiparkinson Agents; Dementia; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Memantine; Middle Aged; Parkinson Disease

2013
Persistent activation of the D1R/Shp-2/Erk1/2 pathway in l-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's disease.
    Neurobiology of disease, 2013, Volume: 54

    Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Blotting, Western; Dyskinesia, Drug-Induced; Immunoprecipitation; Levodopa; Male; MAP Kinase Signaling System; Oxidopamine; Parkinsonian Disorders; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Rats; Rats, Wistar; Receptors, Dopamine D1

2013
Parallel dopamine D1 receptor activity dependence of l-Dopa-induced normal movement and dyskinesia in mice.
    Neuroscience, 2013, Apr-16, Volume: 236

    Topics: Animals; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Immunohistochemistry; Levodopa; Mice; Mice, Mutant Strains; Motor Activity; Receptors, Dopamine D1

2013
Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
    Experimental neurology, 2013, Volume: 247

    Topics: Adamantane; Alternative Splicing; Animals; Antiparkinson Agents; Cocaine; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Gene Expression Regulation; Iodine Isotopes; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, AMPA; RNA, Messenger; Sympatholytics

2013
The nicotine-mediated decline in l-dopa-induced dyskinesias is associated with a decrease in striatal dopamine release.
    Journal of neurochemistry, 2013, Volume: 125, Issue:2

    Topics: Animals; Antiparkinson Agents; Autoradiography; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Male; Nicotine; Nicotinic Agonists; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic

2013
Levodopa-induced dyskinesia in a patient who has normal presynaptic dopaminergic neurons.
    Movement disorders : official journal of the Movement Disorder Society, 2013, Volume: 28, Issue:8

    Topics: Antiparkinson Agents; Brain; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Middle Aged; Parkinsonian Disorders; Positron-Emission Tomography; Tropanes

2013
The effects of BMY-14802 against L-DOPA- and dopamine agonist-induced dyskinesia in the hemiparkinsonian rat.
    Psychopharmacology, 2013, Volume: 227, Issue:3

    Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Parkinson Disease; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D1

2013
Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.
    Movement disorders : official journal of the Movement Disorder Society, 2013, Volume: 28, Issue:8

    Topics: Amantadine; Amphetamine; Animals; Apomorphine; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Medial Forebrain Bundle; Motor Activity; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Piperazines; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Serotonin Receptor Agonists; Time Factors; Tyrosine 3-Monooxygenase

2013
Levodopa-induced dyskinesias in tyrosine hydroxylase deficiency.
    Movement disorders : official journal of the Movement Disorder Society, 2013, Volume: 28, Issue:8

    Topics: Child; Child, Preschool; Dopamine Agents; Dyskinesia, Drug-Induced; Dystonic Disorders; Humans; Infant; Levodopa

2013
Striatal glutamate release in L-DOPA-induced dyskinetic animals.
    PloS one, 2013, Volume: 8, Issue:2

    Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Dopamine; Drug Combinations; Dyskinesia, Drug-Induced; Female; Glutamic Acid; Injections, Intraventricular; Levodopa; Potassium; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin Receptor Agonists; Signal Transduction

2013
Disordered respiration as a levodopa-induced dyskinesia in Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2002, Volume: 17, Issue:3

    Topics: Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Parkinson Disease; Respiration Disorders

2002
L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function.
    Neurobiology of disease, 2002, Volume: 10, Issue:2

    Topics: Afferent Pathways; Animals; Bacterial Proteins; Behavior, Animal; Biomarkers; Brain Mapping; Caudate Nucleus; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Enkephalins; Female; Image Processing, Computer-Assisted; Levodopa; Motor Activity; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-fos; Putamen; Rats; Rats, Sprague-Dawley; RNA, Messenger; Severity of Illness Index; Substantia Nigra; Sympathectomy, Chemical; Transcription Factors

2002
Dopamine reuptake inhibition and failure to evoke dyskinesia in MPTP-treated primates.
    European journal of pharmacology, 2002, Sep-13, Volume: 451, Issue:2

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Motor Activity

2002
Hiccoughs--an unusual dyskinetic side-effect of L-Dopa.
    Age and ageing, 2002, Volume: 31, Issue:5

    Topics: Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Hiccup; Humans; Levodopa; Male; Parkinson Disease

2002
Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation.
    Movement disorders : official journal of the Movement Disorder Society, 2002, Volume: 17, Issue:5

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Arousal; Callithrix; Caudate Nucleus; Corpus Striatum; Culture Techniques; Drug Administration Schedule; Dyskinesia, Drug-Induced; Dyskinesias; Female; In Situ Hybridization; Levodopa; Locomotion; Male; Piribedil; RNA, Messenger; Severity of Illness Index; Time Factors

2002
Levodopa-induced dyskinesia in an autopsy-proven case of progressive supranuclear palsy.
    Movement disorders : official journal of the Movement Disorder Society, 2002, Volume: 17, Issue:5

    Topics: Antiparkinson Agents; Brain; Culture Techniques; Dyskinesia, Drug-Induced; Fatal Outcome; Female; Humans; Levodopa; Middle Aged; Neurofibrillary Tangles; Supranuclear Palsy, Progressive

2002
Transcription factors involved in the pathogenesis of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
    Amino acids, 2002, Volume: 23, Issue:1-3

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Enkephalins; Gene Expression Regulation; Levodopa; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-fos; Rats; Sympatholytics; Transcription Factors

2002
Naloxone reduces levodopa-induced dyskinesias and apomorphine-induced rotations in primate models of parkinsonism.
    Journal of neural transmission (Vienna, Austria : 1996), 2002, Volume: 109, Issue:10

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benserazide; Callithrix; Dopamine; Dopamine Agents; Dopamine Antagonists; Dyskinesia, Drug-Induced; Enkephalins; Female; In Situ Hybridization; Levodopa; Male; Motor Activity; Naloxone; Narcotic Antagonists; Oxidopamine; Parkinson Disease, Secondary; Protein Precursors; RNA; Rotation; Stereotyped Behavior; Sympathectomy, Chemical

2002
Lesioning the thalamus for dyskinesia.
    Stereotactic and functional neurosurgery, 2001, Volume: 77, Issue:1-4

    Topics: Antiparkinson Agents; Antipsychotic Agents; Dyskinesia, Drug-Induced; Dyskinesias; Electrocoagulation; Haloperidol; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Parkinsonian Disorders; Reoperation; Retrospective Studies; Schizophrenia; Stereotaxic Techniques; Sulpiride; Torticollis; Treatment Outcome; Tremor; Ventral Thalamic Nuclei

2001
Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models.
    Experimental neurology, 2002, Volume: 177, Issue:2

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antipsychotic Agents; Behavior, Animal; Dibenzothiazepines; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Quetiapine Fumarate; Rats; Receptor, Serotonin, 5-HT2A; Receptor, Serotonin, 5-HT2C; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Serotonin; Serotonin Antagonists

2002
Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets.
    Neuroscience, 2002, Volume: 115, Issue:4

    Topics: Animals; Antiparkinson Agents; Bromocriptine; Callithrix; Dopamine Uptake Inhibitors; Dyskinesia, Drug-Induced; Enkephalins; Female; Indoles; Levodopa; Male; Mazindol; Neostriatum; Neural Pathways; Neuropeptides; Parkinsonian Disorders; Protein Precursors; Receptors, Purinergic P1; RNA, Messenger; Tachykinins

2002
Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2002, Volume: 17, Issue:6

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benserazide; Callithrix; Corpus Striatum; Dose-Response Relationship, Drug; Dronabinol; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; gamma-Aminobutyric Acid; Globus Pallidus; Levodopa; Male; Motor Skills; Parkinsonian Disorders; Receptors, Cannabinoid; Receptors, Drug

2002
Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2002, Volume: 17, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Motor Activity; Neurologic Examination; Parkinson Disease; Treatment Outcome

2002
Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
    Movement disorders : official journal of the Movement Disorder Society, 2002, Volume: 17, Issue:6

    Topics: Adult; Aged; Antiparkinson Agents; Apomorphine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Infusion Pumps; Levodopa; Long-Term Care; Male; Middle Aged; Parkinson Disease; Treatment Outcome

2002
Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa.
    Movement disorders : official journal of the Movement Disorder Society, 2002, Volume: 17, Issue:6

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; Motor Skills; Neurologic Examination; Parkinsonian Disorders; Recurrence

2002
AMPA receptor antagonist LY293558 reverses preproenkephalin mRNA overexpression in the striatum of 6-OHDA-lesioned-rats treated with L-dopa.
    The European journal of neuroscience, 2002, Volume: 16, Issue:11

    Topics: Animals; Disease Models, Animal; Dizocilpine Maleate; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Enkephalins; Excitatory Amino Acid Antagonists; Gene Expression Regulation; Isoquinolines; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Neostriatum; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; RNA, Messenger; Tetrazoles

2002
Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus).
    Experimental neurology, 2003, Volume: 179, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Callithrix; Disability Evaluation; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Motor Activity; Parkinsonian Disorders; Pergolide; Receptors, Dopamine D1; Receptors, Dopamine D2; Severity of Illness Index

2003
Automatic assessment of levodopa-induced dyskinesias in daily life by neural networks.
    Movement disorders : official journal of the Movement Disorder Society, 2003, Volume: 18, Issue:1

    Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Diagnosis, Computer-Assisted; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Neural Networks, Computer; Neurologic Examination; Observer Variation; Parkinson Disease; Sensitivity and Specificity

2003
Deep brain stimulation of the subthalamic nucleus in Parkinson's disease: long-term follow-up.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2002, Volume: 23 Suppl 2

    Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Electrodes, Implanted; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Subthalamic Nucleus; Time Factors; Treatment Outcome

2002
The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease.
    European journal of neurology, 2003, Volume: 10, Issue:2

    Topics: Aged; Antiparkinson Agents; Catechols; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Time Factors; Treatment Outcome

2003
Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia.
    Journal of neurochemistry, 2003, Volume: 84, Issue:6

    Topics: Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enkephalins; Female; Levodopa; Motor Activity; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-fos; Purinergic P1 Receptor Antagonists; Purines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; RNA, Messenger; Treatment Outcome

2003
Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications.
    Movement disorders : official journal of the Movement Disorder Society, 2003, Volume: 18, Issue:3

    Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Autoradiography; Brain; Case-Control Studies; Dopamine; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Humans; Levodopa; Male; Parkinson Disease; Postmortem Changes; Receptors, GABA; Receptors, GABA-A; Receptors, GABA-B

2003
Movement parameters that distinguish between voluntary movements and levodopa-induced dyskinesia in Parkinson's disease.
    Human movement science, 2003, Volume: 22, Issue:1

    Topics: Acceleration; Activities of Daily Living; Aged; Antiparkinson Agents; Diagnosis, Computer-Assisted; Dyskinesia, Drug-Induced; Female; Humans; Joints; Levodopa; Male; Middle Aged; Monitoring, Physiologic; Neural Networks, Computer; Parkinson Disease; Psychomotor Performance; Signal Processing, Computer-Assisted; Software

2003
[Current preclinical findings on substances against Parkinson's disease].
    Der Nervenarzt, 2003, Volume: 74 Suppl 1

    Topics: Animals; Antiparkinson Agents; Caenorhabditis elegans; Corpus Striatum; Dopamine Agonists; Drug Evaluation, Preclinical; Drugs, Investigational; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Parkinsonian Disorders

2003
Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia.
    Nature neuroscience, 2003, Volume: 6, Issue:5

    Topics: Animals; Corpus Striatum; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Excitatory Postsynaptic Potentials; In Vitro Techniques; Levodopa; Male; Nerve Tissue Proteins; Neuronal Plasticity; Parkinsonian Disorders; Phosphoproteins; Phosphorylation; Rats; Rats, Wistar; Synaptic Transmission

2003
[Fluctuations and dyskinesias as early L-dopa-induced motor complications in severe Parkinsonian's patients].
    Neurologia (Barcelona, Spain), 2003, Volume: 18, Issue:3

    Topics: Aged; Antiparkinson Agents; Apomorphine; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Risk Factors

2003
L-DOPA, dyskinesia and striatal plasticity.
    Nature neuroscience, 2003, Volume: 6, Issue:5

    Topics: Animals; Corpus Striatum; Dyskinesia, Drug-Induced; Humans; Levodopa; Long-Term Potentiation; Neuronal Plasticity

2003
Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure.
    Movement disorders : official journal of the Movement Disorder Society, 2003, Volume: 18, Issue:5

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callithrix; Carbidopa; Catechols; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Locomotion; Male; Nitriles; Parkinsonian Disorders; Pulse Therapy, Drug; Substantia Nigra; Time Factors

2003
Long-term outcome of quetiapine use for psychosis among Parkinsonian patients.
    Movement disorders : official journal of the Movement Disorder Society, 2003, Volume: 18, Issue:5

    Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Dibenzothiazepines; Drug Tolerance; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Outcome Assessment, Health Care; Parkinson Disease; Psychotic Disorders; Quetiapine Fumarate; Retrospective Studies; Severity of Illness Index

2003
Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function.
    Nature medicine, 2003, Volume: 9, Issue:6

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acrylamides; Animals; Antiparkinson Agents; Dopamine Agents; Dopamine Antagonists; Dyskinesia, Drug-Induced; Female; Haplorhini; Humans; Isoquinolines; Levodopa; Molecular Structure; Motor Activity; MPTP Poisoning; Naphthalenes; Neostriatum; Piperazines; Pyrrolidines; Rats; Receptors, Dopamine D2; Receptors, Dopamine D3

2003
L -dopa-induced adverse effects in PD and dopamine transporter gene polymorphism.
    Neurology, 2003, Jun-10, Volume: 60, Issue:11

    Topics: Aged; Antiparkinson Agents; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Parkinson Disease; Polymorphism, Genetic; Psychoses, Substance-Induced; Receptors, Dopamine; Retrospective Studies

2003
D3 receptors and levodopa-induced dyskinesia.
    The Lancet. Neurology, 2003, Volume: 2, Issue:7

    Topics: Animals; Dyskinesia, Drug-Induced; Levodopa; Parkinsonian Disorders; Piperazines; Receptors, Dopamine D2; Receptors, Dopamine D3

2003
Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2003, Volume: 18, Issue:8

    Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Binding, Competitive; Callithrix; Dyskinesia, Drug-Induced; Female; Imidazoles; Indans; Levodopa; Male; Parkinsonian Disorders; Radioligand Assay; Rats; Receptors, Adrenergic; Receptors, AMPA; Receptors, Dopamine; Receptors, GABA; Receptors, Histamine; Receptors, N-Methyl-D-Aspartate; Receptors, Serotonin

2003
Antidyskinetic effect of magnesium sulfate in MPTP-lesioned monkeys.
    Experimental neurology, 2003, Volume: 182, Issue:2

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca mulatta; Magnesium Sulfate; Motor Activity; Parkinsonian Disorders

2003
Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias.
    The European journal of neuroscience, 2003, Volume: 18, Issue:6

    Topics: Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Benzazepines; Benzoxazines; Brain Chemistry; Cannabinoid Receptor Modulators; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine Antagonists; Drug Interactions; Dyskinesia, Drug-Induced; Dyskinesias; Endocannabinoids; Gas Chromatography-Mass Spectrometry; Levodopa; Male; Morpholines; Mouth; Naphthalenes; Oxidopamine; Parkinson Disease; Piperidines; Pyrazoles; Raclopride; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant; Substantia Nigra; Time Factors

2003
Effect of levodopa chronic administration on behavioral changes and fos expression in basal ganglia in rat model of PD.
    Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban, 2003, Volume: 23, Issue:3

    Topics: Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Parkinson Disease; Proto-Oncogene Proteins c-fos; Random Allocation; Rats; Rats, Sprague-Dawley

2003
3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2003, Oct-08, Volume: 23, Issue:27

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; N-Methyl-3,4-methylenedioxyamphetamine; Parkinsonian Disorders; Receptor, Serotonin, 5-HT1B; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Serotonin Receptor Agonists

2003
Development of levodopa-induced dyskinesias in parkinsonian monkeys may depend upon rate of symptom onset and/or duration of symptoms.
    Brain research, 2003, Nov-14, Volume: 990, Issue:1-2

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Appetite; Behavior, Animal; Blinking; Dopamine Agents; Dyskinesia, Drug-Induced; Facial Expression; Feeding Behavior; Levodopa; Macaca fascicularis; Male; Motor Activity; Motor Skills; Parkinson Disease, Secondary; Postural Balance; Posture; Time Factors; Tremor

2003
Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems.
    Neuropharmacology, 2003, Volume: 45, Issue:7

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Dopamine; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Endorphins; Female; Levodopa; Macaca fascicularis; Motor Activity; Naloxone; Naltrexone; Narcotic Antagonists; Parkinson Disease, Secondary; Quinpirole; Receptors, Dopamine D1; Receptors, Dopamine D2; Synaptic Transmission

2003
Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease.
    The New England journal of medicine, 2003, Nov-13, Volume: 349, Issue:20

    Topics: Activities of Daily Living; Adult; Aged; Antiparkinson Agents; Combined Modality Therapy; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Electrodes, Implanted; Female; Follow-Up Studies; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Severity of Illness Index; Subthalamic Nucleus

2003
A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease.
    Experimental neurology, 2003, Volume: 184, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Apomorphine; Denervation; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Macaca fascicularis; Male; Neurons; Oxidopamine; Parkinson Disease, Secondary; Phosphorylation; Purines; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, Dopamine D1; Receptors, Dopamine D2; Sympatholytics

2003
Agonists versus levodopa in PD: the thrilla of whitha.
    Neurology, 2003, Nov-25, Volume: 61, Issue:10

    Topics: Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2003
The art of treating Parkinson disease in the older patient.
    Australian family physician, 2003, Volume: 32, Issue:11

    Topics: Aged; Antiparkinson Agents; Australia; Dopamine Agonists; Dyskinesia, Drug-Induced; Family Practice; Female; Geriatrics; Humans; Levodopa; Male; Motor Activity; Parkinson Disease; Treatment Outcome

2003
Adenosine A(2A) receptors in nonlocomotor features of Parkinson's disease: introduction.
    Neurology, 2003, Dec-09, Volume: 61, Issue:11 Suppl 6

    Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Central Nervous System; Depression; Dyskinesia, Drug-Induced; Humans; Hypotension, Orthostatic; Levodopa; Parkinson Disease; Receptor, Adenosine A2A; Sleep Wake Disorders

2003
Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease.
    Neurology, 2003, Dec-09, Volume: 61, Issue:11 Suppl 6

    Topics: Adenosine A2 Receptor Antagonists; Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dopamine; Dopamine Agonists; Drug Tolerance; Dyskinesia, Drug-Induced; Humans; Levodopa; Mice; Mice, Knockout; Neurons; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Purines; Pyrimidines; Receptor, Adenosine A2A; Synapses; Triazoles

2003
Parkinson's disease, subthalamic stimulation, and selection of candidates: a pathological study.
    Movement disorders : official journal of the Movement Disorder Society, 2003, Volume: 18, Issue:12

    Topics: Aged; Antiparkinson Agents; Cognition Disorders; Disease Progression; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Fatal Outcome; Female; Humans; Levodopa; Neuropsychological Tests; Parkinson Disease; Subthalamic Nucleus; Tremor

2003
Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease.
    Neurobiology of disease, 2003, Volume: 14, Issue:3

    Topics: Aged; Aged, 80 and over; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Binding Sites; Binding, Competitive; Brain; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Humans; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Parkinson Disease; Radioligand Assay; Receptors, N-Methyl-D-Aspartate

2003
Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia.
    Experimental neurology, 2004, Volume: 185, Issue:1

    Topics: Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Enkephalins; Gene Expression; In Situ Hybridization; Indoles; Levodopa; Male; Motor Activity; Opioid Peptides; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Sprague-Dawley; RNA, Messenger; Synaptic Transmission

2004
The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
    Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:1

    Topics: Animals; Antiparkinson Agents; Callithrix; Carbidopa; Chlorobenzenes; Cyclobutanes; Dopamine; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Synergism; Dyskinesia, Drug-Induced; Levodopa; Locomotion; Male; Motor Activity; Motor Skills; Neurologic Examination; Parkinsonian Disorders; Postural Balance; Stereotyped Behavior

2004
Comparison of motor fluctuations and L-dopa-induced dyskinesias in patients with familial and sporadic Parkinson's disease.
    European journal of neurology, 2004, Volume: 11, Issue:2

    Topics: Aged; Chi-Square Distribution; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills Disorders; Parkinson Disease; Statistics, Nonparametric

2004
Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque.
    European journal of pharmacology, 2004, Feb-06, Volume: 485, Issue:1-3

    Topics: Animals; Chorea; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levetiracetam; Levodopa; Macaca fascicularis; MPTP Poisoning; Piracetam

2004
Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model.
    Brain : a journal of neurology, 2004, Volume: 127, Issue:Pt 4

    Topics: Antiparkinson Agents; Biological Clocks; Circadian Rhythm; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Dystonia; Humans; Levodopa; Models, Statistical; Parkinson Disease; Presynaptic Terminals; Synaptic Vesicles

2004
The two faces of L-DOPA: benefits and adverse side effects in the treatment of Encephalitis lethargica, Parkinson's disease, multiple sclerosis and amyotrophic lateral sclerosis.
    Medical hypotheses, 2004, Volume: 62, Issue:2

    Topics: Amyotrophic Lateral Sclerosis; Antioxidants; Antiparkinson Agents; Dopamine Agents; Dyskinesia, Drug-Induced; Gastrointestinal Diseases; Hallucinations; Humans; Levodopa; Multiple Sclerosis; Oxidative Stress; Parkinson Disease; Parkinson Disease, Postencephalitic; Psychoses, Substance-Induced; Sleep Initiation and Maintenance Disorders; Vitamin B Complex

2004
Parkinson's disease patients with bilateral subthalamic deep brain stimulation gain weight.
    Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:2

    Topics: Aged; Antiparkinson Agents; Body Composition; Body Mass Index; Combined Modality Therapy; Dominance, Cerebral; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Energy Metabolism; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Subthalamic Nucleus; Treatment Outcome; Weight Gain

2004
Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys.
    Neurobiology of disease, 2004, Volume: 15, Issue:2

    Topics: Animals; Benzoxazoles; Corpus Striatum; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Glutamic Acid; Levodopa; Macaca fascicularis; Parkinson Disease; Piperidines; Receptors, N-Methyl-D-Aspartate; Treatment Outcome

2004
Clozapine for the treatment of levodopa-induced dyskinesias.
    The Lancet. Neurology, 2004, Volume: 3, Issue:5

    Topics: Antipsychotic Agents; Clozapine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Levodopa; Randomized Controlled Trials as Topic

2004
L-dopa-induced excessive daytime sleepiness in PD: a placebo-controlled case with MSLT assessment.
    Neurology, 2004, Apr-27, Volume: 62, Issue:8

    Topics: Disorders of Excessive Somnolence; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Levodopa; Nocturnal Myoclonus Syndrome; Parkinson Disease; Predictive Value of Tests; Sleep Apnea, Obstructive

2004
Human brain dopamine metabolism in levodopa-induced dyskinesia and wearing-off.
    Parkinsonism & related disorders, 2004, Volume: 10, Issue:4

    Topics: Aged; Aged, 80 and over; Brain; Dopamine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male

2004
Grip force abnormalities in de novo Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:5

    Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Hand Strength; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index

2004
Do on-off variations cause discrepancies in the historical items of the UPDRS?
    Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:5

    Topics: Activities of Daily Living; Antiparkinson Agents; Cannabis; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Phytotherapy

2004
A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function.
    Neurobiology of disease, 2004, Volume: 16, Issue:1

    Topics: Animals; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Mazindol; Mice; Mice, Inbred C57BL; Motor Skills; Oxidopamine; Protein Binding; Substantia Nigra

2004
The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease.
    Experimental neurology, 2004, Volume: 188, Issue:2

    Topics: Animals; Callithrix; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; Parkinsonian Disorders; Piperidines; Range of Motion, Articular; Receptors, N-Methyl-D-Aspartate; Treatment Failure

2004
L-dopa-induced dyskinesia improvement after STN-DBS depends upon medication reduction.
    Neurology, 2004, Jul-13, Volume: 63, Issue:1

    Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Combined Modality Therapy; Corpus Striatum; Deep Brain Stimulation; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Dopamine; Severity of Illness Index

2004
Immediate and sustained relief of levodopa-induced dyskinesias after dorsal relocation of a deep brain stimulation lead. Case report.
    Neurosurgical focus, 2004, Jul-15, Volume: 17, Issue:1

    Topics: Antiparkinson Agents; Device Removal; Dopamine Agonists; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Electrodes, Implanted; Equipment Design; Female; Humans; Leg; Levodopa; Magnetic Resonance Imaging; Microelectrodes; Middle Aged; Parkinson Disease; Remission Induction; Subthalamic Nucleus

2004
Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias.
    Brain : a journal of neurology, 2004, Volume: 127, Issue:Pt 12

    Topics: Aged; Analysis of Variance; Antiparkinson Agents; Caudate Nucleus; Disease Progression; Dopamine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Putamen; Synapses

2004
Impact of the motor complications of Parkinson's disease on the quality of life.
    Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Health Status Indicators; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Neurologic Examination; Parkinson Disease; Psychiatric Status Rating Scales; Quality of Life; Retrospective Studies; Surveys and Questionnaires

2005
Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations.
    Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:10

    Topics: Amantadine; Antiparkinson Agents; Child; Chorea; Dopamine Agents; Dyskinesia, Drug-Induced; GTP Cyclohydrolase; Heterozygote; Humans; Levodopa; Male; Parkinson Disease; Pedigree; Phenotype; Point Mutation

2004
Chronic bilateral subthalamic deep brain stimulation in a patient with homozygous deletion in the parkin gene.
    Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:12

    Topics: Antiparkinson Agents; Deep Brain Stimulation; Disability Evaluation; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Exons; Female; Gene Deletion; Genomic Imprinting; Homozygote; Humans; Levodopa; Male; Parkinsonian Disorders; Polymerase Chain Reaction; Severity of Illness Index; Subthalamic Nucleus; Ubiquitin-Protein Ligases

2004
Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia.
    Neurobiology of disease, 2004, Volume: 17, Issue:2

    Topics: Animals; Calcium-Transporting ATPases; Carrier Proteins; Corpus Striatum; Cytoskeleton; Dopamine Agents; Dyskinesia, Drug-Induced; Energy Metabolism; Gene Expression; Gene Expression Profiling; Homeostasis; Ions; Levodopa; Microfilament Proteins; Mitochondria; Multigene Family; Neurotransmitter Agents; Oligonucleotide Array Sequence Analysis; Phosphoric Monoester Hydrolases; Phosphotransferases; Rats; Rats, Sprague-Dawley; Receptors, Cell Surface; RNA, Messenger; Synapses

2004
Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates.
    Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20, Issue:3

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callithrix; Carbidopa; Catechols; Dopamine Agents; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Injections, Subcutaneous; Levodopa; Locomotion; Male; MPTP Poisoning; Nitriles; Severity of Illness Index; Substantia Nigra; Time Factors

2005
Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia.
    Annals of neurology, 2005, Volume: 57, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Antiparkinson Agents; Autoradiography; Behavior, Animal; Blotting, Western; Cyclin-Dependent Kinase 5; Cyclin-Dependent Kinases; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Guanosine 5'-O-(3-Thiotriphosphate); Immunohistochemistry; In Situ Hybridization; Isotopes; Levodopa; Macaca fascicularis; Membrane Glycoproteins; Membrane Transport Proteins; Motor Activity; Nerve Tissue Proteins; Nortropanes; Parkinsonian Disorders; Phosphoproteins; Radioligand Assay; Receptors, Dopamine D1; Receptors, Dopamine D2; Signal Transduction; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase

2005
Levodopa-dyskinesia incidence by age of Parkinson's disease onset.
    Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20, Issue:3

    Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Antiparkinson Agents; Cohort Studies; Dyskinesia, Drug-Induced; Female; Humans; Incidence; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies

2005
Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20, Issue:4

    Topics: Animals; Anticonvulsants; Antiparkinson Agents; Callithrix; Disease Models, Animal; Dyskinesia, Drug-Induced; Fructose; Levodopa; MPTP Poisoning; Parkinson Disease; Topiramate

2005
Swallowing abnormalities and dyskinesia in Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20, Issue:4

    Topics: Aged; Antiparkinson Agents; Body Mass Index; Deglutition Disorders; Dyskinesia, Drug-Induced; Female; Fluoroscopy; Humans; Levodopa; Male; Middle Aged; Oropharynx; Parkinson Disease; Severity of Illness Index; Videotape Recording

2005
Parkin disease in a Brazilian kindred: Manifesting heterozygotes and clinical follow-up over 10 years.
    Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20, Issue:4

    Topics: Adult; Antiparkinson Agents; Brazil; DNA Mutational Analysis; Dyskinesia, Drug-Induced; Exons; Female; Follow-Up Studies; Foot; Genotype; Heterozygote; Humans; Levodopa; Male; Parkinsonian Disorders; Pedigree; Point Mutation; Ubiquitin-Protein Ligases

2005
A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
    Experimental neurology, 2005, Volume: 191, Issue:2

    Topics: Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Amantadine; Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Dizocilpine Maleate; Dopamine Agents; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Haloperidol; Idazoxan; Levodopa; Male; Motor Activity; Parkinson Disease; Rats; Rats, Sprague-Dawley; Reserpine

2005
Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors.
    Brain : a journal of neurology, 2005, Volume: 128, Issue:Pt 3

    Topics: Animals; Corpus Striatum; Dependovirus; Disease Models, Animal; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Gene Transfer Techniques; Genetic Therapy; Genetic Vectors; Levodopa; Parkinson Disease; Rats; Rats, Sprague-Dawley

2005
Bilateral subthalamotomy in Parkinson's disease: initial and long-term response.
    Brain : a journal of neurology, 2005, Volume: 128, Issue:Pt 3

    Topics: Activities of Daily Living; Adult; Aged; Antiparkinson Agents; Cognition; Combined Modality Therapy; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Motor Skills; Neuropsychological Tests; Parkinson Disease; Pilot Projects; Postoperative Complications; Radiosurgery; Subthalamic Nucleus; Treatment Outcome

2005
Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats.
    Experimental neurology, 2005, Volume: 192, Issue:1

    Topics: Animals; Benserazide; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Disease Models, Animal; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Levodopa; Male; Nitriles; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Treatment Outcome

2005
Dyskinesias in normal squirrel monkeys induced by nomifensine and levodopa.
    Neuropharmacology, 2005, Volume: 48, Issue:3

    Topics: Animals; Drug Combinations; Drug Synergism; Dyskinesia, Drug-Induced; Female; Levodopa; Nomifensine; Saimiri

2005
Involvement of sensorimotor, limbic, and associative basal ganglia domains in L-3,4-dihydroxyphenylalanine-induced dyskinesia.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2005, Feb-23, Volume: 25, Issue:8

    Topics: Animals; Basal Ganglia; Deoxyglucose; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Levodopa; Limbic System; Macaca fascicularis; Motor Cortex; Parkinsonian Disorders; Septal Nuclei; Somatosensory Cortex; Substantia Nigra; Subthalamic Nucleus

2005
Current controversies: levodopa in the treatment of Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20, Issue:5

    Topics: Antiparkinson Agents; Body Weight; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies

2005
Levodopa in the treatment of Parkinson's disease: current controversies.
    Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20, Issue:5

    Topics: Animals; Antiparkinson Agents; Apomorphine; Disease Models, Animal; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Haplorhini; Levodopa; Lisuride; Parkinson Disease; Pergolide

2005
"Levodopa phobia": a new iatrogenic cause of disability in Parkinson disease.
    Neurology, 2005, Mar-08, Volume: 64, Issue:5

    Topics: Aged; Amantadine; Benzothiazoles; Catechols; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Humans; Iatrogenic Disease; Indoles; Levodopa; Male; Middle Aged; Neurology; Neuropharmacology; Neurotoxicity Syndromes; Nitriles; Parkinson Disease; Pramipexole; Selegiline; Thiazoles; Treatment Outcome

2005
Hemiparkinsonism and levodopa-induced dyskinesias after focal nigral lesion.
    Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20, Issue:6

    Topics: Adult; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Magnetic Resonance Imaging; Parkinsonian Disorders; Substantia Nigra

2005
Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson's disease on L-dopa monotherapy.
    Parkinsonism & related disorders, 2005, Volume: 11, Issue:3

    Topics: Age of Onset; Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Neurons; Parkinson Disease; Predictive Value of Tests; Risk Factors

2005
Quantifying drug-induced dyskinesias in the arms using digitised spiral-drawing tasks.
    Journal of neuroscience methods, 2005, May-15, Volume: 144, Issue:1

    Topics: Adolescent; Adult; Aged; Antiparkinson Agents; Arm; Disability Evaluation; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Movement; Neurologic Examination; Parkinson Disease; Psychomotor Performance; Severity of Illness Index; Spectrum Analysis

2005
Pallidal stimulation reduces treatment-induced dyskinesias in "minimal-change" multiple system atrophy.
    Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20, Issue:8

    Topics: Deep Brain Stimulation; Dyskinesia, Drug-Induced; Female; Functional Laterality; Globus Pallidus; Humans; Immunohistochemistry; Levodopa; Magnetic Resonance Imaging; Middle Aged; Multiple System Atrophy; Nerve Tissue Proteins; Neuropsychological Tests; Staining and Labeling; Synucleins; Ubiquitin

2005
A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson's disease.
    Neuroscience research, 2005, Volume: 52, Issue:2

    Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Drug Therapy, Combination; Dynorphins; Dyskinesia, Drug-Induced; Female; Glutamate Decarboxylase; In Situ Hybridization; Levodopa; Parkinson Disease; Rats; Rats, Wistar; Serotonin Receptor Agonists

2005
A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2005, Volume: 19, Issue:9

    Topics: Animals; Arachidonic Acids; Callithrix; Cannabinoid Receptor Modulators; Dyskinesia, Drug-Induced; Endocannabinoids; Female; gamma-Aminobutyric Acid; Glycerides; Levodopa; Male; MPTP Poisoning; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant

2005
Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
    Experimental neurology, 2005, Volume: 194, Issue:1

    Topics: Adenosine A2 Receptor Agonists; Adrenergic Agents; Amantadine; Animals; Antiparkinson Agents; Basal Ganglia; Buspirone; Disease Models, Animal; Disease Progression; Dopamine Agonists; Drug Administration Schedule; Dyskinesia, Drug-Induced; Indoles; Levodopa; Male; Mice; Mice, Inbred C57BL; Oxidopamine; Parkinsonian Disorders; Purines; Receptor, Adenosine A2A; Receptors, Dopamine D2; Reproducibility of Results; Riluzole; Treatment Outcome

2005
The effect of levetiracetam on levodopa induced dyskinesia in patients with Parkinson's disease.
    Parkinsonism & related disorders, 2005, Volume: 11, Issue:5

    Topics: Aged; Anticonvulsants; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levetiracetam; Levodopa; Male; Middle Aged; Parkinson Disease; Piracetam

2005
Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in Parkinsonian monkeys.
    Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20, Issue:7

    Topics: Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Kynurenic Acid; Kynurenine 3-Monooxygenase; Levodopa; Macaca fascicularis; Mixed Function Oxygenases; Motor Activity; Parkinsonian Disorders; Quinolinic Acid; Sulfonamides; Thiazoles; Time Factors

2005
Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20, Issue:9

    Topics: Aged; Anticonvulsants; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levetiracetam; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects; Piracetam

2005
[L-dopa effectiveness decreases over time. What helps Parkinson patients stay mobile?].
    MMW Fortschritte der Medizin, 2005, Jun-02, Volume: 147, Issue:22

    Topics: Antiparkinson Agents; Dopamine Agents; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Long-Term Care; Parkinson Disease; Treatment Outcome

2005
Oscillatory pallidal local field potential activity inversely correlates with limb dyskinesias in Parkinson's disease.
    Experimental neurology, 2005, Volume: 194, Issue:2

    Topics: Action Potentials; Antiparkinson Agents; Arm; Biological Clocks; Dyskinesia, Drug-Induced; Electromyography; Female; Globus Pallidus; Humans; Levodopa; Middle Aged; Muscle, Skeletal; Neurons; Parkinson Disease

2005
Dopamine D1 and D2 receptor contributions to L-DOPA-induced dyskinesia in the dopamine-depleted rat.
    Pharmacology, biochemistry, and behavior, 2005, Volume: 81, Issue:4

    Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Behavior, Animal; Benzazepines; Corpus Striatum; Dopamine; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Synergism; Dyskinesia, Drug-Induced; Hydroxyindoleacetic Acid; Levodopa; Male; Norepinephrine; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Salicylamides; Serotonin

2005
Immunoautoradiographic analysis of NMDA receptor subunits and associated postsynaptic density proteins in the brain of dyskinetic MPTP-treated common marmosets.
    The European journal of neuroscience, 2005, Volume: 21, Issue:12

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Blotting, Western; Brain; Callithrix; Diagnostic Imaging; Disks Large Homolog 4 Protein; Dyskinesia, Drug-Induced; Immunoradiometric Assay; Intracellular Signaling Peptides and Proteins; Levodopa; Membrane Proteins; Nerve Tissue Proteins; Neurofilament Proteins; Protein Subunits; Rats; Receptors, N-Methyl-D-Aspartate; Tyrosine 3-Monooxygenase

2005
Reciprocal interactions between oscillatory activities of different frequencies in the subthalamic region of patients with Parkinson's disease.
    The European journal of neuroscience, 2005, Volume: 22, Issue:1

    Topics: Action Potentials; Adult; Aged; Biological Clocks; Dopamine Agents; Dyskinesia, Drug-Induced; Electrophysiology; Female; Humans; Levodopa; Male; Middle Aged; Neural Pathways; Neurons; Parkinson Disease; Subthalamic Nucleus

2005
Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning.
    The European journal of neuroscience, 2005, Volume: 22, Issue:1

    Topics: Animals; Antiparkinson Agents; Cell Count; Cell Death; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Female; Immunohistochemistry; Levodopa; Macaca fascicularis; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Degeneration; Nerve Tissue Proteins; Neural Pathways; Neurons; Parkinsonian Disorders; Substantia Nigra; Tyrosine 3-Monooxygenase

2005
Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin.
    Movement disorders : official journal of the Movement Disorder Society, 2006, Volume: 21, Issue:1

    Topics: Animals; Antiparkinson Agents; Benserazide; Benzoxazoles; Corpus Striatum; Dopamine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enkephalins; Female; Gene Expression; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Piperidines; Protein Precursors; Receptors, N-Methyl-D-Aspartate; RNA, Messenger

2006
ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
    Biological psychiatry, 2006, Jan-01, Volume: 59, Issue:1

    Topics: Animals; Antiparkinson Agents; Behavior, Animal; Blotting, Western; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Administration Schedule; Dyskinesia, Drug-Induced; Dyskinesias; Enkephalins; Extracellular Signal-Regulated MAP Kinases; Gene Expression; Immunohistochemistry; In Situ Hybridization; Levodopa; Locomotion; Male; Mice; Mice, Inbred C57BL; Motor Activity; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Protein Precursors; Proto-Oncogene Proteins c-fos; RNA, Messenger; Statistics, Nonparametric; Time Factors

2006
Oculogyric dystonic states in early-onset parkinsonism with basal ganglia calcifications.
    Neurology, 2005, Sep-13, Volume: 65, Issue:5

    Topics: Age of Onset; Antiparkinson Agents; Apomorphine; Basal Ganglia; Calcinosis; Dyskinesia, Drug-Induced; Dystonic Disorders; Female; Humans; Levodopa; Middle Aged; Ocular Motility Disorders; Oculomotor Muscles; Parkinsonian Disorders

2005
Unilateral pallidotomy in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets exhibiting levodopa-induced dyskinesia.
    The European journal of neuroscience, 2005, Volume: 22, Issue:6

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Immunohistochemistry; Levodopa; Male; Motor Activity; Movement Disorders; Substantia Nigra; Tyrosine 3-Monooxygenase

2005
DHEA improves symptomatic treatment of moderately and severely impaired MPTP monkeys.
    Neurobiology of aging, 2006, Volume: 27, Issue:11

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dehydroepiandrosterone; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Motor Activity; Parkinsonian Disorders; Severity of Illness Index

2006
Coordinated and spatial upregulation of arc in striatonigral neurons correlates with L-dopa-induced behavioral sensitization in dyskinetic rats.
    Journal of neuropathology and experimental neurology, 2005, Volume: 64, Issue:11

    Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Adrenergic Agents; AIDS-Related Complex; Amphetamine; Analgesics, Non-Narcotic; Animals; Antiparkinson Agents; Behavior, Animal; Carrier Proteins; Central Nervous System Stimulants; Corpus Striatum; Disease Models, Animal; Drug Interactions; Dynorphins; Dyskinesia, Drug-Induced; Functional Laterality; Homer Scaffolding Proteins; Immunohistochemistry; In Situ Hybridization; Levodopa; Male; Motor Activity; Naloxone; Naltrexone; Narcotic Antagonists; Neurons; Oxidopamine; Protein Precursors; Proto-Oncogene Proteins c-fos; Rats; Rats, Wistar; Stereotyped Behavior; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase; Up-Regulation

2005
Low-dose levodopa therapy in Japanese patients with Parkinson's disease: a retrospective study.
    Internal medicine (Tokyo, Japan), 2005, Volume: 44, Issue:9

    Topics: Aged; Amantadine; Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Hallucinations; Humans; Japan; Levodopa; Middle Aged; Parkinson Disease; Quality of Life; Retrospective Studies; Time Factors

2005
Levodopa addiction in idiopathic Parkinson disease.
    Neurology, 2005, Nov-08, Volume: 65, Issue:9

    Topics: Aged; Bipolar Disorder; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychoses, Substance-Induced; Quadriplegia; Spinal Cord Diseases; Substance-Related Disorders

2005
[The role of dopaminagonists in the treatment of Parkinson's disease].
    Praxis, 2005, Oct-19, Volume: 94, Issue:42

    Topics: Aged; Antiparkinson Agents; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Long-Term Care; Neurologic Examination; Neuroprotective Agents; Parkinson Disease

2005
Validation of the l-dopa-induced dyskinesia in the 6-OHDA model and evaluation of the effects of selective dopamine receptor agonists and antagonists.
    Brain research bulletin, 2005, Dec-15, Volume: 68, Issue:1-2

    Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; Dyskinesia, Drug-Induced; Enkephalin, Methionine; Female; Levodopa; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Reproducibility of Results; Sympatholytics

2005
Modulation of torsinA expression in the globus pallidus internus is associated with levodopa-induced dyskinesia in hemiparkinsonian rats.
    Neuroscience letters, 2006, Mar-20, Volume: 396, Issue:1

    Topics: Animals; Cell Count; Disease Models, Animal; Dopamine Agents; Down-Regulation; Dyskinesia, Drug-Induced; Entopeduncular Nucleus; Globus Pallidus; Levodopa; Male; Molecular Chaperones; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar

2006
Loss of synaptic D1 dopamine/N-methyl-D-aspartate glutamate receptor complexes in L-DOPA-induced dyskinesia in the rat.
    Molecular pharmacology, 2006, Volume: 69, Issue:3

    Topics: Animals; Antiparkinson Agents; Cells, Cultured; Corpus Striatum; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Protein Subunits; Rats; Rats, Wistar; Receptors, Dopamine D1; Receptors, N-Methyl-D-Aspartate; Synapses; Transfection

2006
The impact of graft size on the development of dyskinesia following intrastriatal grafting of embryonic dopamine neurons in the rat.
    Neurobiology of disease, 2006, Volume: 22, Issue:2

    Topics: Amphetamine; Animals; Brain Tissue Transplantation; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Dopamine Uptake Inhibitors; Dyskinesia, Drug-Induced; Female; Levodopa; Movement; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotation; Selective Serotonin Reuptake Inhibitors; Substantia Nigra; Transplantation Tolerance

2006
Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2006, Volume: 21, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Genotype; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polymorphism, Genetic; Receptors, Dopamine; Receptors, Opioid, mu; Risk; Smoking

2006
Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patients and parkinsonian monkeys.
    Neurochemistry international, 2006, Volume: 48, Issue:5

    Topics: Aged; Aged, 80 and over; Animals; Arachidonic Acid; Cerebral Cortex; Chromatography, Gas; Dietary Fats; Disease Models, Animal; Docosahexaenoic Acids; Dopamine Agents; Dyskinesia, Drug-Induced; Fatty Acids; Fatty Acids, Unsaturated; Female; Humans; Levodopa; Lipid Metabolism; Macaca fascicularis; Male; Neurons; Parkinson Disease; Parkinsonian Disorders; Postmortem Changes; Species Specificity

2006
Paraphilic behaviours in a parkinsonian patient with hedonistic homeostatic dysregulation.
    The international journal of neuropsychopharmacology, 2006, Volume: 9, Issue:6

    Topics: Antiparkinson Agents; Benserazide; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Homeostasis; Humans; Levodopa; Male; Middle Aged; Mood Disorders; Paraphilic Disorders; Parkinson Disease; Pedophilia; Pergolide

2006
Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias.
    Brain : a journal of neurology, 2006, Volume: 129, Issue:Pt 4

    Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Electric Stimulation; Electromyography; Evoked Potentials, Motor; Female; Humans; Levodopa; Male; Middle Aged; Motor Cortex; Muscle, Skeletal; Neuronal Plasticity; Parkinson Disease; Transcranial Magnetic Stimulation

2006
Age-related differences in levodopa dynamics in Parkinson's: implications for motor complications.
    Brain : a journal of neurology, 2006, Volume: 129, Issue:Pt 4

    Topics: Adult; Age Factors; Age of Onset; Aged; Antiparkinson Agents; Dihydroxyphenylalanine; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tomography, Emission-Computed

2006
Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990.
    Archives of neurology, 2006, Volume: 63, Issue:2

    Topics: Aged; Antiparkinson Agents; Cohort Studies; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Minnesota; Parkinson Disease; Prognosis; Retrospective Studies; Risk Factors; Severity of Illness Index

2006
Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats.
    Journal of neurochemistry, 2006, Volume: 96, Issue:6

    Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Extracellular Fluid; Female; Levodopa; Microdialysis; Microinjections; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Serotonin; Up-Regulation

2006
A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy.
    Clinical neurology and neurosurgery, 2006, Volume: 108, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Dopamine Agonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Hospitals, University; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Patient Admission; Retrospective Studies; Risk Factors; Turkey

2006
Expression of dyskinetic movements and turning behaviour in subchronic L-DOPA 6-hydroxydopamine-treated rats is influenced by the testing environment.
    Behavioural brain research, 2006, Jul-15, Volume: 171, Issue:1

    Topics: Animals; Behavior, Animal; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Environment; Housing, Animal; Levodopa; Male; Oxidopamine; Rats; Rats, Sprague-Dawley; Reproducibility of Results

2006
Levodopa-induced dyskinesia and rotational behavior in hemiparkinsonian rats: independent features or components of the same phenomenon?
    Behavioural brain research, 2006, Jun-30, Volume: 170, Issue:2

    Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Rotation; Time Factors

2006
Bradykinesia in patients with Parkinson's disease having levodopa-induced dyskinesias.
    Brain research bulletin, 2006, May-15, Volume: 69, Issue:5

    Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance

2006
Slow oscillatory activity and levodopa-induced dyskinesias in Parkinson's disease.
    Brain : a journal of neurology, 2006, Volume: 129, Issue:Pt 7

    Topics: Action Potentials; Adult; Aged; Antiparkinson Agents; Apomorphine; Biological Clocks; Combined Modality Therapy; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Electrodes, Implanted; Humans; Levodopa; Middle Aged; Parkinson Disease; Subthalamic Nucleus

2006
Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.
    Synapse (New York, N.Y.), 2006, Sep-01, Volume: 60, Issue:3

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Benzoxazoles; Denervation; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Image Processing, Computer-Assisted; In Situ Hybridization; Levodopa; Macaca fascicularis; Motor Activity; Neuroprotective Agents; Oligonucleotide Probes; Ovariectomy; Parkinson Disease, Secondary; Piperidines; Pyrimidines; Receptor, Adenosine A2A; Receptors, N-Methyl-D-Aspartate; Triazoles

2006
Prognosis of Parkinson's disease: time to stage III, IV, V, and to motor fluctuations.
    Movement disorders : official journal of the Movement Disorder Society, 2006, Volume: 21, Issue:9

    Topics: Adult; Age Factors; Aged; Antiparkinson Agents; Cohort Studies; Disability Evaluation; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Japan; Levodopa; Male; Middle Aged; Mobility Limitation; Neurologic Examination; Parkinson Disease; Prognosis; Retrospective Studies; Severity of Illness Index; Sex Factors

2006
MDMA and fenfluramine reduce L-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation.
    The European journal of neuroscience, 2006, Volume: 23, Issue:10

    Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Fenfluramine; Levodopa; Male; N-Methyl-3,4-methylenedioxyamphetamine; Oxidopamine; Parkinsonian Disorders; Rats; Receptor, Serotonin, 5-HT1A; Serotonin 5-HT1 Receptor Antagonists; Serotonin Agents

2006
Opioids and motor complications in Parkinson's disease.
    Trends in pharmacological sciences, 2006, Volume: 27, Issue:10

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptors, Opioid

2006
The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets.
    European journal of pharmacology, 2006, Sep-28, Volume: 546, Issue:1-3

    Topics: Adenine; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Callithrix; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; Motor Skills; MPTP Poisoning; Triazoles

2006
The influence of levodopa-induced dyskinesias on manual tracking in patients with Parkinson's disease.
    Experimental brain research, 2007, Volume: 176, Issue:3

    Topics: Aged; Analysis of Variance; Antiparkinson Agents; Case-Control Studies; Dyskinesia, Drug-Induced; Human Body; Humans; Levodopa; Middle Aged; Movement; Parkinson Disease; Psychomotor Performance; Rotation; Severity of Illness Index

2007
Enhanced preproenkephalin-B-derived opioid transmission in striatum and subthalamic nucleus converges upon globus pallidus internalis in L-3,4-dihydroxyphenylalanine-induced dyskinesia.
    Biological psychiatry, 2007, Apr-01, Volume: 61, Issue:7

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antiparkinson Agents; Corpus Striatum; Drug Interactions; Dyskinesia, Drug-Induced; Enkephalins; Female; Gene Expression Regulation; In Situ Hybridization; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Protein Precursors; Radioligand Assay; Receptors, Opioid; Regression Analysis; RNA, Messenger; Subthalamic Nucleus

2007
In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\\ increased motor disability.
    The Journal of pharmacology and experimental therapeutics, 2006, Volume: 319, Issue:3

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Benzothiazoles; Callithrix; Data Interpretation, Statistical; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; Piperazines; Pramipexole; Pyridines; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Serotonin Antagonists; Serotonin Receptor Agonists

2006
Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2006, Volume: 21, Issue:11

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Callithrix; Disability Evaluation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Grooming; Hallucinations; Levodopa; Parkinsonian Disorders; Psychomotor Agitation; Psychotic Disorders; Statistics, Nonparametric; Stereotyped Behavior

2006
Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2006, Sep-13, Volume: 26, Issue:37

    Topics: Animals; Antibodies, Monoclonal; Antigens; Basal Ganglia; Biomarkers; Blood-Brain Barrier; Bromodeoxyuridine; Cell Count; Cell Proliferation; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Endothelial Cells; Female; Intermediate Filament Proteins; Levodopa; Motor Activity; Neovascularization, Pathologic; Nerve Tissue Proteins; Nestin; Oxidopamine; Parkinsonian Disorders; Platelet Endothelial Cell Adhesion Molecule-1; Proteoglycans; Rats; Rats, Sprague-Dawley

2006
Punding and dyskinesias.
    Movement disorders : official journal of the Movement Disorder Society, 2006, Volume: 21, Issue:12

    Topics: Aged; Aged, 80 and over; Demography; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Stereotyped Behavior

2006
Long-term monitoring of gait in Parkinson's disease.
    Gait & posture, 2007, Volume: 26, Issue:2

    Topics: Adult; Algorithms; Antiparkinson Agents; Calibration; Computers, Handheld; Drug Monitoring; Dyskinesia, Drug-Induced; Electronics, Medical; Feasibility Studies; Female; Gait; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Monitoring, Ambulatory; Parkinson Disease

2007
Hemiparkinsonism and levodopa-induced dyskinesias following focal nigral lesion.
    Movement disorders : official journal of the Movement Disorder Society, 2006, Volume: 21, Issue:12

    Topics: Antiparkinson Agents; Brain Injuries; Child, Preschool; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Parkinson Disease; Substantia Nigra

2006
Inhaled cocaine used to relieve "off" periods in patients with Parkinson disease and unpredictable motor fluctuations: a report of 2 cases.
    Journal of clinical psychopharmacology, 2006, Volume: 26, Issue:6

    Topics: Administration, Inhalation; Cocaine; Dopamine Uptake Inhibitors; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Middle Aged; Parkinson Disease; Self Medication

2006
Cellular and behavioral effects of 5-HT1A receptor agonist 8-OH-DPAT in a rat model of levodopa-induced motor complications.
    Brain research, 2007, Jan-05, Volume: 1127, Issue:1

    Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Behavior, Animal; Benserazide; Brain; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Female; Levodopa; Phosphorylation; Piperazines; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptors, AMPA; Serotonin; Serotonin 5-HT1 Receptor Agonists; Serotonin Antagonists; Serotonin Receptor Agonists; Synapses; Synaptic Transmission; Treatment Outcome

2007
Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets.
    Experimental neurology, 2007, Volume: 204, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Indoles; Levodopa; Male; Motor Activity

2007
Tamoxifen effect on L-DOPA induced response complications in parkinsonian rats and primates.
    Neuropharmacology, 2007, Volume: 52, Issue:2

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Disease Models, Animal; Drug Administration Schedule; Drug Interactions; Dyskinesia, Drug-Induced; Haplorhini; Levodopa; Male; Models, Biological; Nerve Tissue Proteins; Oxidopamine; Parkinson Disease, Secondary; Protein Kinase C; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors

2007
Motor fluctuations and dyskinesias in advanced/end stage Parkinson's disease: a study from a population of brain donors.
    Journal of neural transmission (Vienna, Austria : 1996), 2007, Volume: 114, Issue:3

    Topics: Age of Onset; Aged; Aged, 80 and over; Aging; Antiparkinson Agents; Brain; Cohort Studies; Disease Progression; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Nerve Degeneration; Neuronal Plasticity; Parkinson Disease; Synaptic Transmission; Tissue Donors

2007
The importance of A9 dopaminergic neurons in mediating the functional benefits of fetal ventral mesencephalon transplants and levodopa-induced dyskinesias.
    Neurobiology of disease, 2007, Volume: 25, Issue:3

    Topics: Animals; Behavior, Animal; Brain Tissue Transplantation; Combined Modality Therapy; Corpus Striatum; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Fetal Tissue Transplantation; G Protein-Coupled Inwardly-Rectifying Potassium Channels; Levodopa; Mesencephalon; Motor Skills; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Recovery of Function; Severity of Illness Index; Sympatholytics

2007
Dihydropteridine reductase deficiency: levodopa's long-term effectiveness without dyskinesia.
    Neurology, 2006, Dec-26, Volume: 67, Issue:12

    Topics: 5-Hydroxytryptophan; Adult; Antidepressive Agents, Second-Generation; Dopamine Agents; Drug Combinations; Dyskinesia, Drug-Induced; Dyskinesias; Humans; Levodopa; Longitudinal Studies; Male; Phenylketonurias; Treatment Outcome

2006
Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2006, Dec-27, Volume: 26, Issue:52

    Topics: Adenosine A2 Receptor Antagonists; Animals; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidopamine; Parkinsonian Disorders; Prosencephalon; Purines; Receptor, Adenosine A2A

2006
Genetic polymorphism of the angiotensin converting enzyme and L-dopa-induced adverse effects in Parkinson's disease.
    Journal of the neurological sciences, 2007, Jan-31, Volume: 252, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Genetic Predisposition to Disease; Homozygote; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Peptidyl-Dipeptidase A; Polymorphism, Genetic; Predictive Value of Tests; Psychoses, Substance-Induced; Risk Factors

2007
Effect of antisense FosB and CREB on the expression of prodynorphin gene in rats with levodopa-induced dyskinesias.
    Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban, 2006, Volume: 26, Issue:5

    Topics: Animals; Corpus Striatum; Cyclic AMP Response Element-Binding Protein; Dyskinesia, Drug-Induced; Enkephalins; Female; Levodopa; Neurons; Oligonucleotides, Antisense; Parkinson Disease; Protein Precursors; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; RNA, Messenger

2006
Abnormal involuntary movements (AIMs) following pulsatile dopaminergic stimulation: severe deterioration and morphological correlates following the loss of locus coeruleus neurons.
    Brain research, 2007, Mar-02, Volume: 1135, Issue:1

    Topics: Adrenergic Uptake Inhibitors; Animals; Cell Death; Desipramine; Disease Models, Animal; Dopamine; Dopamine Agents; Drug Interactions; Dyskinesia, Drug-Induced; Functional Laterality; Levodopa; Locus Coeruleus; Male; Neurons; Norepinephrine; Oxidopamine; Rats; Rats, Wistar; Rotarod Performance Test; Severity of Illness Index; Tyrosine 3-Monooxygenase

2007
Novel 4-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)methylbenzofuran derivatives as selective alpha(2C)-adrenergic receptor antagonists.
    Bioorganic & medicinal chemistry letters, 2007, Mar-15, Volume: 17, Issue:6

    Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Benzofurans; Callithrix; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Indicators and Reagents; Isoquinolines; Levodopa; Receptors, Adrenergic, alpha-2; Structure-Activity Relationship

2007
Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model.
    Behavioural brain research, 2007, Apr-16, Volume: 179, Issue:1

    Topics: Adrenergic Agents; Animals; Cross-Over Studies; Disease Models, Animal; Double-Blind Method; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agents; Levodopa; Male; Neurotransmitter Agents; Parkinsonian Disorders; Random Allocation; Rats; Rotarod Performance Test; Serotonin Agents; Statistics, Nonparametric

2007
Low-frequency repetitive transcranial magnetic stimulation for treatment of levodopa-induced dyskinesias.
    Neurology, 2007, Feb-27, Volume: 68, Issue:9

    Topics: Adult; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Transcranial Magnetic Stimulation; Treatment Outcome

2007
The selective kappa-opioid receptor agonist U50,488 reduces L-dopa-induced dyskinesias but worsens parkinsonism in MPTP-treated primates.
    Experimental neurology, 2007, Volume: 205, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; Antiparkinson Agents; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Hypnotics and Sedatives; Levodopa; Male; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Saimiri; Vomiting

2007
Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates.
    Neurobiology of disease, 2007, Volume: 26, Issue:2

    Topics: Animals; Antiparkinson Agents; Cell Compartmentation; Corpus Striatum; Cytoplasm; Dopamine; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Microscopy, Electron, Transmission; Neurons; Parkinsonian Disorders; Protein Transport; Receptor Aggregation; Receptors, Dopamine D1; Receptors, Dopamine D2; Up-Regulation

2007
Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
    Journal of neurochemistry, 2007, Volume: 101, Issue:2

    Topics: Animals; Antiparkinson Agents; Brain; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Microdialysis; Neural Inhibition; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Substantia Nigra; Synaptic Transmission

2007
Helicobacter pylori eradication and L-dopa absorption in patients with PD and motor fluctuations.
    Neurology, 2007, Mar-27, Volume: 68, Issue:13

    Topics: Antiparkinson Agents; Brain; Cytokines; Dyskinesia, Drug-Induced; Endotoxins; Energy Metabolism; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Intestinal Mucosa; Levodopa; Parkinson Disease

2007
L-dopa dose and the duration and severity of dyskinesia in primed MPTP-treated primates.
    Journal of neural transmission (Vienna, Austria : 1996), 2007, Volume: 114, Issue:9

    Topics: Animals; Callithrix; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; MPTP Poisoning; Severity of Illness Index

2007
Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats.
    Brain : a journal of neurology, 2007, Volume: 130, Issue:Pt 7

    Topics: 5,7-Dihydroxytryptamine; Adrenergic Agents; Animals; Antiparkinson Agents; Chromatography, High Pressure Liquid; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin 5-HT1 Receptor Agonists; Serotonin Agents

2007
Chronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson's disease.
    Neurobiology of disease, 2007, Volume: 27, Issue:1

    Topics: Afferent Pathways; Animals; Antiparkinson Agents; Aphakia; Corpus Striatum; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Levodopa; Mice; Mice, Inbred C57BL; Mice, Neurologic Mutants; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-fos; Substantia Nigra

2007
Proteomic analysis of striatal proteins in the rat model of L-DOPA-induced dyskinesia.
    Journal of neurochemistry, 2007, Volume: 102, Issue:4

    Topics: Analysis of Variance; Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Electrophoresis, Gel, Two-Dimensional; Levodopa; Male; Mass Spectrometry; Proteins; Proteomics; Rats; Rats, Sprague-Dawley; Time Factors

2007
Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
    Neuropharmacology, 2007, Volume: 53, Issue:1

    Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; Drug Administration Schedule; Drug Interactions; Dyskinesia, Drug-Induced; Levodopa; Male; Movement; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Serotonin Antagonists; Spiperone; Sympatholytics; Time Factors

2007
In vivo evidence of D3 dopamine receptor sensitization in parkinsonian primates and rodents with l-DOPA-induced dyskinesias.
    Neurobiology of disease, 2007, Volume: 27, Issue:2

    Topics: Animals; Brain; Cerebrovascular Circulation; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Macaca fascicularis; Magnetic Resonance Imaging; Male; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D3; Tetrahydronaphthalenes

2007
Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2007, Jun-27, Volume: 27, Issue:26

    Topics: Animals; Brain; Cyclic AMP; Disease Models, Animal; Dopamine Agonists; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Extracellular Signal-Regulated MAP Kinases; Histones; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidopamine; Phosphorylation; Receptors, AMPA; Ribosomal Protein S6 Kinases, 90-kDa; Signal Transduction

2007
Possible role for chlorpheniramine in the treatment of L-DOPA induced dyskinesia in Parkinson's disease.
    Pharmacy world & science : PWS, 2008, Volume: 30, Issue:1

    Topics: Animals; Antiparkinson Agents; Chlorpheniramine; Dyskinesia, Drug-Induced; Levodopa; Parkinson Disease; Serotonin Receptor Agonists

2008
Striatal leucine-rich repeat kinase 2 mRNA is increased in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned common marmosets (Callithrix jacchus) with L-3, 4-dihydroxyphenylalanine methyl ester-induced dyskinesia.
    The European journal of neuroscience, 2007, Volume: 26, Issue:1

    Topics: Actins; Aged; Aged, 80 and over; Animals; Antiparkinson Agents; Callithrix; Data Interpretation, Statistical; Dopamine Agents; Dyskinesia, Drug-Induced; Electrophoresis, Polyacrylamide Gel; Female; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Levodopa; Male; Middle Aged; MPTP Poisoning; Neostriatum; Protein Serine-Threonine Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Substantia Nigra

2007
Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys.
    The Journal of pharmacology and experimental therapeutics, 2007, Volume: 323, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Azetidines; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca mulatta; Male; Molecular Structure; Parkinson Disease; Receptor, Cannabinoid, CB1; Triazines

2007
Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2007, Jul-25, Volume: 27, Issue:30

    Topics: Animals; Brain Tissue Transplantation; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Fetal Tissue Transplantation; Levodopa; Neurons; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin

2007
Evaluation of levodopa dose and magnitude of dopamine depletion as risk factors for levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    The Journal of pharmacology and experimental therapeutics, 2007, Volume: 323, Issue:1

    Topics: Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Brain; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Parkinson Disease; Rats; Rats, Sprague-Dawley; Risk Factors; Tyrosine 3-Monooxygenase

2007
Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors.
    Biological psychiatry, 2007, Oct-01, Volume: 62, Issue:7

    Topics: Animals; Benzazepines; Cell Count; Denervation; Dopamine Agents; Dopamine Antagonists; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Enzyme Activation; Female; Fluorescent Antibody Technique; Immunohistochemistry; In Situ Hybridization; Levodopa; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neostriatum; Neurons, Efferent; Phosphorylation; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2

2007
Movement patterns of peak-dose levodopa-induced dyskinesias in patients with Parkinson's disease.
    Brain research bulletin, 2007, Sep-14, Volume: 74, Issue:1-3

    Topics: Aged; Analysis of Variance; Antiparkinson Agents; Case-Control Studies; Dyskinesia, Drug-Induced; Entropy; Evoked Potentials, Motor; Female; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Movement; Neurologic Examination; Parkinson Disease; Spectrum Analysis

2007
Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys.
    Behavioural brain research, 2008, Jan-25, Volume: 186, Issue:2

    Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; Kynurenic Acid; Kynurenine; Kynurenine 3-Monooxygenase; Levodopa; Macaca fascicularis; Motor Activity; Parkinsonian Disorders; Quinolinic Acid; Sulfonamides; Thiazoles; Time Factors

2008
Changes in the prodynorphin gene and DARPP-32 state in 6-OHDA-lesioned rats following long-term treatment with l-dopa.
    Neuroscience letters, 2007, Oct-09, Volume: 426, Issue:1

    Topics: Amino Acid Sequence; Animals; Basal Ganglia; Brain Chemistry; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Drug Administration Schedule; Dyskinesia, Drug-Induced; Enkephalins; Excitatory Amino Acid Antagonists; Female; Gene Expression Regulation; Levodopa; Male; Neural Pathways; Neurotoxins; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Protein Precursors; Rats; Rats, Sprague-Dawley; RNA, Messenger; Threonine; Time

2007
Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors.
    Experimental neurology, 2007, Volume: 208, Issue:1

    Topics: Amidohydrolases; Animals; Antiparkinson Agents; Arachidonic Acids; Basal Ganglia; Benzamides; Benzoxazines; Cannabinoids; Capsaicin; Carbamates; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Endocannabinoids; Levodopa; Male; Morpholines; Naphthalenes; Oxidopamine; Parkinson Disease, Secondary; Polyunsaturated Alkamides; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; TRPV Cation Channels

2007
Intrastriatal inhibition of aromatic amino acid decarboxylase prevents l-DOPA-induced dyskinesia: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine lesioned rats.
    Neurobiology of disease, 2008, Volume: 29, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Aromatic-L-Amino-Acid Decarboxylases; Behavior, Animal; Benserazide; Brain Injuries; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Drug Interactions; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Homovanillic Acid; Levodopa; Male; Microdialysis; Oxidopamine; Rats; Rats, Wistar

2008
Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease.
    Neurobiology of disease, 2008, Volume: 29, Issue:1

    Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Levodopa; Male; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-fos; Pyridines; Rats; Subthalamic Nucleus; Time Factors; Tyrosine 3-Monooxygenase

2008
The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates.
    Experimental neurology, 2007, Volume: 208, Issue:2

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callithrix; Catechols; Dopamine Agents; Dopamine Agonists; Drug Administration Schedule; Drug Synergism; Dyskinesia, Drug-Induced; Female; Indoles; Levodopa; Male; Motor Activity; Nitriles

2007
Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease.
    Brain : a journal of neurology, 2008, Volume: 131, Issue:Pt 1

    Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Caudate Nucleus; Dopamine; Dyskinesia, Drug-Induced; Female; Humans; Hydroxyindoleacetic Acid; Levodopa; Male; Parkinson Disease; Putamen; Serotonin; Serotonin Plasma Membrane Transport Proteins; Tryptophan Hydroxylase

2008
Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys.
    Annals of neurology, 2007, Volume: 62, Issue:6

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Circadian Rhythm; Dyskinesia, Drug-Induced; Levodopa; Nicotine; Nicotinic Agonists; Parkinsonian Disorders; Saimiri; Substantia Nigra; Time Factors

2007
Bilateral subthalamotomy for advanced Parkinson disease.
    Surgical neurology, 2007, Volume: 68 Suppl 1

    Topics: Aged; Catheter Ablation; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Functional Laterality; Humans; Hypokinesia; Levodopa; Male; Microelectrodes; Middle Aged; Muscle Rigidity; Neural Pathways; Parkinson Disease; Radiosurgery; Subthalamic Nucleus; Time; Treatment Outcome; Tremor

2007
Normalization of GABAA receptor specific binding in the substantia nigra reticulata and the prevention of L-dopa-induced dyskinesias in MPTP parkinsonian monkeys.
    Synapse (New York, N.Y.), 2008, Volume: 62, Issue:2

    Topics: Analysis of Variance; Animals; Antiparkinson Agents; Autoradiography; Behavior, Animal; Benzoxazoles; Binding, Competitive; Bridged Bicyclo Compounds, Heterocyclic; Convulsants; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Flunitrazepam; GABA Modulators; Isotopes; Levodopa; Macaca fascicularis; Ovariectomy; Parkinsonian Disorders; Piperidines; Protein Binding; Radiography; Receptors, GABA; Substantia Nigra

2008
l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation.
    Neurobiology of disease, 2008, Volume: 29, Issue:2

    Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Interactions; Dyskinesia, Drug-Induced; Electric Stimulation; In Vitro Techniques; Levodopa; Long-Term Potentiation; Long-Term Synaptic Depression; Male; Motor Activity; Neurons; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Tyrosine 3-Monooxygenase

2008
Basal ganglia group II metabotropic glutamate receptors specific binding in non-human primate model of L-Dopa-induced dyskinesias.
    Neuropharmacology, 2008, Volume: 54, Issue:2

    Topics: Amino Acids; Animals; Antiparkinson Agents; Autoradiography; Basal Ganglia; Behavior, Animal; Cabergoline; Caudate Nucleus; Data Interpretation, Statistical; Dyskinesia, Drug-Induced; Ergolines; Excitatory Amino Acid Antagonists; Female; Levodopa; Macaca fascicularis; Ovariectomy; Putamen; Receptors, Metabotropic Glutamate; Xanthenes

2008
The management approaches to dyskinesia vary from country to country.
    Neuroepidemiology, 2007, Volume: 29, Issue:3-4

    Topics: Antiparkinson Agents; Critical Pathways; Cross-Cultural Comparison; Cross-Sectional Studies; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Europe; Humans; Incidence; Japan; Levodopa; Outcome Assessment, Health Care; Parkinson Disease; Referral and Consultation; Retrospective Studies; United States

2007
Short-term variability in amplitude and motor topography of whole-body involuntary movements in Parkinson's disease dyskinesias and in Huntington's chorea.
    Clinical neurology and neurosurgery, 2008, Volume: 110, Issue:2

    Topics: Aged; Antiparkinson Agents; Arm; Cohort Studies; Dyskinesia, Drug-Induced; Female; Humans; Huntington Disease; Leg; Levodopa; Male; Middle Aged; Parkinson Disease; Posture; Thorax; Time Factors

2008
Participation of the subthalamic nucleus in executive functions: An intracerebral recording study.
    Movement disorders : official journal of the Movement Disorder Society, 2008, Mar-15, Volume: 23, Issue:4

    Topics: Antiparkinson Agents; Cognition Disorders; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Evoked Potentials; Female; Humans; Levodopa; Male; Microelectrodes; Middle Aged; Neuropsychological Tests; Parkinson Disease; Subthalamic Nucleus

2008
The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram.
    Psychopharmacology, 2008, Volume: 197, Issue:2

    Topics: Adrenal Cortex Hormones; Amphetamine; Animals; Anxiety; Blotting, Western; Body Weight; Central Nervous System Stimulants; Citalopram; Dopamine Agents; Drinking; Dyskinesia, Drug-Induced; Image Processing, Computer-Assisted; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1B; Selective Serotonin Reuptake Inhibitors; Serotonin; Stereotyped Behavior; Sympatholytics; Synaptic Transmission

2008
Effect of bilateral subthalamic deep brain stimulation on diphasic dyskinesia.
    Clinical neurology and neurosurgery, 2008, Volume: 110, Issue:4

    Topics: Adult; Antiparkinson Agents; Deep Brain Stimulation; Dominance, Cerebral; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Subthalamic Nucleus

2008
Lesion of the centromedian thalamic nucleus in MPTP-treated monkeys.
    Movement disorders : official journal of the Movement Disorder Society, 2008, Apr-15, Volume: 23, Issue:5

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dyskinesia, Drug-Induced; Functional Laterality; Intralaminar Thalamic Nuclei; Kainic Acid; Levodopa; Macaca fascicularis; Male; Parkinsonian Disorders; Stereotaxic Techniques

2008
Are parkin patients particularly suited for deep-brain stimulation?
    Movement disorders : official journal of the Movement Disorder Society, 2008, Apr-15, Volume: 23, Issue:5

    Topics: Adult; Aged; Antiparkinson Agents; Deep Brain Stimulation; DNA Mutational Analysis; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Genetic Testing; Heterozygote; Homozygote; Humans; Levodopa; Male; Middle Aged; Mutation; Parkinsonian Disorders; Treatment Outcome; Ubiquitin-Protein Ligases

2008
Receptor-activity modifying protein 1 expression is increased in the striatum following repeated L-DOPA administration in a 6-hydroxydopamine lesioned rat model of Parkinson's disease.
    Synapse (New York, N.Y.), 2008, Volume: 62, Issue:4

    Topics: Adrenergic Agents; Animals; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Gene Expression; In Situ Hybridization; Intracellular Signaling Peptides and Proteins; Levodopa; Membrane Proteins; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptor Activity-Modifying Protein 1; Receptor Activity-Modifying Proteins; RNA, Messenger

2008
Striatal proteomic analysis suggests that first L-dopa dose equates to chronic exposure.
    PloS one, 2008, Feb-13, Volume: 3, Issue:2

    Topics: Animals; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Electrophoresis, Gel, Two-Dimensional; Levodopa; Macaca; Mass Spectrometry; Parkinson Disease; Protein Processing, Post-Translational; Proteomics; Rats

2008
Sigma ligands, but not N-methyl-D-aspartate antagonists, reduce levodopa-induced dyskinesias.
    Neuroreport, 2008, Jan-08, Volume: 19, Issue:1

    Topics: Adrenergic Agents; Amphetamine; Animals; Anti-Anxiety Agents; Behavior, Animal; Dextromethorphan; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Levodopa; Ligands; Male; N-Methylaspartate; Neurotoxicity Syndromes; Oxidopamine; Pyrimidines; Rats; Rats, Sprague-Dawley; Time Factors

2008
Relationship between weight, levodopa and dyskinesia: the significance of levodopa dose per kilogram body weight.
    European journal of neurology, 2008, Volume: 15, Issue:5

    Topics: Age Factors; Aged; Antiparkinson Agents; Body Size; Body Weight; Dyskinesia, Drug-Induced; Female; Humans; Indoles; Levodopa; Logistic Models; Male; Middle Aged; Odds Ratio; Parkinson Disease

2008
Striatal histone modifications in models of levodopa-induced dyskinesia.
    Journal of neurochemistry, 2008, Volume: 106, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylation; Animals; Chromatin; Chromosome Aberrations; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Extracellular Signal-Regulated MAP Kinases; Female; Histones; Levodopa; Macaca mulatta; Male; Methylation; Mice; Mice, Inbred C57BL; Parkinsonian Disorders; Phosphorylation; Protein Processing, Post-Translational; Species Specificity

2008
Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice.
    Current protocols in neuroscience, 2007, Volume: Chapter 9

    Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Mice; Oxidopamine; Parkinsonian Disorders; Rats; Sympatholytics

2007
The course of dyskinesia induction by different treatment schedules of levodopa in Parkinsonian rats: is continuous dopaminergic stimulation necessary?
    Movement disorders : official journal of the Movement Disorder Society, 2008, May-15, Volume: 23, Issue:7

    Topics: Animals; Basal Ganglia; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Levodopa; Parkinson Disease; Rats; Rats, Wistar

2008
Problems of levodopa treatment.
    Clinical neurology and neurosurgery, 1984, Volume: 86, Issue:3

    Topics: Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonia; Humans; Levodopa; Long-Term Care; Parkinson Disease; Receptors, Dopamine; Substantia Nigra

1984
Axial apraxia, a distinct phenomenon.
    Clinical neurology and neurosurgery, 1984, Volume: 86, Issue:4

    Topics: Adult; Aged; Apraxias; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease

1984
Dopamine antagonist and agonist treatment of tardive dyskinesia.
    Advances in biochemical psychopharmacology, 1980, Volume: 24

    Topics: Antipsychotic Agents; Benserazide; Benzimidazoles; Dopamine; Dopamine Antagonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Sulpiride

1980
[Electrophysiological and pharmacological analysis of L-dopa-induced dyskinesia and tardive dyskinesia (author's transl)].
    Journal de physiologie, 1981, Volume: 77, Issue:1

    Topics: Antipsychotic Agents; Dopamine Antagonists; Dyskinesia, Drug-Induced; Electromyography; Humans; Levodopa; Parkinson Disease; Piribedil; Receptors, Dopamine

1981
The role of anticholinergic drugs in extra-pyramidal syndromes.
    Neuropharmacology, 1981, Volume: 20, Issue:12B

    Topics: Antipsychotic Agents; Basal Ganglia Diseases; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Movement Disorders; Parasympatholytics; Parkinson Disease

1981
Drug-induced dyskinesias.
    The American journal of nursing, 1982, Volume: 82, Issue:1

    Topics: Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Nursing Assessment; Patient Education as Topic

1982
[Problems and future perspectives in the treatment of Parkinson's disease].
    Tijdschrift voor gerontologie en geriatrie, 1982, Volume: 13, Issue:4

    Topics: Acetylcholine; Antiparkinson Agents; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Neurotransmitter Agents; Parkinson Disease; Receptors, Dopamine; Substantia Nigra

1982
Levodopa and receptor sensitivity modification in tardive dyskinesia.
    Psychopharmacology, 1982, Volume: 78, Issue:1

    Topics: Adult; Aged; Antipsychotic Agents; Benserazide; Bipolar Disorder; Dementia; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Receptors, Dopamine; Schizophrenia

1982
Carbidopa/levodopa therapy of coexistent drug-induced parkinsonism and tardive dyskinesia.
    Advances in neurology, 1983, Volume: 37

    Topics: Aged; Antipsychotic Agents; Carbidopa; Drug Combinations; Drug Evaluation; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Outcome and Process Assessment, Health Care; Parkinson Disease; Parkinson Disease, Secondary

1983
Sustained levodopa therapy in tardive dyskinesia.
    Journal of neurology, neurosurgery, and psychiatry, 1983, Volume: 46, Issue:7

    Topics: Aged; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Schizophrenia

1983
A comparison of two iatrogenic dyskinesias.
    The American journal of psychiatry, 1983, Volume: 140, Issue:11

    Topics: Antipsychotic Agents; Dyskinesia, Drug-Induced; Extremities; Facial Muscles; Female; Humans; Iatrogenic Disease; Jaw; Levodopa; Male; Middle Aged; Parkinson Disease; Tongue

1983
Dopamine agonists in clinical research for new tardive dyskinesia treatments.
    Modern problems of pharmacopsychiatry, 1983, Volume: 21

    Topics: Adult; Aged; Antipsychotic Agents; Apomorphine; Benserazide; Carbidopa; Dopamine; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Hydrazines; Levodopa; Middle Aged; Synaptic Transmission

1983
Coexistence of severe parkinsonism and tardive dyskinesia as side effects of neuroleptic therapy.
    The Journal of clinical psychiatry, 1984, Volume: 45, Issue:1

    Topics: Aged; Antipsychotic Agents; Carbidopa; Corpus Striatum; Depressive Disorder; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Metoclopramide; Parkinson Disease, Secondary; Receptors, Dopamine

1984
Levodopa-induced dyskinesia and thalamotomy.
    Journal of neurology, neurosurgery, and psychiatry, 1984, Volume: 47, Issue:8

    Topics: Adolescent; Adult; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Microsurgery; Middle Aged; Parkinson Disease; Stereotaxic Techniques; Thalamic Nuclei

1984
[Long-term therapy of the Parkinson syndrome].
    Schweizerische medizinische Wochenschrift, 1984, Aug-18, Volume: 114, Issue:33

    Topics: Dopamine Antagonists; Dyskinesia, Drug-Induced; Humans; Hypotension, Orthostatic; Levodopa; Parasympatholytics; Parkinson Disease; Time Factors

1984
Clonidine therapy for tardive dyskinesia and related syndromes.
    Clinical neuropharmacology, 1984, Volume: 7, Issue:3

    Topics: Adult; Aged; Clonidine; Dyskinesia, Drug-Induced; Dystonia; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders

1984
Difficulties in long term management of Parkinson's disease.
    Australian family physician, 1984, Volume: 13, Issue:5 Suppl

    Topics: Dementia; Depression; Dyskinesia, Drug-Induced; Hallucinations; Humans; Levodopa; Parkinson Disease; Time Factors

1984
The drug treatment of Parkinson's disease.
    Australian family physician, 1984, Volume: 13, Issue:5 Suppl

    Topics: Amantadine; Bromocriptine; Cardiovascular Diseases; Chemical Phenomena; Chemistry; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Nausea; Parasympatholytics; Parkinson Disease

1984
[Onset-and end-of-dose dyskinesias induced by L-dopa treatment in a patient with juvenile parkinsonism].
    No to shinkei = Brain and nerve, 1984, Volume: 36, Issue:12

    Topics: Adult; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Parkinson Disease

1984
Fatal hyperpyrexia after withdrawal of levodopa.
    Neurology, 1984, Volume: 34, Issue:2

    Topics: Basal Ganglia Diseases; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Substance Withdrawal Syndrome

1984
What to do when Sinemet fails: Part one.
    Clinical neuropharmacology, 1984, Volume: 7, Issue:2

    Topics: Antiparkinson Agents; Carbidopa; Dementia; Drug Administration Schedule; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Psychoses, Substance-Induced

1984
Difference in erythrocyte catechol-O-methyltransferase activity between Orientals and Caucasians: difference in levodopa tolerance.
    Clinical pharmacology and therapeutics, 1984, Volume: 35, Issue:6

    Topics: Adult; Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Asian People; Catechol O-Methyltransferase; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Erythrocytes; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; White People

1984
Behavioral control of L-dopa induced dyskinesia in Parkinsonism.
    Biofeedback and self-regulation, 1982, Volume: 7, Issue:4

    Topics: Adult; Antiparkinson Agents; Biofeedback, Psychology; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Electromyography; Humans; Levodopa; Male; Relaxation Therapy

1982
[Experimental studies on L-dopa induced dyskinesia (author's transl)].
    No to shinkei = Brain and nerve, 1980, Volume: 32, Issue:2

    Topics: Animals; Carbidopa; Chlorocebus aethiops; Dyskinesia, Drug-Induced; Haplorhini; Levodopa; Motor Activity; Nystagmus, Pathologic

1980
Symptomatic treatment of tardive dyskinesia: a word of caution.
    Schizophrenia bulletin, 1981, Volume: 7, Issue:4

    Topics: Animals; Brain; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Haplorhini; Humans; Levodopa; Muscimol; Rats; Receptors, Cholinergic; Receptors, Dopamine

1981
Long-term treatment of tardive dyskinesia with presynaptically acting dopamine-depleting agents.
    Advances in neurology, 1983, Volume: 37

    Topics: Adult; Aged; alpha-Methyltyrosine; Carbidopa; Dopamine; Dopamine Antagonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Methyltyrosines; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary; Reserpine; Synapses; Tetrabenazine

1983
Abnormal involuntary movements: a study of dopaminergic receptor interaction.
    Advances in neurology, 1983, Volume: 37

    Topics: Aged; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parasympatholytics; Parasympathomimetics; Parkinson Disease; Receptors, Dopamine

1983
Stereotypy and dyskinesias provoked in cats differentiate directly and indirectly-acting psychomotor stimulants.
    Life sciences, 1982, Dec-20, Volume: 31, Issue:25

    Topics: Animals; Apomorphine; Cats; Dextroamphetamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Nomifensine; Piribedil; Receptors, Dopamine; Stereotyped Behavior

1982
[Bromocriptine in the treatment of patients with parkinsonism and dyskinesias induced by levodopa].
    Nederlands tijdschrift voor geneeskunde, 1982, Apr-17, Volume: 126, Issue:16

    Topics: Adult; Aged; Bromocriptine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease

1982
[Two cases of Parkinson's disease with diphasic dyskinesia, seen during levodopa treatment (author's transl)].
    Rinsho shinkeigaku = Clinical neurology, 1982, Volume: 22, Issue:3

    Topics: Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Parkinson Disease

1982
Management of motor side effects of chronic levodopa therapy.
    Clinical neuropharmacology, 1982, Volume: 5 Suppl 1

    Topics: Circadian Rhythm; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

1982
The role of various forms of treatment in the management of Parkinson's disease.
    Clinical neuropharmacology, 1982, Volume: 5 Suppl 1

    Topics: Amantadine; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Ergot Alkaloids; Humans; Levodopa; Parasympatholytics; Parkinson Disease

1982
[Improper treatment of patients with parkinsonism due to drug use].
    Nederlands tijdschrift voor geneeskunde, 1982, Jul-10, Volume: 126, Issue:28

    Topics: Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Psychotropic Drugs

1982
Blink rates in parkinsonism.
    Annals of neurology, 1982, Volume: 12, Issue:6

    Topics: Adult; Aged; Blinking; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease

1982
Complications of chronic levodopa therapy: long-term efficacy of drug holiday.
    Neurology, 1981, Volume: 31, Issue:4

    Topics: Aged; Dyskinesia, Drug-Induced; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Substance Withdrawal Syndrome

1981
The effect of chronic levodopa on haloperidol induced behavioral supersensitivity in the guinea pig.
    Life sciences, 1981, May-11, Volume: 28, Issue:19

    Topics: Animals; Apomorphine; Behavior, Animal; Carbidopa; Dyskinesia, Drug-Induced; Guinea Pigs; Haloperidol; Humans; Levodopa; Male; Stereotyped Behavior; Time Factors

1981
[Anticholinergics and levodopa in Parkinson's disease: an unnecessary combination in patients treated for the 1st time].
    Revista clinica espanola, 1980, Dec-31, Volume: 159, Issue:6

    Topics: Aged; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parasympatholytics; Parkinson Disease

1980
Iris pigmentation (melanin) in idiopathic dystonic syndromes including torticollis.
    Annals of neurology, 1981, Volume: 10, Issue:1

    Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Dyskinesia, Drug-Induced; Dystonia; Eye Color; Humans; Levodopa; Melanins; Middle Aged; Torsion Abnormality; Torticollis; White People

1981
Electroconvulsive therapy in Parkinsonian patients with the "on-off" syndrome.
    Journal of neural transmission, 1980, Volume: 49, Issue:1-2

    Topics: Depression; Dyskinesia, Drug-Induced; Dystonia; Electroconvulsive Therapy; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease

1980
The impact of treatment with levodopa on Parkinson's disease.
    The Quarterly journal of medicine, 1980, Volume: 49, Issue:195

    Topics: Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Hallucinations; Humans; Levodopa; Male; Mental Disorders; Middle Aged; Parkinson Disease

1980
Levodopa-induced dyskinesias are improved by fluoxetine.
    Neurology, 1995, Volume: 45, Issue:10

    Topics: Antiparkinson Agents; Apomorphine; Dyskinesia, Drug-Induced; Fluoxetine; Humans; Levodopa; Middle Aged

1995
Response to L-dopa and evolution of motor fluctuations in the early phase of treatment of Parkinson's disease.
    Clinical and experimental neurology, 1994, Volume: 31

    Topics: Aged; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors

1994
Parkinsonism and bipolar affective disorder.
    Canadian journal of psychiatry. Revue canadienne de psychiatrie, 1995, Volume: 40, Issue:3

    Topics: Aged; Antiparkinson Agents; Bipolar Disorder; Carbidopa; Clonazepam; Dopamine; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Lithium Carbonate; Male; Parkinson Disease, Secondary

1995
What respiratory abnormalities result from neuroleptics and levodopa?
    Chest, 1995, Volume: 108, Issue:2

    Topics: Antipsychotic Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Respiration Disorders

1995
Adverse reactions to Sinemet CR.
    Journal of the American Geriatrics Society, 1995, Volume: 43, Issue:8

    Topics: Aged; Antiparkinson Agents; Carbidopa; Confusion; Delayed-Action Preparations; Drug Combinations; Dyskinesia, Drug-Induced; Hallucinations; Humans; Levodopa

1995
Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA receptors in the striatopallidal complex.
    Brain research, 1995, May-22, Volume: 680, Issue:1-2

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aminoquinolines; Animals; Autoradiography; Corpus Striatum; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Imidazoles; Levodopa; Macaca fascicularis; Parkinson Disease, Secondary; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, GABA

1995
Thalamotomy for the alleviation of levodopa-induced dyskinesia: experimental studies in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated parkinsonian monkey.
    Neuroscience, 1993, Volume: 55, Issue:1

    Topics: Afferent Pathways; Animals; Apomorphine; Axonal Transport; Brain Mapping; Chorea; Dyskinesia, Drug-Induced; Dystonia; Globus Pallidus; Horseradish Peroxidase; Levodopa; Macaca fascicularis; MPTP Poisoning; Parkinson Disease, Secondary; Stereotaxic Techniques; Thalamus; Wheat Germ Agglutinins

1993
[A pharmacological study of levodopa solution therapy for a patient with Parkinson's disease with motor fluctuations].
    Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics, 1995, Volume: 32, Issue:1

    Topics: Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Middle Aged; Parkinson Disease; Solutions

1995
Anticholinergics and dyskinesia.
    Movement disorders : official journal of the Movement Disorder Society, 1994, Volume: 9, Issue:6

    Topics: Aged; Biperiden; Carbidopa; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Neurologic Examination; Parkinson Disease; Tremor; Trihexyphenidyl

1994
Role of D1 receptor mechanisms in the potentiation of motor responses to L-dopa and apomorphine by MK 801 in the reserpine-treated mouse.
    Journal of neural transmission. Parkinson's disease and dementia section, 1994, Volume: 8, Issue:1-2

    Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Dizocilpine Maleate; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Motor Activity; Receptors, Dopamine; Reserpine

1994
Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- exposed monkeys.
    The Journal of pharmacology and experimental therapeutics, 1993, Volume: 267, Issue:1

    Topics: Animals; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Motor Activity; MPTP Poisoning; Parkinson Disease; Receptors, Dopamine D1; Receptors, Dopamine D2

1993
Portable device for quantifying parkinsonian wrist rigidity.
    Movement disorders : official journal of the Movement Disorder Society, 1994, Volume: 9, Issue:1

    Topics: Adult; Aged; Antiparkinson Agents; Antipsychotic Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Muscle Rigidity; Muscle Tonus; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Psychotic Disorders; Risk Factors; Transducers

1994
Zotepine reversibly induces akinesia and rigidity in Parkinson's disease patients with resting tremor or drug-induced psychosis.
    Movement disorders : official journal of the Movement Disorder Society, 1994, Volume: 9, Issue:2

    Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Dibenzothiepins; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Muscle Rigidity; Neurologic Examination; Parkinson Disease; Psychoses, Substance-Induced; Tremor

1994
Do parkinsonian symptoms and levodopa-induced dyskinesias start in the foot?
    Neurology, 1994, Volume: 44, Issue:9

    Topics: Adult; Aged; Dyskinesia, Drug-Induced; Female; Foot; Humans; Levodopa; Male; Middle Aged; Parkinson Disease

1994
Excitotoxic lateral pallidotomy does not relieve L-dopa-induced dyskinesia in MPTP parkinsonian monkeys.
    Brain research, 1994, Jul-04, Volume: 650, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Levodopa; Macaca fascicularis; Parkinson Disease, Secondary

1994
Suppression of dyskinesias in advanced Parkinson's disease: moderate daily clozapine doses provide long-term dyskinesia reduction.
    Movement disorders : official journal of the Movement Disorder Society, 1994, Volume: 9, Issue:4

    Topics: Aged; Clozapine; Disability Evaluation; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Neurologic Examination; Parkinson Disease

1994
Levodopa: rational and irrational pharmacology.
    Annals of neurology, 1994, Volume: 36, Issue:1

    Topics: Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine

1994
Suppression of dyskinesias in advanced Parkinson's disease. II. Increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms.
    Neurology, 1993, Volume: 43, Issue:8

    Topics: Aged; Clozapine; Dihydroxyphenylalanine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease

1993
Role of selective D1 and D2 agonists in inducing dyskinesia in drug-naive MPTP monkeys.
    Advances in neurology, 1993, Volume: 60

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain Mapping; Carbidopa; Corpus Striatum; Dopamine Agents; Dose-Response Relationship, Drug; Down-Regulation; Drug Combinations; Dyskinesia, Drug-Induced; Female; Levodopa; Locomotion; Macaca fascicularis; Parkinson Disease, Secondary; Psychomotor Performance; Receptors, Dopamine D1; Receptors, Dopamine D2

1993
Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys.
    Clinical neuropharmacology, 1993, Volume: 16, Issue:5

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Atropine; Baclofen; Clonidine; Dopamine Agents; Drug Interactions; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Meperidine; Methoxydimethyltryptamines; Neurotransmitter Agents; Yohimbine

1993
A quantitative study of levodopa-induced dyskinesia in Parkinson's disease.
    Journal of neural transmission. Parkinson's disease and dementia section, 1993, Volume: 6, Issue:2

    Topics: Aged; Aged, 80 and over; Basal Ganglia; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Muscle Rigidity; Parkinson Disease; Tremor

1993
Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology.
    Movement disorders : official journal of the Movement Disorder Society, 1994, Volume: 9, Issue:1

    Topics: Activities of Daily Living; Adult; Aged; Chorea; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Dystonia; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Motor Skills; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Receptors, Dopamine D1; Video Recording

1994
Levodopa, rice eating and on-off phenomenon.
    The Ceylon medical journal, 1993, Volume: 38, Issue:4

    Topics: Dietary Carbohydrates; Dietary Proteins; Dyskinesia, Drug-Induced; Humans; Levodopa; Oryza; Parkinson Disease

1993
Apomorphine and diphasic dyskinesia.
    Clinical neuropharmacology, 1994, Volume: 17, Issue:1

    Topics: Aged; Apomorphine; Circadian Rhythm; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease

1994
Severe evening dyskinesias in advanced Parkinson's disease: clinical description, relation to plasma levodopa, and treatment.
    Movement disorders : official journal of the Movement Disorder Society, 1994, Volume: 9, Issue:2

    Topics: Aged; Antiparkinson Agents; Bromocriptine; Carbidopa; Chorea; Circadian Rhythm; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonia; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease

1994
[A case of multiple system atrophy presenting a regular involuntary movement of the neck muscles synchronous with respiration].
    Rinsho shinkeigaku = Clinical neurology, 1993, Volume: 33, Issue:7

    Topics: Amantadine; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Muscular Atrophy; Neck Muscles; Respiration; Trihexyphenidyl

1993
The spectrum of levodopa-related fluctuations in Parkinson's disease.
    Neurology, 1993, Volume: 43, Issue:8

    Topics: Aged; Depression; Dyskinesia, Drug-Induced; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Restless Legs Syndrome; Urinary Incontinence

1993
Risk factors for motor response complications in L-dopa-treated parkinsonian patients.
    Advances in neurology, 1993, Volume: 60

    Topics: Adult; Age Factors; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Motor Activity; Neurologic Examination; Parkinson Disease; Risk Factors

1993
Developing a stable bilateral model of parkinsonism in rhesus monkeys.
    Neuroscience, 1993, Volume: 52, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carbidopa; Carotid Arteries; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Feeding Behavior; Female; Injections, Intra-Arterial; Levodopa; Macaca mulatta; Motor Activity; Parkinson Disease, Secondary

1993
Chronic thalamic stimulation improves tremor and levodopa induced dyskinesias in Parkinson's disease.
    Journal of neurology, neurosurgery, and psychiatry, 1993, Volume: 56, Issue:3

    Topics: Aged; Combined Modality Therapy; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Electromyography; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Prostheses and Implants; Thalamic Nuclei; Tremor

1993
Does tolerance develop to levodopa? Comparison of 2- and 21-H levodopa infusions.
    Movement disorders : official journal of the Movement Disorder Society, 1993, Volume: 8, Issue:2

    Topics: Aged; Carbidopa; Chromatography, High Pressure Liquid; Drug Administration Schedule; Drug Tolerance; Dyskinesia, Drug-Induced; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Tyrosine

1993
Assessment of response fluctuations in Parkinson's disease by ambulatory wrist activity monitoring.
    Acta neurologica Scandinavica, 1993, Volume: 87, Issue:3

    Topics: Adult; Aged; Circadian Rhythm; Data Display; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Microcomputers; Middle Aged; Monitoring, Physiologic; Motor Activity; Neurologic Examination; Parkinson Disease; Signal Processing, Computer-Assisted; Sleep Stages

1993
Worsening of postural tremor in patients with levodopa-induced dyskinesia: a quantitative analysis.
    Clinical neuropharmacology, 1993, Volume: 16, Issue:3

    Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Posture; Tremor

1993
[Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].
    Der Nervenarzt, 1995, Volume: 66, Issue:12

    Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease

1995
Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys.
    Annals of neurology, 1996, Volume: 39, Issue:5

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Chorea; Dyskinesia, Drug-Induced; Dystonia; Excitatory Amino Acid Antagonists; Female; Isoquinolines; Levodopa; Macaca fascicularis; Macaca mulatta; Male; Parkinson Disease, Secondary; Receptors, N-Methyl-D-Aspartate

1996
High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias.
    Movement disorders : official journal of the Movement Disorder Society, 1996, Volume: 11, Issue:3

    Topics: Aged; Antiparkinson Agents; Carbidopa; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Pergolide

1996
[Levodopa-induced dyskinesia in 176 patients with Parkinson's disease].
    Arquivos de neuro-psiquiatria, 1995, Volume: 53, Issue:4

    Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Time Factors

1995
Parkinsonian rigidity, dopa-induced dyskinesia and chorea--dynamic studies on the basal ganglia-thalamocortical motor circuit using PET scan and depth microrecording.
    Acta neurochirurgica. Supplement, 1995, Volume: 64

    Topics: Antiparkinson Agents; Basal Ganglia; Blood Glucose; Brain; Brain Mapping; Cerebral Cortex; Chorea; Deoxyglucose; Dyskinesia, Drug-Induced; Electrodes, Implanted; Energy Metabolism; Fluorodeoxyglucose F18; Globus Pallidus; Humans; Levodopa; Motor Neurons; Neural Pathways; Neurologic Examination; Parkinson Disease; Stereotaxic Techniques; Thalamic Nuclei; Tomography, Emission-Computed; Tremor

1995
Chronic anterior pallidal stimulation for Parkinson's disease.
    Acta neurochirurgica, 1995, Volume: 137, Issue:1-2

    Topics: Antiparkinson Agents; Brain Mapping; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Electrodes, Implanted; Female; Follow-Up Studies; Globus Pallidus; Humans; Levodopa; Middle Aged; Monitoring, Intraoperative; Motor Skills; Neurologic Examination; Parkinson Disease; Signal Processing, Computer-Assisted

1995
Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
    Movement disorders : official journal of the Movement Disorder Society, 1995, Volume: 10, Issue:6

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Antiparkinson Agents; Callithrix; Carbidopa; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Synergism; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Neurologic Examination; Parkinson Disease, Secondary

1995
Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates.
    Movement disorders : official journal of the Movement Disorder Society, 1996, Volume: 11, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Brain; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Motor Skills; Neurologic Examination; Parkinson Disease, Secondary; Receptors, Dopamine D1

1996
Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease.
    Drugs & aging, 1996, Volume: 9, Issue:3

    Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Naloxone; Narcotic Antagonists; Parkinson Disease

1996
Combined effects of cabergoline and L-dopa on parkinsonism in MPTP-treated cynomolgus monkeys.
    Journal of neural transmission (Vienna, Austria : 1996), 1996, Volume: 103, Issue:11

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Cabergoline; Drug Interactions; Dyskinesia, Drug-Induced; Ergolines; Hyperkinesis; Levodopa; Macaca fascicularis; Movement; Parkinson Disease, Secondary

1996
The behavioural effects of pramipexole, a novel dopamine receptor agonist.
    European journal of pharmacology, 1997, Apr-11, Volume: 324, Issue:1

    Topics: Animals; Antiparkinson Agents; Benzazepines; Benzothiazoles; Body Temperature; Catalepsy; Clozapine; Dopamine Agents; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Haloperidol; Injections, Subcutaneous; Levodopa; Male; Mice; Motor Activity; Pramipexole; Rats; Rats, Wistar; Receptors, Dopamine D2; Receptors, Dopamine D3; Spiperone; Stereotyped Behavior; Sulpiride; Thiazoles

1997
Validation of a rodent model of Parkinson's Disease: evidence of a therapeutic window for oral Sinemet.
    Brain research bulletin, 1996, Volume: 39, Issue:6

    Topics: Administration, Oral; Animals; Antiparkinson Agents; Carbidopa; Dose-Response Relationship, Drug; Drug Combinations; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; Levodopa; Male; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Stereotyped Behavior

1996
Selection criteria for unilateral posteroventral pallidotomy.
    Acta neurochirurgica. Supplement, 1997, Volume: 68

    Topics: Antiparkinson Agents; Blood Glucose; Dominance, Cerebral; Dyskinesia, Drug-Induced; Globus Pallidus; Humans; Levodopa; Neurologic Examination; Neuropsychological Tests; Parkinson Disease; Patient Selection; Postoperative Complications; Stereotaxic Techniques; Tomography, Emission-Computed; Treatment Outcome

1997
Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys.
    Neurology, 1997, Volume: 49, Issue:2

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Motor Activity; Parkinson Disease, Secondary; Quinolones; Quinpirole; Receptors, Dopamine D1; Thiophenes

1997
High-frequency stimulation of the globus pallidus internalis in Parkinson's disease: a study of seven cases.
    Journal of neurosurgery, 1997, Volume: 87, Issue:4

    Topics: Adult; Disease Progression; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Electrodes, Implanted; Follow-Up Studies; Gait; Globus Pallidus; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Movement Disorders; Muscle Rigidity; Parkinson Disease; Speech Disorders; Stereotaxic Techniques; Thalamic Nuclei; Treatment Outcome; Tremor

1997
Clinical implications of sustained dopaminergic stimulation.
    Clinical neuropharmacology, 1994, Volume: 17 Suppl 2

    Topics: Aged; Benserazide; Carbidopa; Delayed-Action Preparations; Dopamine Agonists; Drug Combinations; Dyskinesia, Drug-Induced; Follow-Up Studies; Humans; Levodopa; Lisuride; Parkinson Disease; Reaction Time

1994
[Multivariate analysis of the problems of long-term levodopa therapy in Parkinson's disease].
    Rinsho shinkeigaku = Clinical neurology, 1997, Volume: 37, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Multivariate Analysis; Parkinson Disease; Time Factors

1997
Bilateral posteroventral pallidotomy in advanced Parkinson's disease in three patients.
    Movement disorders : official journal of the Movement Disorder Society, 1997, Volume: 12, Issue:5

    Topics: Activities of Daily Living; Age of Onset; Antiparkinson Agents; Drug Resistance; Dyskinesia, Drug-Induced; Dystonia; Female; Follow-Up Studies; Globus Pallidus; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Muscle Rigidity; Parkinson Disease; Pilot Projects; Prospective Studies; Severity of Illness Index; Treatment Outcome

1997
Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias.
    Annals of neurology, 1997, Volume: 42, Issue:5

    Topics: Adult; Aged; Antiparkinson Agents; Binding, Competitive; Brain Chemistry; Brain Mapping; Carbon Radioisotopes; Caudate Nucleus; Diprenorphine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Narcotic Antagonists; Occipital Lobe; Parkinson Disease; Putamen; Receptors, Opioid; Thalamic Nuclei

1997
Motor complications of chronic levodopa therapy in Parkinson's disease.
    Clinical neuropharmacology, 1997, Volume: 20, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease

1997
Effects of increasing doses of apomorphine during stereotaxic neurosurgery in Parkinson's disease: clinical score and internal globus pallidus activity. Short communication.
    Journal of neural transmission (Vienna, Austria : 1996), 1997, Volume: 104, Issue:8-9

    Topics: Antiparkinson Agents; Apomorphine; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Electrophysiology; Globus Pallidus; Humans; Intraoperative Period; Levodopa; Male; Middle Aged; Parkinson Disease; Stereotaxic Techniques

1997
De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
    Movement disorders : official journal of the Movement Disorder Society, 1998, Volume: 13, Issue:2

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Bromocriptine; Callithrix; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Indoles; Levodopa; Male; Motor Skills; Neurologic Examination; Parkinson Disease, Secondary; Receptors, Dopamine D2

1998
Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 1998, Volume: 13, Issue:2

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Infusion Pumps; Infusions, Parenteral; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease; Treatment Outcome

1998
A study of medial pallidotomy for Parkinson's disease: clinical outcome, MRI location and complications.
    Brain : a journal of neurology, 1998, Volume: 121 ( Pt 1)

    Topics: Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Globus Pallidus; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Motor Activity; Parkinson Disease; Postoperative Complications; Treatment Outcome

1998
Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson's disease.
    Brain : a journal of neurology, 1998, Volume: 121 ( Pt 3)

    Topics: Adult; Age of Onset; Dyskinesia, Drug-Induced; Electric Stimulation; Electrodes, Implanted; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Thalamic Nuclei

1998
Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia.
    Brain : a journal of neurology, 1998, Volume: 121 ( Pt 3)

    Topics: Aged; Analysis of Variance; Cerebrovascular Circulation; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Motor Cortex; Multivariate Analysis; Parkinson Disease; Reference Values; Tomography, Emission-Computed, Single-Photon

1998
Tardive dyskinesia in dopa-responsive dystonia: a reappraisal of the dopamine hypothesis of tardive dyskinesia.
    Neurology, 1998, Volume: 50, Issue:4

    Topics: Adult; Anti-Dyskinesia Agents; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Dystonia; Family Health; Female; GTP Cyclohydrolase; Haloperidol; Humans; Levodopa; Male; Point Mutation

1998
Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.
    Journal of neurology, neurosurgery, and psychiatry, 1998, Volume: 64, Issue:5

    Topics: Aged; Antiparkinson Agents; Apomorphine; Chronotherapy; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Infusion Pumps, Implantable; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Treatment Outcome

1998
Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Experimental neurology, 1998, Volume: 151, Issue:2

    Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Behavior, Animal; Bromocriptine; Clonidine; Disease Models, Animal; Dopamine; Dopamine Uptake Inhibitors; Dyskinesia, Drug-Induced; Levodopa; Lisuride; Locomotion; Male; Mazindol; Methoxydimethyltryptamines; Oxidopamine; Parkinson Disease, Secondary; Prosencephalon; Rats; Rats, Sprague-Dawley; Sympatholytics; Tritium; Yohimbine

1998
Current and emerging drug therapies in the management of Parkinson's disease.
    Neurology, 1998, Volume: 50, Issue:6 Suppl 6

    Topics: Antiparkinson Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

1998
Inhibition of levodopa effects by internal pallidal stimulation.
    Movement disorders : official journal of the Movement Disorder Society, 1998, Volume: 13, Issue:4

    Topics: Antiparkinson Agents; Combined Modality Therapy; Dominance, Cerebral; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Electrodes, Implanted; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Parkinson Disease

1998
Conjugate eye deviations as dyskinesias induced by levodopa in Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 1998, Volume: 13, Issue:4

    Topics: Adult; Antiparkinson Agents; Diagnosis, Differential; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Neurologic Examination; Ocular Motility Disorders; Parkinson Disease

1998
Gamma knife radiosurgery as a lesioning technique in movement disorder surgery.
    Journal of neurosurgery, 1998, Volume: 89, Issue:2

    Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Dopamine Agents; Dyskinesia, Drug-Induced; Electroencephalography; Female; Follow-Up Studies; Gait; Globus Pallidus; Hemianopsia; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Motor Skills; Movement Disorders; Muscle Rigidity; Neuropsychological Tests; Parkinson Disease; Radiosurgery; Radiotherapy Dosage; Safety; Single-Blind Method; Thalamus; Tremor

1998
Suprathreshold levodopa doses, dyskinesias, and disability in advanced Parkinson's disease.
    Neurology, 1998, Volume: 51, Issue:2

    Topics: Antiparkinson Agents; Disabled Persons; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Retrospective Studies

1998
Pallidotomy revisited. Analysis of posteroventral pallidotomy.
    Stereotactic and functional neurosurgery, 1997, Volume: 69, Issue:1-4 Pt 2

    Topics: Aged; Dyskinesia, Drug-Induced; Globus Pallidus; Humans; Levodopa; MMPI; Movement Disorders; Muscle Rigidity; Parkinson Disease; Postoperative Period; Stereotaxic Techniques; Thalamic Nuclei; Thalamus; Treatment Outcome; Tremor

1997
Catechol-O-methyltransferase inhibitors in Parkinson's disease.
    Lancet (London, England), 1998, Aug-15, Volume: 352, Issue:9127

    Topics: Aged; Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Confusion; Drug Interactions; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Nitrophenols; Parkinson Disease; Tolcapone

1998
Beneficial effects of combined L-dopa and central anticholinergic in a patient with severe drug-induced parkinsonism and tardive dystonia.
    Canadian journal of psychiatry. Revue canadienne de psychiatrie, 1998, Volume: 43, Issue:6

    Topics: Antiparkinson Agents; Antipsychotic Agents; Cholinergic Antagonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonia; Female; Humans; Levodopa; Middle Aged

1998
Altered thalamic response to levodopa in Parkinson's patients with dopa-induced dyskinesias.
    Proceedings of the National Academy of Sciences of the United States of America, 1998, Sep-29, Volume: 95, Issue:20

    Topics: Adult; Aged; Carbidopa; Case-Control Studies; Cerebrovascular Circulation; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Motor Cortex; Parkinson Disease; Thalamus; Tomography, Emission-Computed

1998
Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys.
    Movement disorders : official journal of the Movement Disorder Society, 1998, Volume: 13, Issue:5

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Injections, Subcutaneous; Levodopa; Macaca fascicularis; Neurologic Examination; Parkinson Disease, Secondary; Receptors, N-Methyl-D-Aspartate

1998
New use for an old drug: amantadine benefits levodopa-induced dyskinesia.
    Movement disorders : official journal of the Movement Disorder Society, 1998, Volume: 13, Issue:5

    Topics: Amantadine; Antiparkinson Agents; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Levodopa; Neurologic Examination

1998
L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA.
    The European journal of neuroscience, 1998, Volume: 10, Issue:8

    Topics: Animals; Autoradiography; Behavior, Animal; Corpus Striatum; Dyskinesia, Drug-Induced; Enkephalins; Female; Gene Expression Regulation; Glutamate Decarboxylase; In Situ Hybridization; Levodopa; Oxidopamine; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; RNA, Messenger; Tachykinins

1998
Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease.
    The New England journal of medicine, 1998, Oct-15, Volume: 339, Issue:16

    Topics: Activities of Daily Living; Antiparkinson Agents; Combined Modality Therapy; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Electrodes, Implanted; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Thalamic Nuclei

1998
Sudden appearance of invalidating dyskinesia-dystonia and off fluctuations after the introduction of levodopa in two dopaminomimetic drug naive patients with stage IV Parkinson's disease.
    Journal of neurology, neurosurgery, and psychiatry, 1998, Volume: 65, Issue:4

    Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Dystonia; Humans; Levodopa; Male; Parkinson Disease; Severity of Illness Index

1998
Treating Parkinson's disease.
    Health news (Waltham, Mass.), 1998, Nov-20, Volume: 4, Issue:14

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Humans; Levodopa; Parkinson Disease; Thalamic Nuclei

1998
Young-onset Parkinson's disease revisited--clinical features, natural history, and mortality.
    Movement disorders : official journal of the Movement Disorder Society, 1998, Volume: 13, Issue:6

    Topics: Adolescent; Adult; Age Factors; Age of Onset; Antiparkinson Agents; Cause of Death; Chi-Square Distribution; Cognition Disorders; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Likelihood Functions; Male; Parkinson Disease; Poisson Distribution; Risk Factors

1998
Gait analysis in patients with Parkinson's disease and motor fluctuations: influence of levodopa and comparison with other measures of motor function.
    Movement disorders : official journal of the Movement Disorder Society, 1998, Volume: 13, Issue:6

    Topics: Aged; Analysis of Variance; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Gait; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Statistics, Nonparametric

1998
Deep brain stimulation in Parkinson's disease: opposite effects of stimulation in the pallidum.
    Movement disorders : official journal of the Movement Disorder Society, 1998, Volume: 13, Issue:6

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Electrodes, Implanted; Globus Pallidus; Humans; Levodopa; Parkinson Disease

1998
Antiparkinsonian and anti-levodopa-induced dyskinesia effects obtained by stimulating the same site within the GPi in PD.
    Neurology, 1998, Volume: 51, Issue:6

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Electric Stimulation; Globus Pallidus; Humans; Levodopa; Middle Aged; Parkinson Disease

1998
Levodopa therapy can ameliorate tetrabenazine-induced parkinsonism.
    Movement disorders : official journal of the Movement Disorder Society, 1999, Volume: 14, Issue:1

    Topics: Aged; Antiparkinson Agents; Blepharospasm; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Middle Aged; Neurologic Examination; Parkinson Disease, Secondary; Recurrence; Sulpiride; Tetrabenazine

1999
Worsening of levodopa-induced dyskinesias by motor and mental tasks.
    Movement disorders : official journal of the Movement Disorder Society, 1999, Volume: 14, Issue:2

    Topics: Analysis of Variance; Antiparkinson Agents; Apomorphine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Problem Solving; Severity of Illness Index; Speech; Volition

1999
Actions of the D1 agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated L-dopa-primed common marmosets.
    Psychopharmacology, 1999, Volume: 142, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adamantane; Animals; Benzopyrans; Callithrix; Disease Models, Animal; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Levodopa; Locomotion; Male; Quinolones; Receptors, Dopamine D1; Thiophenes

1999
Riluzole for levodopa-induced dyskinesias in advanced Parkinson's disease.
    Lancet (London, England), 1999, May-22, Volume: 353, Issue:9166

    Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Riluzole; Treatment Outcome

1999
Protease inhibitors enhance levodopa effects in Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 1999, Volume: 14, Issue:3

    Topics: Antiparkinson Agents; Drug Synergism; Dyskinesia, Drug-Induced; HIV Protease Inhibitors; Humans; Indinavir; Levodopa; Male; Middle Aged; Parkinson Disease

1999
From off-period dystonia to peak-dose chorea. The clinical spectrum of varying subthalamic nucleus activity.
    Brain : a journal of neurology, 1999, Volume: 122 ( Pt 6)

    Topics: Adult; Antiparkinson Agents; Chorea; Dyskinesia, Drug-Induced; Dystonia; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Periodicity; Thalamic Nuclei

1999
Glutamate receptor-mediated mechanisms in levodopa-induced motor fluctuations in an experimental model of parkinsonism.
    Advances in neurology, 1999, Volume: 80

    Topics: Animals; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Levodopa; Male; Parkinson Disease, Secondary; Piperazines; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Glutamate; Rotation; Stereotyped Behavior; Time Factors

1999
Reversal of levodopa failure syndrome by posteroventral-ansa pallidotomy.
    Advances in neurology, 1999, Volume: 80

    Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Globus Pallidus; Humans; Levodopa; Middle Aged; Movement; Treatment Outcome

1999
Improvement of levodopa induced dyskinesias by thalamic deep brain stimulation is related to slight variation in electrode placement: possible involvement of the centre median and parafascicularis complex.
    Journal of neurology, neurosurgery, and psychiatry, 1999, Volume: 67, Issue:3

    Topics: Aged; Dyskinesia, Drug-Induced; Electric Stimulation; Electrodes; Functional Laterality; Humans; Levodopa; Middle Aged; Parkinson Disease; Thalamic Nuclei

1999
Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys.
    The Journal of pharmacology and experimental therapeutics, 1999, Volume: 290, Issue:3

    Topics: Animals; Antiparkinson Agents; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Levodopa; Macaca fascicularis; Male; MPTP Poisoning; Oocytes; Parkinson Disease, Secondary; Rats; Receptors, N-Methyl-D-Aspartate; Valine; Xenopus laevis

1999
Drug treatments of levodopa-induced dyskinesias.
    Lancet (London, England), 1999, Aug-07, Volume: 354, Issue:9177

    Topics: Amantadine; Antiparkinson Agents; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Humans; Levodopa; Patient Selection; Receptors, N-Methyl-D-Aspartate; Riluzole; Treatment Outcome

1999
Dyskinesias assessment: from CAPIT to CAPSIT. Core Assessment Program for Intracerebral Transplantations. Core Assessment Program for Surgical Interventional Therapies.
    Movement disorders : official journal of the Movement Disorder Society, 1999, Volume: 14 Suppl 1

    Topics: Animals; Antiparkinson Agents; Brain; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Levodopa; Neurosurgical Procedures; Parkinson Disease; Self-Assessment; Treatment Outcome

1999
A unified dyskinesias rating scale for L-dopa-induced dyskinesias?
    Movement disorders : official journal of the Movement Disorder Society, 1999, Volume: 14 Suppl 1

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Severity of Illness Index

1999
Mirtazapine treats resting tremor, essential tremor, and levodopa-induced dyskinesias.
    Neurology, 1999, Sep-22, Volume: 53, Issue:5

    Topics: Adrenergic alpha-Antagonists; Aged; Dyskinesia, Drug-Induced; Dyskinesias; Female; Humans; Levodopa; Male; Mianserin; Middle Aged; Mirtazapine; Parkinson Disease

1999
Levodopa-induced dyskinesias treated by pallidotomy.
    Journal of the neurological sciences, 1999, Aug-01, Volume: 167, Issue:1

    Topics: Adult; Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Parkinson Disease

1999
Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD.
    Neurology, 1999, Oct-22, Volume: 53, Issue:7

    Topics: Adult; Aged; Alleles; Antiparkinson Agents; Case-Control Studies; Dyskinesia, Drug-Induced; Dyskinesias; Female; Gene Frequency; Genetic Predisposition to Disease; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polymorphism, Genetic; Receptors, Dopamine D2; Tandem Repeat Sequences

1999
Sub-chronic administration of the dopamine D(1) antagonist SKF 83959 in bilaterally MPTP-treated rhesus monkeys: stable therapeutic effects and wearing-off dyskinesia.
    Psychopharmacology, 1999, Volume: 146, Issue:3

    Topics: Animals; Antiparkinson Agents; Dopamine Antagonists; Dyskinesia, Drug-Induced; Levodopa; Macaca mulatta; Male; MPTP Poisoning; Parkinson Disease; Receptors, Dopamine D1

1999
Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias.
    Annals of neurology, 1999, Volume: 46, Issue:5

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Dyskinesias; Electrophysiology; Eye Movements; Globus Pallidus; Levodopa; Macaca mulatta; Motor Activity; Neurons; Parkinsonian Disorders

1999
Maximizing the benefit:risk ratio of levodopa therapy in Parkinson's disease.
    Pharmacotherapy, 1999, Volume: 19, Issue:11 Pt 2

    Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Disease Progression; Dopamine Agonists; Dyskinesia, Drug-Induced; Dyskinesias; Humans; Levodopa; Odds Ratio; Parkinson Disease

1999
Risk factors for levodopa-induced dyskinesias in Parkinson's disease.
    Journal of neurology, 1999, Volume: 246, Issue:12

    Topics: Age of Onset; Aged; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Multivariate Analysis; Parkinson Disease; Risk Factors; Survival Analysis; Time Factors

1999
High frequency stimulation of the subthalamic nucleus and levodopa induced dyskinesias in Parkinson's disease.
    Journal of neurology, neurosurgery, and psychiatry, 2000, Volume: 68, Issue:1

    Topics: Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Humans; Levodopa; Parkinson Disease; Thalamic Nuclei

2000
Weight gain following unilateral pallidotomy in Parkinson's disease.
    Acta neurologica Scandinavica, 2000, Volume: 101, Issue:2

    Topics: Dyskinesia, Drug-Induced; Eating; Globus Pallidus; Humans; Levodopa; Linear Models; Longitudinal Studies; Motor Activity; Neuropsychological Tests; Nutrition Assessment; Parkinsonian Disorders; Severity of Illness Index; Smell; Stereotaxic Techniques; Surveys and Questionnaires; Weight Gain

2000
Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys.
    Naunyn-Schmiedeberg's archives of pharmacology, 2000, Volume: 361, Issue:2

    Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; gamma-Aminobutyric Acid; Idazoxan; Levodopa; Macaca fascicularis; Motor Activity; MPTP Poisoning; Norepinephrine; Parkinson Disease

2000
Levodopa toxicity in Parkinson disease: reality or myth? Reality--practice patterns should change.
    Archives of neurology, 2000, Volume: 57, Issue:3

    Topics: Antiparkinson Agents; Diagnosis, Differential; Disease Progression; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Research Design; Treatment Outcome

2000
Is levodopa toxic?
    Archives of neurology, 2000, Volume: 57, Issue:3

    Topics: Antiparkinson Agents; Diagnosis, Differential; Disease Progression; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Time Factors

2000
Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
    Experimental neurology, 2000, Volume: 162, Issue:2

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Callithrix; Carbidopa; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Injections, Intraperitoneal; Levodopa; Male; Motor Activity; Parkinson Disease, Secondary; Purinergic P1 Receptor Antagonists; Purines; Quinpirole; Receptor, Adenosine A2A; Receptors, Dopamine D1; Receptors, Dopamine D2

2000
Levodopa-induced dyskinesias in autopsy-proven cortical-basal ganglionic degeneration.
    Movement disorders : official journal of the Movement Disorder Society, 2000, Volume: 15, Issue:2

    Topics: Aged; Antiparkinson Agents; Basal Ganglia; Basal Ganglia Diseases; Cerebral Cortex; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Neurodegenerative Diseases; Neurologic Examination; Parkinson Disease

2000
Neuropsychological outcome of GPi pallidotomy and GPi or STN deep brain stimulation in Parkinson's disease.
    Brain and cognition, 2000, Volume: 42, Issue:3

    Topics: Adult; Aged; Basal Ganglia; Brain; Cognition Disorders; Dyskinesia, Drug-Induced; Electric Stimulation; Female; Globus Pallidus; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Neurosurgical Procedures; Parkinson Disease; Postoperative Complications; Preoperative Care; Subthalamic Nucleus; Surveys and Questionnaires

2000
[Efficacy and safety of posteroventral pallidotomy for the treatment of advanced Parkinson's disease].
    Medicina clinica, 2000, Feb-19, Volume: 114, Issue:6

    Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Stereotaxic Techniques; Treatment Outcome

2000
Bilateral subthalamic stimulation for Parkinson's disease by using three-dimensional stereotactic magnetic resonance imaging and electrophysiological guidance.
    Journal of neurosurgery, 2000, Volume: 92, Issue:4

    Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Electrodes, Implanted; Electroencephalography; Female; Follow-Up Studies; Humans; Levodopa; Magnetic Resonance Imaging; Male; Mesencephalon; Middle Aged; Monitoring, Intraoperative; Movement; Parkinson Disease; Patient Care Planning; Radiology, Interventional; Red Nucleus; Safety; Stereotaxic Techniques; Subthalamic Nucleus; Tremor

2000
Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA.
    The European journal of neuroscience, 2000, Volume: 12, Issue:3

    Topics: Animals; Autoradiography; Brain; Brain Chemistry; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine Agents; Dyskinesia, Drug-Induced; Enkephalins; Female; In Situ Hybridization; Levodopa; Macaca fascicularis; Male; Nitriles; Oligonucleotide Probes; Protein Precursors; Receptors, Purinergic P1; RNA, Messenger; Tachykinins

2000
AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys.
    Neurology, 2000, Apr-25, Volume: 54, Issue:8

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzodiazepines; Dioxoles; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Levodopa; Macaca fascicularis; Male; Motor Activity; Parkinson Disease, Secondary; Piperidines; Receptors, AMPA; Severity of Illness Index

2000
Serotonergic decompensation in the akinetic expression of Parkinson's disease.
    The International journal of neuroscience, 2000, Volume: 101, Issue:1-4

    Topics: Brain; Chromatography, High Pressure Liquid; Dopamine; Dyskinesia, Drug-Induced; Homovanillic Acid; Humans; Levodopa; Methoxyhydroxyphenylglycol; Norepinephrine; Parkinson Disease; Serotonin; Synaptic Transmission

2000
The predictive validity of the drug-naive bilaterally MPTP-treated monkey as a model of Parkinson's disease: effects of L-DOPA and the D1 agonist SKF 82958.
    Behavioural pharmacology, 1999, Volume: 10, Issue:2

    Topics: Animals; Antiparkinson Agents; Arm; Behavior, Animal; Benzazepines; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Dystonia; Electroencephalography; Epilepsy; Levodopa; Macaca mulatta; Male; Motor Activity; Movement; MPTP Poisoning; Parkinson Disease, Secondary; Predictive Value of Tests; Receptors, Dopamine D1

1999
Levodopa-induced dyskinesias in Parkinson's disease: is sensitization reversible?
    Annals of neurology, 2000, Volume: 47, Issue:5

    Topics: Adult; Aged; Antiparkinson Agents; Disability Evaluation; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Electrodes, Implanted; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Subthalamic Nucleus

2000
Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model.
    Movement disorders : official journal of the Movement Disorder Society, 2000, Volume: 15, Issue:3

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain Mapping; Corpus Striatum; Denervation; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Neurons; Parkinson Disease, Secondary; Receptors, Dopamine; Saimiri; Substantia Nigra

2000
Differential progression of motor impairment in levodopa-treated Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2000, Volume: 15, Issue:3

    Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Disability Evaluation; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Longitudinal Studies; Male; Motor Skills; Neurologic Examination; Parkinson Disease

2000
Effects of oligonucleotide antisense to dopamine D(1A) receptor messenger RNA in a rodent model of levodopa-induced dyskinesia.
    Neuroscience, 2000, Volume: 98, Issue:1

    Topics: Animals; Antiparkinson Agents; Apomorphine; Autoradiography; Behavior, Animal; Cocaine; Denervation; Disease Models, Animal; Dopamine Antagonists; Dopamine Uptake Inhibitors; Dyskinesia, Drug-Induced; Gene Expression; Levodopa; Male; Oligonucleotides, Antisense; Oxidopamine; Phenotype; Raclopride; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; RNA, Messenger; Rotation; Substantia Nigra; Sympatholytics; Tritium

2000
Treatments for Parkinson's disease.
    Health news (Waltham, Mass.), 2000, Volume: 6, Issue:6

    Topics: Antiparkinson Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Indoles; Levodopa; Parkinson Disease

2000
Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Brain : a journal of neurology, 2000, Volume: 123 ( Pt 7)

    Topics: Animals; Antiparkinson Agents; Autoradiography; Behavior, Animal; Brain Tissue Transplantation; Dopamine; Dyskinesia, Drug-Induced; Female; Fetal Tissue Transplantation; Hydroxydopamines; Image Processing, Computer-Assisted; In Situ Hybridization; Levodopa; Mesencephalon; Neostriatum; Nerve Endings; Neurons; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Sympathomimetics

2000
Antidyskinetic effect of JL-18, a clozapine analog, in parkinsonian monkeys.
    European journal of pharmacology, 2000, Jul-07, Volume: 399, Issue:2-3

    Topics: Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Benserazide; Clozapine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Motor Activity; Parkinsonian Disorders

2000
Reduction of dyskinesia and induction of akinesia induced by morphine in two parkinsonian patients with severe sciatica.
    Journal of neural transmission (Vienna, Austria : 1996), 1999, Volume: 106, Issue:7-8

    Topics: Aged; Analgesics, Opioid; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Hypokinesia; Intervertebral Disc Displacement; Levodopa; Lumbar Vertebrae; Male; Middle Aged; Morphine; Parkinson Disease; Sciatica

1999
Subhypnotic doses of zolpidem oppose dopaminergic-induced dyskinesia in Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2000, Volume: 15, Issue:4

    Topics: Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; GABA Agonists; Humans; Levodopa; Middle Aged; Parkinson Disease; Pyridines; Zolpidem

2000
Ropinirole as compared with levodopa in Parkinson's disease.
    The New England journal of medicine, 2000, Sep-21, Volume: 343, Issue:12

    Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Indoles; Levodopa; Parkinson Disease

2000
Ropinirole as compared with levodopa in Parkinson's disease.
    The New England journal of medicine, 2000, Sep-21, Volume: 343, Issue:12

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Indoles; Levodopa; Parkinson Disease; Sleep

2000
Ropinirole as compared with levodopa in Parkinson's disease.
    The New England journal of medicine, 2000, Sep-21, Volume: 343, Issue:12

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Hallucinations; Humans; Indoles; Levodopa; Parkinson Disease

2000
Ropinirole as compared with levodopa in Parkinson's disease.
    The New England journal of medicine, 2000, Sep-21, Volume: 343, Issue:12

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Indoles; Levodopa; Parkinson Disease; Quality of Life

2000
Endogenous dopaminergic tone and dopamine agonist action.
    Movement disorders : official journal of the Movement Disorder Society, 2000, Volume: 15, Issue:5

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adamantane; alpha-Methyltyrosine; Animals; Antiparkinson Agents; Apomorphine; Benzopyrans; Callithrix; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; Levodopa; Locomotion; Male; Quinpirole; Receptors, Dopamine D1; Receptors, Dopamine D2; Tyrosine 3-Monooxygenase

2000
The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting from L-dopa.
    Movement disorders : official journal of the Movement Disorder Society, 2000, Volume: 15, Issue:5

    Topics: Adult; Antiparkinson Agents; Dopamine Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Humans; Levodopa; Male; Memantine; N-Methylaspartate; Parkinsonian Disorders; Treatment Outcome

2000
Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study.
    Brain : a journal of neurology, 2000, Volume: 123 ( Pt 11)

    Topics: Age of Onset; Aged; Disease Progression; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Outpatients; Parkinson Disease; Prevalence; Quality of Life; Regression Analysis; Treatment Outcome

2000
[Amantadine for the treatment of levodopa dyskinesias in Parkinson's disease].
    Medicina, 2000, Volume: 60, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Prospective Studies; Severity of Illness Index; Statistics, Nonparametric

2000
Dopamine-receptor stimulation: biobehavioral and biochemical consequences.
    Trends in neurosciences, 2000, Volume: 23, Issue:10 Suppl

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Haplorhini; Levodopa; Neural Inhibition; Neuropeptides; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Receptors, Dopamine; Receptors, GABA; Receptors, Glutamate; Signal Transduction

2000
Detection and assessment of the severity of levodopa-induced dyskinesia in patients with Parkinson's disease by neural networks.
    Movement disorders : official journal of the Movement Disorder Society, 2000, Volume: 15, Issue:6

    Topics: Activities of Daily Living; Adult; Antiparkinson Agents; Diagnosis, Computer-Assisted; Diagnosis, Differential; Dyskinesia, Drug-Induced; Feasibility Studies; Humans; Levodopa; Movement; Neural Networks, Computer; Parkinson Disease; Predictive Value of Tests; Severity of Illness Index

2000
Effect of subthalamic nucleus stimulation on levodopa-induced dyskinesia in Parkinson's disease.
    Neurology, 2000, Dec-26, Volume: 55, Issue:12

    Topics: Adult; Aged; Dyskinesia, Drug-Induced; Electric Stimulation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Thalamic Nuclei

2000
Effects of acute and repeated treatment with a novel dopamine D2 receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys.
    European journal of pharmacology, 2001, Feb-02, Volume: 412, Issue:3

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benserazide; Dopamine Agents; Dopamine Antagonists; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Macaca fascicularis; Motor Activity; Parkinsonian Disorders; Piperidines; Receptors, Dopamine D2

2001
GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosets.
    The European journal of neuroscience, 2001, Volume: 13, Issue:3

    Topics: Animals; Antiparkinson Agents; Body Weight; Callithrix; Corpus Striatum; Disease Models, Animal; Dopamine Uptake Inhibitors; Dyskinesia, Drug-Induced; Enkephalins; Female; Gene Expression; Glial Cell Line-Derived Neurotrophic Factor; Levodopa; Locomotion; Male; Mazindol; MPTP Poisoning; Nerve Growth Factors; Nerve Tissue Proteins; Neuroprotective Agents; Protein Precursors; Recovery of Function; RNA, Messenger; Substantia Nigra; Tachykinins; Tritium; Tyrosine 3-Monooxygenase

2001
Accelerometric assessment of levodopa-induced dyskinesias in Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2001, Volume: 16, Issue:1

    Topics: Acceleration; Activities of Daily Living; Aged; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Parkinson Disease; Reproducibility of Results; Severity of Illness Index

2001
High dose naltrexone for dyskinesias induced by levodopa.
    Journal of neurology, neurosurgery, and psychiatry, 2001, Volume: 70, Issue:4

    Topics: Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Naltrexone; Reproducibility of Results

2001
Does stimulation of the GPi control dyskinesia by activating inhibitory axons?
    Movement disorders : official journal of the Movement Disorder Society, 2001, Volume: 16, Issue:2

    Topics: Action Potentials; Aged; Antiparkinson Agents; Axons; Dyskinesia, Drug-Induced; Electric Stimulation; Electrodes, Implanted; Evoked Potentials, Visual; Female; Functional Laterality; Globus Pallidus; Humans; Levodopa; Microelectrodes; Monitoring, Intraoperative; Neural Inhibition; Parkinson Disease; Periodicity

2001
Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of l-DOPA-induced dyskinesia.
    Neurobiology of disease, 2001, Volume: 8, Issue:2

    Topics: Animals; Basal Ganglia; Behavior, Animal; Binding Sites; Cerebral Cortex; Diprenorphine; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Enkephalins; Female; Levodopa; Narcotic Antagonists; Oxidopamine; Protein Precursors; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Opioid; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu; RNA, Messenger; Sympatholytics; Tritium

2001
[L-dopa-induced movement disorders in Parkinson disease. Amantadine improves dyskinesia].
    MMW Fortschritte der Medizin, 2001, May-28, Volume: 143 Suppl 2

    Topics: Amantadine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

2001
[Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].
    Revue neurologique, 2001, Volume: 157, Issue:5

    Topics: Age Distribution; Aged; Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; France; Health Care Costs; Humans; Levodopa; Male; Parkinson Disease; Quality of Life; Retrospective Studies; Severity of Illness Index; Sex Distribution

2001
Switch-over from tolcapone to entacapone in severe Parkinson's disease patients.
    European neurology, 2001, Volume: 46, Issue:1

    Topics: Aged; Antiparkinson Agents; Benzophenones; Catechols; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Mental Disorders; Middle Aged; Nitriles; Nitrophenols; Parkinson Disease; Substance Withdrawal Syndrome; Tolcapone

2001
Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus).
    Movement disorders : official journal of the Movement Disorder Society, 2001, Volume: 16, Issue:4

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callithrix; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Indoles; Levodopa; Neurologic Examination; Parkinsonian Disorders

2001
Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan.
    Movement disorders : official journal of the Movement Disorder Society, 2001, Volume: 16, Issue:4

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Apomorphine; Callithrix; Corpus Striatum; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Idazoxan; Levodopa; Male; Neurologic Examination; Neurons; Norepinephrine; Substantia Nigra

2001
L-dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations.
    Psychopharmacology, 2001, Volume: 156, Issue:4

    Topics: Animals; Behavior, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Male; Movement Disorders

2001
Levodopa induces dyskinesias in normal squirrel monkeys.
    Annals of neurology, 2001, Volume: 50, Issue:2

    Topics: Animals; Dyskinesia, Drug-Induced; Levodopa; Motor Activity; Reference Values; Saimiri

2001
Early morning off-medication dyskinesias, dystonia, and choreic subtypes.
    Archives of neurology, 2001, Volume: 58, Issue:9

    Topics: Adult; Aged; Antiparkinson Agents; Brain Tissue Transplantation; Chorea; Dyskinesia, Drug-Induced; Dystonic Disorders; Female; Fetal Tissue Transplantation; Globus Pallidus; Humans; Incidence; Levodopa; Male; Middle Aged; Parkinson Disease

2001
Relationship between lesion location and the outcome of pallidotomy for Parkinson's disease.
    Journal of neurology, 2001, Volume: 248 Suppl 3

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Electrodes, Implanted; Female; Globus Pallidus; Humans; Intelligence Tests; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Neurosurgical Procedures; Parkinson Disease; Retrospective Studies; Treatment Outcome

2001
Chronic high dose L-dopa treatment does not alter the levels of dopamine D-1, D-2 or D-3 receptor in the striatum of normal monkeys: an autoradiographic study.
    Journal of neural transmission (Vienna, Austria : 1996), 2001, Volume: 108, Issue:8-9

    Topics: Animals; Benzazepines; Dopamine Agents; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Male; Neostriatum; Neurons; Radioligand Assay; Receptor, Adenosine A2A; Receptors, Dopamine; Receptors, Purinergic P1

2001
MK-801 alters the effects of priming with L-DOPA on dopamine D1 receptor-induced changes in neuropeptide mRNA levels in the rat striatal output neurons.
    Synapse (New York, N.Y.), 2002, Volume: 43, Issue:1

    Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Disease Models, Animal; Dizocilpine Maleate; Dopamine Agents; Dopamine Agonists; Drug Interactions; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Excitatory Amino Acid Antagonists; Immunohistochemistry; Levodopa; Male; Motor Activity; Neostriatum; Neurons; Neuropeptides; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Wistar; Receptors, Dopamine D1; Receptors, N-Methyl-D-Aspartate; RNA, Messenger; Tachykinins; Tyrosine 3-Monooxygenase

2002
Phenotypic characterisation of autosomal recessive PARK6-linked parkinsonism in three unrelated Italian families.
    Movement disorders : official journal of the Movement Disorder Society, 2001, Volume: 16, Issue:6

    Topics: Adult; Age of Onset; Aged; Chromosomes, Human, Pair 1; Diagnosis, Differential; Disease Progression; Dyskinesia, Drug-Induced; Female; Functional Laterality; Gait Disorders, Neurologic; Genes, Recessive; Haplotypes; Humans; Italy; Levodopa; Lod Score; Male; Middle Aged; Parkinsonian Disorders; Pedigree; Phenotype; Syndrome; Tremor; Videotape Recording

2001
Effect of subthalamic nucleus stimulation on levodopa-induced dyskinesia in Parkinson's disease. 2000.
    Neurology, 2001, Volume: 57, Issue:10 Suppl 3

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; History, 20th Century; Humans; Levodopa; Parkinson Disease; Subthalamic Nucleus

2001
[A clinical analysis of L-dopa induced dyskinesia treated by posteroventral pallidotomy for Parkinson's disease].
    Zhonghua wai ke za zhi [Chinese journal of surgery], 1999, Volume: 37, Issue:8

    Topics: Adult; Aged; Antiparkinson Agents; Combined Modality Therapy; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Humans; Levodopa; Male; Microelectrodes; Middle Aged; Parkinson Disease; Stereotaxic Techniques; Treatment Outcome

1999
Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up.
    Movement disorders : official journal of the Movement Disorder Society, 2002, Volume: 17, Issue:1

    Topics: Antiparkinson Agents; Apomorphine; Dopamine Agonists; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Treatment Outcome

2002
Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias.
    Journal of neuropathology and experimental neurology, 2002, Volume: 61, Issue:2

    Topics: Age Factors; Aged; Aged, 80 and over; Antiparkinson Agents; Caudate Nucleus; Dyskinesia, Drug-Induced; Enkephalins; Humans; In Situ Hybridization; Levodopa; Parkinson Disease; Protein Precursors; Putamen; RNA, Messenger; Statistics as Topic

2002
Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease.
    The European journal of neuroscience, 2002, Volume: 15, Issue:1

    Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Behavior, Animal; Bromocriptine; Dyskinesia, Drug-Induced; Female; Gait; Levodopa; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Rotation; Stereotyped Behavior; Sympatholytics

2002
Dystonia in multiple system atrophy.
    Journal of neurology, neurosurgery, and psychiatry, 2002, Volume: 72, Issue:3

    Topics: Aged; Brain; Dyskinesia, Drug-Induced; Dystonia; Female; Humans; Levodopa; Male; Middle Aged; Multiple System Atrophy; Neurologic Examination; Parkinson Disease, Secondary

2002
Literature alert.
    Current neurology and neuroscience reports, 2001, Volume: 1, Issue:4

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Fetal Tissue Transplantation; Humans; Incidence; Indoles; Levodopa; Neurons; Parkinson Disease

2001
Force overflow and levodopa-induced dyskinesias in Parkinson's disease.
    Brain : a journal of neurology, 2002, Volume: 125, Issue:Pt 4

    Topics: Aged; Antiparkinson Agents; Biomechanical Phenomena; Dyskinesia, Drug-Induced; Hand Strength; Humans; Levodopa; Middle Aged; Movement; Muscle Contraction; Parkinson Disease; Weight-Bearing

2002
Levodopa-induced dyskinesias in normal squirrel monkeys.
    Annals of neurology, 2002, Volume: 51, Issue:4

    Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Saimiri

2002
The role of glutamatergic transmission in the pathogenesis of levodopa-induced dyskinesias. Potential therapeutic approaches.
    Neurologia i neurochirurgia polska, 2001, Volume: 35 Suppl 3

    Topics: Anticonvulsants; Antiparkinson Agents; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agents; Glutamic Acid; Humans; Levodopa; Parkinson Disease; Riluzole

2001
[Rush dyskinesia scale or Goetz scale].
    Revue neurologique, 2002, Volume: 158, Issue:5 Pt 1

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Severity of Illness Index

2002
A pharmacologic model of Huntington's chorea.
    The Journal of pharmacy and pharmacology, 1976, Volume: 28, Issue:8

    Topics: Animals; Carbachol; Catheterization; Clozapine; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Haloperidol; Huntington Disease; Hydrazines; Levodopa; Male; Phentolamine; Rats; Trifluoperazine; Tyramine

1976
Paradoxical response to dopamine agonists in tardive dyskinesia.
    The American journal of psychiatry, 1977, Volume: 134, Issue:7

    Topics: Adrenergic alpha-Agonists; Adult; Amantadine; Apomorphine; Benztropine; Clozapine; Deanol; Dextroamphetamine; Dose-Response Relationship, Drug; Drug Antagonism; Drug Tolerance; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Levodopa; Physostigmine; Receptors, Dopamine; Reserpine; Stimulation, Chemical; Thioridazine

1977
[Potential therapeutic activity of GABA-mimetic drugs in neuropsychiatry].
    Schweizer Archiv fur Neurologie, Neurochirurgie und Psychiatrie = Archives suisses de neurologie, neurochirurgie et de psychiatrie, 1979, Volume: 125, Issue:2

    Topics: 4-Aminobutyrate Transaminase; Basal Ganglia Diseases; Bicuculline; Dopamine; Dyskinesia, Drug-Induced; Epilepsy; Extrapyramidal Tracts; gamma-Aminobutyric Acid; Humans; Huntington Disease; Levodopa; Limbic System; Neural Pathways; Neurons; Neurotransmitter Agents; Parkinson Disease; Psychopharmacology

1979
Tiapride in Parkinson's disease.
    Lancet (London, England), 1978, Nov-18, Volume: 2, Issue:8099

    Topics: Antiparkinson Agents; Benzamides; Drug Evaluation; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Placebos

1978
Long-term effects of home-made levodopa in 43 cases of paralysis agitans.
    Chinese medical journal, 1979, Volume: 92, Issue:11

    Topics: Adult; Aged; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors

1979
Oscillations in performance in levodopa-treated parkinsonians: treatment with bromocriptine and L-deprenyl.
    Clinical and experimental neurology, 1979, Volume: 16

    Topics: Bromocriptine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline

1979
Therapeutics of disordered movement.
    American family physician, 1977, Volume: 16, Issue:3

    Topics: Carbidopa; Chorea; Drug Administration Schedule; Dyskinesia, Drug-Induced; Dystonia Musculorum Deformans; Hepatolenticular Degeneration; Humans; Huntington Disease; Levodopa; Movement Disorders; Parasympatholytics; Parkinson Disease; Receptors, Cholinergic; Receptors, Dopamine; Tremor

1977
Recent advances in the biochemical pharmacology of extrapyramidal movement disorders.
    Advances in experimental medicine and biology, 1977, Volume: 90

    Topics: Animals; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Homovanillic Acid; Humans; Huntington Disease; Levodopa; Parkinson Disease; Receptors, Dopamine; Stereotyped Behavior; Synapses; Tranquilizing Agents

1977
Estrogens, dopamine and dyskinesias.
    Canadian Psychiatric Association journal, 1978, Volume: 23, Issue:1

    Topics: Dyskinesia, Drug-Induced; Estrogens, Conjugated (USP); Female; Humans; Levodopa; Middle Aged; Receptors, Dopamine; Tranquilizing Agents

1978
Levodopa-induced dopaminergic hypersensitivity in the pathogenesis of psychiatric and neurologic disorders.
    International journal of neurology, 1979, Volume: 13, Issue:1-4

    Topics: Adult; Aged; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Mental Disorders; Middle Aged; Receptors, Dopamine

1979
L-3,4-dihydroxyphenylalanine-induced hypersensitivity simulating features of denervation.
    Proceedings of the National Academy of Sciences of the United States of America, 1977, Volume: 74, Issue:5

    Topics: Adenylyl Cyclases; Animals; Behavior, Animal; Caudate Nucleus; Denervation; Dopamine; Dyskinesia, Drug-Induced; Enzyme Activation; Levodopa; Mice

1977
Relationship between tardive dyskinesia, L-Dopa-induced hyperkinesia and parkinsonism.
    Psychopharmacology, 1977, Mar-16, Volume: 51, Issue:3

    Topics: Adult; Age Factors; Aged; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Oral Manifestations; Parkinson Disease; Tranquilizing Agents

1977
[Sustained levodopa efficacy in parkinsonism. Results of a four-year long-term follow-up study (author's transl)].
    Der Nervenarzt, 1977, Volume: 48, Issue:4

    Topics: Activities of Daily Living; Aged; Amantadine; Carboxy-Lyases; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Hyperkinesis; Levodopa; Long-Term Care; Male; Middle Aged; Motor Activity; Parasympatholytics; Parkinson Disease, Secondary; Therapeutic Equivalency; Time Factors

1977
[Comparative studies of L-DOPA alone and combination with a peripheral DOPA decarboxylase inhibitor, HCL-benserazide, on Parkinson's disease-part I: clinical aspects (author's transl)].
    No to shinkei = Brain and nerve, 1979, Volume: 31, Issue:3

    Topics: Adult; Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Blood Pressure; Dopa Decarboxylase; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease

1979
Tiapride in levodopa-induced involuntary movements.
    Journal of neurology, neurosurgery, and psychiatry, 1979, Volume: 42, Issue:4

    Topics: Aged; Benzamides; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease

1979
Dopamine agonists reverse the elevated 3H-neuroleptic binding in neuroleptic-pretreated rats.
    Life sciences, 1979, Apr-16, Volume: 24, Issue:16

    Topics: Animals; Apomorphine; Bromocriptine; Carbidopa; Corpus Striatum; Dyskinesia, Drug-Induced; Haloperidol; Levodopa; Male; Radioligand Assay; Rats; Receptors, Dopamine; Receptors, Drug; Spiperone

1979
[Abnormal movements induced by psychotropic drugs].
    L'Encephale, 1979, Volume: 5, Issue:1

    Topics: Chorea; Dyskinesia, Drug-Induced; Humans; Levodopa; Lithium; Movement Disorders; Parkinson Disease, Secondary; Psychotropic Drugs; Receptors, Dopamine; Receptors, Drug; Tremor

1979
Role of the caudate nucleus in production of dyskinesia [proceedings].
    Applied neurophysiology, 1979, Volume: 42, Issue:5

    Topics: Animals; Apomorphine; Cats; Caudate Nucleus; Dopamine; Dyskinesia, Drug-Induced; Electric Stimulation; Levodopa; Movement Disorders; Neural Pathways; Substantia Nigra; Tremor

1979
[Value of sulpiride and tiapride in geriatrics. Antagonism between Parkinson disease and chorea].
    Lille medical : journal de la Faculte de medecine et de pharmacie de l'Universite de Lille, 1979, Nov-17, Volume: Suppl 1

    Topics: Aged; Benzamides; Chorea; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Sulpiride; Tiapamil Hydrochloride

1979
Antagonism by piperidine of levodopa effects in Parkinson disease.
    Neurology, 1977, Volume: 27, Issue:9

    Topics: Aged; Chemical Phenomena; Chemistry; Dose-Response Relationship, Drug; Drug Evaluation; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Piperidines

1977
Methylphenidate-induced chorea: case report and pharmacologic implications.
    Neurology, 1978, Volume: 28, Issue:10

    Topics: Animals; Attention Deficit Disorder with Hyperactivity; Brain; Child; Child, Preschool; Chorea; Dopamine; Dyskinesia, Drug-Induced; Guinea Pigs; Humans; Hyperkinesis; Levodopa; Male; Methylphenidate; Stereotyped Behavior

1978
L-dopa induced dyskinesias in asymmetrical parkinsonism.
    Acta neurologica latinoamericana, 1979, Volume: 25, Issue:1-2

    Topics: Adult; Aged; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Nerve Degeneration; Neural Pathways; Parkinson Disease

1979
[Results of determination of plasma methoxydopa in parkinsonian patients with or without dyskinesia induced by L-Dopa].
    Revue neurologique, 1977, Volume: 133, Issue:11

    Topics: Aged; Dihydroxyphenylalanine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease

1977
Plasma O-methyldopa in levodopa-induced dyskinesias. A bioclinical investigation.
    Acta neurologica Scandinavica, 1977, Volume: 56, Issue:6

    Topics: Aged; Benserazide; Carbidopa; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Methyldopa; Middle Aged; Parkinson Disease

1977
[On and off phenomenon].
    Nihon rinsho. Japanese journal of clinical medicine, 1977,Spring, Volume: 35 Suppl 1

    Topics: Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Parkinson Disease

1977
Levodopa-induced dopamine receptor hypersensitivity.
    Transactions of the American Neurological Association, 1977, Volume: 102

    Topics: Animals; Apomorphine; Dextroamphetamine; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Mice; Receptors, Dopamine; Stereotyped Behavior

1977
Factors influencing the occurrence of "on-off" symptoms during long-term treatment with L-dopa.
    Acta medica Scandinavica, 1978, Volume: 203, Issue:1-2

    Topics: Adult; Aged; Drug Evaluation; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Follow-Up Studies; Humans; Levodopa; Metoclopramide; Middle Aged; Parkinson Disease, Secondary; Time Factors

1978
Respiratory dyskinesias: extrapyramidal dysfunction and dyspnea.
    Annals of internal medicine, 1978, Volume: 88, Issue:3

    Topics: Adult; Basal Ganglia Diseases; Central Nervous System; Dyskinesia, Drug-Induced; Dyspnea; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Receptors, Dopamine; Tranquilizing Agents

1978
Effect of new dopamine-blocking agent (oxiperomide) on drug-induced dyskinesias in Parkinson's disease and spontaneous dyskinesias.
    British medical journal, 1978, Apr-15, Volume: 1, Issue:6118

    Topics: Aged; Benzimidazoles; Bromocriptine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease

1978
Onset and end-of-dose levodopa-induced dyskinesias. Possible treatment by increasing the daily doses of levodopa.
    Archives of neurology, 1978, Volume: 35, Issue:5

    Topics: Aged; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged

1978
Receptor-cell sensitivity modification (RSM) as a model for pathogenesis and treatment of tardive dyskinesia.
    Psychopharmacology bulletin, 1978, Volume: 14, Issue:4

    Topics: Animals; Carbidopa; Disease Models, Animal; Drug Combinations; Dyskinesia, Drug-Induced; Hydrazines; Levodopa; Rats; Receptors, Dopamine

1978
[Abnormal movements of patients with Parkinsonism treated with L-dopa and anomalies of dopamine metabolism].
    Revue neurologique, 1977, Volume: 133, Issue:1

    Topics: Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Homovanillic Acid; Humans; Levodopa; Male; Middle Aged; Parkinson Disease

1977
Plasma DOPA levels and growth hormone response to levodopa in parkinsomism.
    Journal of neurology, neurosurgery, and psychiatry, 1977, Volume: 40, Issue:2

    Topics: Adult; Aged; Dihydroxyphenylalanine; Dyskinesia, Drug-Induced; Female; Growth Hormone; Humans; Levodopa; Male; Middle Aged; Parkinson Disease

1977
The relationship between parkinsonism and tardive dyskinesia.
    The American journal of psychiatry, 1977, Volume: 134, Issue:7

    Topics: Age Factors; Aminobutyrates; Baclofen; Basal Ganglia; Biperiden; Choline; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Methyltyrosines; Mouth; Parkinson Disease; Piperidines; Tranquilizing Agents

1977
Does O-methyl-dopa play a role in levodopa-induced dyskinesias?
    Acta neurologica Scandinavica, 1977, Volume: 56, Issue:1

    Topics: Adult; Aged; Benserazide; Carbidopa; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Methyldopa; Middle Aged; Parkinson Disease

1977
Ocular dyskinesias in patients with Parkinson's disease treated with levodopa.
    Annals of neurology, 1977, Volume: 1, Issue:2

    Topics: Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Oculomotor Muscles; Parkinson Disease; Syndrome

1977
["Beginning and end of dose" dyskinesias caused by L-DOPA].
    Revue neurologique, 1977, Volume: 133, Issue:5

    Topics: Benserazide; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease

1977
A neuroendocrine study of supersensitivity in tardive dyskinesia.
    Archives of general psychiatry, 1977, Volume: 34, Issue:10

    Topics: Adult; Apomorphine; Chronic Disease; Dyskinesia, Drug-Induced; Female; Growth Hormone; Humans; Hypothalamus; Levodopa; Male; Middle Aged; Prolactin; Receptors, Dopamine; Schizophrenia; Tranquilizing Agents

1977
[Effects and side effects of levodopa in parkinsonism - results of a collaborative study. (4) Dyskinesia caused by levodopa].
    Rinsho shinkeigaku = Clinical neurology, 1976, Volume: 16, Issue:12

    Topics: Adult; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease

1976
[Oral dyskinesia (author's transl)].
    No to shinkei = Brain and nerve, 1976, Volume: 28, Issue:4

    Topics: Aged; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Masticatory Muscles; Movement Disorders; Tongue Habits; Trihexyphenidyl

1976
Bromocriptine in Parkinsonism: long-term treatment, dose response, and comparison with levodopa.
    Journal of neurology, neurosurgery, and psychiatry, 1976, Volume: 39, Issue:11

    Topics: Aged; Bromocriptine; Dose-Response Relationship, Drug; Drug Evaluation; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Ergolines; Female; Follow-Up Studies; Growth Hormone; Humans; Levodopa; Male; Metoclopramide; Middle Aged; Parkinson Disease; Receptors, Dopamine

1976
Levodopa induced ON-OFF motor fluctuations in Parkinson's disease related to rhythmical masticatory jaw movements.
    Journal of neurology, neurosurgery, and psychiatry, 1992, Volume: 55, Issue:4

    Topics: Administration, Oral; Aged; Corpus Striatum; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Mastication; Masticatory Muscles; Middle Aged; Neurologic Examination; Neurons; Parkinson Disease; Receptors, Dopamine; Stereotyped Behavior; Synaptic Transmission

1992
Accelerated growth of malignant melanoma by levodopa in Parkinson's disease and role of the pineal gland.
    The International journal of neuroscience, 1992, Volume: 63, Issue:1-2

    Topics: Combined Modality Therapy; Corpus Striatum; Dyskinesia, Drug-Induced; Electric Stimulation; Equipment Design; Humans; Levodopa; Magnetics; Male; Melatonin; Middle Aged; Parkinson Disease; Pineal Gland

1992
Magnetic fields in the treatment of Parkinson's disease.
    The International journal of neuroscience, 1992, Volume: 63, Issue:1-2

    Topics: Combined Modality Therapy; Corpus Striatum; Dyskinesia, Drug-Induced; Electric Stimulation; Equipment Design; Humans; Levodopa; Magnetics; Male; Melatonin; Middle Aged; Parkinson Disease; Pineal Gland

1992
Levodopa.
    Lancet (London, England), 1992, Jan-18, Volume: 339, Issue:8786

    Topics: Dyskinesia, Drug-Induced; Humans; Levodopa; Motor Activity; Neurons; Parkinson Disease; Substantia Nigra; Time Factors

1992
Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification.
    Movement disorders : official journal of the Movement Disorder Society, 1992, Volume: 7, Issue:2

    Topics: Aged; Apomorphine; Chlorpromazine; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Electromyography; Female; Humans; Levodopa; Lisuride; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Receptors, Dopamine; Sulpiride

1992
Partial dopamine agonist therapy of levodopa-induced dyskinesias.
    Neurology, 1992, Volume: 42, Issue:6

    Topics: Adult; Aged; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Levodopa; Lisuride; Middle Aged; Movement

1992
Long-term observation of chronic subcutaneous administration of lisuride in the treatment of motor fluctuations in Parkinson's disease.
    Journal of neural transmission. Parkinson's disease and dementia section, 1992, Volume: 4

    Topics: Aged; Dyskinesia, Drug-Induced; Female; Humans; Injections, Subcutaneous; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease; Psychomotor Performance

1992
Effect of estrogen and progesterone on L-dopa induced dyskinesia in MPTP-treated monkeys.
    Neuroscience letters, 1992, Jan-20, Volume: 135, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Estradiol; Female; Levodopa; Macaca fascicularis; Parkinson Disease, Secondary; Progesterone

1992
Controlled-release carbidopa-levodopa: old drug--new drug. Introduction.
    Neurology, 1992, Volume: 42, Issue:1 Suppl 1

    Topics: Carbidopa; Circadian Rhythm; Delayed-Action Preparations; Dyskinesia, Drug-Induced; Evaluation Studies as Topic; Humans; Levodopa; Parkinson Disease

1992
The use of Sinemet CR in the management of mild to moderate Parkinson's disease.
    Neurology, 1992, Volume: 42, Issue:1 Suppl 1

    Topics: Carbidopa; Drug Administration Schedule; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Levodopa; Movement; Parkinson Disease; Patient Compliance; Patient Education as Topic; Tissue Distribution

1992
[Dopa-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated hemiparkinsonian monkeys].
    Zhonghua shen jing jing shen ke za zhi = Chinese journal of neurology and psychiatry, 1992, Volume: 25, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamines; Animals; Apomorphine; Benserazide; Carboxy-Lyases; Drug Combinations; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca mulatta; Parkinson Disease, Secondary

1992
Gamma vinyl GABA in the treatment of levodopa-induced dyskinesias in Parkinson's disease.
    Journal of neurology, neurosurgery, and psychiatry, 1992, Volume: 55, Issue:5

    Topics: 4-Aminobutyrate Transaminase; Adult; Aged; Aminocaproates; Chorea; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Neurologic Examination; Parkinson Disease; Vigabatrin

1992
Paradoxical akinetic response to apomorphine in parkinsonism.
    Journal of neurology, neurosurgery, and psychiatry, 1992, Volume: 55, Issue:5

    Topics: Apomorphine; Benserazide; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease

1992
Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L-dopa in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys.
    The Journal of pharmacology and experimental therapeutics, 1991, Volume: 259, Issue:1

    Topics: Animals; Dopamine Agents; Dopamine Antagonists; Drug Interactions; Dyskinesia, Drug-Induced; Female; Levodopa; Locomotion; Macaca fascicularis; MPTP Poisoning; Parkinson Disease, Secondary

1991
Is levodopa harmful?
    Lancet (London, England), 1991, Nov-09, Volume: 338, Issue:8776

    Topics: Aged; Aged, 80 and over; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Parkinson Disease

1991
Early onset parkinsonism in Chinese.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 1991, Volume: 90, Issue:10

    Topics: Adolescent; Adult; Age Factors; China; Circadian Rhythm; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Parkinson Disease, Secondary

1991
Motor blocks in Parkinson's disease.
    Neurology, 1992, Volume: 42, Issue:2

    Topics: Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Risk Factors

1992
A computational model of levodopa pharmacodynamics in Parkinson's disease.
    Clinical neuropharmacology, 1991, Volume: 14, Issue:6

    Topics: Basal Ganglia; Corpus Striatum; Drug Tolerance; Dyskinesia, Drug-Induced; Humans; Levodopa; Neural Networks, Computer; Parkinson Disease

1991
Dopaminergic activity and idiopathic edema.
    Hospital & community psychiatry, 1991, Volume: 42, Issue:3

    Topics: Adult; Brain; Diuresis; Dopamine; Dyskinesia, Drug-Induced; Edema; Female; Galactorrhea; Haloperidol; Humans; Levodopa; Receptors, Dopamine; Substance Withdrawal Syndrome

1991
[Levodopa and controlled release benserazide in the handling of motor fluctuations in Parkinson's disease].
    Revista medica de Chile, 1991, Volume: 119, Issue:9

    Topics: Aged; Benserazide; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Time Factors

1991
Naloxone reverses L-dopa induced overstimulation effects in a Parkinson's disease animal model analogue.
    Life sciences, 1991, Volume: 48, Issue:13

    Topics: Animals; Carbidopa; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Hydroxydopamines; Levodopa; Male; Mesencephalon; Naloxone; Oxidopamine; Parkinson Disease; Rats; Rats, Inbred Strains; Time Factors

1991
Psychotic complications of long-term levodopa treatment of Parkinson's disease.
    Acta neurologica Scandinavica, 1991, Volume: 84, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Psychoses, Substance-Induced

1991
New concepts in the treatment of Parkinson's disease.
    American family physician, 1990, Volume: 41, Issue:2

    Topics: Antiparkinson Agents; Carbidopa; Diet; Dopamine Agents; Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Intestinal Absorption; Levodopa; Parkinson Disease; Selegiline

1990
Neurotransmitter and receptor alterations in the rat persistent dyskinesia model induced by iminodipropionitrile.
    European neurology, 1990, Volume: 30 Suppl 1

    Topics: Animals; Apomorphine; Autoradiography; Benzazepines; Brain Chemistry; Bromocriptine; Ceruletide; Dyskinesia, Drug-Induced; Levodopa; Male; Neurotoxins; Neurotransmitter Agents; Nitriles; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Muscarinic

1990
Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease.
    Neurology, 1991, Volume: 41, Issue:2 ( Pt 1)

    Topics: Adult; Aging; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Movement; Parkinson Disease; Probability; Severity of Illness Index; Time Factors

1991
Sickness due to levodopa-induced neck dyskinesias in Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 1991, Volume: 6, Issue:1

    Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Middle Aged; Nausea; Parkinson Disease; Vomiting

1991
"Early" initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease.
    Neurology, 1991, Volume: 41, Issue:5

    Topics: Aged; Analysis of Variance; Cohort Studies; Dementia; Dyskinesia, Drug-Induced; Follow-Up Studies; Humans; Levodopa; Middle Aged; Motor Activity; Parkinson Disease

1991
Acute effects of pulsatile levodopa administration on central dopamine pharmacodynamics.
    Neurology, 1991, Volume: 41, Issue:5

    Topics: Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Time Factors

1991
Buspirone in the treatment of levodopa induced dyskinesias.
    Journal of neurology, neurosurgery, and psychiatry, 1991, Volume: 54, Issue:4

    Topics: Adult; Aged; Apomorphine; Buspirone; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease

1991
Differential effects of D1 and D2 agonists in MPTP-treated primates: functional implications for Parkinson's disease.
    Neurology, 1990, Volume: 40, Issue:6

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Behavior, Animal; Benzazepines; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Oxazines; Parkinson Disease, Secondary; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Saimiri

1990
A blinded study of the suppressibility of involuntary movements in Huntington's chorea, tardive dyskinesia, and L-dopa-induced chorea.
    Clinical neuropharmacology, 1990, Volume: 13, Issue:3

    Topics: Chorea; Diagnosis, Differential; Dyskinesia, Drug-Induced; Humans; Huntington Disease; Levodopa; Parkinson Disease; Videotape Recording

1990
Terguride in the treatment of Parkinson disease: preliminary experience.
    Italian journal of neurological sciences, 1990, Volume: 11, Issue:4

    Topics: Dyskinesia, Drug-Induced; Humans; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease

1990
Nigrostriatal damage is required for induction of dyskinesias by L-DOPA in squirrel monkeys.
    Clinical neuropharmacology, 1990, Volume: 13, Issue:5

    Topics: Animals; Corpus Striatum; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Saimiri; Substantia Nigra

1990
Preliminary report on adrenal medullary grafting and cografting with sural nerve in the treatment of hemiparkinson monkeys.
    Progress in brain research, 1990, Volume: 82

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Animals; Apomorphine; Behavior, Animal; Carbidopa; Caudate Nucleus; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Macaca mulatta; Motor Activity; Parkinson Disease; Sural Nerve; Transplantation, Heterotopic

1990
CCK-8S inhibits L-dopa-induced dyskinesias in parkinsonian squirrel monkeys.
    Neurology, 1990, Volume: 40, Issue:4

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Parkinson Disease, Secondary; Saimiri; Sincalide

1990
Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia.
    Journal of neurology, neurosurgery, and psychiatry, 1990, Volume: 53, Issue:3

    Topics: Aged; Antiparkinson Agents; Benserazide; Carbidopa; Carboxy-Lyases; Dose-Response Relationship, Drug; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Hydrazines; Levodopa; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease

1990
['New wine in old bottles'; therapy for Parkinson disease using subcutaneous apomorphine].
    Nederlands tijdschrift voor geneeskunde, 1990, May-05, Volume: 134, Issue:18

    Topics: Aged; Antiparkinson Agents; Apomorphine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease

1990
Sustained enteral administration of levodopa increases and interrupted infusion decreases levodopa dose requirements.
    Neurology, 1990, Volume: 40, Issue:6

    Topics: Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Infusion Pumps; Infusions, Parenteral; Intubation, Gastrointestinal; Levodopa; Male; Middle Aged; Parkinson Disease

1990
Characterisation of dyskinesias induced by L-dopa in MPTP-treated squirrel monkeys.
    Psychopharmacology, 1990, Volume: 102, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chorea; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Saimiri

1990
Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage.
    Pharmacology, biochemistry, and behavior, 1989, Volume: 34, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Ergolines; Levodopa; Macaca fascicularis; Parkinson Disease, Secondary; Quinpirole

1989
NB-355: a novel prodrug for L-DOPA with reduced risk for peak-dose dyskinesias in MPTP-treated squirrel monkeys.
    Clinical neuropharmacology, 1989, Volume: 12, Issue:5

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Motor Activity; Parkinson Disease, Secondary; Prodrugs; Saimiri; Time Factors

1989
Adrenal medullary autograft transplantation into the striatum of patients with Parkinson's disease.
    Mayo Clinic proceedings, 1989, Volume: 64, Issue:3

    Topics: Adrenal Medulla; Adult; Carbidopa; Caudate Nucleus; Drug Combinations; Dyskinesia, Drug-Induced; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Postoperative Complications; Stereotaxic Techniques

1989
Blink reflex in dyskinetic and nondyskinetic patients with Parkinson's disease.
    European neurology, 1989, Volume: 29, Issue:2

    Topics: Adult; Aged; Blinking; Dyskinesia, Drug-Induced; Electric Stimulation; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease

1989
Levodopa and 3-O-methyldopa plasma levels in parkinsonian patients with stable and fluctuating motor response.
    Clinical neuropharmacology, 1989, Volume: 12, Issue:1

    Topics: Aged; Carbidopa; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tyrosine

1989
Pathogenesis of dyskinesias in Parkinson's disease.
    Annals of neurology, 1989, Volume: 25, Issue:5

    Topics: Adult; Aged; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors

1989
Recent developments in the treatment of Parkinson's disease.
    Geriatrics, 1985, Volume: 40, Issue:2

    Topics: Aged; Aging; Amantadine; Diagnosis, Differential; Drug Administration Schedule; Dyskinesia, Drug-Induced; Histamine H1 Antagonists; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Physical Exertion

1985
A therapeutic approach to tardive dyskinesia.
    The Journal of clinical psychiatry, 1985, Volume: 46, Issue:4 Pt 2

    Topics: Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Colitis; Depressive Disorder; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Methyltyrosines; Middle Aged; Nausea; Paranoid Disorders; Psychomotor Agitation; Psychoses, Substance-Induced; Psychotic Disorders; Receptors, Dopamine; Reserpine; Tetrabenazine; Time Factors

1985
The effect of dopamine antagonists in spontaneous and tardive dyskinesia.
    Psychopharmacology. Supplementum, 1985, Volume: 2

    Topics: Antipsychotic Agents; Dopamine Antagonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Huntington Disease; Levodopa; Receptors, Dopamine; Tourette Syndrome

1985
When to use levodopa in parkinsonism.
    Lancet (London, England), 1986, Jun-07, Volume: 1, Issue:8493

    Topics: Acute Disease; Aged; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Parkinson Disease

1986
Painful Parkinson's disease.
    Lancet (London, England), 1986, Jun-14, Volume: 1, Issue:8494

    Topics: Acute Disease; Adult; Aged; Antiparkinson Agents; Benserazide; Carbidopa; Drug Administration Schedule; Drug Combinations; Dyskinesia, Drug-Induced; Dystonia; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Pain; Parkinson Disease; Time Factors

1986
When should levodopa be started?
    Lancet (London, England), 1986, Oct-25, Volume: 2, Issue:8513

    Topics: Adult; Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease

1986
Coexistent tardive dyskinesia and parkinsonism.
    Clinical neuropharmacology, 1987, Volume: 10, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary; Reserpine; Tetrabenazine

1987
Ethical issues in drug studies.
    The American journal of psychiatry, 1988, Volume: 145, Issue:3

    Topics: Antipsychotic Agents; Dyskinesia, Drug-Induced; Ethics, Medical; Humans; Levodopa; Research; Schizophrenia; Schizophrenic Psychology

1988
Behavioural effects of (+)-4-propyl-9-hydroxynaphthoxazine in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Naunyn-Schmiedeberg's archives of pharmacology, 1988, Volume: 338, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Macaca fascicularis; Male; Oxazines; Parkinson Disease, Secondary; Pyridines

1988
Experimental study on resting tremor and L-dopa-induced dyskinesia.
    European neurology, 1987, Volume: 26 Suppl 1

    Topics: Animals; Cercopithecus; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Macaca; Movement Disorders; Receptors, Dopamine; Receptors, Dopamine D2; Tegmentum Mesencephali; Tremor

1987
Lisuride infusion pump in Parkinson's disease. A report of two cases.
    Journal of neural transmission. Supplementum, 1988, Volume: 27

    Topics: Aged; Drug Administration Schedule; Drug Eruptions; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Ergolines; Humans; Levodopa; Lisuride; Mental Disorders; Parkinson Disease

1988
Pathophysiology of L-dopa-induced abnormal involuntary movements.
    Psychopharmacology. Supplementum, 1985, Volume: 2

    Topics: Brain; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Neural Pathways; Parkinson Disease; Receptors, Dopamine; Spiperone; Substance Withdrawal Syndrome; Substantia Nigra; Synapses; Synaptic Transmission

1985
Naloxone treatment of L-dopa-induced dyskinesias in Parkinson's disease.
    The American journal of psychiatry, 1986, Volume: 143, Issue:1

    Topics: Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Naloxone; Parkinson Disease; Receptors, Opioid

1986
Resolution of dyskinesia and the "on-off" phenomenon in thyrotoxic patients with Parkinson's disease after antithyroid treatment.
    British medical journal (Clinical research ed.), 1986, Jul-05, Volume: 293, Issue:6538

    Topics: Aged; Carbimazole; Dyskinesia, Drug-Induced; Female; Humans; Hyperthyroidism; Levodopa; Movement Disorders; Parkinson Disease

1986
Parkinson's disease in the elderly: a long-term efficacy study of levodopa/benserazide combination therapy.
    Pharmatherapeutica, 1986, Volume: 4, Issue:9

    Topics: Aged; Aged, 80 and over; Benserazide; Bromocriptine; Confusion; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Hydrazines; Levodopa; Long-Term Care; Male; Middle Aged; Parkinson Disease

1986
Open pilot trial of ritanserin in parkinsonism.
    Clinical neuropharmacology, 1986, Volume: 9, Issue:5

    Topics: Aged; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Pilot Projects; Piperidines; Ritanserin

1986
[Long-term problems of levodopa therapy in Parkinson disease].
    Schweizerische medizinische Wochenschrift, 1987, Mar-07, Volume: 117, Issue:10

    Topics: Adult; Aged; Chromatography, High Pressure Liquid; Dihydroxyphenylalanine; Dyskinesia, Drug-Induced; Humans; Levodopa; Life Expectancy; Parkinson Disease; Time Factors

1987
Isoniazid therapy in Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 1988, Volume: 3, Issue:2

    Topics: Aged; Dyskinesia, Drug-Induced; Female; Humans; Isoniazid; Levodopa; Male; Middle Aged; Parkinson Disease

1988
Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I.
    Annals of neurology, 1988, Volume: 24, Issue:3

    Topics: Adult; Aged; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Time Factors

1988
Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II.
    Annals of neurology, 1988, Volume: 24, Issue:3

    Topics: Adult; Aged; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease

1988
Outpatient treatment of Parkinson's disease.
    European neurology, 1988, Volume: 28, Issue:3

    Topics: Ambulatory Care; Benserazide; Bromocriptine; Carboxy-Lyases; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Retrospective Studies

1988
A comparison of clinical and pathological features of young- and old-onset Parkinson's disease.
    Neurology, 1988, Volume: 38, Issue:9

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Muscular Diseases; Parkinson Disease; Personality; Substantia Nigra

1988
Parkinson's disease.
    Comprehensive therapy, 1986, Volume: 12, Issue:3

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Benserazide; Carbidopa; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parasympatholytics; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Rats

1986
Abnormal eye-head coordination in Parkinson's disease patients after administration of levodopa: a possible substrate of levodopa-induced dyskinesia.
    Journal of neurology, neurosurgery, and psychiatry, 1986, Volume: 49, Issue:7

    Topics: Aged; Dyskinesia, Drug-Induced; Eye Movements; Head; Humans; Levodopa; Middle Aged; Movement; Parkinson Disease; Reflex, Abnormal; Vestibule, Labyrinth

1986
Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Journal of the neurological sciences, 1987, Volume: 78, Issue:3

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Macaca fascicularis; Parkinson Disease, Secondary; Pyridines

1987
Young onset Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 1987, Volume: 2, Issue:2

    Topics: Adult; Age Factors; Circadian Rhythm; Dementia; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Parkinson Disease; Pedigree; Risk Factors; Tremor

1987
Response of tardive and L-dopa-induced dyskinesias to antidepressants.
    The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 1987, Volume: 14, Issue:4

    Topics: Aged; Antidepressive Agents; Depressive Disorder; Desipramine; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Trazodone

1987
Long-term follow-up of early dopa treatment in Parkinson's disease.
    Annals of neurology, 1986, Volume: 19, Issue:4

    Topics: Dementia; Disability Evaluation; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors

1986
[An analysis of long-term L-dopa treatment on 122 cases of Parkinson's disease over 14 years--when should L-dopa therapy be initiated?].
    Rinsho shinkeigaku = Clinical neurology, 1986, Volume: 26, Issue:4

    Topics: Adult; Aged; Drug Evaluation; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors

1986
[Therapy in Parkinson syndrome].
    Deutsche medizinische Wochenschrift (1946), 1986, Oct-10, Volume: 111, Issue:41

    Topics: Drug Tolerance; Dyskinesia, Drug-Induced; Humans; Levodopa

1986
Respiratory dyskinesia in Parkinson's disease.
    Neurology, 1986, Volume: 36, Issue:2

    Topics: Aged; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Parkinson Disease; Respiration Disorders; Tiapamil Hydrochloride

1986
Intravenous lisuride corrects oscillations of motor performance in Parkinson's disease.
    Annals of neurology, 1986, Volume: 19, Issue:1

    Topics: Adult; Aged; Domperidone; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Ergolines; Female; Humans; Injections, Intravenous; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease

1986
Efficacy of pergolide and mesulergine.
    European neurology, 1986, Volume: 25, Issue:2

    Topics: Aged; Antiparkinson Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Ergolines; Humans; Levodopa; Middle Aged; Parkinson Disease; Pergolide

1986
Chronic agonist therapy for Parkinson's disease: a 5-year study of bromocriptine and pergolide.
    Neurology, 1985, Volume: 35, Issue:5

    Topics: Aged; Antiparkinson Agents; Bromocriptine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonia; Ergolines; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Nausea; Outcome and Process Assessment, Health Care; Parkinson Disease; Pergolide; Time Factors

1985
Levodopa-induced dyskinesia: clinical observations.
    Journal of neurology, 1985, Volume: 232, Issue:1

    Topics: Adult; Aged; Carbidopa; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Risk

1985
The symptoms of patients treated for Parkinson's disease.
    Clinical neuropharmacology, 1985, Volume: 8, Issue:2

    Topics: Adult; Age Factors; Aged; Carboxy-Lyases; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Parasympatholytics; Parkinson Disease; Surveys and Questionnaires

1985
[Tiapride in persistent dyskinesias following long-term L-dopa for parkinsonism].
    Harefuah, 1985, Mar-01, Volume: 108, Issue:5

    Topics: Aged; Benzamides; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tiapamil Hydrochloride

1985
[Useful data on parkinsonian syndromes].
    Medicina clinica, 1985, May-25, Volume: 84, Issue:20

    Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Movement Disorders; Parkinson Disease, Secondary

1985
[Oral lisuride in Parkinson's disease].
    Medicina clinica, 1985, Sep-21, Volume: 85, Issue:8

    Topics: Adult; Aged; Bromocriptine; Drug Evaluation; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Ergolines; Female; Humans; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease

1985
[Long-term evaluation of tiapride in patients with various forms of dyskinesia].
    No to shinkei = Brain and nerve, 1985, Volume: 37, Issue:10

    Topics: Benzamides; Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Levodopa; Meige Syndrome; Movement Disorders; Safety; Tiapamil Hydrochloride

1985